Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
YUKON DRUG PROGRAMSFORMULARY
Insured Health & Hearing Services (H-2) Printed: 2017-01-26Health and Social Services
Preamble Contents
CONTACT ADDRESSES AND PHONE NUMBERS 1
PREFACE / THE FORMULARY / DRUG REVIEW PROCESS 2
POLICY FOR FORMULARY DELETION 3
ELIGIBILITY FOR CHRONIC DISEASE PROGRAM 4
ELIGIBILITY FOR CHILDREN’S DRUG & OPTICAL PROGRAM 5
ELIGIBILITY FOR PHARMACARE PROGRAM 6
ELIGIBILITY FOR PALLIATIVE CARE COVERAGE 7
PRESCRIPTIONS 8
EXCEPTION DRUG STATUS 9
APPLICATION REVIEW FOR EXCEPTION DRUG STATUS 10
PHARMACARE AND EXTENDED BENEFITS 11
CHRONIC DISEASE AND DISABILITY 12
DOSAGE ABBREVIATIONS 13
PHARMACEUTICAL MANUFACTURERS LIST 14
1
CONTACT ADDRESSES AND PHONE NUMBERS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
2
PREFACE / THE FORMULARY / DRUG REVIEW PROCESS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
3
POLICY FOR FORMULARY DELETION
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
4
ELIGIBILITY FOR CHRONIC DISEASE PROGRAM
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
5
ELIGIBILITY FOR CHILDREN’S DRUG & OPTICAL PROGRAM
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
6
ELIGIBILITY FOR PHARMACARE PROGRAM
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
7
ELIGIBILITY FOR PALLIATIVE CARE COVERAGE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
8
PRESCRIPTIONS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
9
EXCEPTION DRUG STATUS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
10
APPLICATION REVIEW FOR EXCEPTION DRUG STATUS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
11
PHARMACARE AND EXTENDED BENEFITS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
12
CHRONIC DISEASE AND DISABILITY
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
13
DOSAGE ABBREVIATIONS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
14
PHARMACEUTICAL MANUFACTURERS LIST
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
15
PHARMACEUTICAL MANUFACTURERS LIST
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
16
PHRM/CHRN/CDO/F02:10.00 null
02:00 null
ARTIFICIAL SALIVA
N/A
9123456 ARTIFICIAL SALIVA 0.2 N N N NN/A /null
04:00 ANTIHISTAMINE DRUGS
04:00.00 ANTIHISTAMINE DRUGS ------------------------------------------------------------
OLOPATADINE
0.1%
0235891 SANDOZ OLOPATADINE 5.23 Y N Y YSDZ /ML
0223314 PATANOL OPH DROPS 5.95 Y N Y YALC /ML
0230505 APO-OLOPATADINE 5.226 Y N Y YAPX /ML
0240398 CO OLOPATADINE 5.23 Y N Y YCOB /ML
0.2%
0240409 ACT OLOPATADINE 0.2% 10.45 Y N Y YACT /ML
0240282 APO-OLOPATADINE 10.45 Y N Y YAPX /ML
OLOPATDINE
0.2%
0242017 SANDOZ OLOPATADINE 0.2% 10.45 Y N Y YSDZ /ML
TRIMEPRAZINE
2.5MG
0192630 PANECTYL 0.36 Y N Y YAVT /TB
5MG
0192629 PANECTYL 0.44 Y N Y YAVT /TB
04:08.00 SECOND GENERATION ANTIHISTAMINES -----------------------------------------------
LORATADINE
10MG
0224388 APO-LORATADINE 0.63 N N Y NAPX /TB
08:00 ANTI-INFECTIVE AGENTS
08:04.00 AMEBICIDES ---------------------------------------------------------------------
DIIODOHYDROXYQUIN
650MG
0199775 DIODOQUIN 0.7545 Y N Y YGLW /TB
08:08.00 ANTHELMINTICS ------------------------------------------------------------------
MEBENDAZOLE
100MG
0055673 VERMOX 4.74 Y N Y YJAN /TB
PYRANTEL PAMOATE
125MG
0194436 COMBANTRIN 1.11 N N Y NPFI /TB
50MG/ML
0194435 COMBANTRIN SUSP 0.2789 N N Y NPFI /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
17
PHRM/CHRN/CDO/F08:12.02 AMINOGLYCOSIDES
08:00 ANTI-INFECTIVE AGENTS (continued)
GENTAMICIN S04
08:12.02 AMINOGLYCOSIDES ----------------------------------------------------------------
10MG/ML
0226853 GENTAMICIN (2ML) 2.354 E E N YSDZ /ML
40MG/ML
0224265 GENTAMICIN (20ML) 4.26 E E N YSDZ /ML
TOBRAMYCIN
28MG
0236515 TOBI PODHALER 14.05 E E N YNVR /EA
TOBRAMYCIN SULFATE
40MG/ML
0224121 TOBRAMYCIN (2ML) INJ 3.71 E E N YSAB /ML
60MG/ML
0223963 TOBI INHALATION 54.49 E E N YCCL /ML
08:12.04 ANTIBIOTICS (ANTIFUNGALS) ------------------------------------------------------
FLUCONAZOLE
10MG/ML
0202415 DIFLUCAN PDR FOR SUSP 1 Y E Y YPFI /ML
100MG
0224564 PMS-FLUCONAZOLE 2.29 Y E Y YPMS /TB
0223737 APO-FLUCONAZOLE 2.29 Y E Y YAPX /TB
0224529 GEN-FLUCONAZOLE 2.29 Y E Y YGPM /TB
0089181 DIFLUCAN 8.6008 Y E Y YPFI /TB
0228127 CO-FLUCONAZOLE 2.29 Y E Y YCOB /TB
0223697 NOVO-FLUCONAZOLE 2.29 Y E Y YNOP /TB
150MG
0214144 DIFLUCAN 13.29 Y E Y YPFI /CP
0228234 PMS-FLUCONAZOLE 0.94 Y E Y NPMS /CP
0235213 APO-FLUCONAZOLE 11.83 Y E Y NAPX /CP
0232341 CO-FLUCONAZOLE 8.76 Y E Y NCOB /CP
0224364 NOVO-FLUCONAZOLE 9.19 Y E Y NNOP /CP
0224189 APO-FLUCONAZOLE 3.94 Y E Y NAPX /CP
0224569 GEN-FLUCONAZOLE 8.76 Y E Y NGPM /CP
0231169 CANESORAL 15.42 Y E Y YBAY /CP
4MG/ML
0089183 DIFLUCAN SUSP 0.3756 Y E Y YPFI /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
18
PHRM/CHRN/CDO/F08:12.04 ANTIBIOTICS (ANTIFUNGALS) (continued)
08:00 ANTI-INFECTIVE AGENTS (continued)
FLUCONAZOLE (continued)
50MG
0223697 NOVO-FLUCONAZOLE 1.29 Y E Y YNOP /TB
0228126 CO-FLUCONAZOLE 1.29 Y E Y YCOB /TB
0224564 PMS-FLUCONAZOLE 1.29 Y E Y YPMS /TB
0224529 GEN-FLUCONAZOLE 1.29 Y E Y YGPM /TB
0089180 DIFLUCAN 4.8482 Y E Y YPFI /TB
0223737 APO-FLUCONAZOLE 1.29 Y E Y YAPX /TB
ITRACONAZOLE
10MG/ML
0223134 SPORANOX ORAL SOLN 0.78 E E Y YJAN /ML
100MG
0204745 SPORANOX 4.62 E E Y YJAN /CP
KETOCONAZOLE
200MG
0223106 NOVO-KETOCONAZOLE 0.94 Y E Y YNOP /TB
0223723 APO-KETOCONAZOLE 0.94 Y E Y YAPX /TB
NYSTATIN
100000U/ML
0243344 JAMP-NYSTATIN ORAL SUSP 0.05 Y E Y YJPC
/ML
0219420 RATIO-NYSTATIN ORAL SUSP 0.05 Y E Y YRTP /ML
0079266 PMS-NYSTATIN ORAL SUSP 0.05 Y E Y YPMS /ML
TERBINAFINE
250MG
0223989 APO-TERBINAFINE 1.85 Y E Y YAPX /TB
0224034 NOVO-TERBINAFINE 1.85 Y E Y YNOP /TB
0224250 GEN-TERBINAFINE 1.85 Y E Y YGPM /TB
0235312 SANIS-TERBINAFINE 1.85 Y E Y YSAN /TB
0203111 LAMISIL 4.21 Y E Y YNVR /TB
0229427 PMS-TERBINAFINE 1.85 Y E Y YPMS /TB
0225472 CO-TERBINAFINE 1.85 Y E Y YCOB /TB
VORICONAZOLE
200MG
0239925 SANDOZ-VORICONAZOLE 12.78 E E N YSDZ /TB
0225647 VFEND 51.11 E E N YPFI /TB
50MG
0239924 SANDOZ-VORICONAZOLE 3.2 E E N YSDZ /TB
08:12.06 CEPHALOSPORINS -----------------------------------------------------------------
CEFACLOR
25MG/ML
0046520 CECLOR SUSP 0.12 Y E Y YPHL /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
19
PHRM/CHRN/CDO/F08:12.06 CEPHALOSPORINS
08:00 ANTI-INFECTIVE AGENTS (continued)
CEFACLOR (continued)
250MG
0223169 NOVO-CEFACLOR 0.9697 Y E Y YNOP /CP
0223026 APO-CEFACLOR 0.9697 Y E Y YAPX /CP
50MG/ML
0046521 CECLOR SUSP 0.22 Y E Y YPHL /ML
500MG
0223026 APO-CEFACLOR 1.93 Y E Y YAPX /CP
0223169 NOVO-CEFACLOR 1.93 Y E Y YNOP /CP
75MG/ML
0223750 APO-CEFACLOR SUSP 0.201 Y E Y YAPX /ML
0083280 CECLOR BID SUSP 0.2871 Y E Y YPHL /ML
CEFAZOLIN SODIUM
1GM PDR
0210812 CEFAZOLIN 1GM INJ PDR 3.23 Y E N YNOP /VL
CEFIXIME
20MG/ML
0086896 SUPRAX SUSP 0.43 Y E Y YAVT /ML
400MG
0086898 SUPRAX 3.62 Y E Y YAVT /TB
0243277 AURO-CEFIXIME 3.08 Y E Y YAUR /TB
CEFPROZIL
25MG/ML
0216367 CEFZIL SUSP 0.19 Y E Y YBMY /ML
0229394 APO-CEFPROZIL SUSP 0.12 Y E Y YAPX /ML
250MG
0229352 RAN-CEFPROZIL 1.13 Y E Y YRAN /TB
0216365 CEFZIL 1.93 Y E Y YBMY /TB
0229299 APO-CEFPROZIL 0.43 Y E Y YAPX /TB
50MG/ML
0216368 CEFZIL SUSP 0.38 Y E Y YBMY /ML
0229395 APO-CEFPROZIL SUSP 0.24 Y E Y YAPX /ML
500MG
0229353 RAN-CEFPROZIL 2.22 Y E Y YRAN /TB
0216366 CEFZIL 3.78 Y E Y YBMY /TB
0229300 APO-CEFPROZIL 0.85 Y E Y YAPX /TB
CEFTAZIDIME
1G/VIAL
0088697 CEFTAZIDIME FOR INJECTION 32 Y E N YPPC /VL
6GM VIAL
0221223 FORTAZ 6GM VIAL 122.89 Y E N YGSK /VL
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
20
PHRM/CHRN/CDO/F08:12.06 CEPHALOSPORINS (continued)
08:00 ANTI-INFECTIVE AGENTS (continued)
CEFTRIAXONE
CEFTRIAXONE
1GM
0229287 APO-CEFTRIAXONE FOR INJ 12.49 Y E N YAPX /VL
0229227 SANDOZ CEFTRIAXONE FOR INJ (1G 12.495 Y E N YSDZ /VL
2GM
0229228 SANDOZ CEFTRIAXONE FOR INJ (2G 24.14 Y E N YSDZ /VL
0229288 APO-CEFTRIAXONE FOR INJ 24.14 Y E N YAPX /VL
0232562 CEFTRIAXONE SODIUM FOR INJECTI 24.14 Y E Y YSTE /VL
CEFUROXIME AXETIL
25MG/ML
0221230 CEFTIN SUSP 0.17 Y E Y YGSK /ML
250MG
0234482 AURO-CEFUROXIME 0.72 Y E Y YAUR /TB
0224439 APO-CEFUROXIME 0.72 Y E Y YAPX /TB
0224265 RATIO-CEFUROXIME 0.72 Y E Y YRTP /TB
0221227 CEFTIN 1.68 Y E Y YGSK /TB
500MG
0234483 AURO-CEFUROXIME 1.43 Y E Y YAUR /TB
0224439 APO-CEFUROXIME 1.43 Y E Y YAPX /TB
0224265 RATIO-CEFUROXIME 1.43 Y E Y YRTP /TB
0221228 CEFTIN 3.32 Y E Y YGSK /TB
CEPHALEXIN
25MG/ML
0034210 NOVO-LEXIN SUSP 0.18 Y E Y YNOP /ML
250MG
0034208 NOVO-LEXIN 0.37 Y E Y YNOP /CP
0076872 APO-CEPHALEX 0.23 Y E Y YAPX /TB
0058341 NOVO-LEXIN 0.23 Y E Y YNOP /TB
50MG/ML
0034209 NOVO-LEXIN SUSP 0.35 Y E Y YNOP /ML
500MG
0034211 NOVO-LEXIN 0.69 Y E Y YNOP /CP
0086588 NU-CEPHALEX 0.299 Y N N YNXP /TB
0058342 NOVO-LEXIN 0.45 Y E Y YNOP /TB
0076871 APO-CEPHALEX 0.45 Y E Y YAPX /TB
08:12.12 MACROLIDES ---------------------------------------------------------------------
AZITHROMYCIN
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
21
PHRM/CHRN/CDO/F08:12.12 MACROLIDES (continued)
08:00 ANTI-INFECTIVE AGENTS (continued)
AZITHROMYCIN (continued)
20MG/ML
0233238 SDZ-AZITHRO 20M/ML (15ML) 0.37 Y E Y YSDZ /ML
0231515 NOVO-AZITHROMYCIN 0.37 Y E Y YNOP /ML
0227438 PMS-AZITHROMYCIN 0.37 Y E Y YPMS /ML
0222371 ZITHROMAX SUSP 1.09 Y E Y YPFI /ML
250MG
0226784 NOVO-AZITHROMYCIN 1.23 Y E Y YNOP /TB
0226582 SANDOZ AZITHROMYCIN 1.23 Y E Y YSDZ /TB
0226163 PMS-AZITHROMYCIN 1.23 Y E Y YPMS /TB
0233088 SANIS-AZITHROMYCIN 1.23 Y E Y YSAN /TB
0225534 CO AZITHROMYCIN 1.23 Y E Y YCOB /TB
0224742 APO-AZITHROMYCIN 1.23 Y E Y YAPX /TB
0221202 ZITHROMAX 5.03 Y E Y YPFI /TB
0227835 MYLAN-AZITHROMYCIN 1.23 Y E Y YMYL /TB
0227528 RATIO AZITHROMYCIN 1.23 Y E Y YRPH /TB
40MG/ML
0222372 ZITHROMAX SUSP 1.5087 Y E Y YPFI /ML
0231516 NOVO-AZITHROMYCIN 1.058 Y E Y YNOP /ML
0233239 SDZ-AZITHRO 40M/ML (15ML) 1.058 Y E Y YSDZ /ML
0227439 PMS-AZITHROMYCIN 1.058 Y E Y YPMS /ML
0227457 GD-AZITHROMYCIN 0.53 Y E Y YGDI /ML
600MG
0225608 CO AZITHROMYCIN 6 Y E Y YCOB /TB
0223114 ZITHROMAX 12.07 Y E Y YPFI /TB
0233091 SANIS-AZITHROMYCIN 6 Y E Y YSAN /TB
0226164 PMS-AZITHROMYCIN 6 Y E Y YPMS /TB
CLARITHROMYCIN
25MG/ML
0240898 CLARITHROMYCIN 0.2 Y E Y YSAI /ML
0239044 ACCEL-CLARITHROMYCIN 0.2 Y E Y YACC /ML
0214690 BIAXIN SUSP 0.3 Y E Y YABB /ML
250MG
0224781 RATIO-CLARITHROMYCIN 0.41 Y E Y YRTP /TB
0224757 PMS-CLARITHROMYCIN 0.41 Y E Y YPMS /TB
0226653 SDZ-CLARITHROMYCIN 0.41 Y E Y YSDZ /TB
0236142 RAN-CLARITHROMYCIN 0.41 Y E Y YRAN /TB
0198485 BIAXIN 1.683 Y E Y YABB /TB
0227474 APO-CLARITHROMYCIN 0.41 Y E Y YAPX /TB
0224885 MYLAN-CLARITHROMYCIN 0.41 Y E Y YMYL /TB
0224880 TEVA-CLARITHROMYCIN 0.42 Y E Y YTVM /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
22
PHRM/CHRN/CDO/F08:12.12 MACROLIDES (continued)
08:00 ANTI-INFECTIVE AGENTS (continued)
CLARITHROMYCIN (continued)
250/5ML
0239045 ACCEL-CLARITHROMYCIN 0.4 Y E Y YACC /ML
250MG/5ML
0240899 CLARITHROMYCIN 0.4 Y E Y YSAI /ML
0224464 BIAXIN SUSP 0.58 Y E Y YABB /ML
500MG
0226654 SDZ-CLARITHROMYCIN 1.63 Y E Y YSDZ /TB
0224885 MYLAN-CLARITHROMYCIN 1.63 Y E Y YMYL /TB
0224880 TEVA-CLARITHROMYCIN 1.63 Y E Y YTVM /TB
0224781 RATIO-CLARITHROMYCIN 1.63 Y E Y YRTP /TB
0224757 PMS-CLARITHROMYCIN 1.63 Y E Y YPMS /TB
0227475 APO-CLARITHROMYCIN 1.63 Y E Y YAPX /TB
0236143 RAN-CLARITHROMYCIN 1.63 Y E Y YRAN /TB
0212671 BIAXIN 3.33 Y E Y YABB /TB
500MG XL
0241334 APO-CLARITHROMYCIN XL 1.26 Y E Y YAPX /TB
0224475 BIAXIN XL 2.5144 Y E Y YABB /TB
ERYTHROMYCIN BASE
250MG
0072667 APO-ERYTHRO CAP (E-C PELLETS) 0.39 Y E Y YAPX /CP
0060714 ERYC CAPSULE ( E-C PELLETS) 0.22 Y E Y YPFI /CP
0068202 APO-ERYTHRO-BASE 0.18 Y E Y YAPX /TB
333MG
0087345 ERYC CAPSULE ( E-C PELLETS) 0.478 Y E Y YPFI /CP
0192593 APO ERYTHRO CAP(E-C PELLETS) 0.43 Y E Y YAPX /CP
ERYTHROMYCIN
25MG/ML
0002117 NOVO-RYTHRO ESTOLATE SUSP 0.0368 Y E Y YNOP /ML
50MG/ML
0026259 NOVO-RYTHRO ESTOLATE SUSP 0.13 Y E Y YNOP /ML
ERYTHROMYCIN
40MG/ML
0060585 NOVO-RYTHRO ETHYLSUCC.SUSP 0.097 Y E Y YNOP /ML
0000029 EES 200 SUSP 0.0796 Y E Y YABB /ML
80MG/ML
0045361 EES 400 SUSP 0.1207 Y E Y YABB /ML
0065231 NOVO-RYTHRO ETHYLSUCC.SUSP 0.14 Y E Y YNOP /ML
ERYTHROMYCIN
250MG
0054567 APO-ERYTHRO-S EC CAPSULE 0.21 Y E Y YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
23
PHRM/CHRN/CDO/F08:12.16 PENICILLINS
08:00 ANTI-INFECTIVE AGENTS (continued)
AMOXICILLIN (AMOXYCILLIN)
08:12.16 PENICILLINS --------------------------------------------------------------------
125MG
0203634 TEVA-AMOX CHEW TAB 0.458 Y E Y YTVM /TB
25MG/ML
0223024 PMS-AMOXICILLIN 0.0353 Y E Y YPMS /ML
0235276 SANIS-AMOX LOW SUGAR SUSP 0.0353 Y E Y YSAN /ML
0235274 SANIS-AMOXICILLIN SUSP 0.0353 Y E Y YSAN /ML
0045214 TEVA-AMOX SUSP 0.0353 Y E Y YTVM /ML
0193417 TEVA-AMOX LOW SUGAR SUSP 0.0353 Y E Y YTVM /ML
0062813 APO-AMOXI SUSP 0.0353 Y E Y YAPX /ML
250MG
0235271 SANIS-AMOXICILLIN 250 0.18 Y E Y YSAN /CP
0223024 PMS-AMOXICILLIN 0.18 Y E N YPMS /CP
0062811 APO-AMOXI 0.18 Y E Y YAPX /CP
0040672 TEVA-AMOX 250 0.18 Y E Y YTVM /CP
0223817 GEN-AMOXICILLIN 0.18 Y E Y YGPM /CP
0203635 TEVA-AMOX CHEW TAB 0.68 Y E Y YTVM /TB
50MG/ML
0193416 TEVA-AMOX LOW SUGAR SUSP 0.054 Y E Y YTVM /ML
0223024 PMS-AMOXICILLIN 0.054 Y E Y YPMS /ML
0235278 SANIS-AMOX LOW SUGAR SUSP 0.054 Y E Y YSAN /ML
0235275 SANIS-AMOXICILLIN SUSP 0.054 Y E Y YSAN /ML
0062815 APO-AMOXI SUSP 0.054 Y E Y YAPX /ML
0045213 TEVA-AMOX SUSP 0.054 Y E Y YTVM /ML
500MG
0223817 GEN-AMOXICILLIN 0.342 Y E Y YGPM /CP
0235272 SANIS-AMOXICILLIN 500 0.342 Y E Y YSAN /CP
0062812 APO-AMOXI 0.342 Y E Y YAPX /CP
0040671 TEVA-AMOX 500 0.342 Y E Y YTVM /CP
0223024 PMS-AMOXICILLIN 0.342 Y E Y YPMS /CP
AMOXICILLIN/CLAVULAN
125MG/31.2
0224398 APO-AMOXI CLAV SUSP 0.052 Y E Y YAPX /ML
0224464 RATIO-ACLAVULANATE 125F SUSP 0.052 Y E Y YRAT /ML
0191688 CLAVULIN-125F SUSP (125/5ML) 0.117 Y E Y YGSK /ML
200MG/26.5
0223883 CLAVULIN-200 SUSP (200MG/5ML) 0.144 Y E Y YGSK /ML
250MG/125
0224335 APO-AMOXI CLAV 250/125 TAB 0.9375 Y E Y YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
24
PHRM/CHRN/CDO/F08:12.16 PENICILLINS (continued)
08:00 ANTI-INFECTIVE AGENTS (continued)
AMOXICILLIN/CLAVULANIC ACID (continued)
250MG/62.5
0224464 RATIO-ACLAVULANATE 250F SUSP 0.183 Y E Y YRAT /ML
0191687 CLAVULIN-250F SUSP (250/5ML) 0.2011 Y E Y YGSK /ML
0224398 APO-AMOXI CLAV SUSP 0.183 Y E Y YAPX /ML
400MG/57
0223883 CLAVULIN-400 SUSP (400MG/5ML) 0.2753 Y E Y YGSK /ML
500MG/125
0224335 APO-AMOXI CLAV 500/125 TAB 7.4 Y E Y YAPX /TB
0224377 RATIO-AMOXI CLAV TAB 0.668 Y E Y YRTP /TB
0191685 CLAVULIN-500 TAB 7.4 Y E Y YGSK /TB
875MG/125
0223882 CLAVULIN-875 TAB 2.2203 Y E Y YGSK /TB
0224702 RATIO-AMOXI CLAV TAB 0.56 Y E Y YRTP /TB
0224813 NOVO-CLAVAMOXIN 0.555 Y E Y YNOP /TB
0224562 APO-AMOXI CLAV TAB 0.56 Y E Y YAPO /TB
AMPICILLIN
250MG
0002087 NOVO-AMPICILLIN 0.38 Y E Y YNOP /CP
0060327 APO-AMPI 0.0819 Y E Y YAPX /CP
500MG
0002088 NOVO-AMPICILLIN 0.73 Y E Y YNOP /CP
0060329 APO-AMPI 0.73 Y E Y YAPX /CP
CLOXACILLIN
25MG/ML
0064463 APO-CLOXI ORAL LIQUID 0.045 Y E Y YAPX /ML
0033775 NOVO-CLOXIN ORAL LIQUID 0.091 Y E Y YNOP /ML
250MG
0033776 NOVO-CLOXIN 0.37 Y E Y YNOP /CP
0061829 APO-CLOXI 0.185 Y E Y YAPX /CP
500MG
0061828 APO-CLOXI 0.3498 Y E Y YAPX /CP
0033777 NOVO-CLOXIN 0.73 Y E Y YNOP /CP
0191242 CLOXACILLIN SODIUM VIAL 5.51 Y E N YNOP /VL
PENICILLIN V
25MG/ML
0064222 APO-PEN-VK ORAL SOLN 0.054 Y E Y YAPX /ML
300MG
0064221 APO-PEN-VK 0.19 Y E Y YAPX /TB
0002120 NOVO-PEN-VK 0.071 Y E Y YNOP /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
25
PHRM/CHRN/CDO/F08:12.16 PENICILLINS (continued)
08:00 ANTI-INFECTIVE AGENTS (continued)
PENICILLIN V (POTASSIUM) (continued)
300MG/5ML
0064223 APO-PEN VK PWS SUSP 0.062 Y E Y YAPX /ML
0039160 NOVO-PEN-VK SUSP 0.047 Y E Y YNOP /ML
PIPERACILLIN/TAZOBAC
3GM/375MG
0217079 TAZOCIN INJ 17.88 Y E N YWYA /VL
08:12.24 TETRACYCLINES ------------------------------------------------------------------
DOXYCYCLINE
100MG
0074071 APO-DOXY 0.59 Y E Y YAPX /CP
0072525 TEVA-DOXYLIN 0.59 Y E Y YTVM /CP
0235123 SANIS-DOXYCYCLINE 0.586 Y E Y YSAN /CP
0081712 DOXYCIN 0.586 Y E Y YRIV /CP
0002436 VIBRAMYCIN 1.75 Y E Y YPFI /CP
0087425 APO-DOXY 0.59 Y E Y YAPX /TB
0235124 SANIS-DOXYCYCLINE TB 0.59 Y E Y YSAN /TB
0086075 DOXYCIN 0.586 Y E Y YRIV /TB
0215857 TEVA-DOXYLIN TB 0.59 Y E Y YTVM /TB
MINOCYCLINE HCL
100MG
0223923 PMS-MINOCYCLINE 1.0332 Y E Y YPMS /CP
0229442 PMS-MINOCYCLINE HCL 0.59 Y E Y Ynull /CP
0223731 SANDOZ-MINOCYCLINE 0.59 Y E Y YSDZ /CP
0208410 APO-MINOCYCLINE 0.59 Y E Y YAPX /CP
0210815 TEVA-MINOCYCLINE 0.59 Y E Y YTVM /CP
0228723 SANIS-MINOCYCLINE 0.59 Y E Y YSAN /CP
0223073 GEN-MINOCYCLINE 0.59 Y E Y YGPM /CP
0191414 RATIO-MINOCYCLINE 1.0332 Y E Y YRTP /CP
50MG
0229441 PMS-MINOCYCLINE 0.31 Y E Y YPMS /CP
0191413 RATIO-MINOCYCLINE 0.535 Y E Y YRTP /CP
0208409 APO-MINOCYCLINE 0.31 Y E Y YAPX /CP
0223731 SANDOZ-MINOCYCLINE 0.31 Y E Y YSAN /CP
0223073 GEN-MINOCYCLINE 0.31 Y E Y YGPM /CP
0228722 SANIS-MINOCYCLINE 0.31 Y E Y YSAN /CP
0210814 TEVA-MINOCYCLINE 0.31 Y E Y YTVM /CP
0223923 PMS-MINOCYCLINE 0.535 Y E Y YPMS /CP
TETRACYCLINE
250MG
0058092 APO-TETRA 0.07 Y E Y YAPX /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
26
PHRM/CHRN/CDO/F08:12.28 ANTIBIOTICS (MISCELLANEOUS ANTIBIOTICS)
08:00 ANTI-INFECTIVE AGENTS (continued)
CLINDAMYCIN HCL
08:12.28 ANTIBIOTICS (MISCELLANEOUS ANTIBIOTICS) ----------------------------------------
150MG
0224523 APO-CLINDAMYCIN 0.22 Y E Y YAPX /CP
0225833 GEN-CLINDAMYCIN 0.22 Y E Y YGEN /CP
0224170 NOVO-CLINDAMYCIN 0.22 Y E Y YPHU /CP
0003057 DALACIN C 0.95 Y E Y YPHU /CP
300MG
0224523 APO-CLINDAMYCIN 0.44 Y E Y YAPX /CP
0225835 GEN-CLINDAMYCIN 0.44 Y E Y YGEN /CP
0218286 DALACIN C 1.9 Y E Y YPHU /CP
0224171 NOVO-CLINDAMYCIN 0.44 Y E Y YNOP /CP
CLINDAMYCIN
15MG/ML
0022585 DALACIN C SOLN 0.13 Y E Y YPHU /ML
RIFABUTIN
150MG
0206378 MYCOBUTIN 5.2 Y E N YPHU /CP
RIFAMPIN
150MG
0039344 ROFACT 0.66 Y E N YICN /CP
300MG
0034361 ROFACT 1.03 Y E N YICN /CP
RIFAXIMIN
550MG
0241070 ZAXINE 7.68 E E N YLUP /TB
VANCOMYCIN HCL
125MG
0240774 JAMP-VANCOMYCIN 5.18 Y E N YJPC
/CP
0080043 VANCOCIN 5.18 Y E N YLIL /CP
0237747 VANCOMYCIN HYDROCHLORIDE 5.18 Y E N YPPC /CP
250MG
0078871 VANCOCIN 10.36 Y E N YLIL /CP
500MG
0223019 VANCOMYCIN HCL INJ (VIAL) 42.77 Y E N YHOS /VL
0239462 VANCOMYCIN HCL FOR INJECTION 31.05 Y E N YSDZ /VL
0234285 VAL-VANCOMYCIN 31.05 Y E N YVAE /VL
08:18.00 ANTIVIRALS ---------------------------------------------------------------------
ACYCLOVIR
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
27
PHRM/CHRN/CDO/F08:18.00 ANTIVIRALS (continued)
08:00 ANTI-INFECTIVE AGENTS (continued)
ACYCLOVIR (continued)
200MG
0220762 APO-ACYCLOVIR 0.64 Y E Y YAPX /TB
0224278 GEN-ACYCLOVIR 0.64 Y E Y YGPM /TB
0063450 ZOVIRAX 1.326 Y E Y YGSK /TB
0207862 RATIO-AVIRAX 0.64 Y E Y YRTP /TB
200MG/5ML
0088615 ZOVIRAX SUSP 0.26 Y E Y YGSK /ML
400MG
0207863 RATIO-AVIRAX 1.27 Y E Y YRTP /TB
0224246 GEN-ACYCLOVIR 1.27 Y E Y YGPM /TB
0191162 ZOVIRAX WELLSTAT PAC 2.67 Y E Y YGSK /TB
0220764 APO-ACYCLOVIR 1.27 Y E Y YAPX /TB
800MG
0224246 GEN-ACYCLOVIR 1.27 Y E Y YGPM /TB
0220765 APO-ACYCLOVIR 1.27 Y E Y YAPX /TB
0228597 TEVA-ACYCLOVIR 1.27 Y E Y YTEV /TB
0207865 RATIO-AVIRAX 1.27 Y E Y YRTP /TB
AMANTADINE
10MG/ML
0202282 PMS-AMANTADINE SYRUP 0.11 Y E Y YPMS /ML
100MG
0199040 PMS-AMANTADINE 0.53 Y E Y YPMS /CP
0213920 GEN-AMANTADINE 0.518 Y E Y YGPM /CP
FAMCICLOVIR
125MG
0222911 FAMVIR 2.96 Y E Y YGSK /TB
0229202 APO-FAMCICLOVIR 2.02 Y E Y YAPX /TB
0227863 SANDOZ-FAMCICLOVIR 2.02 Y E Y YSDZ /TB
0227808 PMS-FAMCICLOVIR 2.02 Y E Y YPMS /TB
250MG
0229204 APO-FAMCICLOVIR 2.72 Y E Y YAPX /TB
0227864 SANDOZ-FAMCICLOVIR 2.72 Y E Y YSDZ /TB
0227810 PMS-FAMCICLOVIR 2.72 Y E Y YPMS /TB
0222912 FAMVIR 4.02 Y E Y YGSK /TB
5OOMG
0230570 ACT FAMCICLOVIR 4.23 Y E Y YACT /TB
500MG
0227811 PMS-FAMCICLOVIR 4.23 Y E Y YPMS /TB
0227865 SANDOZ-FAMCICLOVIR 4.23 Y E Y YSDZ /TB
0229206 APO-FAMCICLOVIR 4.23 Y E Y YAPX /TB
0217710 FAMVIR 7.18 Y E Y YGSK /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
28
PHRM/CHRN/CDO/F08:18.00 ANTIVIRALS (continued)
08:00 ANTI-INFECTIVE AGENTS (continued)
GANCICLOVIR SO4
GANCICLOVIR SO4
500MG
0216269 CYTOVENE INJ 4.1214 Y E N YHLR /ML
RIBAVIRIN/PEGINTERFER
200MG180UG
0225342 PEGASYS RBV (CAPS+0.5MLVIAL) 395.84 E E N YHLR /KT
0225341 PEGASYS RBV (CAPS+1MLVIAL) 395.84 E E N YHLR /KT
RIBAVIRIN/PEGINTERFER
200MG100UG
0225460 PEGETRON REDIPEN(70CP+2VL) 774.77 E E N YSCH /KT
200MG120UG
0225463 PEGETRON REDIPEN(70CP+2VL) 856.12 E E N YSCH /KT
200MG150UG
0225464 PEGETRON REDIPEN(84CP+2VL) 856.12 E E N YSCH /KT
0224603 PEGETRON ( 84CP / 2VL / KIT) 856.12 E E N YSCH /KT
200MG50UG
0224602 PEGETRON ( 56CP / 2VL / KIT) 774.77 E E N YSCH /KT
200MG80UG
0225458 PEGETRON REDIPEN(56CP+2VL) 774.77 E E N YSCH /KT
VALACYCLOVIR
1000MG
0235156 MYLAN-VALACYCLOVIR 3.392 Y E Y YMYL /TB
0224655 VALTREX 6.89 Y E Y YGSK /TB
0238123 PMS-VALACYCLOVIR 1.72 Y N N YPMS /TB
0235470 APO-VALACYCLOVIR 1.72 Y E Y YAPX /TB
500MG
0235753 TEVA-VALACYCLOVIR 0.85 Y E Y YTEV /TB
0229845 PMS-VALACYCLOVIR 0.86 Y E Y YPMS /TB
0229582 APO-VALACYCLOVIR 0.86 Y E Y YAPX /TB
0240504 AURO-VALACYCLOVIR 0.85 Y E Y YAUR /TB
0221949 VALTREX 3.44 Y E Y YGSK /TB
0233174 CO-VALACYCLOVIR 0.85 Y E Y YCOB /TB
0235157 MYLAN-VALACYCLOVIR 0.85 Y E Y YMYL /TB
VALGANCICLOVIR
450MG
0239382 APO-VALGANCICLOVIR 17.41 E E N YAPX /TB
0224577 VALCYTE 23.21 E E N YHLR /TB
08:18.08 ANTIRETROVIRAL AGENTS ----------------------------------------------------------
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
29
PHRM/CHRN/CDO/F08:18.08 ANTIRETROVIRAL AGENTS
08:00 ANTI-INFECTIVE AGENTS (continued)
ABACAVIR
ABACAVIR
300MG
0224035 ZIAGEN TAB 6.87 Y Y N YGSK /TB
0239676 APO-ABACAVIR 5.92 Y Y N YAPX /TB
ABACAVIR (ABACAVIR
20MG/ML
0224035 ZIAGEN 0.457 Y Y N YGSK /ML
ABACAVIR/DOLUTEGRAV
600/50/300MG
0243093 TRIUMEQ 41.38 E E N YVII /TB
ABACAVIR/LAMIVUDINE
600/300MG
0239953 APO-ABACAVIR-LAMIVUDINE 20.36 Y Y N YAPX /TB
ABACAVIR/LAMIVUDINE/
300/150/300MG
0241625 APO-ABACAVIR-LAMIVUDINE- 15.46 Y Y N YAPX /TB
0224475 TRIZIVIR 17.94 Y Y N YGSK /TB
ADEFOVIR DIPIVOXIL
10MG
0242033 APO-ADEFOVIR 24.34 E E N YAPX /TB
0224782 HEPSERA 24.34 E E N YGIL /TB
ATAZANAVIR
150MG
0224861 REYATAZ 11.06 Y Y N YBMY /CP
200 MG
0224861 REYATAZ 11.06 Y Y N YBMY /CP
300MG
0229417 REYATAZ 22.12 Y Y N YBMY /CP
COBICISTAT/DARUNAVIR
150/800MG
0242650 PREZCOBIX 23.87 E E N YJAN /TB
COBICISTAT/EMTRICITA
150MG/200MG/150MG/
0239713 STRIBILD 45.52 E E N YGSI /TB
DARUNAVIR
800MG
0239305 PREZISTA 21.72 E E N YJAN /TB
DIDANOSINE
125MG
0224459 VIDEX EC 3.86 Y Y N YBRI /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
30
PHRM/CHRN/CDO/F08:18.08 ANTIRETROVIRAL AGENTS (continued)
08:00 ANTI-INFECTIVE AGENTS (continued)
DIDANOSINE (continued)
200MG
0224459 VIDEX EC 6.17 Y Y N YBRI /CP
250MG
0224459 VIDEX EC 7.64 Y Y N YBRI /CP
400MG
0224459 VIDEX EC 12.36 Y Y N YBRI /CP
DOLUTEGRAVIR
50MG
0241494 TIVICAY 18.67 E E N YVII /TB
EFAVIRENZ
200MG
0223988 SUSTIVA 4.98 Y Y N YMSD /CP
50MG
0223988 SUSTIVA 1.25 Y Y N YMSD /CP
600MG
0241842 AURO-EFAVIRENZ 11.21 Y Y N YAUR /TB
0224604 SUSTIVA 14.95 Y Y N YBMY /TB
0238976 TEVA-EFAVIRENZ 11.21 Y Y N YTEV /TB
0238152 MYLAN-EFAVIRENZ 11.21 Y Y N YMYL /TB
EFAVIRENZ/TENOFOVIR/
600MG/300/200
0230069 ATRIPLA 43.25 E E N YBMY /TB
EMTRICITABINE/RILPIVIRI
200/25/300MG
0237412 COMPLERA 42.53 E E N YGSI /TB
ENTECAVIR
0.5MG
0244877 AURO-ENTECAVIR 5.5 E E N YAUR /TB
0239695 APO-ENTECAVIR 11 E E N YAPX /TB
0228222 BARACLUDE 22 E E N YBMY /TB
INDINAVIR SULPHATE
200MG
0222916 CRIXIVAN 1.35 Y Y N YMSD /CP
KIVEXA
600/300MG
0226934 ABACAVIR/LAMIVUDINE 23.62 Y Y N YVII /TB
LAMIVUDINE
10MG/ML
0219269 3TC ORAL SOLN 0.31 Y Y N YGSK /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
31
PHRM/CHRN/CDO/F08:18.08 ANTIRETROVIRAL AGENTS (continued)
08:00 ANTI-INFECTIVE AGENTS (continued)
LAMIVUDINE (continued)
100MG
0239323 APO-LAMIVUDINE HBV 3.53 Y Y N YAPX /TB
0223919 HEPTOVIR 4.71 Y Y N YGSK /TB
150 MG
0236905 APO-LAMIVUDINE 3.63 Y Y N YAPX /TB
150MG
0219268 3TC 4.84 Y Y N YGSK /TB
300 MG
0236906 APO-LAMIVUDINE 7.25 Y Y N YAPX /TB
300MG
0224782 3TC 9.67 Y Y N YGSK /TB
LAMIVUDINE/ZIDOVUDI
150MG/300MG
0223921 COMBIVIR TAB 10.44 Y Y N YGSK /TB
0237554 APO-LAMIVUDINE/ZIDOVUDINE 7.83 Y Y N YAPX /TB
0238724 TEVA-LAMIVUDINE/ZIDOVUDINE 7.83 Y Y N YTVM /TB
LOPINAVIR/RITONAVIR
200MG/50MG
0228553 KALETRA 5.69 Y Y N YABB /TB
NELFINAVIR MESYLATE
250MG
0223861 VIRACEPT 1.85 Y Y N YAGR /TB
50MG/GM
0223861 VIRACEPT ORAL POWDER 0.37 Y Y N YAGR /GM
NEVIRAPINE
200MG
0231860 AURO-NEVIRAPINE 2.47 Y Y N YAUR /TB
0223874 VIRAMUNE 4.94 Y Y N YBOE /TB
0235289 TEVA-NEVIRAPINE 2.47 Y Y N YTVM /TB
0240577 PMS-NEVIRAPINE 2.47 Y Y N YPMS /TB
RALTEGRAVIR
400MG
0230188 ISENTRESS 13.5 E E N YMSD /TB
RILPIVIRINE HCL
25MG
0237060 EDURANT 14.7 E E N YJAN /TB
RITONAVIR
100MG
0224148 NORVIR SEC 1.4671 Y Y N YABB /CP
0235759 NORVIR 1.4671 Y Y N YABB /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
32
PHRM/CHRN/CDO/F08:18.08 ANTIRETROVIRAL AGENTS (continued)
08:00 ANTI-INFECTIVE AGENTS (continued)
RITONAVIR (continued)
80MG/ML
0222914 NORVIR ORAL SOLN 1.2 Y Y N YABB /ML
SAQUINAVIR
200MG
0221696 INVIRASE 1.87 Y Y N YHLR /CP
STAVUDINE
15MG
0221608 ZERIT 4.7 Y Y N YBRI /CP
20MG
0221609 ZERIT 4.89 Y Y N YBRI /CP
30MG
0221610 ZERIT 5.1 Y Y N YBRI /CP
40MG
0221611 ZERIT 5.29 Y Y N YBRI /CP
TENOFOVIR
300MG
0224712 VIREAD 18.77 E E N YGIL /TB
TENOFOVIR/EMTRICITAB
200MG/300MG
0227490 TRUVADA 28.04 E E N YGIL /TB
ZIDOVUDINE
10MG/ML
0190265 RETROVIR SOLN 0.197 Y Y N YGSK /ML
0190264 RETROVIR INJ 16.59 Y Y N YGSK /VL
100MG
0190266 RETROVIR 1.86 Y Y N YGSK /CP
0194632 APO-ZIDOVUDINE 1.4 Y Y N YAPX /CP
08:18.32 NUCLEOSIDES AND NUCLEOTIDES ----------------------------------------------------
RIBAVIRIN
200MG
0243921 IBAVYR 7.25 E E N YPED /TB
400MG
0242589 IBAVYR 14.5 E E N YPED /TB
600MG
0242590 IBAVYR 21.75 E E N YPED /TB
08:18.40 HCV Protease Inhibitors --------------------------------------------------------
LEDIPASVIR/SOFOSBUVIR
90MG/400MG
0243222 HARVONI 797.619 E E N YGIL /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
33
PHRM/CHRN/CDO/F08:18.40 HCV Protease Inhibitors
08:00 ANTI-INFECTIVE AGENTS (continued)
OMBITASVIR/PARITAPREVIR/RITONA
OMBITASVIR/PARITAPRE
250/12.5/75/50MG
0243602 HOLKIRA PAK 688.52 E E N YABV /DY
SIMEPREVIR
150MG
0241644 GALEXOS 434.55 E E N YJAN /CP
08:18.92 MISCELLANEOUS ANTIVIRALS -------------------------------------------------------
BOCEPREVIR
200MG
0237081 VICTRELIS 2100 E E N YMRK /EA
BOCEPREVIR/RIBAVIRIN/
200MG/80MCG/0.5ML
0237144 VICTRELIS TRIPLE 2652.55 E E N YMRK /KT
SOFOSBUVIR
400MG
0241835 SOVALDI 654.76 E E N YGSI /TB
TELAPREVIR
375MG
0237155 INCIVEK 69.381 E E N YVER /KT
08:20.00 ANTIMALARIAL AGENTS ------------------------------------------------------------
HYDROXYCHLOROQUINE
200MG
0224669 APO-HYDROXYQUINE 0.26 Y Y N YAPX /TB
0225260 MYLAN-HYDROXYCHLOROQUINE 0.26 Y Y N YGPM /TB
0201770 PLAQUENIL 0.63 Y Y N YSAW /TB
0242499 MINT-HYDROXYCHLOROQUINE 0.26 Y Y N YMNT /TB
08:22.00 QUINOLONES ---------------------------------------------------------------------
CIPROFLOXACIN
100MG/ML
0223751 CIPRO SUSP 0.58 Y E N YBAY /ML
1000MG XL
0225178 CIPRO XL 3.11 Y E N YBAY /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
34
PHRM/CHRN/CDO/F08:22.00 QUINOLONES (continued)
08:00 ANTI-INFECTIVE AGENTS (continued)
CIPROFLOXACIN (continued)
250MG
0222952 APO-CIPROFLOX 0.62 Y E N YAPX /TB
0230372 RAN-CIPROFLOX 0.62 Y E N YRAN /TB
0216173 TEVA-CIPROFLOXACIN 0.62 Y E N YTVM /TB
0224564 MYLAN-CIPROFLOXACIN 0.62 Y E N YMYL /TB
0235331 SANIS-CIPROFLOXACIN 0.62 Y E N YSAN /TB
0231742 MINT-CIPROFLOXACIN 0.62 Y E N YMNT /TB
0224682 RATIO-CIPROFLOXACIN 0.62 Y E N YRTP /TB
0224875 SANDOZ-CIPROFLOXACIN 0.62 Y E N YSDZ /TB
0224843 PMS-CIPROFLOXACIN 0.62 Y E N YPMS /TB
0215595 CIPRO 2.5 Y E N YBAY /TB
0224733 CO CIPROFLOXACIN 0.62 Y E N YCOB /TB
500MG
0224734 CO CIPROFLOXACIN 0.7 Y E Y YCOB /TB
0224564 MYLAN-CIPROFLOXACIN 0.7 Y E N YMYL /TB
0230373 RAN-CIPROFLOX 0.7 Y E N YRAN /TB
0235332 SANIS-CIPROFLOXACIN 0.7 Y E Y YSAN /TB
0231743 MINT-CIPROFLOXACIN 0.7 Y E N YMNT /TB
0242356 MINT-CIPROFLOX 0.7 Y E N YMNT /TB
0215596 CIPRO 2.82 Y E N YBAY /TB
0224682 RATIO-CIPROFLOXACIN 0.7 Y E N YRTP /TB
0222952 APO-CIPROFLOX 0.7 Y E N YAPX /TB
0216174 TEVA-CIPROFLOXACIN 0.7 Y E N YTVM /TB
0224875 SANDOZ-CIPROFLOXACIN 0.7 Y E N YSDZ /TB
0224843 PMS-CIPROFLOXACIN 0.7 Y E N YPMS /TB
500 MG XL
0224791 CIPRO XL 3.11 Y E N YBAY /TB
0241643 PMS-CIPROFLOXACIN XL 1.88 Y E N YPMS /TB
750MG
0224875 SANDOZ-CIPROFLOXACIN 1.28 Y E N YSDZ /TB
0224564 MYLAN-CIPROFLOXACIN 1.28 Y E N YMYL /TB
0230374 RAN-CIPROFLOX 1.28 Y E N YRAN /TB
0224734 CO CIPROFLOXACIN 1.28 Y E N YCOB /TB
0224843 PMS-CIPROFLOXACIN 1.28 Y E N YPMS /TB
0215597 CIPRO 5.1118 Y E N YBAY /TB
0224682 RATIO-CIPROFLOXACIN 1.28 Y E N YRPH /TB
0216175 TEVA-CIPROFLOXACIN 1.28 Y E N YTVM /TB
0222952 APO-CIPROFLOX 1.28 Y E N YAPO /TB
0235333 SANIS-CIPROFLOXACIN 1.28 Y E N YSAN /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
35
PHRM/CHRN/CDO/F08:22.00 QUINOLONES (continued)
08:00 ANTI-INFECTIVE AGENTS (continued)
LEVOFLOXACIN
LEVOFLOXACIN
250MG
0231542 CO LEVOFLOXACIN 1.2 Y E N YCOB /TB
0228467 PMS-LEVOFLOXACIN 1.2 Y E N YPMS /TB
0228470 APO-LEVOFLOXACIN 1.2 Y E N YAPX /TB
0229863 SANDOZ LEVOFLOXACIN 1.2 Y E N YSDZ /TB
0231397 MYLAN-LEVOFLOXACIN 1.2 Y E N YMYL /TB
0224826 NOVO-LEVOFLOXACIN 1.2 Y E N YNOP /TB
0223684 LEVAQUIN 6.01 Y E N YJAN /TB
500MG
0228468 PMS-LEVOFLOXACIN 1.37 Y E N YPMS /TB
0228471 APO-LEVOFLOXACIN 1.37 Y E N YAPX /TB
0231398 MYLAN-LEVOFLOXACIN 1.37 Y E N YMYL /TB
0229864 SANDOZ LEVOFLOXACIN 1.37 Y E N YSDZ /TB
0231543 CO LEVOFLOXACIN 1.37 Y E N YCOB /TB
0224826 NOVO-LEVOFLOXACIN 1.37 Y E N YNOP /TB
0223684 LEVAQUIN 6.85 Y E N YJAN /TB
750MG
0232594 APO-LEVOFLOXACIN 4.85 Y E N YAPX /TB
0231544 CO LEVOFLOXACIN 4.85 Y E N YCOB /TB
0224680 LEVAQUIN 11.8 Y E N YJAN /TB
0230558 PMS-LEVOFLOXACIN 4.85 Y E N YCOB /TB
0229865 SANDOZ LEVOFLOXACIN 4.85 Y E N YSDZ /TB
0228564 NOVO-LEVOFLOXACIN 4.85 Y E N YNOP /TB
LEVOFLOXACIN IV
5MG/ML
0223683 LEVAQUIN INJ (IV BAG) 0.305 E E N YJAN /ML
MOXIFLOXACIN
400MG
0224296 AVELOX 6.09 E E N YBAY /TB
0243224 AURO-MOXIFLOXACIN 1.52 E E N YAUR /TB
0240492 APO-MOXIFLOXACIN 1.52 E E N YSDZ /TB
0237570 TEVA-MOXIFLOXACIN 1.52 E E N YTVM /TB
NORFLOXACIN
400MG
0223768 NOVO-NORFLOXACIN 0.54 Y E Y YNOP /TB
0224659 PMS-NORFLOXACIN 0.545 Y E Y YPMS /TB
0222952 APO-NORFLOX 0.54 Y E Y YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
36
PHRM/CHRN/CDO/F08:26.00 SULFONES
08:00 ANTI-INFECTIVE AGENTS (continued)
DAPSONE
08:26.00 SULFONES -----------------------------------------------------------------------
100MG
0204151 DAPSONE 1.3391 Y E Y YJAP /TB
08:36.00 URINARY ANTI-INFECTIVES --------------------------------------------------------
METHENAMINE
500MG
0049901 MANDELAMINE ENTERIC TAB 0.37 Y N N YPFI /TB
NITROFURANTOIN
100MG
0223101 NOVO-FURANTOIN CAP 0.7 Y E Y YNOP /CP
0031273 APO-NITROFURANTOIN 0.22 Y E Y YAPX /TB
50MG
0223101 NOVO-FURANTOIN CAP 0.35 Y E Y YNOP /CP
0031951 APO-NITROFURANTOIN 0.17 Y E Y YAPX /TB
NITROFURANTOIN
100MG
0206366 MACROBID MACROCRYSTALS 0.71 Y E Y YPGA /CP
TRIMETHOPRIM
100MG
0224311 APO-TRIMETHOPRIM 0.2566 Y E Y YAPO /TB
200MG
0224311 APO-TRIMETHOPRIM 0.5273 Y E Y YAPO /TB
08:40.00 MISCELLANEOUS ANTI-INFECTIVES --------------------------------------------------
ATOVAQUONE
150MG/ML
0221742 MEPRON SUSP 2.66 Y E N YGSK /ML
METRONIDAZOLE
250MG
0054506 APO-METRONIDAZOLE 0.059 Y E Y YAPX /TB
500MG
0224856 APO-METRONIDAZOLE 0.7 Y E Y YAPX /CP
0192685 FLAGYL 1.07 Y E Y YAVT /CP
0078313 TRIKACIDE 0.7 Y E Y YPMS /CP
SULFA/TRIMETH(CO-
100/20MG
0044526 APO-SULFATRIM PEDIATRIC TAB 0.0911 Y E Y YAPX /TB
400/80MG
0051063 NOVO-TRIMEL TAB 0.05 Y E Y YNOP /TB
0044527 APO-SULFATRIM TAB 0.05 Y E Y YAPX /TB
40/8MG
0072654 NOVO-TRIMEL SUSP(40/8/ML) 0.1 Y E Y YNOP /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
37
PHRM/CHRN/CDO/F08:40.00 MISCELLANEOUS ANTI-INFECTIVES (continued)
08:00 ANTI-INFECTIVE AGENTS (continued)
SULFA/TRIMETH(CO-TRIMOXAZOLE) (continued)
800/160
0051064 NOVO-TRIMEL DS TAB 0.1221 Y E Y YNOP /TB
0044528 APO-SULFATRIM DS TAB 0.1221 Y E Y YAPX /TB
10:00 ANTINEOPLASTIC AGENTS
10:00.00 ANTINEOPLASTIC AGENTS ----------------------------------------------------------
ABIRATERONE ACETATE
250MG
0237106 ZYTIGA 29.18 E E N YJAN /TB
AFATINIB
20MG
0241566 GIOTRIF 73.3 E E N YBOE /TB
30MG
0241567 GIOTRIF 73.3 E E N YBOE /TB
40MG
0241568 GIOTRIF 73.3 E E N YBOE /TB
ANAGRELIDE HCL
0.5MG
0226010 SANDOZ-ANAGRELIDE 3.3491 Y Y N YSDZ /CP
0225305 GEN-ANAGRELIDE 5.78 Y Y N YGPM /CP
0227494 PMS-ANAGRELIDE 3.3491 Y Y N YPMS /CP
0223685 AGRYLIN 5.78 Y Y N YRBP /CP
ANASTROZOLE
1MG
0233846 SANDOZ-ANASTROZOLE 2.55 Y Y N YSDZ /TB
0237442 APO-ANASTROZOLE 2.55 Y Y N YAPX /TB
0232073 PMS-ANASTROZOLE 2.55 Y Y N YPMS /TB
0222413 ARIMIDEX 5.12 Y Y N YAST /TB
0236565 TARO-ANASTROZOLE 1.27 Y Y N YTAR /TB
BEVACIZUMAB
25MG/ML
0227099 AVASTIN 125 E E N YHLR /ML
BICALUTAMIDE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
38
PHRM/CHRN/CDO/F10:00.00 ANTINEOPLASTIC AGENTS (continued)
10:00 ANTINEOPLASTIC AGENTS (continued)
BICALUTAMIDE (continued)
50 MG
0227022 NOVO-BICALUTAMIDE 6.87 Y Y N YNOP /TB
0218447 CASODEX 6.87 Y Y N YAST /TB
0227608 SANDOZ-BICALUTAMIDE 4.0573 Y Y N YSDZ /TB
0230240 MYLAN-BICALUTAMIDE 4.0573 Y Y N YMYL /TB
0229606 APO-BICALUTAMIDE 4.06 Y Y N YAPX /TB
0227433 CO-BICALUTAMIDE 4.0573 Y Y N YCOB /TB
0227558 PMS-BICALUTAMIDE 4.0573 Y Y N YPMS /TB
0237132 RAN-BICALUTAMIDE 4.06 Y Y N YRAN /TB
0227770 RATIO-BICALUTAMIDE 4.0573 Y Y N YRPH /TB
50MG
0232598 TEVA-BICALUTAMIDE 4.057 Y Y N YWHL /TB
BOSUTINIB
100MG
0241914 BOSULIF 36.59 E E N YPFI /TB
500MG
0241915 BOSULIF 146.34 E E N YPFI /TB
CAPECITABINE
150 MG
0240002 TEVA-CAPECITABINE 1.46 E E N YTVM /TB
0242675 ACH-CAPECITABINE 1.46 E E N YACH /TB
0223845 XELODA 1.83 E E N YHLR /TB
500 MG
0240003 TEVA-CAPECITABINE 4.88 E E N YTVM /TB
0242676 ACH-CAPECITABINE 4.88 E E N YACH /TB
0223845 XELODA 6.1 E E N YHLR /TB
0242192 SANDOZ CAPECITABINE 4.88 E E N YSDZ /TB
CHLORAMBUCIL
2MG
0000462 LEUKERAN 1.43 Y Y N YGSK /TB
CRIZOTINIB
200MG
0238425 XALKORI 146.67 E E N YPFI /CP
250MG
0238426 XALKORI 146.67 E E N YPFI /CP
CYCLOPHOSPAMIDE
10MG/ML
0224179 PROCYTOX 0.3537 Y Y N YAST /ML
25MG
0224179 PROCYTOX 0.5 Y Y N YAST /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
39
PHRM/CHRN/CDO/F10:00.00 ANTINEOPLASTIC AGENTS (continued)
10:00 ANTINEOPLASTIC AGENTS (continued)
CYCLOPHOSPAMIDE (continued)
50MG
0224179 PROCYTOX 1.22 Y Y N YAST /TB
CYPROTERONE ACETATE
50MG
0224589 APO-CYPROTERONE 1.41 Y Y N YAPX /TB
0070443 ANDROCUR 1.4 Y Y N YBEX /TB
DABRAFENIB MESYLATE
50MG
0240960 TAFINLAR 42.22 E E N YGSK /CP
75MG
0240961 TAFINLAR 63.33 E E N YGSK /CP
DASATINIB
100 MG
0232019 SPRYCEL 152.86 E E N YBMY /TB
DEGARELIX
120MG
0233703 FIRMAGON 405.5 Y N N YFEI /VL
80MG
0233702 FIRMAGON 300 Y N N YFEI /VL
DOCETAXEL
40ML/.5ML
0217709 TAXOTERE INJ 5.71 Y Y N YAVT /ML
40ML/2ML
0217708 TAXOTERE INJ 22.84 Y Y N YAVT /ML
ENZALUTAMIDE
40MG
0240732 XTANDI 28.35 E E N YASL /CP
ERLOTINIB
100MG
0237770 TEVA-ERLOTINIB 47.47 E E N YTVM /TB
0226901 TARCEVA 53.33 E E N YHLR /TB
150MG
0226902 TARCEVA 80 E E N YHLR /TB
0237771 TEVA-ERLOTINIB 71.2 E E N YTVM /TB
25MG
0237769 TEVA-ERLOTINIB 11.87 E E N YTVM /TB
ETOPOSIDE
50MG
0061619 VEPESID 37.33 Y Y N YBRI /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
40
PHRM/CHRN/CDO/F10:00.00 ANTINEOPLASTIC AGENTS (continued)
10:00 ANTINEOPLASTIC AGENTS (continued)
EVEROLIMUS
EVEROLIMUS
10MG
0233952 AFINITOR 200.09 E E N YNVR /TB
2.5MG
0236925 AFINITOR 200.09 E E N YNVR /TB
5MG
0233950 AFINITOR 200.09 E E N YNVR /TB
EXEMESTANE
25MG
0224270 AROMASIN 5.28 Y Y N YPMS /TB
0239018 ACT EXEMESTANE 3.9 Y Y N YACT /TB
FLUDARABINE
10MG
0224622 FLUDARA 37 Y Y N YBEX /TB
FLUTAMIDE
250MG
0223856 APO-FLUTAMIDE 1.35 Y Y N YAPX /TB
0223008 NOVO-FLUTAMIDE 1.35 Y Y N YNOP /TB
0063772 EUFLEX TAB 1.46 Y Y N YSCH /TB
GEFITINIB
250MG
0224867 IRESSA 73.3 E E N YAST /TB
HYDROXYUREA
500MG
0224292 MYLAN-HYDROXYUREA 1.02 Y Y N YMYL /CP
0224793 APO-HYDROXYUREA 1.0203 Y Y N YAPX /CP
0234309 SANIS-HYDROXYUREA 1.02 Y Y N YSAN /CP
0046528 HYDREA 1.02 Y Y N YSQU /CP
IBRUTINIB
140MG
0243440 IMBRUVICA 90.65 E E N YJAN /CP
IDELALISIB
100MG
0243879 ZYDELIG 85.35 E E N YGSI /TB
150MG
0243880 ZYDELIG 85.35 E E N YGSI /TB
IMATINIB
100 MG
0225327 GLEEVEC 27.88 E E N YNVR /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
41
PHRM/CHRN/CDO/F10:00.00 ANTINEOPLASTIC AGENTS (continued)
10:00 ANTINEOPLASTIC AGENTS (continued)
IMATINIB (continued)
100MG
0235533 APO-IMATINIB 20.46 E E N YAPX /TB
0239980 TEVA-IMATINIB 20.46 E E N YTVM /TB
400 MG
0225328 GLEEVEC 111.52 E E N YNVR /TB
400MG
0235534 APO-IMATINIB 81.82 E E N YAPX /TB
0239981 TEVA-IMATINIB 81.82 E E N YTEV /TB
INTERFERON ALFA-2B
10 MILL IU
0222340 INTRON-A KIT 125.82 E E N YSCH /KT
10M IU/1ML
0223867 INTRON-A INJ 121.53 E E N YSCH /KT
18M IU/PEN
0224069 INTRON A PEN MULTIDOSE KIT 218.76 E E N YSCH /KT
18M IU/3ML
0223867 INTRON-A INJ 72.92 E E N YSCH /KT
30M IU/PEN
0224069 INTRON A PEN MULTIDOSE KIT 350.1 E E N YSCH /KT
60M IU/PEN
0224069 INTRON A PEN MULTIDOSE KIT 719 E E N YSCH /KT
IPILIMUMAB
5MG/ML
0237938 YERVOY 580 E E N YBMY /ML
LAPATINIB
250MG
0232644 TYKERB 23.5 E E N YGSK /TB
LENALIDOMIDE
10MG
0230490 REVLIMID 361 E E N YCEL /CP
15MG
0231769 REVLIMID 382 E E N YCEL /CP
20MG
0244060 REVLIMID 403 E E N YCEL /CP
25MG
0231771 REVLIMID 424 E E N YCEL /CP
5MG
0230489 REVLIMID 340 E E N YCEL /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
42
PHRM/CHRN/CDO/F10:00.00 ANTINEOPLASTIC AGENTS (continued)
10:00 ANTINEOPLASTIC AGENTS (continued)
LETROZOLE
LETROZOLE
2.5MG
0235851 APO-LETROZOLE 2.76 Y Y N YAPX /TB
0237342 MAR-LETROZOLE 3.06 Y Y N YMRC /TB
0234481 SANDOZ-LETROZOLE 2.76 Y Y N YSDZ /TB
0234365 TEVA-LETROZOLE 2.76 Y Y N YTVM /TB
0233845 LETROZOLE USP 2.76 Y Y N YACC /TB
0232231 MED-LETROZOLE 3.06 Y Y N YMED /TB
0230911 PMS-LETROZOLE 2.76 Y Y N YPMS /TB
0234896 LETROZOLE 2.76 Y Y N YACT /TB
0237216 MYLAN-LETROZOLE 2.76 Y Y N YMYL /TB
0223138 FEMARA 6.89 Y Y N YNVR /TB
LEUPROLIDE
11.25MG
0223983 LUPRON DEPOT INJ 1034.41 Y Y N YABB /VI
22.5MG
0223024 LUPRON DEPOT INJ 1071 Y Y N YABB /KT
0224824 ELIGARD 22.5MG 891 Y Y N YAVT /SYR
3.75MG/ML
0088450 LUPRON DEPOT INJ 347.18 Y Y N YABB /KT
30MG
0224899 ELIGARD 30MG 1285.2 Y Y N YAVT /SYR
0223983 LUPRON DEPOT INJ 1428 Y Y N YABB /VI
45MG
0226889 ELIGARD 45MG 1450 Y Y N YAVT /SYR
7.5MG
0224823 ELIGARD 7.5MG 310.72 Y Y N YAVT /SYR
7.5MG/ML
0083627 LUPRON DEPOT INJ 387.97 Y Y N YABB /KT
LOMUSTINE
10MG
0036043 CEENU 7.08 Y Y N YBMY /CP
100MG
0036041 CEENU 20.16 Y Y N YBMY /CP
40MG
0036042 CEENU 12.21 Y Y N YBMY /CP
MEGESTROL ACETATE
160MG
0219592 APO-MEGESTROL 4.26 Y Y N YAPX /TB
40MG
0219591 APO-MEGESTROL 1.01 Y Y N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
43
PHRM/CHRN/CDO/F10:00.00 ANTINEOPLASTIC AGENTS (continued)
10:00 ANTINEOPLASTIC AGENTS (continued)
MEGESTROL ACETATE (continued)
40MG/ML
0216897 MEGACE OS SUSP 1.8 Y Y N YBMY /ML
MELPHALAN
2MG
0000471 ALKERAN 1.65 Y Y N YGSK /TB
MERCAPTOPURINE
50MG
0241527 MERCAPTOPURINE TABLETS USP 2.86 Y Y N YSTE /TB
0000472 PURINETHOL 2.86 Y Y N YGSK /TB
METHOTREXATE
10 MG
0218275 METHOTREXATE 2.71 Y Y N YDBU /TB
2.5MG
0218296 APO-METHOTREXATE 0.63 Y Y Y YDBU /TB
0217069 METHOTREXATE 0.64 Y Y Y YWYA /TB
0224479 RATIO-METHOTREXATE 0.63 Y Y Y YRTP /TB
METHOTREXATE SODIUM
10MG/ML
0218294 METHOTREXATE INJ 7.87 Y Y N YDBU /ML
25MG/ML
0218295 METHOTREXATE INJ 6.84 Y Y N YDBU /ML
0218277 METHOTREXATE INJ 5.63 Y Y N YDBU /ML
0209970 METHOTREXATE INJ 5.63 Y Y N YNOP /ML
METHOTREXATE SODIUM
25MG/ML
0239842 SANDOZ-METHOTREXATE 5.63 Y Y N YSDZ /ML
NILUTAMIDE
50MG
0222186 ANANDRON 2.24 Y Y N YAVT /TB
OBINUTUZUMAB
25MG/ML
0243480 GAZYVA 5275.5 E E N YHLR /VL
PAZOPANIB HCL
200MG
0235230 VOTRIENT 34.41 Y Y N YGSK /TB
PEMBROLIZUMAB
50MG
0244115 KEYTRUDA 2200 E E N YMSD /VL
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
44
PHRM/CHRN/CDO/F10:00.00 ANTINEOPLASTIC AGENTS (continued)
10:00 ANTINEOPLASTIC AGENTS (continued)
PERTUZUMAB/TRASTUZUMAB
PERTUZUMAB/TRASTUZ
420/440MG
0240502 PERJETA-HERCEPTIN 5929.89 E N N YHLR /KT
POMALIDOMIDE
1MG
0241958 POMALYST 500 E E N YCEL /CP
2MG
0241959 POMALYST 500 E E N YCEL /CP
3MG
0241960 POMALYST 500 E E N YCEL /CP
4MG
0241961 POMALYST 500 E E N YCEL /CP
PONATINIB HCL
15MG
0243733 ICLUSIG 142.84 E E N YPAL /TB
45MG
0243734 ICLUSIG 331.48 E E N YPAL /TB
PROCARBAZINE
50MG
0001275 MATULANE 57.49 Y Y N YN/A /CP
RAMUCIRUMAB
10MG/ML
0244380 CYRAMZA 626.28 E E N YLIL /VL
REGORAFENIB
40MG
0240339 STIVARGA 72.62 E E N YBAY /TB
RITUXIMAB
10 MG/ML
0224192 RITUXAN IV SOL (2 X10ML PK) 46.63 E E N YHLR /EA
ROMIDEPSIN
10MG/VL
0241429 ISTODAX 2582 E E N YCEL /EA
RUXOLITINIB
15MG
0238801 JAKAVI 82.19 E N N YNVR /TB
20MG
0238802 JAKAVI 82.19 E N N YNVR /TB
5MG
0238800 JAKAVI 82.19 E N N YNVR /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
45
PHRM/CHRN/CDO/F10:00.00 ANTINEOPLASTIC AGENTS (continued)
10:00 ANTINEOPLASTIC AGENTS (continued)
SUNITINIB
SUNITINIB
12.5MG
0228079 SUTENT 63.72 E E N YPFI /CP
25MG
0228080 SUTENT 127.44 E E N YPFI /CP
50MG
0228081 SUTENT 254.88 E E N YPFI /CP
TAMOXIFEN CITRATE
10MG
0081240 APO-TAMOX 0.18 Y Y N YAPX /TB
0208842 GEN-TAMOXIFEN 0.18 Y Y N YGPM /TB
0085196 NOVO-TAMOXIFEN 0.18 Y Y N YNOP /TB
20MG
0085197 NOVO-TAMOXIFEN 0.35 Y Y N YNOP /TB
0204848 NOLVADEX-D 0.37 Y Y N YAST /TB
0208985 GEN-TAMOXIFEN 0.35 Y Y N YGPM /TB
0081239 APO-TAMOX 0.35 Y Y N YAPX /TB
TEMOZOLOMIDE
100MG
0224109 TEMODAL 156.01 Y Y N YSCH /CP
0244351 TARO-TEMOZOLOMIDE 113.6 Y Y N YTAR /CP
140MG
0231279 TEMODAL 218.41 Y Y N YSCH /CP
0244353 TARO-TEMOZOLOMIDE 159.04 Y Y N YTAR /CP
20MG
0224109 TEMODAL 31.2 Y Y N YSCH /CP
0244348 TARO-TEMOZOLOMIDE 22.72 Y Y N YTAR /CP
250MG
0244355 TARO-TEMOZOLOMIDE 283.98 Y Y N YTAR /CP
0224109 TEMODAL 390 Y Y N YSCH /CP
5MG
0244347 TARO-TEMOZOLOMIDE 6.63 Y Y N YTAR /CP
0224109 TEMODAL 7.8 Y Y N YSCH /CP
TRAMETINIB
0.5MG
0240962 MEKINIST 72.5 E E N YGSK /TB
2MG
0240965 MEKINIST 290 E E N YGSK /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
46
PHRM/CHRN/CDO/F10:00.00 ANTINEOPLASTIC AGENTS (continued)
10:00 ANTINEOPLASTIC AGENTS (continued)
TRASTUZUMAB EMTANSINE
TRASTUZUMAB
20MG/ML
0241236 KADCYLA 20 E E N YHLR /ML
VISMODEGIB
150MG
0240926 ERIVEDGE 294.22 E E N YHLR /CP
12:00 AUTONOMIC DRUGS
12:04.00 PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS ---------------------------------------
BETHANECHOL
10MG
0194795 DUVOID 0.3 Y Y N YRBP /TB
0075917 PMS-BETHANECHOL 0.3 Y Y N YPMS /TB
25MG
0073916 PMS-BETHANECHOL 0.48 Y Y N YPMS /TB
0194793 DUVOID 0.48 Y Y N YRBP /TB
50MG
0194792 DUVOID 0.63 Y Y N YRBP /TB
DONEPEZIL
10MG
0242849 SEPTA DONEPEZIL 0.83 E E N YSEP
/TB
0241987 ACCEL-DONEPEZIL 0.81 E E N YACC /TB
0223204 ARICEPT 4.86 E E N YPFI /TB
0236227 APO-DONEPEZIL 0.83 E E N YAPX /TB
0234061 TEVA-DONEPEZIL 0.83 E E N YTVM /TB
0232868 SANDOZ DONEPEZIL 0.83 E E N YSDZ /TB
0232235 PMS-DONEPEZIL 0.83 E E N YPMS /TB
0240265 DONEPEZIL HYDROCHLORIDE 0.83 E E N YACD /TB
0240058 AURO-DONEPEZIL 0.83 E E N YAUR /TB
0239760 CO DONEPEZIL 0.83 E E N YCOB /TB
0238151 RAN-DONEPEZIL 0.83 E E N YRAN /TB
5MG
0240264 DONEPEZIL HYDROCHLORIDE 0.83 E E N YACD /TB
0242848 SEPTA DONEPEZIL 0.83 E E N YSEP
/TB
0238150 RAN-DONEPEZIL 0.83 E E N YRAN /TB
0241986 ACCEL-DONEPEZIL 0.81 E E N YACC /TB
0239759 CO DONEPEZIL 0.83 E E N YCOB /TB
0223204 ARICEPT 4.86 E E N YPFI /TB
0236226 APO-DONEPEZIL 0.83 E E N YAPX /TB
0234060 TEVA-DONEPEZIL 0.83 E E N YTVM /TB
0232866 SANDOZ DONEPEZIL 0.83 E E N YSDZ /TB
0232233 PMS-DONEPEZIL 0.83 E E N YPMS /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
47
PHRM/CHRN/CDO/F12:04.00 PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS (continued)
12:00 AUTONOMIC DRUGS (continued)
DONEPEZIL HYSROCHLORIDE
DONEPEZIL
5MG
0240441 JAMP-DONEPEZIL 0.83 E E N YJPC
/TB
GALANTAMINE
16MG
0239838 PMS-GALANTAMINE ER 1.25 E E N YPMS /CP
0231695 PAT-GALANTAMINE 1.25 E E N YPAT /CP
0237796 TEVA-GALANTAMINE 1.25 E E N YTVM /CP
0233944 MYLAN-GALANTAMINE 1.25 E E N YMYL /CP
0226672 REMINYL ER 5.15 E E N YJAN /CP
24MG
0237797 TEVA-GALANTAMINE 1.25 E E N YTVM /CP
0226673 REMINYL ER 5.15 E E N YJAN /CP
0239839 PMS-GALANTAMINE ER 1.25 E E N YPMS /CP
0233945 MYLAN-GALANTAMINE 1.25 E E N YMYL /CP
8MG
0233943 MYLAN-GALANTAMINE 1.25 E E N YMYL /CP
0226671 REMINYL ER 5.15 E E N YJAN /CP
0237795 TEVA-GALANTAMINE 1.25 E E N YTVM /CP
0239837 PMS-GALANTAMINE ER 1.25 E E N YPMS /CP
NEOSTIGMINE BROMIDE
15MG
0086994 PROSTIGMIN 0.48 Y N N YICN /TB
PILOCARPINE HCL
5MG
0221634 SALAGEN 1.38 Y N N YPHU /TB
0240248 PILOCARPINE HYDROCHLORIDE 0.78 Y N N YSTE /TB
PYRIDOSTIGMINE
180MG
0086995 MESTINON 1.04 Y N N YICN /TB
60MG
0086996 MESTINON 0.48 Y N N YICN /TB
RIVASTIGMINE
1.5MG
0230603 PMS-RIVASTIGMINE 0.65 E E N YPMS /CP
0232456 SDZ-RIVASTIGMINE 0.65 E E N YSDZ /CP
0233671 APO-RIVASTIGMINE 0.65 E E N YAPX /CP
0224211 EXELON 2.61 E E N YNVR /CP
18MG/10 SQ CM
0230285 EXELON PATCH 4.5 E E N YNVR /PT
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
48
PHRM/CHRN/CDO/F12:04.00 PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS (continued)
12:00 AUTONOMIC DRUGS (continued)
RIVASTIGMINE (continued)
3MG
0233672 APO-RIVASTIGMINE 0.65 E E N YAPX /CP
0230604 PMS-RIVASTIGMINE 0.65 E E N YPMS /CP
0232457 SDZ-RIVASTIGMINE 0.65 E E N YSDZ /CP
0224211 EXELON 2.61 E E N YNVR /CP
4.5MG
0230605 PMS-RIVASTIGMINE 0.65 E E N YPMS /CP
0232459 SDZ-RIVASTIGMINE 0.65 E E N YNVR /CP
0233673 APO-RIVASTIGMINE 0.65 E E N YAPX /CP
0224211 EXELON 2.61 E E N YNVR /CP
6MG
0224211 EXELON 2.61 E E N YNVR /CP
0233675 APO-RIVASTIGMINE 0.65 E E N YAPX /CP
0230606 PMS-RIVASTIGMINE 1.303 E E N YPMS /CP
0232460 SDZ-RIVASTIGMINE 0.65 E E N YSDZ /TB
9MG/5 SQ CM
0230284 EXELON PATCH 4.86 E E N YNVR /PT
12:08.04 ANTIPARKINSONIAN AGENTS --------------------------------------------------------
BENZTROPINE MESYLATE
1MG
0070653 PMS-BENZTROPINE TAB 0.05 Y Y N YPMS /TB
1MG/ML
0223890 BENZTROPINE OMEGA (2ML) 7.65 Y Y N YOMG /ML
2MG
0042685 APO-BENZTROPINE 0.06 Y Y N YAPX /TB
0058726 PMS-BENZTROPINE 0.05 Y Y N YPMS /TB
ETHOPROPAZINE
50MG
0192774 PARSITAN 0.23 Y Y N YAVT /TB
PROCYCLIDINE HCL
0.5MG/ML
0058736 PMS-PROCYCLIDINE ELIXIR 0.27 Y Y N YPMS /ML
2.5MG
0064939 PMS-PROCYCLIDINE 0.07 Y Y N YPMS /TB
5MG
0058735 PMS-PROCYCLIDINE 0.14 Y Y N YPMS /TB
TRIHEXYPHENIDYL HCL
2MG
0054505 APO-TRIHEX 0.04 Y Y N YAPX /TB
5MG
0054507 APO-TRIHEX 0.07 Y Y N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
49
PHRM/CHRN/CDO/F12:08.08 ANTIMUSCARINICS ANTISPASMODICS
12:00 AUTONOMIC DRUGS (continued)
ACLIDINIUM BROMIDE
12:08.08 ANTIMUSCARINICS ANTISPASMODICS -------------------------------------------------
400MCG
0240972 TUDORZA 0.89 E E N YALM /DS
ACLIDINIUM/FORMOTER
400/12MCG
0243953 DUAKLIR GENUAIR 1 E E N YAST /DS
BELLADONNA/ERGOT/P
.2/.6/40MG
0017614 BELLERGAL SPACETABS SRT 1.45 Y N N YNVR /TB
GLYCOPYRRONIUM
50UG CP
0239493 SEEBRI BREEZHALER 1.77 E E N YNVO /CP
GLYCOPYRRONIUM/IND
50/110MCG
0241828 ULTIBRO BREEZHALER 2.68 E E N YNVR /DS
HYOSCINE
10MG
0036381 BUSCOPAN 0.34 Y N Y YBOE /TB
IPRATROPIUM
0.5/2.5MG
0223167 COMBIVENT (2.5ML) INHAL. SOLN 0.603 Y Y N YBOE /ML
0224606 GEN-COMBO STERINEBS (2.5ML) 0.411 Y Y N YGEN /ML
0224378 RATIO-IPRA SAL UDV (2.5ML) 0.2936 Y Y N YRAT /ML
IPRATROPIUM BROMIDE
125MCG/ML
0209717 RATIO-IPRATROPIUM UDV 6.59 Y Y N YRTP /ML
0223113 PMS-IPRATROPIUM (20X2ML) 6.59 Y Y N YPMS /ML
20MCG/DS
0224768 ATROVENT HFA INHALER 0.1 Y Y N YBOE /DS
21MCG/DOSE
0224608 APO-IPRAVENT NASAL SPRAY 0.76 Y N Y YAPO /DS
0223962 PMS-IPRATROPIUM NASAL SPRAY 0.76 Y N Y YPMS /DS
0216370 ATROVENT NASAL SPRAY 0.99 Y N Y YBOE /DS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
50
PHRM/CHRN/CDO/F12:08.08 ANTIMUSCARINICS ANTISPASMODICS (continued)
12:00 AUTONOMIC DRUGS (continued)
IPRATROPIUM BROMIDE (continued)
250MCG/ML
0209716 RATIO-IPRATROPIUM UDV (2ML) 0.659 Y Y N YRTP /ML
0212622 APO-IPRAVENT INHAL.SOLN 0.32 Y Y N YAPX /ML
0221047 NOVO-IPRAMIDE INHAL. SOLN 0.32 Y Y N YNOP /ML
0221622 GEN-IPRATROPIUM (2ML) 6.59 Y Y N YGPM /ML
0223913 GEN-IPRATROPIUM INHAL. SOLN 0.32 Y Y N YGPM /ML
0223113 PMS-IPRATROPIUM INHAL. SOLN 0.32 Y Y N YPMS /ML
0223124 PMS-IPRATROPIUM (1ML UD) 0.659 Y Y N YPMS /ML
0223124 PMS-IPRATROPIUM (2ML) 6.59 Y Y N YPMS /ML
42MCG/DOSE
0224608 APO-IPRAVENT NASAL SPRAY 1.49 Y N Y YAPO /DS
0216371 ATROVENT NASAL SPRAY 1.99 Y N Y YBOE /DS
IPRATROPIUM/SALBUTA
0.5/2.5MG
0227269 TEVA-COMBO STERINEBS 0.53 Y Y N YTVM /ML
20/100MCG
0241910 COMBIVENT RESPIMAT 0.24 Y Y N YBOE /DS
OLODATEROL/TIOTROPI
2.5/2.5MCG
0244188 INSPIOLTO RESPIMAT 2.03 E E N YBOE /DS
OPIUM & BELLADONNA
65MG/15MG
0190186 OPIUM & BELLADONNA SUP. 4.14 Y E N YSDZ /SP
PINAVERIUM BROMIDE
100MG
0223068 DICETEL 100 MG 0.62 Y N Y YSLV /TB
50MG
0195059 DICETEL 0.35 Y N Y YSLV /TB
TIOTROPIUM
18 MCG CP
0224679 SPIRIVA (CP FOR INHALATION) 1.73 E E N YBOE /CP
2.5MCG
0243538 SPIRIVA RESPIMAT 1.73 E E N YBOE /DS
TRIMEBUTINE MALEATE
100MG
0224566 APO-TRIMEBUTINE 0.269 Y N Y YAPX /TB
200MG
0080349 MODULON 0.7 Y N Y YAXC /TB
0224566 APO-TRIMEBUTINE 0.5235 Y N Y YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
51
PHRM/CHRN/CDO/F12:08.08 ANTIMUSCARINICS ANTISPASMODICS (continued)
12:00 AUTONOMIC DRUGS (continued)
UMECLIDINIUM
UMECLIDINIUM
62.5MCG
0242359 INCRUSE ELLIPTA 1.67 E E N YGSK /EA
12:12.00 SYMPATHOMIMETIC (ADRENERGIC) AGENTS --------------------------------------------
EPINEPHRINE
0.15MG/DS
0226820 TWINJECT 0.15MG AUTO-INJECTOR 82.46 E N Y YPAL /EA
0057865 EPIPEN JR INJ 83.86 E N Y YDEY /EA
0.15MG/0.15ML
0238205 ALLERJECT 83.35 E N Y YWHL /EA
0.3MG/DS
0224731 TWINJECT 0.3MG AUTO-INJECTOR 82.46 E N Y YPAL /EA
0050955 EPIPEN INJ 1:1000 INJ 83.86 E N Y YDEY /EA
0.3MG/0.3ML
0238206 ALLERJECT 83.35 E N Y YWHL /EA
EPINEPHRINE HCL
1MG/ML
0072189 EPINEPHRINE (1ML) INJ 3.85 E N Y YABB /ML
0015535 ADRENALIN INJ 30ML VIAL 0.72 E N Y YPFI /VL
FLUTICASONE
100UG/25UG
0240887 BREO ELLIPTA 2.74 E E N YGSK /DS
200UG/25UG
0244418 BREO ELLIPTA 4.29 E E N YGSK /DS
FORMOTEROL
12MCG/CP
0223089 FORADIL (CP FOR INHALATION) 0.84 E E N YNVR /CP
12MCG/DS
0223722 OXEZE TURBUHALER 0.74 E E N YAST /DS
6 MCG/DS
0223722 OXEZE TURBUHALER 0.56 E E N YAST /DS
FORMOTEROL
100/6MCG
0224538 SYMBICORT 100 TURBUHALER 0.53 E E N YAST /DS
200/6MCG
0224538 SYMBICORT 200 TURBUHALER 0.69 E E N YAST /DS
INDACATEROL
75MCG
0237693 ONBREZ BREEZHALER 1.55 E E N YNVO /DS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
52
PHRM/CHRN/CDO/F12:12.00 SYMPATHOMIMETIC (ADRENERGIC) AGENTS (continued)
12:00 AUTONOMIC DRUGS (continued)
IPRATROPIUM/FENOTEROL
IPRATROPIUM/FENOTER
0.5/1.25MG
0214863 DUOVENT INHAL. SOLN 0.8264 Y Y N YBOE /ML
MIDODRINE
2.5MG
0227867 APO-MIDODRINE 0.34 Y Y N YAPX /TB
5MG
0227868 MIDODRINE 0.59 Y Y N YAPX /TB
ORCIPRENALINE SO4
2MG/ML
0223678 APO-ORCIPRENALINE SYRUP 0.06 Y Y Y YAPX /ML
SALBUTAMOL
0.4MG/ML
0209118 PMS-SALBUTAMOL ORAL LIQUID 0.0486 Y Y Y YPMS /ML
0.5MG/ML
0220824 PMS-SALBUTAMOL INHAL. SOLN 0.07 Y Y Y YPMS /ML
0223936 RATIO-SALBUTAMOL INHAL. SOLN 0.07 Y Y Y YRAT /ML
1MG/ML
0220822 PMS-SALBUTAMOL INHAL. SOLN 0.6085 Y Y Y YPMS /ML
0198686 RATIO-SALBUTAMOL INHAL. SOLN 0.2434 Y Y Y YRTP /ML
0221341 VENTOLIN NEBULES P.F. 1.0335 Y Y Y YGSK /ML
0192693 GEN-SALBUTAMOL STERINEB 0.2434 Y Y Y YGPM /ML
100MCG/DS
0241985 SALBUTAMOL HFA 0.03 Y Y Y YSAI /DS
0224149 VENTOLIN HFA INHALER 0.0325 Y Y Y YGSK /DS
0224566 APO-SALVENT CFC FREE INHALER 0.03 Y Y Y YAPX /DS
0232645 TEVA-SALBUTAMOL 0.03 Y Y Y YTVM /DS
0223257 AIROMIR (CFC-FREE) INHALER 0.026 Y Y Y YHLR /DS
2MG
0214684 APO-SALVENT TAB 0.13 Y Y Y YAPX /TB
2MG/ML
0221342 VENTOLIN NEBULES P.F. 0.797 Y Y Y YGCH /ML
0220823 PMS-SALBUTAMOL INHAL. SOLN 0.2748 Y Y Y YPMS /ML
0223936 RATIO-SALBUTAMOL INHAL. SOLN 0.2748 Y Y Y YRTP /ML
0217336 GEN-SALBUTAMOL STERINEB 0.27 Y Y Y YGPM /ML
4MG
0214685 APO-SALVENT TAB 0.2134 Y Y Y YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
53
PHRM/CHRN/CDO/F12:12.00 SYMPATHOMIMETIC (ADRENERGIC) AGENTS (continued)
12:00 AUTONOMIC DRUGS (continued)
SALBUTAMOL (SALBUTAMOL SO4) (continued)
5MG/ML
0206957 PMS-SALBUTAMOL INHAL.SOLN 0.35 Y Y Y YPMS /ML
0215441 SANDOZ-SALBUTAMOL INH SOLN 0.35 Y Y Y YSDZ /ML
0086080 RATIO-SALBUTAMOL INHAL SOLN 0.35 Y Y Y YRTP /ML
0221348 VENTOLIN INHAL. SOLN. 1.02 Y Y Y YGSK /ML
SALMETEROL
100MCG/DS
0224083 ADVAIR 100 DISKUS 1.36 E E N YGSK /DS
250MCG/DS
0224083 ADVAIR 250 DISKUS 1.62 E E N YGSK /DS
25/125MCG
0224512 ADVAIR 0.81 E E N YGSK /DS
25/250MCG
0224512 ADVAIR 1.15 E E N YGSK /DS
500MCG/DS
0224083 ADVAIR 500 DISKUS 2.31 E E N YGSK /DS
SALMETEROL
50MCG/DOSE
0223112 SEREVENT DISKUS 0.94 E E N YGSK /DS
0221426 SEREVENT DISKHALER DISK 0.94 E E N YGSK /DS
TERBUTALINE SULPHATE
0.5MG/DOSE
0078661 BRICANYL TURBUHALER 0.08 Y Y Y YAST /DS
UMECLIDINIUM/VILANTE
62.5/25MCG
0241840 ANORO ELLIPTA 2.7 E E N YGSK /DS
12:16.00 SYMPATHOLYTIC (ADRENERGIC BLOCKING) AGENTS -------------------------------------
ALMOTRIPTAN MALATE
12.5MG
0224812 AXERT 13.04 Y N Y YJAN /TB
6.25MG
0224812 AXERT 13.04 Y N Y YJAN /TB
BELLADONNA
100MG
0017609 CAFERGOT 0.828 Y N Y YNVR /TB
DIHYDROERGOTAMINE
1MG/ML
0224116 DIHYDROERGOTAMINE MESYLAT 3.793 Y N Y YSAB /ML
0002724 DIHYDROERGOTAMINE-SANDOZ 3.878 Y N Y YNVR /ML
4MG/ML
0222894 MIGRANAL NASAL SPRAY 10.356 Y N Y YNVR /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
54
PHRM/CHRN/CDO/F12:16.00 SYMPATHOLYTIC (ADRENERGIC BLOCKING) AGENTS (continued)
12:00 AUTONOMIC DRUGS (continued)
FLUNARIZINE HCL
FLUNARIZINE HCL
5MG
0224608 APO-FLUNARIZINE 0.72 Y N Y YAPX /CP
NARATRIPTAN HCL
1MG
0223782 AMERGE 14.17 Y N Y YGSK /TB
0231429 NOVO-NARATRIPTAN 11.34 Y N Y YTVM /TB
2.5MG
0231430 NOVO-NARATRIPTAN 6.14 Y N Y YTVM /TB
0223782 AMERGE 14.94 Y N Y YGSK /TB
PIZOTYLINE HYDROGEN
0.5MG
0032932 SANDOMIGRAN 0.37 Y N Y YNVR /TB
1MG
0051155 SANDOMIGRAN DS 0.69 Y N Y YNVR /TB
RIZATRIPTAN
10MG
0224051 MAXALT WAFERS 16.52 Y N N YMSD /EA
0239337 PMS-RIZATRIPTAN RDT 3.71 Y N N YPMS /EA
0237474 CO RIZATRIPTAN ODT 3.7 Y N N YCOB /EA
0238046 JAMP-RIZATRIPTAN 3.71 Y N N YJAM /TB
0237967 MAR-RIZATRIPTAN 4.31 Y N N YMAR /TB
0244291 RIZATRIPTAN ODT 3.72 Y N N YSAI /TB
0243958 MINT-RIZATRIPTAN ODT 4.13 Y N N YMNT /TB
0224052 MAXALT 16.52 Y N N YMSD /TB
0235188 SANDOZ-RIZATRIPTAN 3.71 Y N N YSDZ /TB
5MG
0239336 PMS-RIZATRIPTAN RDT 3.71 Y N N Ynull /EA
0224051 MAXALT WAFERS 16.52 Y N N YMSD /EA
SUMATRIPTAN
100MG
0225790 CO SUMATRIPTAN 7.86 Y N Y YCOB /TB
0223936 TEVA-SUMATRIPTAN 7.86 Y N Y YTVM /TB
0225644 PMS-SUMATRIPTAN 7.86 Y N Y YPMS /TB
0221216 IMITREX DF 16.7 Y N Y YGSK /TB
0228683 TEVA-SUMATRIPTAN DF 7.86 Y N Y YTVM /TB
0228654 SANIS-SUMATRIPTAN 7.86 Y N Y YSAN /TB
0226892 GEN-SUMATRIPTAN 7.86 Y N Y YGPM /TB
0226839 APO-SUMATRIPTAN 7.86 Y N Y YAPX /TB
0226303 SANDOZ-SUMATRIPTAN 7.86 Y N Y YSDZ /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
55
PHRM/CHRN/CDO/F12:16.00 SYMPATHOLYTIC (ADRENERGIC BLOCKING) AGENTS (continued)
12:00 AUTONOMIC DRUGS (continued)
SUMATRIPTAN (continued)
20MG
0223042 IMITREX NASAL SPRAY 15.03 Y N Y YGSK /EA
25MG
0226890 GEN-SUMATRIPTAN 8.99 Y N Y YGPM /TB
5MG
0223041 IMITREX NASAL SPRAY 14.6 Y N Y YGSK /EA
50MG
0225789 CO SUMATRIPTAN 7.14 Y N Y YCOB /TB
0225643 PMS-SUMATRIPTAN 7.14 Y N Y YPMS /TB
0221215 IMITREX DF 15.16 Y N Y YGSK /TB
0228652 SANIS-SUMATRIPTAN 7.14 Y N Y YSAN /TB
0226891 GEN-SUMATRIPTAN 7.14 Y N Y YGPM /TB
0226838 APO-SUMATRIPTAN 7.14 Y N Y YAPX /TB
6MG/0.5ML
0221218 IMITREX INJ 79.43 Y N Y YGSK /EA
0236169 TARO-SUMATRIPTAN 33.18 Y N Y YTAR /EA
ZOLMITRIPTAN
2.5MG
0232422 PMS-ZOLMITRIPTAN 3.54 Y N Y YPMS /TB
0236298 SDZ-ZOLMITRIPTAN 4.61 Y N Y YSDZ /TB
0223866 ZOMIG 14.01 Y N Y YAST /TB
0231396 TEVA-ZOLMITRIPTAN 3.54 Y N Y YTVM /TB
0236903 MYLAN-ZOLMITRIPTAN 4.61 Y N Y YMYL /TB
2.5MG ODT
0242847 SEPTA-ZOLMITRIPTAN-ODT 2.97 Y N Y YSPT /TB
0236299 SDZ-ZOLMITRIPTAN ODT 4.61 Y N Y YSDZ /TB
0232476 PMS-ZOLMITRIPTAN ODT 4.61 Y N Y YPMS /TB
0234254 TEVA-ZOLMITRIPTAN ODT 4.61 Y N Y YTVM /TB
0224304 ZOMIG RAPIMELT 14.15 Y N Y YAST /TB
12:20.00 SKELETAL MUSCLE RELAXANTS ------------------------------------------------------
BACLOFEN
10MG
0208839 MYLAN-BACLOFEN 0.16 Y Y Y YMYL /TB
0213933 APO-BACLOFEN 0.16 Y Y Y YAPX /TB
0206373 PMS-BACLOFEN 0.77 Y Y Y YPMS /TB
0045588 LIORESAL 0.77 Y Y Y YNVR /TB
0223650 RATIO-BACLOFEN 0.16 Y Y Y YRPH /TB
0228702 SANIS-BACLOFEN 0.16 Y Y Y YSAN /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
56
PHRM/CHRN/CDO/F12:20.00 SKELETAL MUSCLE RELAXANTS (continued)
12:00 AUTONOMIC DRUGS (continued)
BACLOFEN (continued)
20MG
0223650 RATIO-BACLOFEN 0.31 Y Y Y YRPH /TB
0206374 PMS-BACLOFEN 1.49 Y Y Y YPMS /TB
0228704 SANIS-BACLOFEN 0.31 Y Y Y YSAN /TB
0063657 LIORESAL-DS 1.49 Y Y Y YNVR /TB
0213939 APO-BACLOFEN 0.31 Y Y Y YAPX /TB
0208840 GEN-BACLOFEN 0.31 Y Y Y YGPM /TB
CYCLOBENZAPRINE HCL
10MG
0223650 RATIO-CYCLOBENZAPRINE 0.37 Y Y Y YRPH /TB
0228706 SANIS-CYCLOBENZAPRINE 0.3727 Y Y Y YSAN /TB
0217714 APO-CYCLOBENZAPRINE 0.3727 Y Y Y YAPX /TB
0221204 PMS-CYCLOBENZAPRINE 0.3727 Y Y Y YPMS /TB
0208005 NOVO-CYCLOPRINE 0.3727 Y Y Y YNOP /TB
0223135 GEN-CYCLOPRINE 0.3727 Y Y Y YGPM /TB
DANTROLENE SODIUM
100MG
0199765 DANTRIUM 0.7684 Y Y N YPGA /CP
25MG
0199760 DANTRIUM 0.39 Y Y N YPGA /CP
METHOCARBAMOL/ACET
400/325MG
0202680 ROBAXACET S 0.403 Y N N NWHI /CP
0223079 MUSCLE & BACK PAIN RELIEF 0.11 Y N N NVIT /CP
0224305 MUSCLE & BACK PAIN RELIEF 0.1014 Y N N NLIF /TB
400/500MG
0223117 ROBAXACET EXTRA STRENGTH 0.443 Y N N NWHI /CP
0223914 EX STRENGTH MUSCLE & BACK 0.2089 Y N N NVIT /CP
0224305 MUSCLE & BACK PAIN RELIEF 0.1566 Y N N NLIF /TB
METHOCARBAMOL/COD
400/15MG
0193478 ROBAXISAL C1/4 0.96 Y N N YWHI /TB
400/30MG
0193479 ROBAXISAL C1/2 1.12 Y N N YWHI /TB
400/8MG
0193476 ROBAXACET-8 0.681 Y N N NWHI /TB
ORPHENADRINE CITRATE
100MG
0196615 NORFLEX 0.776 Y N N NMDA /TB
0224355 SANDOZ-ORPHENADRINE CITRATE 0.75 Y N N NSDZ /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
57
PHRM/CHRN/CDO/F12:92.00 MISCELLANEOUS AUTONOMIC DRUGS
12:00 AUTONOMIC DRUGS (continued)
VARENICLINE
12:92.00 MISCELLANEOUS AUTONOMIC DRUGS --------------------------------------------------
0.5MG
0229117 CHAMPIX 1.84 Y N N YPFI /TB
0.5/1.0MG
0229830 CHAMPIX STARTER KIT(25) 1.84 Y N N YPFI /TB
1.0MG
0229118 CHAMPIX 1.84 Y N N YPFI /TB
20:00 BLOOD FORMATION AND COAGULATION
20:04.04 IRON PREPARATIONS --------------------------------------------------------------
FERROUS FUMARATE
300MG
0223755 EURO-FER 0.1397 Y N Y NEUR /CP
0003108 FERROUS FUMARATE 300 MG 0.11 Y N Y NWAM /CP
8002423 JAMP-FERROUS FUMARATE 300MG 0.13 Y N Y NJPC
/CP
0048206 NEO FER 0.203 Y N Y NNEO /CP
0192342 PALAFER CAPS 0.2293 Y N Y NGSK /CP
FERROUS GLUCONATE
300MG
8000043 NOVO-FERROUS GLUCONATE 0.025 Y N Y NNOP /TB
0224453 FERROUS GLUCONATE 0.025 Y N Y NWHL /TB
0054503 APO-FERROUS GLUCONATE 0.04 Y N Y NAPC /TB
0003109 FERROUS GLUCONATE 0.021 Y N Y NWAM /TB
324MG
0058272 FERROUS GLUCONATE 0.0246 Y N Y NVTH /TB
FERROUS SULPHATE
300MG
0034691 FERROUS SULPHATE SC 0.023 Y N Y NPHM /TB
0003110 FERROUS SULPHATE 0.0625 Y N Y NWAM /TB
0058632 PMS-FERROUS SULFATE 0.0296 Y N Y NPMS /TB
0078211 FERROUS SULPHATE 0.0279 Y N Y NVTH /TB
8000331 FERROUS SULPHATE 0.0296 Y N Y NGFR /TB
0191251 APO-FERROUS SULPHATE 0.024 Y N Y NAPC /TB
0212547 SULFATE FERREUX 0.023 Y N Y NWHL /TB
IRON (FERRIC
12.5MG
0224333 FERRLECIT INJ 5.272 E E N YAVT /ML
IRON (FERROUS
150MG/5ML
0001788 FERINSOL 0.052 E N Y NMEA /ML
8000829 JAMP-FERROUS SULFATE 0.04 E N Y NJPC
/null
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
58
PHRM/CHRN/CDO/F20:04.04 IRON PREPARATIONS (continued)
20:00 BLOOD FORMATION AND COAGULATION (continued)
IRON (FERROUS SULFATE) (continued)
75MG/ML
0076295 FER IN SOL DROPS 0.256 E N Y NMEJ /ML
IRON DEXTRAN
50MG/ML
0222178 INFUFER (2ML) INJ 14.75 E E N YSAB /ML
IRON POLYSACCHARIDE
150MG
8001321 FERAMAX 0.435 E E N YBSY /CP
IRON SUCROSE
20 MG/ML
0224371 VENOFER 7.5 E E N YWHL /ML
20:12.04 ANTICOAGULANTS -----------------------------------------------------------------
ACENOCOUMAROL
1MG
0001038 SINTROM 0.55 Y Y Y YNVR /TB
4MG
0001039 SINTROM 1.71 Y Y Y YNVR /TB
APIXABAN
2.5MG
0237723 ELIQUIS 1.6 E E N YBMS /TB
5MG
0239771 ELIQUIS 1.6 E E N YBMS /TB
DALTEPARIN SODIUM
10000IU SYR
0235265 FRAGMIN 10000IU(ANTI-XA)/0. 20.478 Y E N YPFI /SYR
12500IU SYR
0235266 FRAGMIN 12500IU(ANTI-XA)/0. 25.83 Y E N YPFI /SYR
15000IU SYR
0235267 FRAGMIN 15000IU(ANTI-XA)/0.6 31.61 Y E N YPFI /SYR
18000IU SYR
0235268 FRAGMIN 18000IU(ANTI-XA)/0.2M 36.32 Y E N YPFI /SYR
2500IU SYR
0213262 FRAGMIN '2500IU(ANTI-XA)/0.2ML 5.12 Y E N YPFI /SYR
25000IU/ML VIAL
0223117 FRAGMIN (3.8ML VIAL) 153.58 Y E N YPHU /VL
5000IU SYR
0213264 FRAGMIN '5000IU(ANTI-XA)/0.2ML 10.33 Y E N YPFI /SYR
7500IU SYR
0235264 FRAGMIN 7500IU(ANTI-XA)/0.3ML 15.358 Y E N YPFI /SYR
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
59
PHRM/CHRN/CDO/F20:12.04 ANTICOAGULANTS (continued)
20:00 BLOOD FORMATION AND COAGULATION (continued)
ENOXAPARIN
ENOXAPARIN
100MG/ML
0223656 LOVENOX (WITH PRESERV.) (3 ML 21.2 Y E N YAVT /ML
150MG/ML
0237846 LOVENOX HP 32.44 Y E N YSAN /ML
150 MG/ML
0224269 LOVENOX-HP 25.44 Y E N YAVT /SYR
30 MG/.3MG
0201247 LOVENOX SYR (30MG/0.3ML) 6.19 Y E N YAVT /EA
40 MG/.4ML
0223688 LOVENOX SYRINGE 8.48 Y E N YAVT /EA
60 MG/.6ML
0237842 LOVENOX SYR (60MG/0.6ML) 12.72 Y E N YAVT /EA
FONDAPARINUX SODIUM
2.5MG/0.5ML
0240685 FONDAPARINUX SODIUM INJ 11.19 E E N YDRR /SYR
0224553 ARIXTRA SYRINGES 15.99 E E N YGSK /SYR
7.5MG/0.6ML
0240689 FONDAPARINUX SODIUM INJ 18.14 E E N YDRR /SYR
0225805 ARIXTRA SYRINGES 25.91 E E N YGSK /SYR
HEPARIN
10UNIT/ML
0072532 HEPARIN LOCK-FLUSH SOLN 0.329 Y Y N YWHL /ML
100UNIT/ML
0072752 HEPARIN LEO 100UNIT/ML INJ 4.65 Y Y N YLEO /ML
0072531 HEPARIN LOCK-FLUSH SOLN 0.282 Y Y N YHOS /ML
1000UN/ML
0226431 HEPARIN INJ 0.57 Y Y N YPHC /ML
0045381 HEPARIN LEO INJ 5.47 Y Y N YLEO /ML
10000UN/ML
0057971 HEPARIN LEO INJ (5ML) 2.606 Y Y N YLEO /ML
NADROPARIN CALCIUM
19000U/ML
0224011 FRAXIPARINE FORTE 18.11 Y E N YGCH /SYR
RIVAROXABAN
10MG
0231698 XARELTO 2.84 E E N YBAY /TB
TINZAPARIN
10000IU
0216784 INNOHEP 10X2ML INJ 17.01 Y E N YLEO /ML
0223147 INNOHEP 2X0.5ML INJ 36.75 Y E N YLEO /SYR
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
60
PHRM/CHRN/CDO/F20:12.04 ANTICOAGULANTS (continued)
20:00 BLOOD FORMATION AND COAGULATION (continued)
TINZAPARIN (continued)
20000IU
0222951 INNOHEP (2X 2ML VIALS 37.68 Y E N YLEO /EA
WARFARIN
1MG
0224292 APO-WARFARIN 0.08 Y Y Y YAPX /TB
0224268 TARO-WARFARIN 0.08 Y Y Y YTAR /TB
0224446 MYLAN-WARFARIN 0.08 Y Y Y YMYL /TB
0191831 COUMADIN 0.36 Y Y Y YBMY /TB
0226527 NOVO-WARFARIN 0.08 Y Y Y YNOP /TB
0234402 SANIS-WARFARIN 0.08 Y Y Y YSAN /TB
10MG
0224268 TARO-WARFARIN 0.12 Y Y Y YTAR /TB
0234411 SANIS-WARFARIN 0.12 Y Y Y YSAN /TB
0224292 APO-WARFARIN 0.12 Y Y Y YAPX /TB
0224446 MYLAN-WARFARIN 0.12 Y Y Y YMYL /TB
0191836 COUMADIN 0.55 Y Y Y YBMY /TB
2MG
0191833 COUMADIN 0.38 Y Y Y YBMY /TB
0226528 NOVO-WARFARIN 0.08 Y Y Y YNOP /TB
0224446 MYLAN-WARFARIN 0.08 Y Y Y YGPM /TB
0224292 APO-WARFARIN 0.08 Y Y Y YAPX /TB
0234403 SANIS-WARFARIN 0.08 Y Y Y YSAN /TB
0224268 TARO-WARFARIN 0.08 Y Y Y YTAR /TB
2.5MG
0224446 MYLAN-WARFARIN 0.07 Y Y Y YMYL /TB
0224268 TARO-WARFARIN 0.07 Y Y Y YTAR /TB
0224292 APO-WARFARIN 0.07 Y Y Y YAPX /TB
0191834 COUMADIN 0.3 Y Y Y YBMY /TB
0234404 SANIS-WARFARIN 0.07 Y Y Y YSAN /TB
0226530 NOVO-WARFARIN 0.07 Y Y Y YNOP /TB
3MG
0224561 APO-WARFARIN 0.1 Y Y Y YAPX /TB
0228749 MYLAN-WARFARIN 0.1 Y Y Y YMYL /TB
0226531 NOVO-WARFARIN 0.1 Y Y Y YNOP /TB
0224268 TARO-WARFARIN 0.1 Y Y Y YTAR /TB
0234406 SANIS-WARFARIN 0.1 Y Y Y YSAN /TB
0224020 COUMADIN 0.47 Y Y Y YBMY /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
61
PHRM/CHRN/CDO/F20:12.04 ANTICOAGULANTS (continued)
20:00 BLOOD FORMATION AND COAGULATION (continued)
WARFARIN (continued)
4MG
0224268 TARO-WARFARIN 0.1 Y Y Y YTAR /TB
0224446 MYLAN-WARFARIN 0.1 Y Y Y YGPM /TB
0200795 COUMADIN 0.47 Y Y Y YBMY /TB
0234407 SANIS-WARFARIN 0.1 Y Y Y YSAN /TB
0226533 NOVO-WARFARIN 0.1 Y Y Y YNOP /TB
0224292 APO-WARFARIN 0.1 Y Y Y YAPX /TB
5MG
0226534 NOVO-WARFARIN 0.07 Y Y Y YNOP /TB
0191835 COUMADIN 0.31 Y Y Y YBMY /TB
0224292 APO-WARFARIN 0.07 Y Y Y YAPX /TB
0224268 TARO-WARFARIN 0.07 Y Y Y YTAR /TB
0234408 SANIS-WARFARIN 0.07 Y Y Y YSAN /TB
0224446 MYLAN-WARFARIN 0.07 Y Y Y YMYL /TB
6MG
0228750 MYLAN-WARFARIN 0.2805 Y Y Y YMYL /TB
0234409 SANIS-WARFARIN 0.2805 Y Y Y YSAN /TB
0224268 TARO-WARFARIN 0.18 Y Y Y YTAR /TB
0224020 COUMADIN 0.47 Y Y Y YBMY /TB
7.5MG
0224269 TARO-WARFARIN 0.19 Y Y Y YTAR /TB
0228752 MYLAN-WARFARIN 0.3014 Y Y Y YMYL /TB
0234410 SANIS-WARFARIN 0.3014 Y Y Y YSAN /TB
20:12.18 PLATELET AGGREGATION INHIBITORS ------------------------------------------------
TICAGRELOR
90MG
0236854 BRILINTA 1.5 E E N YAST /TB
20:15.00 null -------------------------------------------------------------------------------
(SEE A/P FILES)
N/A
0000004 (SEE A/P FILES) 0 N Y N YN/A /null
20:16.00 HEMATOPOIETIC AGENTS -----------------------------------------------------------
DARBEPOETIN ALFA
10MCG/.4ML
0239231 ARANESP 107.2 E E N YAMG /KT
100MCG/.5ML
0239177 ARANESP (HSA-FREE)4X0.5MLSYR 1072 E E N YAMG /KT
150MCG/0.3
0224636 ARANESP (HSA-FREE)4X0.3MLSYR 1608 E E N YAMG /KT
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
62
PHRM/CHRN/CDO/F20:16.00 HEMATOPOIETIC AGENTS (continued)
20:00 BLOOD FORMATION AND COAGULATION (continued)
DARBEPOETIN ALFA (continued)
20MCG/.5ML
0224635 ARANESP (HSA-FREE)4X0.5MLSYR 214.4 E E N YAMG /KT
0239232 ARANESP (HSA-FREE)4X0.5ML 214.4 E E N YAMG /KT
30MCG/.3ML
0224635 ARANESP (HSA-FREE)4X0.3MLSYR 321.6 E E N YAMG /KT
40MCG/.4ML
0239174 ARANESP-(HSA-FREE) 428.8 E E N YAMG /KT
500MCG/ML
0239179 ARANESP-(HSA-FREE) 1608 E E N YAMG /KT
50UG/0.5ML
0239175 ARANESP (HSA-FREE) 134 E E N YAMG /ML
60MCG/.3ML
0239235 ARANESP-(HSA-FREE) 643.2 E E N YAMG /KT
80MCG/.4ML
0224635 ARANESP (HSA-FREE)4X0.4MLSYR 857.6 E E N YAMG /KT
EPOETIN ALFA
1000IU
0223158 EPREX (0.5MLX6 SYR/KIT) 85.5 E E N YJAN /KT
10000IU
0223158 EPREX (1ML X 6 SYR/KIT) 855 E E N YJAN /KT
2000IU
0223158 EPREX (0.5ML X 6 SYR/KIT) 171 E E N YJAN /KT
20000IU
0224323 EPREX (0.5ML X 1 SYR/KIT) 267.9 E E N YJAN /KT
3000IU
0223158 EPREX (0.3ML X 6 SYR/KIT) 256.5 E E N YJAN /KT
30000IU
0228868 EPREX STERILE SOLUTION 357.19 E E N YJAN /KT
4000IU
0223158 EPREX (0.4ML X 6 SYR/KIT) 342 E E N YJAN /KT
40000IU
0224072 EPREX (1ML X 1 SYR/KIT) 420.94 E E N YJAN /KT
5000IU
0224340 EPREX (0.5ML X 6 SYR/KIT) 427.5 E E N YJAN /KT
6000IU
0224340 EPREX (0.6ML X 6 SYR/KIT) 513 E E N YJAN /KT
8000IU
0224340 EPREX (0.8ML X 6 SYR/KIT) 684 E E N YJAN /KT
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
63
PHRM/CHRN/CDO/F20:16.00 HEMATOPOIETIC AGENTS (continued)
20:00 BLOOD FORMATION AND COAGULATION (continued)
FILGRASTIM
FILGRASTIM
300MCG/ML
0196801 NEUPOGEN (10X1.0ML) INJ 173.19 E E N YAMG /KT
PEGFILGRASTIM
10MG/ML
0224979 NEULASTA 6MG (0.6ML SYR) 2504.97 E E N YAMG /EA
20:24.00 HEMORRHEOLOGIC AGENTS ----------------------------------------------------------
CLOPIDOGREL
75MG
0223868 PLAVIX 2.71 Y Y N YSAW /TB
0230302 CO-CLOPIDOGREL 0.47 Y Y N YCOB /TB
0235153 MYLAN-CLOPIDOGREL 0.47 Y Y N YMYL /TB
0234800 PMS-CLOPIDOGREL 0.47 Y Y N YPMS /TB
0240055 CLOPIDOGREL 0.47 Y Y N YSAI /TB
0240891 MINT-CLOPIDOGREL 0.47 Y Y N YMNT /TB
0235931 SDZ-CLOPIDOGREL 0.47 Y Y N YSDZ /TB
0225276 APO-CLOPIDOGREL 0.47 Y Y N YAPX /TB
PENTOXIFYLLINE
400MG
0223009 APO-PENTOXIFYLLINE 0.58 Y Y N YAPX /TB
TICLOPIDINE HCL
250MG
0223648 TEVA-TICLOPIDINE 0.6885 Y Y N YTVM /TB
0234304 SANIS-TICLOPIDINE 0.31 Y Y N YSAN /TB
0223770 APO-TICLOPIDINE 0.31 Y Y N YAPX /TB
0223974 GEN-TICLOPIDINE 0.31 Y Y N YGPM /TB
24:00 CARDIOVASCULAR DRUGS
24:04.00 CARDIAC DRUGS ------------------------------------------------------------------
ACEBUTOLOL HCL
100MG
0225759 SANDOZ-ACEBUTOLOL 0.163 Y Y N YSDZ /TB
0220451 TEVA-ACEBUTOLOL 0.08 Y Y N YTVM /TB
0228624 SANIS-ACEBUTOLOL 0.08 Y Y N YSAN /TB
0223772 MYLAN-ACEBUTOLOL 0.08 Y Y N YMYL /TB
0223788 MYLAN-ACEBUTOLOL (TYPE S) 0.08 Y Y N YMYL /TB
0214760 APO-ACEBUTOLOL 0.08 Y Y N YAPX /TB
0192654 SECTRAL 0.35 Y Y N YAVT /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
64
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
ACEBUTOLOL HCL (continued)
200MG
0220452 TEVA-ACEBUTOLOL 0.12 Y Y N YTVM /TB
0228625 SANIS-ACEBUTOLOL 0.12 Y Y N YSAN /TB
0214761 APO-ACEBUTOLOL 0.12 Y Y N YAPX /TB
0223772 MYLAN-ACEBUTOLOL 0.12 Y Y N YMYL /TB
0225760 SANDOZ-ACEBUTOLOL 0.244 Y Y N YSDZ /TB
0223788 MYLAN-ACEBUTOLOL (TYPE S) 0.12 Y Y N YMYL /TB
0192655 SECTRAL 0.53 Y Y N YAVT /TB
400MG
0192657 SECTRAL 1.05 Y Y N YAVT /TB
0223772 MYLAN-ACEBUTOLOL 0.25 Y Y N YMYL /TB
0223788 MYLAN-ACEBUTOLOL TYPE S 0.25 Y Y N YMYL /TB
0225761 SANDOZ-ACEBUTOLOL 0.4848 Y Y N YSDZ /TB
0214762 APO-ACEBUTOLOL 0.25 Y Y N YAPX /TB
0220453 TEVA-ACEBUTOLOL 0.25 Y Y N YTVM /TB
0228626 SANIS-ACEBUTOLOL 0.25 Y Y N YSAN /TB
AMIODARONE
100MG
0229217 PMS-AMIODARONE 0.76 Y Y N YPMS /TB
200MG
0236433 SANIS-AMIODARONE 0.51 Y Y N YSAN /TB
0224060 MYLAN-AMIODARONE 0.51 Y Y N YMYL /TB
0203628 CORDARONE 2.0589 Y Y N YWYA /TB
0224007 RATIO-AMIODARONE 0.515 Y Y N YRTP /TB
0223983 TEVA-AMIODARONE 0.51 Y Y N YTVM /TB
0224247 PMS-AMIODARONE 0.51 Y Y N YPMS /TB
0224383 SANDOZ-AMIODARONE 0.515 Y Y N YSDZ /TB
0224619 APO-AMIODARONE 0.51 Y Y N YAPX /TB
AMLODIPINE BESYLATE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
65
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
AMLODIPINE BESYLATE (continued)
10MG
0227212 GEN-AMLODIPINE 0.36 Y Y N YGPM /TB
0233129 SANIS-AMLODIPINE 0.36 Y Y N YSAN /TB
0229749 CO-AMLODIPINE 0.36 Y Y N YCOB /TB
0232186 RAN-AMLODIPINE 0.36 Y Y N YRAN /TB
0236267 MINT-AMLODIPINE 0.36 Y Y Y YMNT /TB
0228439 SDZ-AMLODIPINE 0.36 Y Y N YSDZ /TB
0228407 PMS-AMLODIPINE 0.36 Y Y N YPMS /TB
0227338 AP0-AMLODIPINE 0.36 Y Y N YAPX /TB
0087893 NORVASC 1.99 Y Y N YPFI /TB
0237877 ODAN-AMLODIPINE BESYLATE 0.36 Y Y N YODN /TB
0225050 TEVA-AMLODIPINE 0.36 Y Y N YTVM /TB
0225961 RATIO-AMLODIPINE 0.36 Y Y N YRTP /TB
2.5MG
0229747 CO-AMLODIPINE 0.333 Y Y N YCOB /TB
0233047 SDZ-AMLODIPINE 0.14 Y Y N YSDZ /TB
0229514 PMS-AMLODIPINE 0.14 Y Y N YPMS /TB
5MG
0228438 SDZ-AMLODIPINE 0.242 Y Y N YSDZ /TB
0232185 RAN-AMLODIPINE 0.242 Y Y N YRAN /TB
0228406 PMS-AMLODIPINE 0.242 Y Y N YPMS /TB
0087892 NORVASC 1.34 Y Y N YPFI /TB
0237876 ODAN-AMLODIPINE BESYLATE 0.242 Y Y N YODN /TB
0233128 SANIS-AMLODIPINE 0.242 Y Y N YSAN /TB
0236265 MINT-AMLODIPINE BESYLATE 0.242 Y Y N YMNT /TB
0227337 APO-AMLODIPINE 0.242 Y Y N YAPX /TB
0227211 GEN-AMLODIPINE 0.242 Y Y N YGPM /TB
0225049 TEVA-AMLODIPINE 0.242 Y Y N YTVM /TB
0225960 RATIO-AMLODIPINE 0.242 Y Y N YRTP /TB
0229748 CO-AMLODIPINE 0.242 Y Y N YCOB /TB
ATENOLOL
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
66
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
ATENOLOL (continued)
100MG
0223760 PMS-ATENOLOL 0.24 Y Y N YPMS /TB
0203954 TENORMIN 1.01 Y Y N YAST /TB
0191205 NOVO-ATENOL 0.24 Y Y N YNOP /TB
0214743 GEN-ATENOLOL 0.24 Y Y N YGPM /TB
0217180 RATIO-ATENOLOL 0.24 Y Y N YRTP /TB
0077369 APO-ATENOL 0.24 Y Y N YAPX /TB
0236804 MINT-ATENOL 0.24 Y Y N YMNT /TB
0237199 MAR-ATENOLOL 0.24 Y Y N YMAR /TB
0226799 RAN-ATENOLOL 0.24 Y Y N YRAN /TB
0225555 CO-ATENOLOL 0.24 Y Y N YCOB /TB
0223173 SANDOZ-ATENOLOL 3.78 Y Y N YSDZ /TB
25MG
0236801 MINT-ATENOL 0.068 Y Y N YMNT /TB
0224658 PMS-ATENOLOL 0.068 Y Y N YPMS /TB
0237197 MAR-ATENOLOL 0.068 Y Y N YMAR /TB
0237396 RAN-ATENOLOL 0.07 Y Y N YRAN /TB
0226666 NOVO ATENOLOL 0.068 Y Y N YNOP /TB
0230364 MYLAN-ATENOLOL 0.068 Y Y N YMYL /TB
50MG
0237198 MAR-ATENOLOL 0.14 Y Y N YWHL /TB
0226798 RAN-ATENOLOL 0.14 Y Y N YRAN /TB
0225554 CO-ATENOLOL 0.14 Y Y N YCOB /TB
0223173 SANDOZ-ATENOLOL 0.23 Y Y N YSDZ /TB
0236802 MINT-ATENOLOL 0.14 Y Y N YMNT /TB
0077368 APO-ATENOL 0.62 Y Y N YAPX /TB
0217179 RATIO-ATENOLOL 0.14 Y Y N YRTP /TB
0214689 GEN-ATENOLOL 0.14 Y Y N YGPM /TB
0223760 PMS-ATENOLOL 0.14 Y Y N YPMS /TB
0203953 TENORMIN 0.62 Y Y N YAST /TB
0191206 NOVO-ATENOL 0.14 Y Y N YNOP /TB
BISOPROLOL FUMARATE
10MG
0230264 PMS-BISOPROLOL 0.15 Y Y N YPMS /TB
0225617 APO-BISOPROLOL 0.15 Y Y N YAPX /TB
0239159 SANIS-BISOPROLOL FUMARATE 0.15 Y Y N YSAI /TB
0226748 NOVO-BISOPROLOL 0.15 Y Y N YNOP /TB
0224744 SANDOZ-BISOPROLOL 0.15 Y Y N YSDZ /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
67
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
BISOPROLOL FUMARATE (continued)
5MG
0224743 SANDOZ-BISOPROLOL 0.1 Y Y N YSDZ /TB
0225613 APO-BISOPROLOL 0.1 Y Y N YAPX /TB
0230263 PMS-BISOPROLOL 0.1 Y Y N YPMS /TB
0239158 SANIS-BISOPROLOL FUMARATE 0.1 Y Y N YSAI /TB
0238441 MYLAN-BISOPROLOL 0.1 Y Y N YMYL /TB
0226747 NOVO-BISOPROLOL 0.1 Y Y N YNOP /TB
CAPTOPRIL
100MG
0089362 APO-CAPTO 0.519 Y Y N YAPX /TB
0223020 PMS-CAPTOPRIL 1.0395 Y Y N YPMS /TB
0194299 NOVO-CAPTORIL 0.519 Y Y N YNOP /TB
0216359 GEN-CAPTOPRIL 0.52 Y Y N YGPM /TB
12.5MG
0223020 PMS-CAPTOPRIL 0.212 Y Y N YPMS /TB
0194296 NOVO-CAPTORIL 0.106 Y Y N YNOP /TB
0089359 APO-CAPTO 0.106 Y Y N YAPX /TB
0216355 GEN-CAPTOPRIL 0.11 Y Y N YGPM /TB
25MG
0194297 NOVO-CAPTORIL 0.15 Y Y N YNOP /TB
0089360 APO-CAPTO 0.15 Y Y N YAPX /TB
0216357 GEN-CAPTOPRIL 0.15 Y Y N YGPM /TB
0223020 PMS-CAPTOPRIL 0.3 Y Y N YPMS /TB
50MG
0223020 PMS-CAPTOPRIL 0.559 Y Y N YPMS /TB
0194298 NOVO-CAPTORIL 0.279 Y Y N YNOP /TB
0089361 APO-CAPTO 0.279 Y Y N YAPX /TB
0216358 GEN-CAPTOPRIL 0.28 Y Y N YGPM /TB
6.25MG
0199955 APO-CAPTO 0.12 Y Y N YAPX /TB
CARVEDILOL
12.5MG
0224653 TEVA-CARVEDILOL 0.8001 Y Y N YTVM /TB
0225232 RATIO-CARVEDILOL 0.34 Y Y N YRTP /TB
0226804 RAN-CARVEDILOL 0.34 Y Y N YRAN /TB
0236494 SANIS-CARVEDILOL 0.34 Y Y N YSAN /TB
0234755 MYLAN-CARVEDILOL 0.34 Y Y N YMYL /TB
0224793 APO-CARVEDILOL 0.34 Y Y N YAPX /TB
0224591 PMS-CARVEDILOL 0.34 Y Y N YPMS /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
68
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
CARVEDILOL (continued)
25MG
0224591 PMS-CARVEDILOL 0.34 Y Y N YPMS /TB
0236495 SANIS-CARVEDILOL 0.34 Y Y N YSAN /TB
0224653 TEVA-CARVEDILOL 0.8001 Y Y N YTVM /TB
0225233 RATIO-CARVEDILOL 0.34 Y Y N YRTP /TB
0226805 RAN-CARVEDILOL 0.34 Y Y N YRAN /TB
0224793 APO-CARVEDILOL 0.34 Y Y N YAPX /TB
0234757 MYLAN-CARVEDILOL 0.34 Y Y N YMYL /TB
3.125MG
0225230 RATIO-CARVEDILOL 0.34 Y Y N YRPH /TB
0234751 MYLAN-CARVEDILOL 0.34 Y Y N YMYL /TB
0224652 TEVA-CARVEDILOL 0.8001 Y Y N YTVM /TB
0226802 RAN-CARVEDILOL 0.34 Y Y N YRAN /TB
0224793 APO-CARVEDILOL 0.34 Y Y N YAPX /TB
0236491 SANIS-CARVEDILOL 0.34 Y Y N YSAN /TB
0224591 PMS-CARVEDILOL 0.34 Y Y N YPMS /TB
6.25MG
0234752 MYLAN-CARVEDILOL 0.34 Y Y N YMYL /TB
0236492 SANIS-CARVEDILOL 0.34 Y Y N YSAN /TB
0226803 RAN-CARVEDILOL 0.34 Y Y N YRAN /TB
0225231 RATIO-CARVEDILOL 0.34 Y Y N YRTO /TB
0224653 TEVA-CARVEDILOL 0.8001 Y Y N YTVM /TB
0224793 APO-CARVEDILOL 0.34 Y Y N YAPX /TB
0224591 PMS-CARVEDILOL 0.34 Y Y N YPMS /TB
DIGOXIN
0.05MG/ML
0224232 TOLOXIN 1.09 Y Y N YPED /ML
0.0625MG
0224542 PMS-DIGOXIN 0.152 Y Y N YPMS /TB
0233570 TOLOXIN 0.26 Y Y N YMM /TB
0228123 APO-DIGOXIN 0.152 Y Y N YAPX /TB
0224232 LANOXIN 0.2402 Y Y N YVIR /TB
0.125MG
0224542 PMS-DIGOXIN 0.1412 Y Y N YPMS /TB
0233571 TOLOXIN 0.26 Y Y N YMM /TB
0224232 LANOXIN CSD 0.2402 Y Y N YVIR /TB
0228122 APO-DIGOXIN 0.1412 Y Y N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
69
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
DIGOXIN (continued)
0.25MG
0224232 LANOXIN 0.2402 Y Y N YVIR /TB
0233572 TOLOXIN 0.26 Y Y N YMM /TB
0224542 PMS-DIGOXIN 0.1412 Y Y N YPMS /TB
0228120 APO-DIGOXIN 0.1412 Y Y N YAPX /TB
DILTIAZEM HCL
120MG
0209724 CARDIZEM CD 1.61 Y Y N YBVL /CP
0222978 RATIO-DILTIAZEM CD 0.35 Y Y N YRTP /CP
0237061 CO-DILTIAZEM CD 0.35 Y Y N YCOB /CP
0223099 APO-DILTIAZ CD 0.35 Y Y N YAPX /CP
0240042 DILTIAZEM CD 0.35 Y Y N YSAI /CP
0235575 PMS-DILTIAZEM CD 0.35 Y Y N YPMS /CP
0224253 NOVO-DILTAZEM CD 0.35 Y Y N YNOP /CP
0224333 SANDOZ-DILTIAZEM CD 0.35 Y Y N YSDZ /CP
120MG ER
0223115 TIAZAC 0.89 Y Y N YBVL /CP
0227160 NOVO-DILTIAZEM ER 0.21 Y Y N YNOP /CP
0224591 SANDOZ DILTIAZEM T 0.21 Y Y N YSDZ /CP
0225673 TIAZAC XC 0.83 Y Y N YBVL /TB
180MG
0224253 NOVO-DILTAZEM CD 0.47 Y Y N YNOP /CP
0237063 CO DILTIAZEM CD 0.47 Y Y N YCOB /CP
0235576 PMS-DILTIAZEM CD 0.47 Y Y N YPMS /CP
0240044 DILTIAZEM CD 0.47 Y Y N YSAI /CP
0222978 RATIO-DILTIAZEM CD 0.47 Y Y N YRTP /CP
0224333 SANDOZ-DILTIAZEM CD 0.47 Y Y N YSDZ /CP
0223099 APO-DILTIAZ CD 0.47 Y Y N YAPX /CP
0209725 CARDIZEM CD 2.14 Y Y N YBVL /CP
180MG ER
0224591 SANDOZ DILTIAZEM T 0.29 Y Y N YSDZ /CP
0227161 NOVO DILTIAZEM ER 0.29 Y Y N YNOP /CP
0223115 TIAZAC 1.17 Y Y N YBVL /CP
0225674 TIAZAC XC 1.11 Y Y N YBVL /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
70
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
DILTIAZEM HCL (continued)
240MG
0224254 NOVO-DILTAZEM CD 0.62 Y Y N YNOP /CP
0223099 APO-DILTIAZ CD 0.62 Y Y N YAPX /CP
0224334 SANDOZ-DILTIAZEM CD 0.62 Y Y N YSDZ /CP
0235577 PMS-DILTIAZEM CD 0.62 Y Y N YPMS /CP
0222978 RATIO-DILTIAZEM CD 0.62 Y Y N YRTP /CP
0209726 CARDIZEM CD 2.83 Y Y N YBVL /CP
0240045 DILTIAZEM CD 0.62 Y Y N YSAI /CP
240MG ER
0224592 SANDOZ DILTIAZEM T 0.38 Y Y N YSDZ /CP
0227162 NOVO-DILTIAZEM ER 0.38 Y Y N YNOP /CP
0237050 COBALT-DILTIAZEM HCL 0.383 Y Y N YCOB /CP
0223115 TIAZAC 1.58 Y Y N YBVL /CP
0225675 TIAZAC XC 1.47 Y Y N YDVL /TB
30MG
0086292 NOVO-DILTAZEM 0.19 Y Y N YNOP /TB
0077137 APO-DILTIAZ 0.19 Y Y N YAPX /TB
300MG
0224334 SANDOZ-DILTIAZEM CD 0.78 Y Y N YSDZ /CP
0222952 APO-DILTIAZ CD 0.78 Y Y N YAPX /CP
0240046 DILTIAZEM CD 0.78 Y Y N YSAI /CP
0224254 NOVO-DILTAZEM CD 0.78 Y Y N YNOP /CP
0209727 CARDIZEM CD 3.29 Y Y N YBVL /CP
0222978 RATIO-DILTIAZEM CD 1.7652 Y Y N YRTP /CP
300MG ER
0224592 SANDOZ DILTIAZEM T 0.47 Y Y N YSDZ /CP
0223115 TIAZAC 1.96 Y Y N YBVL /CP
0227164 NOVO-DILTIAZEM ER 0.47 Y Y N YNOP /CP
0225676 TIAZAC XC 1.47 Y Y N YBVL /TB
360MG
0237052 CO DILTIAZEM T 0.58 Y Y N YCOB /CP
360MG ER
0227165 NOVO-DILTIAZEM ER 0.58 Y Y N YNOP /CP
0224592 SANDOZ DILTIAZEM T 0.58 Y Y N YSDZ /CP
0223115 TIAZAC 2.38 Y Y N YBVL /CP
0225677 TIAZAC XC 1.47 Y Y N YBVL /TB
60MG
0077138 APO-DILTIAZ 0.33 Y Y N YAPX /TB
0086293 NOVO-DILTAZEM 0.33 Y Y N YNOP /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
71
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
EANALAPRIL MALEATE
EANALAPRIL MALEATE
10MG
0240067 ENALAPRIL 0.26 Y Y N YSAI /TB
ENALAPRIL
10MG
0235225 RAN-ENALAPRIL 0.26 Y Y N YRAN /TB
ENALAPRIL /HCTZ
10MG/25MG
0230023 NOVO-ENALAPRIL/HCTZ 0.5479 Y Y N YNOP /TB
0235293 APO-ENALAPRIL/HCTZ 1.07 Y Y N YAPX /TB
0065729 VASERETIC 1.26 Y Y N YMSD /TB
5MG/12.5MG
0235292 APO-ENALAPRIL/HCTZ 0.49 Y Y N YAPX /TB
0230022 NOVO-ENALAPRIL/HCTZ 0.49 Y Y N YNOP /TB
ENALAPRIL MALEATE
10MG
0230000 RATIO-ENALAPRIL 0.5932 Y Y N YRTP /TB
0230005 MYLAN-ENALAPRIL 0.26 Y Y N YMYL /TB
0229996 SANDOZ ENALAPRIL 0.26 Y Y N YSDZ /TB
0201989 APO-ENALAPRIL 0.26 Y Y N YAPX /TB
0067090 VASOTEC 1.26 Y Y N YMSD /TB
0229189 CO-ENALAPRIL 0.26 Y Y N YCOB /TB
2.5MG
0229993 SANDOZ ENALAPRIL 0.19 Y Y N YSDZ /TB
0229998 RATIO-ENALAPRIL 0.4172 Y Y N YRTP /TB
0230003 MYLAN-ENALAPRIL 0.19 Y Y N YMYL /TB
0085179 VASOTEC 0.89 Y Y N YMSD /TB
0202002 APO-ENALAPRIL 0.19 Y Y N YAPX /TB
0229187 CO-ENALAPRIL 0.19 Y Y N YCOB /TB
0240065 ENALAPRIL 0.19 Y Y N YSAI /null
20MG
0230006 MYLAN-ENALAPRIL 0.32 Y Y N YMYL /TB
0230002 RATIO-ENALAPRIL 0.7156 Y Y N YRTP /TB
0229997 SANDOZ ENALAPRIL 0.32 Y Y N YSDZ /TB
0229190 CO-ENALAPRIL 0.32 Y Y N YCOB /TB
0240068 ENALAPRIL 0.32 Y Y N YSAI /TB
0067092 VASOTEC 1.52 Y Y N YMSD /TB
0201990 APO-ENALAPRIL 0.32 Y Y N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
72
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
ENALAPRIL MALEATE (continued)
5MG
0230004 MYLAN-ENALAPRIL 0.22 Y Y N YMYL /TB
0229999 RATIO-ENALAPRIL 0.4935 Y Y N YRTP /TB
0070887 VASOTEC 1.05 Y Y N YMSD /TB
0240066 ENALAPRIL 0.22 Y Y N YSAI /TB
0229188 CO-ENALAPRIL 0.22 Y Y N YCOB /TB
0229994 SANDOZ ENALAPRIL 0.22 Y Y N YSDZ /TB
0201988 APO-ENALAPRIL 0.22 Y Y N YAPX /TB
ENALAPRIL SODIUM
2MG
0235223 RAN-ENALAPRIL 0.192 Y Y N YRAN /TB
20MG
0235226 RAN-ENALAPRIL 0.32 Y Y N YRAN /TB
4MG
0230008 PMS-ENALAPRIL 4MG(5MG) 0.22 Y Y N YPMS /TB
8MG
0230009 PMS-ENALAPRIL 0.26 Y Y N YPMS /TB
0223300 TEVA-ENALAPRIL 0.26 Y Y N YTVM /TB
FLECAINIDE
100MG
0227554 APO-FLECAINIDE 0.79 Y Y N YAPX /TB
0196620 TAMBOCOR 1.077 Y Y N YMDA /TB
50MG
0196619 TAMBOCOR 0.5384 Y Y N YMDA /TB
0227553 APO-FLECAINIDE 0.4 Y Y N YAPX /TB
LISINOPRIL
10MG
0229424 RAN-LISINOPRIL 0.16 Y Y N YRAN /TB
0221750 APO-LISINOPRIL (TYPE Z) 0.16 Y Y N YAPX /TB
0228920 SANDOZ LISINOPRIL 0.16 Y Y N YSDZ /TB
0227145 CO-LISINOPRIL 0.16 Y Y N YCOB /TB
0229988 RATIO-LISINOPRIL Z 0.16 Y Y N YRTP /TB
0228512 NOVO-LISINOPRIL 0.16 Y Y N YNOP /TB
0083939 PRINIVIL 0.8 Y Y N YMSD /TB
0204937 ZESTRIL 0.69 Y Y N YAST /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
73
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
LISINOPRIL (continued)
20MG
0227147 CO-LISINOPRIL 0.19 Y Y N YCOB /TB
0221751 APO-LISINOPRIL (TYPE Z) 0.19 Y Y N YAPX /TB
0229989 RATIO-LISINOPRIL Z 0.195 Y Y N YRTP /TB
0204938 ZESTRIL 0.83 Y Y N YAST /TB
0229425 RAN-LISINOPRIL 0.19 Y Y N YRAN /TB
0228922 SANDOZ LISINOPRIL 0.19 Y Y N YSDZ /TB
0083941 PRINIVIL 0.96 Y Y N YMSD /TB
0228513 NOVO-LISINOPRIL 0.19 Y Y N YNOP /TB
5MG
0229987 RATIO-LISINOPRIL Z 0.13 Y Y N YRTP /TB
0229423 RAN-LISINOPRIL 0.13 Y Y N YRAN /TB
0228511 NOVO-LISINOPRIL 0.13 Y Y N YNOP /TB
0083938 PRINIVIL 0.64 Y Y N YMSD /TB
0204933 ZESTRIL 0.58 Y Y N YAST /TB
0221748 APO-LISINOPRIL 0.13 Y Y N YAPX /TB
0227144 CO-LISINOPRIL 0.13 Y Y N YCOB /TB
0228919 SANDOZ LISINOPRIL 0.13 Y Y N YSDZ /TB
LISINOPRIL/HYDROCHLO
10/12.5MG
0230236 SDZ-LISINOPRIL/HCT 0.21 Y Y N YSDZ /TB
0236294 LISINOPRIL/HCTZ (TYPE Z) 0.21 Y Y N YSAI /TB
0210372 ZESTORETIC 0.89 Y Y N YAST /TB
0226197 APO-LISINOPRIL/HCTZ 0.208 Y Y N YAPX /TB
20/12.5MG
0230177 TEVA-LISINOPRIL/HCTZ (TYPE Z) 0.25 Y Y N YTEV /TB
0230237 SDZ-LISINOPRIL/HCT 0.25 Y Y N YSDZ /TB
0204573 ZESTORETIC 1.07 Y Y N YAST /TB
0088441 PRINZIDE 0.95 Y Y N YMSD /TB
0236295 LISINOPRIL/HCTZ (TYPE Z) 0.25 Y Y N YSAI /TB
0226198 APO-LISINOPRIL/HCTZ 0.25 Y Y N YAPX /TB
20/25MG
0230178 TEVA-LISINOPRIL/HCTZ (TYPE Z) 0.25 Y Y N YTVM /TB
0229775 MYLAN-LISINOPRIL HCTZ 0.25 Y Y N YMYL /TB
0236296 LISINOPRIL/HCTZ (TYPE Z) 0.25 Y Y N YSAI /TB
0230238 SDZ-LISINOPRIL/HCT 0.25 Y Y N YSDZ /TB
0204572 ZESTORETIC 1.07 Y Y N YAST /TB
METOPROLOL TARTRATE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
74
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
METOPROLOL TARTRATE (continued)
100MG
0223080 RTP-METOPROLOL-L 0.13 Y Y N YRTP /TB
0084265 TEVA-METOPROL (UNCOATED) 0.13 Y Y N YTVM /TB
0064804 TEVA-METOPROL 0.13 Y Y N YTVM /TB
0217455 GEN-METOPROLOL (TYPE L) 0.13 Y Y N YGPM /TB
0235040 SANIS-METOPROLOL FC-TYPE L 0.13 Y Y N YSAN /TB
0075117 APO-METOPROLOL-TYPE L 0.13 Y Y N YAPX /TB
0039743 LOPRESOR 0.65 Y Y N YNVR /TB
0061864 APO-METOPROLOL 0.13 Y Y N YAPX /TB
100MG SR
0230339 SDZ-METOPROLOL SR 0.12 Y Y N YSDZ /TB
0065885 LOPRESOR-SR 0.36 Y Y N YNVR /TB
0228516 APO-METOPROLOL SR 0.12 Y Y N YAPX /TB
200MG SR
0230341 SDZ METOPROLOL SR 200MG 0.25 Y Y N YSDZ /TB
0053456 LOPRESOR-SR 0.65 Y Y N YNVR /TB
0228517 APO-METOPROLOL SR 0.25 Y Y N YAPX /TB
25MG
0224601 APO-METOPROLOL 0.06 Y Y N YAPX /TB
0224885 PMS-METOPROLOL-L 0.06 Y Y N YPMS /TB
0226189 TEVA-METOPROLOL 0.06 Y Y N YTVM /TB
0230205 MYLAN-METOPROLOL-TYPE L 0.06 Y Y N YMYL /TB
50MG
0235418 SANDOZ METOPROLOL (TYPE L) 0.06 Y Y N YSDZ /TB
0235039 SANIS-METOPROLOL FC-TYPE L 0.06 Y Y N YSAN /TB
0223080 PMS-METOPROLOL-L 0.06 Y Y N YPMS /TB
0061863 APO-METOPROLOL 0.06 Y Y N YAPX /TB
0217454 GEN-METOPROLOL (TYPE L) 0.06 Y Y N YGPM /TB
0064803 TEVA-METOPROL 0.06 Y Y N YTVM /TB
0039742 LOPRESOR 0.3 Y Y N YNVR /TB
0084264 TEVA-METOPROL (UNCOATED) 0.06 Y Y N YTVM /TB
0074935 APO-METOPROLOL-TYPE L 0.06 Y Y N YAPX /TB
MEXILETINE HCL
100MG
0223035 NOVO-MEXILETINE 1.35 Y Y N YNOP /CP
200MG
0223036 NOVO-MEXILETINE 1.81 Y Y N YNOP /CP
NADOLOL
160MG
0078247 APO-NADOL 1.2 Y Y N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
75
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
NADOLOL (continued)
40MG
0212675 NOVO-NADOLOL 0.25 Y Y N YNOP /TB
0078250 APO-NADOL 0.45 Y Y N YAPX /TB
80MG
0078246 APO-NADOL 0.37 Y Y N YAPX /TB
0212676 NOVO-NADOLOL 0.35 Y Y N YNOP /TB
NIFEDIPINE
10MG
0075590 APO-NIFED 0.49 Y Y Y YAPX /CP
20MG ER
0223761 ADALAT XL 1.25 Y Y Y YBAY /TB
30MG ER
0215590 ADALAT XL 0.62 Y Y Y YBAY /TB
0234916 MYLAN-NIFEDIPINE XR 30 0.62 Y Y Y YMYL /TB
5MG
0072511 APO-NIFED 0.37 Y Y Y YAPX /CP
60MG ER
0232114 MYLAN-NIFEDIPINE XR 60 0.94 Y Y Y YMYL /TB
0215599 ADALAT XL 0.94 Y Y Y YBAY /TB
PINDOLOL
10MG
0086901 NOVO-PINDOL 0.23 Y Y N YNOP /TB
0075588 APO-PINDOL 0.23 Y Y N YAPX /TB
0044317 VISKEN 1.11 Y Y N YNVR /TB
0223153 PMS-PINDOLOL 0.23 Y Y N YPMS /TB
15MG
0041728 VISKEN 1.435 Y Y N YNVR /TB
0075589 APO-PINDOL 0.34 Y Y N YAPX /TB
0086902 NOVO-PINDOL 0.34 Y Y N YNOP /TB
0223153 PMS-PINDOLOL 0.34 Y Y N YNVR /TB
5MG
0223153 PMS-PINDOLOL 0.14 Y Y N YPMS /TB
0075587 APO-PINDOL 0.14 Y Y N YAPX /TB
0086900 NOVO-PINDOL 0.14 Y Y N YNOP /TB
0041727 VISKEN 0.65 Y Y N YNVR /TB
PROCAINAMIDE HCL
250MG
0071332 APO-PROCAINAMIDE 0.1763 Y Y N YAPX /CP
250MG SR
0063869 PROCAN-SR 0.47 Y Y N YPFI /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
76
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
PROCAINAMIDE HCL (continued)
375MG
0071333 APO-PROCAINAMIDE 0.2301 Y Y N YAPX /CP
500MG
0071334 APO-PROCAINAMIDE 0.306 Y Y N YAPX /CP
500MG SR
0063867 PROCAN-SR 0.65 Y Y N YPFI /TB
750MG SR
0063868 PROCAN-SR 1.05 Y Y N YPFI /TB
PROPAFENONE HCL
150MG
0224332 APO-PROPAFENONE 0.3 Y Y N YAPX /TB
0229455 PMS-PROPAFENONE 0.427 Y Y N YPMS /TB
0224372 PMS-PROPAFENONE 0.4275 Y Y N YPMS /TB
0234305 SANIS-PROPAFENONE 0.4303 Y Y N YSAN /TB
0060370 RYTHMOL 1.26 Y Y N YABB /TB
0224537 GEN-PROPAFENONE 0.3 Y Y N YGPM /TB
300MG
0224372 PMS-PROPAFENONE 0.7537 Y Y N YPMS /TB
0060371 RYTHMOL 2.22 Y Y N YABB /TB
0234306 SANIS-PROPAFENONE 0.754 Y Y N YSAN /TB
0224332 APO-PROPAFENONE 0.53 Y Y N YAPX /TB
0224537 GEN-PROPAFENONE 0.52 Y Y N YGPH /TB
PROPRANOLOL
10MG
0049648 NOVO-PRANOL 0.05 Y Y Y YNOP /TB
0040278 APO-PROPRANOLOL 0.05 Y Y Y YAPX /TB
0058225 PMS-PROPRANOLOL 0.05 Y Y Y YPMS /TB
120MG
0050433 APO-PROPRANOLOL 0.3091 Y Y Y YAPX /TB
120MG LA
0204226 INDERAL-LA 1.09 Y Y Y YWYA /CP
160MG LA
0204227 INDERAL-LA 1.15 Y Y Y YWYA /CP
20MG
0074067 NOVO-PRANOL 0.09 Y Y Y YNOP /TB
0066371 APO-PROPRANOLOL 0.03 Y Y Y YAPX /TB
40MG
0049649 NOVO-PRANOL 0.09 Y Y Y YNOP /TB
0058226 PMS-PROPRANOLOL 0.0348 Y Y Y YPMS /TB
0040275 APO-PROPRANOLOL 0.0348 Y Y Y YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
77
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
PROPRANOLOL (continued)
60MG LA
0204223 INDERAL-LA 0.56 Y Y Y YWYA /CP
80MG
0058227 PMS-PROPRANOLOL 0.06 Y Y Y YPMS /TB
0049650 NOVO-PRANOL 0.14 Y Y Y YNOP /TB
0040276 APO-PROPRANOLOL 0.06 Y Y Y YAPX /TB
80MG LA
0204225 INDERAL-LA 0.63 Y Y Y YWYA /CP
RAMIPRIL
1.25MG
0222182 ALTACE 0.72 Y Y N YHLR /CP
0229536 PMS-RAMIPRIL 0.128 Y Y N YPMS /CP
0228769 RATIO-RAMIPRIL 0.1274 Y Y N YRPH /CP
0231050 RAN-RAMIPRIL 0.13 Y Y N YRAN /CP
0225151 APO-RAMIPRIL 0.13 Y Y N YAPX /CP
0229548 CO-RAMIPRIL 0.13 Y Y N YCOB /CP
10MG
0222185 ALTACE 1.06 Y Y N YHLR /CP
0242132 MINT-RAMIPRIL 0.19 Y Y N YMNT /CP
0231054 RAN-RAMIPRIL 0.19 Y Y N YRAN /CP
0237486 SANIS-RAMIPRIL 0.19 Y Y N YSAI /CP
0225158 APO-RAMIPRIL 0.19 Y Y N YAPX /CP
0228772 RATIO-RAMIPRIL 0.1862 Y Y N YRPH /CP
0224791 PMS-RAMIPRIL 0.1862 Y Y N YPMS /CP
0224794 NOVO-RAMIPRIL 0.19 Y Y N YNOP /CP
15MG
0242050 MAR-RAMIPRIL 0.86 Y Y N YMAR /CP
0228111 ALTACE 1.17 Y Y N YAVT /CP
0232538 APO-RAMIPRIL 0.86 Y Y N YAPX /CP
0231119 RATIO-RAMIPRIL 0.86 Y Y N YRTP /CP
2.5MG
0237484 SANIS-RAMIPRIL 0.15 Y Y N YSAI /CP
0224791 PMS-RAMIPRIL 0.147 Y Y N YPMS /CP
0224794 NOVO-RAMIPRIL 0.15 Y Y N YNOP /CP
0228770 RATIO-RAMIPRIL 0.147 Y Y N YRPH /CP
0229549 CO-RAMIPRIL 0.15 Y Y N YCOB /CP
0231051 RAN-RAMIPRIL 0.15 Y Y N YRAN /CP
0222183 ALTACE 0.83 Y Y N YHLR /CP
0242130 MINT-RAMIPRIL 0.15 Y Y N YMNT /CP
0225153 APO-RAMIPRIL 0.15 Y Y N YAPX /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
78
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
RAMIPRIL (continued)
5MG
0237485 SANIS-RAMIPRIL 0.15 Y Y N YSAI /CP
0242131 MINT-RAMIPRIL 0.147 Y Y N YMNT /CP
0222184 ALTACE 0.83 Y Y N YHLR /CP
0224794 NOVO-RAMIPRIL 0.15 Y Y N YNOP /CP
0224791 PMS-RAMIPRIL 0.147 Y Y N YPMS /CP
0228771 RATIO-RAMIPRIL 0.147 Y Y N YRPH /CP
0225157 APO-RAMIPRIL 0.15 Y Y N YAPX /CP
0231053 RAN-RAMIPRIL 0.15 Y Y N YRAN /CP
0229550 CO-RAMIPRIL 0.15 Y Y N YCOB /CP
RAMIPRIL/HCTZ
10MG/12.5MG
0241265 RAMIPRIL-HCTZ 0.26 Y Y N YSAI /TB
0234215 PMS-RAMIPRIL/HCTZ 0.26 Y Y N YPMS /TB
0228316 ALTACE HCT 0.488 Y Y N YAVT /TB
10MG/25MG
0234217 PMS-RAMIPRIL/HCTZ 0.26 Y Y N YPMS /TB
0241267 RAMIPRIL-HCTZ 0.26 Y Y N YSAI /TB
2.5MG/12.5MG
0234213 PMS-RAMIPRIL/HCTZ 0.16 Y Y N YPMS /TB
0228313 ALTACE HCT 0.2989 Y Y N YAVT /TB
0228318 ALTACE HCT 0.488 Y Y N YAVT /TB
5MG/12.5MG
0234214 PMS-RAMIPRIL/HCTZ 0.21 Y Y N YPMS /TB
0228315 ALTACE HCT 0.382 Y Y N YAVT /TB
0241264 RAMIPRIL-HCTZ 0.21 Y Y N YSAI /TB
5MG/25MG
0234216 PMS-RAMIPRIL/HCTZ 0.21 Y Y N YPMS /TB
0228317 ALTACE HCT 0.382 Y Y N YAVT /TB
SOTALOL HCL
160MG
0227063 CO-SOTALOL 0.41 Y Y N YCOB /TB
0223832 PMS-SOTALOL 0.16 Y Y N YPMS /TB
0223118 NOVO-SOTALOL 0.21 Y Y N YNOP /TB
0216779 APO-SOTALOL 0.16 Y Y N YAPX /TB
0222977 GEN-SOTALOL 0.16 Y Y N YGPM /TB
0208423 RATIO-SOTALOL 0.16 Y Y N YRTP /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
79
PHRM/CHRN/CDO/F24:04.00 CARDIAC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
SOTALOL HCL (continued)
80MG
0227062 CO-SOTALOL 0.37 Y Y N YCOB /TB
0236861 JAMP-SOTALOL 0.3 Y Y N YJPC
/TB
0223832 PMS-SOTALOL 0.3 Y Y N YPMS /TB
0221042 APO-SOTALOL 0.3 Y Y N YAPX /TB
0223118 NOVO-SOTALOL 0.3 Y Y N YNOP /TB
0208422 RATIO-SOTALOL 0.3 Y Y N YRTP /TB
0222977 GEN-SOTALOL 0.3 Y Y N YGPM /TB
TIMOLOL MALEATE
10MG
0194781 NOVO-TIMOL 0.26 Y Y N YNOP /TB
0075585 APO-TIMOL 0.26 Y Y N YAPX /TB
20MG
0075586 APO-TIMOL 0.5 Y Y N YAPX /TB
0194782 NOVO-TIMOL 0.5 Y Y N YNOP /TB
5MG
0194779 NOVO-TIMOL 0.16 Y Y N YNOP /TB
0075584 APO-TIMOL 0.16 Y Y N YAPX /TB
VERAPAMIL HCL
120MG
0223792 GEN-VERAPAMIL 0.43 Y Y Y YGPM /TB
0078249 APO-VERAP 0.43 Y Y Y YAPX /TB
120MG SR
0190712 ISOPTIN SR 1.45 Y Y Y YABB /TB
0221034 GEN-VERAPAMIL SR 0.51 Y Y Y YGPM /TB
0224689 APO-VERAPAMIL 0.51 Y Y Y YAPX /TB
180MG SR
0221035 GEN-VERAPAMIL SR 0.52 Y Y Y YGPM /TB
0193431 ISOPTIN SR 1.63 Y Y Y YABB /TB
0224689 APO-VERAPAMIL 0.52 Y Y Y YAPX /TB
240MG SR
0221036 GEN-VERAPAMIL SR 0.51 Y Y Y YGPM /TB
0223779 PMS-VERAPAMIL SR 0.51 Y Y Y YPMS /TB
0074255 ISOPTIN SR 2.18 Y Y Y YABB /TB
0224689 APO-VERAPAMIL 0.51 Y Y Y YAPX /TB
0221192 NOVO-VERAMIL SR 0.51 Y Y Y YNOP /TB
80MG
0223792 GEN-VERAPAMIL 0.2735 Y Y Y YGPM /TB
0078248 APO-VERAP 0.2735 Y Y Y YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
80
PHRM/CHRN/CDO/F24:04.04 ANTIARRHYTHMIC AGENTS
24:00 CARDIOVASCULAR DRUGS (continued)
DISOPYRAMIDE
24:04.04 ANTIARRHYTHMIC AGENTS ----------------------------------------------------------
100MG
0222480 RYTHMODAN 0.28 Y N N YAVT /CP
24:06.00 ANTILIPEMIC DRUGS --------------------------------------------------------------
ATORVASTATIN
10MG
0235029 RATIO-ATORVASTATIN 0.31 Y Y N YRTP /TB
0232494 SDZ-ATORVASTATIN 0.31 Y Y N YSDZ /TB
0234870 SANIS ATORVASTATIN 0.31 Y Y N YSAN /TB
0231370 RAN-ATORVASTATIN 0.31 Y Y N YRAN /TB
0231089 CO-ATORVASTATIN 0.3138 Y Y N YCOB /TB
0230267 TEVA-ATORVASTATIN 0.3138 Y Y N YTVM /TB
0229526 APO-ATORVASTATIN 0.31 Y Y N YAPX /TB
0223071 LIPITOR 1.77 Y Y N YPFI /TB
0237320 MYLAN-ATORVASTATIN CALCIUM 0.31 Y Y N YMYL /TB
20MG
0234871 SANIS ATORVASTATIN 0.39 Y Y N YSAN /TB
0232495 SDZ-ATORVASTATIN 0.39 Y Y N YSDZ /TB
0229528 APO-ATORVASTATIN 0.39 Y Y N YAPX /TB
0231371 RAN-ATORVASTATIN 0.39 Y Y N YRAN /TB
0235031 RATIO-ATORVASTATIN 0.39 Y Y N YRTP /TB
0230268 TEVA-ATORVASTATIN 0.39 Y Y N YTVM /TB
0239938 PMS-ATORVASTATIN 0.39 Y Y N YPMS /TB
0237321 MYLAN-ATORVASTATIN CALCIUM 0.39 Y Y N YMYL /TB
0231090 CO-ATORVASTATIN 0.39 Y Y N YCOB /TB
0223071 LIPITOR 2.21 Y Y N YPFI /TB
40MG
0234872 SANIS ATORVASTATIN 0.42 Y Y N YSAN /TB
0235032 RATIO-ATORVASTATIN 0.42 Y Y N YRTP /TB
0237323 MYLAN-ATORVASTATIN CALCIUM 0.42 Y Y N YMYL /TB
0223071 LIPITOR 2.38 Y Y N YPFI /TB
0229529 APO-ATORVASTATIN 0.42 Y Y N YAPX /TB
0232496 SDZ-ATORVASTATIN 0.42 Y Y N YSDZ /TB
0230269 TEVA-ATORVASTATIN 0.42 Y Y N YTVM /TB
0231091 CO-ATORVASTATIN 0.42 Y Y N YCOB /TB
0231372 RAN-ATORVASTATIN 0.42 Y Y N YRAN /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
81
PHRM/CHRN/CDO/F24:06.00 ANTILIPEMIC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
ATORVASTATIN CALCIUM (continued)
80MG
0234874 SANIS ATORVASTATIN 0.42 Y Y N YSAN /TB
0235033 RATIO-ATORVASTATIN 0.42 Y Y N YRTP /TB
0231375 RAN-ATORVASTATIN 0.42 Y Y N YRAN /TB
0231092 CO-ATORVASTATIN 0.42 Y Y N YCOB /TB
0230271 TEVA-ATORVASTATIN 0.4216 Y Y N YTVM /TB
0232497 SDZ-ATORVASTATIN 0.42 Y Y N YSDZ /TB
0229531 APO-ATORVASTATIN 0.42 Y Y N YAPX /TB
0224309 LIPITOR 2.38 Y Y N YPFI /TB
BEZAFIBRATE
200MG
0224033 PMS-BEZAFIBRATE 0.8833 Y Y N YPMS /TB
400MG
0208352 BEZALIP SR 2.22 Y Y N YHLR /TB
CHOLESTYRAMINE RESIN
444MG/G
0221032 PMS-CHOLESTYRAMINE RG (4GX30) 1.53 Y Y N YPMS /GM
800MG/G
0089096 PMS-CHOLESTYRAMINE (4GX30) 1.53 Y Y N YPMS /GM
COLESTIPOL HCL RESIN
1G
0213268 COLESTID 0.26 Y Y N YPHU /TB
5G
0064297 COLESTID GRANULES 5.66 Y Y N YPHU /GM
7.5G
0213269 COLESTID GRANULES 0.9346 Y Y N YPHU /GM
EZETIMIBE
10 MG
0242782 APO-EZETIMIBE 0.33 E E N YAPX /TB
0241677 SANDOZ EZETIMIBE 0.33 E E N YSDZ /TB
0242323 JAMP-EZETIMIBE 0.33 E E N YJPC
/TB
0242324 MINT-EZETIMIBE 0.33 E E N YMNT /TB
0224752 EZETROL 1.84 E E N YMSD /TB
10MG
0241471 ACT EZETIMIBE 0.33 E E N YACT /TB
0243130 EZETIMIBE 0.33 E E N YSAI /TB
FENOFIBRATE
100MG
0222598 APO-FENOFIBRATE 0.61 Y Y N YAPX /CP
0235657 FENOFIBRATE-S 0.54 Y Y N YSAI /TB
0228804 SANDOZ FENOFIBRATE S 0.54 Y Y N YSDZ /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
82
PHRM/CHRN/CDO/F24:06.00 ANTILIPEMIC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
FENOFIBRATE (continued)
100MG T
0224160 LIPIDIL SUPRA 1.11 Y Y N YFFR /TB
0224685 APO-FENO-SUPER 0.54 Y Y N YAPX /TB
0228908 NOVO-FENOFIBRATE-S 0.54 Y Y N YNOP /TB
160MG
0228805 SANDOZ FENOFIBRATE S 0.27 Y Y N YSDZ /TB
0235658 FENOFIBRATE-S 0.27 Y Y N YSAI /TB
160MG T
0224686 APO-FENO-SUPER 0.27 Y Y N YAPX /TB
0228909 NOVO-FENOFIBRATE-S 0.27 Y Y N YNOP /TB
0224160 LIPIDIL SUPRA 1.28 Y Y N YFOU /TB
200MG
0223178 PMS-FENOFIBRATE MICRO 1.089 Y Y N YPMS /CP
0224021 GEN-FENOFIBRATE MICRO 0.27 Y Y N YGPM /CP
0223986 APO-FENO-MICRO 0.27 Y Y N YAPX /CP
0224355 NOVO-FENOFIBRATE MICRO 0.27 Y Y N YNOP /CP
0214695 LIPIDIL-MICRO 1.09 Y Y N YFFR /CP
0227355 PMS-FENOFIBRATE MICRO 0.27 Y Y N YPMS /CP
0228609 SANIS-FENOFIBRATE MICRO 0.27 Y Y N YSAN /CP
0225003 RATIO-FENOFIBRATE MC 0.27 Y Y N YTRP /CP
FLUVASTATIN SODIUM
20MG
0206156 LESCOL 0.91 Y Y N YNVR /CP
0240023 SANDOZ FLUVASTATIN 0.22 Y Y N YSDZ /CP
0229922 TEVA-FLUVASTATIN 0.22 Y Y N YTVM /CP
40MG
0206157 LESCOL 1.28 Y Y N YNVR /CP
0240024 SANDOZ FLUVASTATIN 0.31 Y Y N YSDZ /CP
GEMFIBROZIL
300MG
0218540 GEN-GEMFIBROZIL 0.13 Y Y N YGPM /CP
0223995 PMS-GEMFIBROZIL 0.13 Y Y N YPMS /CP
0197957 APO-GEMFIBROZIL 0.13 Y Y N YAPX /CP
0224170 NOVO-GEMFIBROZIL 0.13 Y Y N YNOP /CP
600MG
0214207 NOVO-GEMFIBROZIL 0.52 Y Y N YNOP /TB
0223047 GEN-GEMFIBROZIL 0.52 Y Y N YGPM /TB
0223018 PMS-GEMFIBROZIL 0.52 Y Y N YPMS /TB
0197958 APO-GEMFIBROZIL 0.52 Y Y N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
83
PHRM/CHRN/CDO/F24:06.00 ANTILIPEMIC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
LOVASTATIN
LOVASTATIN
20MG
0079586 MEVACOR 2 Y Y N YMSD /TB
0222017 APO-LOVASTATIN 0.49 Y Y N YAPX /TB
0224312 MYLAN-LOVASTATIN 0.49 Y Y N YMYL /TB
0224601 PMS-LOVASTATIN 0.49 Y Y N YPMS /TB
0224654 TEVA-LOVASTATIN 0.49 Y Y N YTVM /TB
0224705 SANDOZ-LOVASTATIN 0.49 Y Y N YSDZ /TB
0224857 CO LOVASTATIN 0.49 Y Y N YCOB /TB
0235322 SANIS-LOVASTATIN 0.49 Y Y N YSAN /TB
40MG
0224601 PMS-LOVASTATIN 0.9 Y Y N YPMS /TB
0224857 CO LOVASTATIN 0.9 Y Y N YCOB /TB
0224654 TEVA-LOVASTATIN 0.9 Y Y N YTVM /TB
0079585 MEVACOR 3.66 Y Y N YMSD /TB
0235323 SANIS-LOVASTATIN 0.9 Y Y N YSAN /TB
0224312 MYLAN-LOVASTATIN 0.9 Y Y N YMYL /TB
0222018 APO-LOVASTATIN 0.9 Y Y N YAPX /TB
0224705 SANDOZ-LOVASTATIN 0.9 Y Y N YSDZ /TB
PRAVASTATIN
10MG
0224785 SANDOZ-PRAVASTATIN 0.41 Y Y N YSDZ /TB
0224765 PMS-PRAVASTATIN 0.41 Y Y N YPMS /TB
0228442 RAN-PRAVASTATIN 0.41 Y Y N YRAN /TB
0089374 PRAVACHOL 0.953 Y Y N YSQU /TB
0235654 SANIS-PRAVASTATIN 0.41 Y Y N YSAN /TB
0224350 APO-PRAVASTATIN 0.41 Y Y N YAPX /TB
0224700 TEVA-PRAVASTATIN 0.41 Y Y N YTVM /TB
0224693 RATIO-PRAVASTATIN 0.953 Y Y N YRPH /TB
0225709 GEN-PRAVASTATIN 0.41 Y Y N YGPM /TB
0224818 CO PRAVASTATIN 0.41 Y Y N YCOB /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
84
PHRM/CHRN/CDO/F24:06.00 ANTILIPEMIC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
PRAVASTATIN (continued)
20MG
0228444 RAN-PRAVASTATIN 0.48 Y Y N YRAN /TB
0089375 PRAVACHOL 1.1243 Y Y N YSQU /TB
0235655 SANIS-PRAVASTATIN 0.48 Y Y N YSAN /TB
0224700 TEVA-PRAVASTATIN 0.48 Y Y N YTVM /TB
0231747 MINT-PRAVASTATIN 0.48 Y N N YMNT /TB
0224785 SANDOZ-PRAVASTATIN 0.48 Y Y N YSDZ /TB
0225710 GEN-PRAVASTATIN 0.48 Y Y N YGPM /TB
0224350 APO-PRAVASTATIN 0.48 Y Y N YAPX /TB
0224818 CO PRAVASTATIN 0.48 Y Y N YCOB /TB
0224693 RATIO-PRAVASTATIN 1.1243 Y Y N YRPH /TB
0224765 PMS-PRAVASTATIN 0.48 Y Y N YPMS /TB
40MG
0224350 APO-PRAVASTATIN 0.58 Y Y N YAPX /TB
0228445 RAN-PRAVASTATIN 0.58 Y Y N YRAN /TB
0224701 TEVA-PRAVASTATIN 0.58 Y Y N YTVM /TB
0224765 PMS-PRAVASTATIN 0.58 Y Y N YPMS /TB
0224785 SANDOZ-PRAVASTATIN 0.58 Y Y N YSDZ /TB
0224818 CO PRAVASTATIN 0.58 Y Y N YCOB /TB
0225711 GEN-PRAVASTATIN 0.58 Y Y N YGPM /TB
0222205 PRAVACHOL 1.3543 Y Y N YSQU /TB
0224693 RATIO-PRAVASTATIN 1.3543 Y Y N YRPH /TB
0235656 SANIS-PRAVASTATIN 0.58 Y Y N YSAN /TB
ROSUVASTATIN
10MG
0235461 TEVA-ROSUVASTATIN 0.24 Y Y N YTVM /TB
0224716 CRESTOR 1.4 Y Y N YAST /TB
0237853 PMS-ROSUVASTATIN 0.24 Y Y N YPMS /TB
0238265 RAN-ROSUVASTATIN 0.24 Y Y N YRAN /TB
0233977 CO-ROSUVASTATIN 0.24 Y Y N YCOB /TB
0233873 SANDOZ-ROSUVASTATIN 0.24 Y Y N YSDZ /TB
0233798 APO-ROSUVASTATIN 0.24 Y Y N YAPX /TB
0239780 MINT-ROSUVASTATIN 0.24 Y Y N YMNT /TB
0240563 ROSUVASTATIN 0.24 Y Y N YSAI /TB
0238127 MYLAN-ROSUVASTATIN 0.24 Y Y N YMYL /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
85
PHRM/CHRN/CDO/F24:06.00 ANTILIPEMIC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
ROSUVASTATIN (continued)
20MG
0233978 CO-ROSUVASTATIN 0.3 Y Y N YCOB /TB
0233874 SANDOZ-ROSUVASTATIN 0.3 Y Y N YSDZ /TB
0233799 APO-ROSUVASTATIN 0.3 Y Y N YAPX /TB
0237855 PMS-ROSUVASTATIN 0.3 Y Y N YPMS /TB
0238266 RAN-ROSUVASTATIN 0.3 Y Y N YRAN /TB
0238128 MYLAN-ROSUVASTATIN 0.3 Y Y N YMYL /TB
0239781 MINT-ROSUVASTATIN 0.3 Y Y N YMNT /TB
0240564 ROSUVASTATIN 0.3 Y Y N YSAI /TB
0224716 CRESTOR 1.75 Y Y N YAST /TB
0235462 TEVA-ROSUVASTATIN 0.3 Y Y N YTVM /TB
40MG
0235463 TEVA-ROSUVASTATIN 0.36 Y Y N YTVM /TB
0237856 PMS-ROSUVASTATIN 0.36 Y Y N YPMS /TB
0239783 MINT-ROSUVASTATIN 0.36 Y Y N YMNT /TB
0233800 APO-ROSUVASTATIN 0.36 Y Y N YAPX /TB
0233980 CO-ROSUVASTATIN 0.36 Y Y N YCOB /TB
0240565 ROSUVASTATIN 0.36 Y Y N YSAI /TB
0224716 CRESTOR 2.05 Y Y N YAST /TB
0238267 RAN-ROSUVASTATIN 0.36 Y Y N YRAN /TB
0238130 MYLAN-ROSUVASTATIN 0.36 Y Y N YMYL /TB
0233875 SANDOZ-ROSUVASTATIN 0.36 Y Y N YSDZ /TB
5MG
0238126 MYLAN-ROSUVASTATIN 0.23 Y Y N YMYL /TB
0237852 PMS-ROSUVASTATIN 0.23 Y Y N YPMS /TB
0233976 CO-ROSUVASTATIN 0.23 Y Y N YCOB /TB
0233872 SANDOZ-ROSUVASTATIN 0.23 Y Y N YSDZ /TB
0238264 RAN-ROSUVASTATIN 0.23 Y Y N YRAN /TB
0235460 TEVA-ROSUVASTATIN 0.23 Y Y N YTVM /TB
0226554 CRESTOR 1.32 Y Y N YAST /TB
0240562 ROSUVASTATIN 0.23 Y Y N YSAI /TB
0233797 APO-ROSUVASTATIN 0.23 Y Y N YAPX /TB
SIMVASTATIN
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
86
PHRM/CHRN/CDO/F24:06.00 ANTILIPEMIC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
SIMVASTATIN (continued)
10MG
0232915 RAN-SIMVASTATIN 0.36 Y Y N YRAN /TB
0225015 TEVA-SIMVASTATIN 0.36 Y Y N YNOP /TB
0228473 SANIS-SIMVASTATIN 0.36 Y Y N YSAN /TB
0088433 ZOCOR 2.34 Y Y N YMSD /TB
0226926 PMS-SIMVASTATIN 0.36 Y Y N YPMS /TB
0237294 MINT-SIMVASTATIN 0.36 Y Y N YMNT /TB
0224658 MYLAN-SIMVASTATIN 0.36 Y Y N YGPM /TB
0224810 CO SIMVASTATIN 0.36 Y Y N YCOB /TB
0224782 SANDOZ-SIMVASTATIN 0.36 Y Y N YSDZ /TB
0224701 APO-SIMVASTATIN 0.36 Y Y N YAPX /TB
0224706 RATIO-SIMVASTATIN 0.36 Y Y N YRPH /TB
20MG
0232916 RAN-SIMVASTATIN 0.45 Y Y N YRAN /TB
0225016 TEVA-SIMVASTATIN 0.45 Y Y N YNOP /TB
0228475 SANIS-SIMVASTATIN 0.45 Y Y N YSAN /TB
0088434 ZOCOR 2.89 Y Y N YMSD /TB
0226927 PMS-SIMVASTATIN 0.45 Y Y N YPMS /TB
0224701 APO-SIMVASTATIN 0.45 Y Y N YAPX /TB
0224706 RATIO-SIMVASTATIN 0.45 Y Y N YRPH /TB
0224783 SANDOZ-SIMVASTATIN 0.45 Y Y N YSDZ /TB
0224810 CO-SIMVASTATIN 0.45 Y Y N YCOB /TB
0224673 MYLAN-SIMVASTATIN 0.45 Y Y N YGPM /TB
0237295 MINT-SIMVASTATIN 0.45 Y Y N YMNT /TB
40MG
0237296 MINT-SIMVASTATIN 0.45 Y Y N YMNT /TB
0224783 SANDOZ-SIMVASTATIN 0.45 Y Y N YSDZ /TB
0232917 RAN-SIMVASTATIN 0.45 Y Y N YRAN /TB
0224707 RATIO-SIMVASTATIN 0.45 Y Y N YRPH /TB
0225017 TEVA-SIMVASTATIN 0.45 Y Y N YNOP /TB
0224701 APO-SIMVASTATIN 0.45 Y Y N YAPX /TB
0226928 PMS-SIMVASTATIN 0.45 Y Y N YPMS /TB
0088435 ZOCOR 2.89 Y Y N YMSD /TB
0224810 CO SIMVASTATIN 0.45 Y Y N YCOB /TB
0228476 SANIS-SIMVASTATIN 0.45 Y Y N YSAN /TB
0225265 PMS-SIMVASTATIN 1.386 Y Y N YPMS /TB
0224658 MYLAN-SIMVASTATIN 0.45 Y Y N YGPM /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
87
PHRM/CHRN/CDO/F24:06.00 ANTILIPEMIC DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
SIMVASTATIN (continued)
5MG
0224810 CO SIMVASTATIN 0.18 Y Y N YCOB /TB
0225014 TEVA-SIMVASTATIN 0.18 Y Y N YNOP /TB
0228472 SANIS-SIMVASTATIN 0.18 Y Y N YSAN /TB
0224782 SANDOZ-SIMVASTATIN 0.567 Y Y N YSDZ /TB
0088432 ZOCOR 1.19 Y Y N YMSD /TB
0226925 PMS-SIMVASTATIN 0.18 Y Y N YPMS /TB
0232913 RAN-SIMVASTATIN 0.18 Y Y N YRAN /TB
0237293 MINT-SIMVASTATIN 0.18 Y Y N YMNT /TB
0224701 APO-SIMVASTATIN 0.18 Y Y N YAPX /TB
0224658 MYLAN-SIMVASTATIN 0.18 Y Y N YGPM /TB
80MG
0237297 MINT-SIMVASTATIN 0.45 Y Y N YMNT /TB
0224658 MYLAN-SIMVASTATIN 0.45 Y Y N YGPM /TB
0224033 ZOCOR 2.76 Y Y N YMSD /TB
0224810 CO-SIMVASTATIN 0.45 Y Y N YCOB /TB
0224783 SANDOZ-SIMVASTATIN 0.45 Y Y N YSDZ /TB
0224707 RATIO-SIMVASTATIN 0.45 Y Y N YRPH /TB
0224701 APO-SIMVASTATIN 0.45 Y Y N YAPX /TB
0226929 PMS-SIMVASTATIN 0.45 Y Y N YPMS /TB
0228477 SANIS-SIMVASTATIN 0.45 Y Y N YSAN /TB
0225018 TEVA-SIMVASTATIN 0.45 Y Y N YNOP /TB
0232918 RAN-SIMVASTATIN 0.45 Y Y N YRAN /TB
24:06.04 BILE ACID SEQUESTRANTS ---------------------------------------------------------
COLESEVELAM
625MG
0237395 LODALIS 1.1 Y Y N Ynull /TB
24:06.06 FRIBIC ACID DERIVATIVES --------------------------------------------------------
FENOFIBRATE
145MG
0239070 SANDOZ FENOFIBRATE E 0.91 Y Y N YSDZ /TB
0226908 LIPIDIL EZ 1.1 Y Y N YBGP /TB
48MG
0239069 SANDOZ FENOFIBRATE E 0.36 Y Y N YSDZ /TB
24:08.00 HYPOTENSIVE DRUGS --------------------------------------------------------------
ATENOLOL/CHLORTHALI
100/25MG
0204998 TENORETIC 1.12 Y Y N YAST /TB
0224876 APO-ATENIDONE 1.12 Y Y N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
88
PHRM/CHRN/CDO/F24:08.00 HYPOTENSIVE DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
ATENOLOL/CHLORTHALIDONE (continued)
50/25MG
0204996 TENORETIC 0.68 Y Y N YAST /TB
0224876 APO-ATENIDONE 0.68 Y Y N YAPX /TB
BENAZEPRIL HCL
10MG
0229034 APO-BENAZEPRIL 0.6595 Y Y N YAPX /TB
20MG
0227391 APO-BENAZEPRIL 1.21 Y Y N YAPX /TB
0088585 LOTENSIN 1.21 Y Y N YNVR /TB
5MG
0229033 APO-BENAZEPRIL 0.89 Y Y N YAPX /TB
0088583 LOTENSIN 0.89 Y Y N YNVR /TB
CANDESARTAN
16MG
0238070 RAN-CANDESARTAN 0.29 Y Y N YRAN /TB
0236536 APO-CANDESARTAN 0.29 Y Y N YAPX /TB
0223909 ATACAND 1.2 Y Y N YAST /TB
0232697 SDZ-CANDESARTAN 0.29 Y Y N YSDZ /TB
0237654 CO-CANDESARTAN 0.29 Y Y N YCOB /TB
0238893 SANIS - CANDESARTAN CILEXETIL 0.29 Y Y N YSAI /TB
32MG
0237655 CO-CANDESARTAN 0.29 Y Y N YCOB /TB
0241734 SANDOZ CANDESARTAN 0.29 Y Y N YSDZ /TB
0231165 ATACAND 1.2 Y Y N YAST /TB
4MG
0232695 SDZ-CANDESARTAN 0.34 Y Y N YSDZ /TB
0237912 MYLAN-CANDESARTAN 0.34 Y Y N YMYL /TB
0238068 RAN-CANDESARTAN 0.34 Y Y N YRAN /TB
0236534 APO-CANDESARTAN 0.34 Y Y N YAPX /TB
0237652 CO-CANDESARTAN 0.34 Y Y N YCOB /TB
0223909 ATACAND 0.72 Y Y N YAST /TB
0238890 CANDESARTAN 0.34 Y Y N YSAI /TB
8MG
0238069 RAN-CANDESARTAN 0.29 Y Y N YRAN /TB
0236631 TEVA-CANDESARTAN 0.29 Y Y N YTVM /TB
0236535 APO-CANDESARTAN 0.29 Y Y N YAPX /TB
0232696 SDZ-CANDESARTAN 0.29 Y Y N YSDZ /TB
0238892 SANIS-CANDESARTAN CILEXETIL 0.29 Y Y N YSAI /TB
0237653 CO-CANDESARTAN 0.29 Y Y N YCOB /TB
0223909 ATACAND 1.2 Y Y N YAST /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
89
PHRM/CHRN/CDO/F24:08.00 HYPOTENSIVE DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
CANDESARTAN/HCTZ
CANDESARTAN/HCTZ
16/12.5 MG
0238865 CO CANDESARTAN/HCT 0.299 Y Y N YCOB /TB
16/12.5MG
0236786 APO-CANDESARTAN/HCTZ 0.3 Y Y N YAPX /TB
0232790 SANDOZ-CANDESARTAN/HCTZ 0.3 Y Y N YSDZ /TB
0224402 ATACAND PLUS 1.2 Y Y N YAST /TB
0237489 MYLAN-CANDESARTAN/HCTZ 0.299 Y Y N YMYL /TB
32/12.5MG
0233292 ATACAND PLUS 1.2 Y Y N YAST /TB
0239512 APO-CANDESARTAN/HCTZ 0.3 Y Y N YAPX /TB
CANDESARTAN/HYDROC
16/12.5
0239480 CANDESARTAN/HCTZ 0.299 Y Y N YSAI /TB
CANDESARTEN
32
0243584 CANDESARTAN 0.29 Y Y N YSAI /TB
CILAZAPRIL
1 MG
0229113 APO-CILAZAPRIL 0.1557 Y Y N YAPX /TB
0235096 SANIS-CILAZAPRIL 0.3717 Y Y N YSAN /TB
0226635 TEVA-CILAZAPRIL 0.1557 Y Y N YTVM /TB
0228044 PMS-CILAZAPRIL 0.1557 Y Y N YPMS /TB
0228377 GEN-CILAZAPRIL 0.16 Y Y N YGPM /TB
2.5 MG
0228045 PMS-CILAZAPRIL 0.1795 Y Y N YPMS /TB
0235097 SANIS-CILAZAPRIL 0.18 Y Y N YSAN /TB
0229114 APO-CILAZAPRIL 0.1795 Y Y N YAPX /TB
0226636 TEVA-CILAZAPRIL 0.1795 Y Y N YTVM /TB
0191147 INHIBACE 0.74 Y Y N YHLR /TB
0228378 GEN-CILAZAPRIL 0.18 Y Y N YGPM /TB
0228521 CO CILAZAPRIL 0.18 Y Y N YCOB /TB
5 MG
0229115 APO-CILAZAPRIL 0.21 Y Y N YAPX /TB
0228046 PMS-CILAZAPRIL 0.21 Y Y N YPMS /TB
0228522 CO CILAZAPRIL 0.21 Y Y N YCOB /TB
0235099 SANIS-CILAZAPRIL 0.21 Y Y N YSAN /TB
0228379 GEN-CILAZAPRIL 0.21 Y Y N YGPM /TB
0191148 INHIBACE 0.86 Y Y N YHLR /TB
0226637 TEVA-CILAZAPRIL 0.21 Y Y N YTVM /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
90
PHRM/CHRN/CDO/F24:08.00 HYPOTENSIVE DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
CILAZAPRIL/HCTZ
CILAZAPRIL/HCTZ
5MG/12.5MG
0228498 APO-CILAZAPRIL/HCTZ 0.417 Y Y N YAPX /TB
0231373 TEVA-CILAZAPRIL/HCTZ 0.417 Y Y N YTVM /TB
0218147 INHIBACE PLUS 0.86 Y Y N YHLR /TB
CLONIDINE HCL
0.025MG
0224873 APO-CLONIDINE 0.1817 Y N N YAPX /TB
0051925 DIXARIT 0.27 Y N N YBOE /TB
0230416 TEVA-CLONIDINE 0.26 Y Y Y YTVM /TB
0.1MG
0204612 TEVA-CLONIDINE 0.1765 Y Y N YTVM /TB
0025952 CATAPRES 0.19 Y Y N YBOE /TB
0086894 APO-CLONIDINE 0.1765 Y Y N YAPX /TB
0.2MG
0086895 APO-CLONIDINE 0.3149 Y Y N YAPX /TB
0029188 CATAPRES 0.3306 Y Y N YBOE /TB
0204614 TEVA-CLONIDINE 0.3149 Y Y N YTVM /TB
DOXAZOSIN MESYLATE
1MG
0195810 CARDURA-1 0.58 Y Y N YPFI /TB
0224272 NOVO-DOXAZOSIN 0.14 Y Y N YNOP /TB
0224049 GEN-DOXAZOSIN 0.14 Y Y N YGPM /TB
0224058 APO-DOXAZOSIN 0.14 Y Y N YAPX /TB
2MG
0195809 CARDURA-2 0.7 Y Y N YPFI /TB
0224049 GEN-DOXAZOSIN 0.17 Y Y N YGPM /TB
0224272 NOVO-DOXAZOSIN 0.17 Y Y N YNOP /TB
0224058 APO-DOXAZOSIN 0.17 Y Y N YAPX /TB
4MG
0224059 APO-DOXAZOSIN 0.22 Y Y N YAPX /TB
0195811 CARDURA-4 0.91 Y Y N YPFI /TB
0224273 NOVO-DOXAZOSIN 0.22 Y Y N YNOP /TB
0224050 GEN-DOXAZOSIN 0.22 Y Y N YGPM /TB
EPROSARTAN
400MG
0224043 TEVETEN 0.72 Y Y N YSLV /TB
600MG
0224394 TEVETEN 1.11 Y Y N YSLV /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
91
PHRM/CHRN/CDO/F24:08.00 HYPOTENSIVE DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
EPROSARTAN/HYDROCHLOROTHIAZIDE
EPROSARTAN/HYDROCH
600/12.5MG
0225363 TEVETEN PLUS 1.11 Y Y N YABB /TB
FELODIPINE
10MG
0222200 RENEDIL 0.67 Y Y N YHLR /TB
0228027 SANDOZ FELODIPINE 0.84 Y Y N YSDZ /TB
0085178 PLENDIL 1.03 Y Y N YAST /TB
2.5MG
0222198 RENEDIL 0.32 Y Y N YHLR /TB
0205777 PLENDIL 0.54 Y Y N YAST /TB
5MG
0228026 SANDOZ FELODIPINE 0.56 Y Y N YSDZ /TB
0222199 RENEDIL 0.46 Y Y N YHLR /TB
0085177 PLENDIL 0.69 Y Y N YAST /TB
FOSINOPRIL
10MG
0226600 APO-FOSINOPRIL 0.22 Y Y N YAPX /TB
0226240 MYLAN-FOSINOPRIL 0.22 Y Y N YGEN /TB
0224780 NOVO-FOSINOPRIL 0.22 Y Y N YNOP /TB
0225594 PMS-FOSINOPRIL 0.4977 Y Y N YPMS /TB
20MG
0226601 APO-FOSINOPRIL 0.26 Y Y N YAPX /TB
0226242 MYLAN-FOSINOPRIL 0.26 Y Y N YGEN /TB
0224780 NOVO-FOSINOPRIL 0.26 Y Y N YNOP /TB
0225595 PMS-FOSINOPRIL 0.5987 Y Y N YPMS /TB
HYDRALAZINE HCL
10MG
0044161 APO-HYDRALAZINE 0.13 Y Y N YAPX /TB
25MG
0044162 APO-HYDRALAZINE 0.23 Y Y N YAPX /TB
50MG
0044163 APO-HYDRALAZINE 0.36 Y Y N YAPX /TB
INDAPAMIDE/PERINDOP
1.25MG/4MG
0224656 COVERSYL PLUS 1.01 Y Y N YSEV /TB
2.5MG/8MG
0232165 COVERSYL PLUS HD 1.13 Y Y N YSEV /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
92
PHRM/CHRN/CDO/F24:08.00 HYPOTENSIVE DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
IRBESARTAN
IRBESARTAN
150MG
0232808 CO-IRBESARTAN 0.3025 Y Y N YCOB /TB
0223792 AVAPRO 1.27 Y Y N YBMY /TB
0232848 SDZ-IRBESARTAN 0.3 Y Y N YSDZ /TB
0231707 PMS-IRBESARTAN 0.3 Y Y N YPMS /TB
0231641 RATIO-IRBESARTAN 0.3 Y Y N YRTP /TB
0231599 TEVA-IRBESARTAN 0.3 Y Y N YTVM /TB
0237237 SANIS-IRBESARTAN 0.3 Y Y N YSAI /TB
300MG
0237239 SANIS-IRBESARTAN 0.3 Y Y N YSAI /TB
0223792 AVAPRO 1.27 Y Y N YBMY /TB
0231708 PMS-IRBESARTAN 0.3 Y Y N YPMS /TB
0231640 RATIO-IRBESARTAN 0.3 Y Y N YRTP /TB
0231600 TEVA-IRBESARTAN 0.3 Y Y N YTVM /TB
0232849 SDZ-IRBESARTAN 0.3 Y Y N YSDZ /TB
0232810 CO-IRBESARTAN 0.3 Y Y N YCOB /TB
75MG
0232846 SDZ-IRBESARTAN 0.3 Y Y N YSDZ /TB
0223792 AVAPRO 1.27 Y Y N YBMY /TB
0237234 SANIS-IRBESARTAN 0.3 Y Y N YSAI /TB
0231706 PMS-IRBESARTAN 0.3 Y Y N YPMS /TB
0231639 RATIO-IRBESARTAN 0.3 Y Y N YRTP /TB
0231597 TEVA-IRBESARTAN 0.3 Y Y N YTVM /TB
0232807 CO-IRBESARTAN 0.3 Y Y N YCOB /TB
IRBESARTAN/HYDROCHL
150/12.5MG
0233051 RATIO-IRBESARTAN/HCTZ 0.3 Y Y N YRTP /TB
0232851 PMS-IRBESARTAN/HCTZ 0.3 Y Y N YPMS /TB
0233742 SDZ-IRBESARTAN HCT 0.3 Y Y N YSDZ /TB
0224181 AVALIDE 1.27 Y Y N YSAN /TB
0231601 TEVA-IRBESARTAN/HCTZ 0.3 Y Y N YTVM /TB
0235739 CO-IRBESARTAN/HCTZ 0.3 Y Y N YCOB /TB
150MG/12.5MG
0237288 SANIS- 0.3 Y Y N YSAI /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
93
PHRM/CHRN/CDO/F24:08.00 HYPOTENSIVE DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
IRBESARTAN/HYDROCHLOROTHIAZIDE (continued)
300/12.5MG
0233052 RATIO-IRBESARTAN/HCTZ 0.3 Y Y N YRTP /TB
0232852 PMS-IRBESARTAN/HCTZ 0.3 Y Y N YPMS /TB
0231602 TEVA-IRBESARTAN/HCTZ 0.3 Y Y N YTVM /TB
0224181 AVALIDE 1.27 Y Y N YSAN /TB
0235740 CO-IRBESARTAN/HCTZ 0.3 Y Y N YCOB /TB
0233743 SDZ-IRBESARTAN HCT 0.3 Y Y N YSDZ /TB
300MG/12.5MG
0237289 SANIS- 0.3 Y Y N YSAI /TB
300/25MG
0235741 CO-IRBESARTAN/HCTZ 0.3 Y Y N YCOB /TB
0231604 TEVA-IRBESARTAN/HCTZ 0.3 Y Y N YTVM /TB
0233744 SDZ-IRBESARTAN HCT 0.3 Y Y N YSDZ /TB
0233053 RATIO-IRBESARTAN/HCTZ 0.3 Y Y N YRTP /TB
0232853 PMS-IRBESARTAN/HCTZ 0.3 Y Y N YPMS /TB
300MG/25MG
0237290 SANIS- 0.3 Y Y N YSAI /TB
LABETALOL HCL
100MG
0210627 TRANDATE 0.33 Y Y N YRBP /TB
200MG
0210628 TRANDATE 0.58 Y Y N YRBP /TB
LOSARTAN
100/12.5MG
0236244 SANDOZ-LOSARTAN 0.31 Y Y N YSDZ /TB
0237124 APO-LOSARTAN-HCTZ 100/12.5 0.31 Y Y N YAPX /TB
100MG/12.5MG
0237714 TEVA-LOSARTAN 0.31 Y Y N YTVM /TB
0237808 MYLAN-LOSARTAN 0.31 Y Y N YMYL /TB
0229784 HYZAAR 100/12.5 1.35 Y Y N YMSD /TB
100/25MG
0237715 TEVA-LOSARTAN 0.31 Y Y N YTVM /TB
0231338 SANDOZ-LOSARTAN 0.31 Y Y N YSDZ /TB
0224100 HYZAAR DS 100/25 1.37 Y Y N YMSD /TB
0237125 APO-LOSARTAN-HCTZ 100/25 0.31 Y Y N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
94
PHRM/CHRN/CDO/F24:08.00 HYPOTENSIVE DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
LOSARTAN /HYDROCHLOROTHIAZIDE (continued)
50/12.5MG
0237807 MYLAN-LOSARTAN 0.31 Y Y N YMYL /TB
0238965 MINT-LOSARTAN/HCTZ 0.3147 Y Y N YMNT /TB
0235826 TEVA-LOSARTAN 0.31 Y Y N YTVM /TB
0237123 APO-LOSARTAN-HCTZ 50/12.5 0.31 Y Y N YAPX /TB
0231337 SANDOZ-LOSARTAN 0.31 Y Y N YSDZ /TB
0223004 HYZAAR 50/12.5 1.37 Y Y N YMSD /TB
LOSARTAN POTASSIUM
100MG
0236829 MYLAN-LOSARTAN 0.31 Y Y N YMYL /TB
0238889 SANIS-LOSARTAN POTASSIUM 0.31 Y Y N YSAI /TB
0235351 APO-LOSARTAN 0.31 Y Y N YAPX /TB
0240576 MINT-LOSARTAN 0.36 Y Y N YMNT /TB
0218288 COZAAR 1.37 Y Y N YMSD /TB
0230977 PMS-LOSARTAN 0.31 Y Y N YPMS /TB
0231335 SANDOZ-LOSARTAN POTASSIUM 0.31 Y Y N Ynull /TB
0235797 TEVA-LOSARTAN POTASSIUM 0.31 Y Y N YTVM /TB
0235484 COBALT-LOSARTAN POTASSIUM 0.31 Y Y N YCOB /TB
25MG
0235482 COBALT-LOSARTAN POTASSIUM 0.56 Y Y N YCOB /TB
0237905 APO-LOSARTAN 0.31 Y Y N YAPX /TB
0238083 TEVA-LOSARTAN POTASSIUM 0.31 Y Y N YTVM /TB
0236827 MYLAN-LOSARTAN 0.31 Y Y N YMYL /TB
0231333 SANDOZ-LOSARTAN POTASSIUM 0.31 Y Y N YSDZ /TB
0230975 PMS-LOSARTAN 0.31 Y Y N YPMS /TB
0218281 COZAAR 1.37 Y Y N YMSD /TB
0238886 SANIS-LOSARTAN 0.31 Y Y N YSAI /TB
50MG
0218287 COZAAR 1.3 Y Y N YMSD /TB
0231334 SANDOZ-LOSARTAN POTASSIUM 0.31 Y Y N YSDZ /TB
0236828 MYLAN-LOSARTAN 0.31 Y Y N YMYL /TB
0235796 TEVA-LOSARTAN POTASSIUM 0.31 Y Y N YTVM /TB
0238887 SANIS-LOSARTAN POTASSIUM 0.31 Y Y N YSAI /TB
0235350 APO-LOSARTAN 0.36 Y Y N YAPX /TB
0235483 COBALT-LOSARTAN POTASSIUM 0.31 Y Y N YCOB /TB
0240574 MINT-LOSARTAN 0.36 Y Y N YMNT /TB
0230976 PMS-LOSARTAN 0.31 Y Y N YPMS /TB
LOSARTAN/HYDROCHLO
100/12.5MG
0238966 MINT-LOSARTAN/HCTZ 0.31 Y Y N YMNT /TB
0238827 CO LOSARTAN/HCT 0.31 Y Y N YCOB /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
95
PHRM/CHRN/CDO/F24:08.00 HYPOTENSIVE DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
LOSARTAN/HYDROCHLOROTHIAZIDE (continued)
100/25MG
0242766 LOSARTAN/HCTZ 0.31 Y Y N YSAI /TB
0238828 CO LOSARTAN/HCT 0.31 Y Y N YCOB /TB
0238967 MINT-LOSARTAN/HCTZ DS 0.31 Y Y N YMNT /TB
0239224 PMS-LOSARTAN-HCTZ 0.31 Y Y N YPMS /TB
50/12.5MG
0242764 LOSARTAN/HCTZ 0.31 Y Y N YSAN /TB
0238825 CO 0.31 Y Y N YCOB /TB
0239222 PMS-LOSARTAN-HCTZ 0.31 Y Y N YPMS /TB
METHYLDOPA
125MG
0036025 APO-METHYLDOPA 0.1 Y Y N YAPX /TB
250MG
0036026 APO-METHYLDOPA 0.14 Y Y N YAPX /TB
500MG
0042683 APO-METHYLDOPA 0.25 Y Y N YAPX /TB
METHYLDOPA/HYDROC
250/15MG
0044170 APO-METHAZIDE-15 0.168 Y Y N YAPX /TB
250/25MG
0044171 APO-METHAZIDE-25 0.1835 Y Y N YAPX /TB
MINOXIDIL
10MG
0051450 LONITEN 0.76 Y Y N YPHU /TB
2.5MG
0051449 LONITEN 0.35 Y Y N YPHU /TB
OLMESARTAN
20MG
0231866 OLMETEC 1.08 Y Y N YSCP /TB
40MG
0231867 OLMETEC 1.08 Y Y N YSCP /TB
OLMESARTAN/HYDROC
20/12.5MG
0231961 OLMETEC PLUS 1.08 Y Y N YMSD /TB
40/25MG
0231963 OLMETEC PLUS 1.1 Y Y N YMSD /TB
PERINDOPRIL ERBUMINE
2MG
0212327 COVERSYL 0.65 Y Y N YSEV /TB
4MG
0212328 COVERSYL 0.81 Y Y N YSEV /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
96
PHRM/CHRN/CDO/F24:08.00 HYPOTENSIVE DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
PERINDOPRIL ERBUMINE (continued)
8MG
0224662 COVERSYL 1.14 Y Y N YSEV /TB
PINDOLOL/HYDROCHLO
10/25MG
0056862 VISKAZIDE 1 Y Y N YNVR /TB
10/50MG
0056863 VISKAZIDE 1 Y Y N YNVR /TB
PRAZOSIN
1MG
0088280 APO-PRAZO 0.26 Y Y N YAPX /TB
0193419 NOVO-PRAZIN 0.26 Y Y N YNOP /TB
2MG
0193420 NOVO-PRAZIN 0.36 Y Y N YNOP /TB
0088282 APO-PRAZO 0.36 Y Y N YAPX /TB
5MG
0193422 NOVO-PRAZIN 0.5 Y Y N YNOP /TB
0088283 APO-PRAZO 0.49 Y Y N YAPX /TB
QUINAPRIL HCL
10MG
0194767 ACCUPRIL 0.91 Y Y N YPFI /TB
0224850 APO-QUINAPRIL 0.69 Y Y N Ynull /TB
0229099 GD-QUINAPRIL 0.69 Y Y N YGDI /TB
0234056 PMS-QUINAPRIL 0.69 Y Y N YPMS /TB
20MG
0234057 PMS-QUINAPRIL 0.69 Y Y N YPMS /TB
0194768 ACCUPRIL 0.91 Y Y N YPFI /TB
0224850 APO-QUINAPRIL 0.23 Y Y N YAPX /TB
0229100 GD-QUINAPRIL 0.23 Y Y N YGDI /TB
40MG
0194769 ACCUPRIL 0.91 Y Y N YPFI /TB
0224850 APO-QUINAPRIL 0.69 Y Y N YAPX /TB
0234058 PMS-QUINAPRIL 0.69 Y Y N YPMS /TB
5MG
0194766 ACCUPRIL 0.91 Y Y N YPFI /TB
0224849 APO-QUINAPRIL 0.69 Y Y N YAPX /TB
QUINAPRIL/HYDROCHLO
10/12.5MG
0223736 ACCURETIC 0.91 Y Y N YPFI /TB
0240876 APO-QUINAPRIL/HCTZ 0.69 Y Y N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
97
PHRM/CHRN/CDO/F24:08.00 HYPOTENSIVE DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
QUINAPRIL/HYDROCHLOROTHIAZIDE (continued)
20/12.5MG
0240877 APO-QUINAPRIL/HCTZ 0.69 Y Y N YAPX /TB
0223736 ACCURETIC 0.91 Y Y N YPFI /TB
25/20MG
0240878 APO- 0.65 Y Y N YAPX /TB
0223736 ACCURETIC 0.87 Y Y N YPFI /TB
TELMISARTAN
40MG
0232017 TEVA-TELMISARTAN 0.28 Y Y N YTVM /TB
0237671 MYLAN-TELMISARTAN 0.28 Y Y N YMYL /TB
0237595 SANDOZ-TELMISARTAN 0.28 Y Y N YSDZ /TB
0224076 MICARDIS 1.17 Y Y N YBOE /TB
0238894 SANIS-TELMISARTAN 0.28 Y Y N YSAI /TB
80MG
0239325 ACT TELMISARTAN 0.28 Y Y N YACT /TB
0224077 MICARDIS 1.17 Y Y N YBOE /TB
0232018 TEVA-TELMISARTAN 0.28 Y Y N YTVM /TB
0237672 MYLAN-TELMISARTAN 0.28 Y Y N YMYL /TB
0237596 SANDOZ-TELMISARTAN 0.28 Y Y N YSDZ /TB
0238895 SANIS-TELMISARTAN 0.282 Y Y N YSAI /TB
TELMISARTAN/AMLODIPI
5/40MG
0237102 TWYNSTA 0.68 Y Y N YBOE /TB
5/80MG
0237104 TWYNSTA 0.68 Y Y N YBOE /TB
80/10MG
0237105 TWYNSTA 0.68 Y Y N YBOE /TB
TELMISARTAN/HCTZ
80/12.5MG
0239355 SANDOZ-TELMISARTAN/HCTZ 0.28 Y Y N YSDZ /TB
0233028 TEVA-TELMISARTAN/HCTZ 0.28 Y Y N YTVM /TB
0239535 TELMISARTAN/HCTZ 0.28 Y Y N YSAI /TB
0237356 MYLAN-TELMISARTAN/HCTZ 0.28 Y Y N YMYL /TB
0224434 MICARDIS PLUS 1.17 Y Y N YBOE /TB
80/25MG
0239356 SANDOZ-TELMISARTAN HCT 0.28 Y Y N YSDZ /TB
0237357 MYLAN-TELMISARTAN/HCTZ 0.28 Y Y N YMYL /TB
0237925 TEVA-TELMISARTAN/HCTZ 0.28 Y Y N YTVM /TB
0240167 PMS-TELMISARTAN-HCTZ 0.28 Y Y N YPMS /TB
0239536 TELMISARTAN/HCTZ 0.28 Y Y N YSAI /TB
0231870 MICARDIS PLUS 1.17 Y Y N YBOE /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
98
PHRM/CHRN/CDO/F24:08.00 HYPOTENSIVE DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
TERAZOSIN HCL
TERAZOSIN HCL
1MG
0224351 PMS-TERAZOSIN 0.18 Y Y N YPMS /TB
0081865 HYTRIN 0.79 Y Y N YABB /TB
0221894 RATIO-TERAZOSIN 0.18 Y Y N YRTP /TB
0235047 SANIS-TERAZOSIN 0.18 Y Y N YSAN /TB
0223450 APO-TERAZOSIN 0.18 Y Y N YAPX /TB
0223080 TEVA-TERAZOSIN 0.18 Y Y N YTVM /TB
10MG
0223080 TEVA-TERAZOSIN 0.46 Y Y N YTVM /TB
0235050 SANIS-TERAZOSIN 0.46 Y Y N YSAN /TB
0224352 PMS-TERAZOSIN 0.46 Y Y N YPMS /TB
0081867 HYTRIN 1.99 Y Y N YABB /TB
0223450 APO-TERAZOSIN 0.46 Y Y N YAPX /TB
0221898 RATIO-TERAZOSIN 0.46 Y Y N YRTP /TB
2MG
0224351 PMS-TERAZOSIN 0.23 Y Y N YPMS /TB
0223080 TEVA-TERAZOSIN 0.23 Y Y N YTVM /TB
0081868 HYTRIN 0.99 Y Y N YABB /TB
0221896 RATIO-TERAZOSIN 0.23 Y Y N YRTP /TB
0223450 APO-TERAZOSIN 0.23 Y Y N YAPX /TB
0235048 SANIS-TERAZOSIN 0.23 Y Y N YSAN /TB
5MG
0235049 SANIS-TERAZOSIN 0.32 Y Y N YSAN /TB
0223450 APO-TERAZOSIN 0.32 Y Y N YAPX /TB
0224352 PMS-TERAZOSIN 0.32 Y Y N YPMS /TB
0223080 TEVA-TERAZOSIN 0.32 Y Y N YTVM /TB
0221897 RATIO-TERAZOSIN 0.32 Y Y N YRTP /TB
0081866 HYTRIN 1.36 Y Y N YABB /TB
TRANDOLAPRIL
0.5MG
0223145 MAVIK 0.27 Y Y N YABB /CP
1MG
0223145 MAVIK 0.69 Y Y N YABB /CP
2MG
0223146 MAVIK 0.79 Y Y N YABB /CP
4MG
0223926 MAVIK 0.98 Y Y N YABB /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
99
PHRM/CHRN/CDO/F24:08.00 HYPOTENSIVE DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
TRIAMTERENE/HYDROCHLOROTHIAZID
TRIAMTERENE/HYDROC
50/25MG
0053265 NOVO-TRIAMZIDE 0.0608 Y Y N YNOP /TB
0044177 APO-TRIAZIDE 0.0608 Y Y N YAPX /TB
VALSARTAN
160MG
0233750 CO-VALSARTAN 0.3 Y Y N YCOB /TB
0224478 DIOVAN 1.199 Y Y N YNVR /TB
0235676 SDZ-VALSARTAN 0.3 Y Y N YSDZ /TB
0236311 RAN-VALSARTAN 0.3 Y Y N YRAN /TB
0235667 TEVA-VALSARTAN 0.3 Y Y N YTVM /TB
320MG
0233751 CO-VALSARTAN 0.284 Y Y N YCOB /TB
0236697 VALSARTAN 0.28 Y Y N YSAI /TB
0235677 SANDOZ VALSARTAN 0.284 Y Y N YSDZ /TB
0235668 TEVA-VALSARTAN 0.28 Y Y N YTVM /TB
40MG
0236694 SANIS-VALSARTAN 0.523 Y Y N YSAI /TB
0227052 DIOVAN 1.167 Y Y N YNVR /TB
0235674 SDZ-VALSARTAN 0.52 Y Y N YSDZ /TB
0231299 PMS-VALSARTAN 0.52 Y Y N YRAN /TB
0236306 RAN-VALSARTAN 0.291 Y Y N YRAN /TB
0235664 TEVA-VALSARTAN 0.52 Y Y N YTVM /TB
0233748 CO-VALSARTAN 0.58 Y Y N YCOB /TB
80MG
0235665 TEVA-VALSARTAN 0.3 Y Y N YTVM /TB
0236695 SANIS-VALSARTAN 0.3 Y Y N YSAI /TB
0224478 DIOVAN 1.2 Y Y N YNVO /TB
0233749 CO-VALSARTAN 0.57 Y Y N YCOB /TB
0236310 RAN-VALSARTAN 0.3 Y Y N YRAN /TB
0235675 SDZ-VALSARTAN 0.3 Y Y N YSDZ /TB
VALSARTAN/HYDROCHL
160/12.5MG
0235700 TEVA-VALSARTAN/HCTZ 0.3 Y Y N YTVM /TB
0224190 DIOVAN-HCT 1.2 Y Y N YNVR /TB
0236701 SANIS- 0.3 Y Y N YSAI /TB
0235670 SDZ-VALSARTAN/HCTZ 0.3 Y Y N YSDZ /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
100
PHRM/CHRN/CDO/F24:08.00 HYPOTENSIVE DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
VALSARTAN/HYDROCHLOROTHIAZIDE (continued)
160/25MG
0224695 DIOVAN-HCT 1.2 Y Y N YNVR /TB
0235701 TEVA-VALSARTAN/HCTZ 0.3 Y Y N YTVM /TB
0235671 SDZ-VALSARTAN/HCTZ 0.3 Y Y N YSDZ /TB
0236702 SANIS- 0.3 Y Y N YSAI /TB
320/12.5MG
0236703 VALSARTAN HCT 0.29 Y Y N YSAI /TB
0235672 SDZ-VALSARTAN/HCTZ 0.29 Y Y N YSDZ /TB
320/25MG
0236704 SANIS- 0.29 Y Y N YSAI /TB
0235704 TEVA-VALSARTAN/HCTZ 0.29 Y Y N YTVM /TB
0235673 SDZ-VALSARTAN/HCTZ 0.29 Y Y N YSDZ /TB
80/12.5MG
0224190 DIOVAN-HCT 1.19 Y Y N YNVR /TB
0235669 SDZ-VALSARTAN/HCTZ 0.3 Y Y N YSDZ /TB
0236700 VALSARTAN HCT 0.3 Y Y N YSAN /TB
0235699 TEVA-VALSARTAN/HCTZ 0.3 Y Y N YTVM /TB
24:12.00 VASODILATING DRUGS -------------------------------------------------------------
DIPYRIDAMOLE
25MG
0089564 APO-DIPYRIDAMOLE (FC) 0.2633 Y Y N YAPX /TB
50MG
0089565 APO-DIPYRIDAMOLE FC 0.3685 Y Y N YAPX /TB
75MG
0089566 APO-DIPYRIDAMOLE-FC 0.4963 Y Y N YAPX /TB
DIPYRIDAMOLE/ASA
200MG/25MG
0224211 AGGRENOX 0.85 E E N YBOE /CP
ISOSORBIDE DINITRATE
10MG
0044168 APO-ISDN 0.04 Y Y N YAPX /TB
30MG
0044169 APO-ISDN 0.09 Y Y N YAPX /TB
5MG
0067094 APO-ISDN 0.06 Y Y N YAPX /TB
ISOSORBIDE-5
60MG
0212655 IMDUR 0.71 Y Y N YAST /TB
0230128 PMS-ISMN 0.35 Y Y N YPMS /TB
0227283 APO-ISMN 0.35 Y Y N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
101
PHRM/CHRN/CDO/F24:12.00 VASODILATING DRUGS (continued)
24:00 CARDIOVASCULAR DRUGS (continued)
NITROGLYCERIN
NITROGLYCERIN
0.2MG/HR
0058422 TRANSDERM-NITRO 0.2 PATCH 0.77 Y Y N YNVR /PT
0223073 TRINIPATCH 0.2 PATCH 0.59 Y Y N YSAN /PT
0240744 MYLAN-NITRO PATCH 0.2 0.45 Y Y N YMYL /PT
0216280 MINITRAN 0.2 PATCH 0.62 Y Y N YMDA /PT
0191191 NITRO-DUR 0.2 PATCH 0.62 Y Y N YKEY /PT
0.3MG
0003761 NITROSTAT SL TAB 0.12 Y Y N YPFI /TB
0.4MG/HR
0191190 NITRO-DUR 0.4 PATCH 0.71 Y Y N YKEY /PT
0240745 MYLAN-NITRO PATCH 0.4 0.47 Y Y N YMYL /PT
0085238 TRANSDERM-NITRO 0.4 PATCH 0.87 Y Y N YNVR /PT
0223073 TRINIPATCH 0.4 PATCH 0.69 Y Y N YSAN /PT
0216352 MINITRAN 0.4 PATCH 0.7 Y Y N YMDA /PT
0.6MG
0003762 NITROSTAT SL TAB 0.12 Y Y N YPFI /TB
0.6MG/HR
0223073 TRINIPATCH 0.6 PATCH 0.69 Y Y N YSAN /PT
0240746 MYLAN-NITRO PATCH 0.6 0.47 Y Y N Ynull /PT
0216353 MINITRAN 0.6 PATCH 0.7 Y Y N YMDA /PT
0204615 TRANSDERM-NITRO 0.6 PATCH 0.87 Y Y N YNVR /PT
0191192 NITRO-DUR 0.6 PATCH 0.71 Y Y N YKEY /PT
0.8MG/HR
0240747 MYLAN-NITRO PATCH 0.8 0.87 Y Y N YMYL /PT
0201127 NITRO-DUR 0.8 PATCH 1.22 Y Y N YKEY /PT
2%
0192645 NITROL 2% OINTMENT 0.68 Y Y N YAVT /GM
200 DOSE
0239343 APO-NITROGLYCERIN 0.04 Y Y N YAPX /DS
0224358 GEN-NITRO SUBLINGUAL SPR 0.04 Y Y N YN/A /DS
0223899 RHO-NITRO PUMPSPRAY 0.04 Y Y N YRHO /DS
0223144 NITROLINGUAL PUMP SPRAY 0.07 Y Y N YAVT /DS
SILDENAFIL
20MG
0231950 RATIO-SILDENAFIL R 7.29 E E N YRTP /TB
0227940 REVATIO 11.12 N E N YPFI /TB
TADALAFIL
20MG
0242193 APO-TADALAFIL PAH 11.47 E E N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
102
PHRM/CHRN/CDO/F24:12.92 MISCELLANEOUS VASODILATATING AGENTS
24:00 CARDIOVASCULAR DRUGS (continued)
RIOCIGUAT
24:12.92 MISCELLANEOUS VASODILATATING AGENTS --------------------------------------------
0.5MG
0241276 ADEMPAS 42.75 E N N YBAY /TB
1MG
0241277 ADEMPAS 42.75 E N N YBAY /TB
1.5MG
0241279 ADEMPAS 42.75 E N N YBAY /TB
2MG
0241280 ADEMPAS 42.75 E N N YBAY /TB
2.5MG
0241281 ADEMPAS 42.75 E N N YBAY /TB
24:32.20 MINERALOCORTICOID (ALDOSTERONE) RECEPTOR ANTAGONISTS ---------------------------
EPLERENONE
25MG
0232305 INSPRA 2.64 E E N YPFI /TB
50MG
0232306 INSPRA 2.64 E E N YPFI /TB
28:00 CENTRAL NERVOUS SYSTEM DRUGS
28:08.04 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS ------------------------------------------
ACETYLSALICYLIC ACID
150MG/SUP
0078554 ASA SUPPOSITORIES 0.95 Y N N NPMS /SP
325MG
0001033 ENTROPHEN E.C. 0.028 Y N N NWAM /TB
0053033 ASA 325MG 0.022 Y N N NWHL /TB
0003614 ASA 0.03 Y N N NWAM /TB
0228452 PMS-ASA EC 0.03 Y N N NPMS /TB
0004085 PMS-ASA 0.059 Y N N NPMS /TB
0021666 NOVASEN E.C. 0.0304 Y N N NNOP /TB
0205016 ENTROPHEN 0.0503 Y N N NWAM /TB
0215041 COATED ASPIRIN S E-C 0.05 Y N N NBAY /TB
650MG
0190539 ENTROPHEN 650MG E.C. 0.0862 Y N N NWAM /CP
0058286 ASA 650 SUPPOS. 1.1 Y N N NPMS /SP
0022929 NOVASEN E.C. 0.052 Y N N NNOP /TB
0001034 ENTROPHEN E.C. 0.08 Y N N NWAM /TB
80MG
0200901 ASAPHEN 0.056 Y N N NPMS /TB
0223854 ASAPHEN E.C. 0.056 Y N N NPMS /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
103
PHRM/CHRN/CDO/F28:08.04 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
ACETYLSALICYLIC ACID (continued)
81MG
0237217 ASA 81 MG 0.053 Y N N NVIT /TB
0223772 COATED ASPIRIN DAILY LOW 0.08 Y N N NBAY /TB
0242681 ASA EC 0.53 Y N N NSAI /TB
0224310 LIFE DAILY LOW DOSE ASA EC 0.0725 Y N N NPMS /TB
0224499 ASA 81MG(MEDICINE CENTER)EC 0.0725 Y N N NMCT /TB
0224389 EXACT ASA 81 MG EC 0.0725 Y N N NEXA /TB
0224380 EQUATE DAILY LOW-DOSE ASA 0.0725 Y N N NWAL /TB
0228370 PMS-ASA EC (BLUE) 0.053 Y N N NPMS /TB
0224228 ENTROPHEN 81MG EC 0.06 Y N N NPMS /TB
CELECOXIB
100MG
0229197 GD-CELECOXIB 0.17 Y Y Y YGEN /CP
0232124 SANDOZ CELECOXIB 0.17 Y Y Y YSDZ /CP
0235544 PMS-CELECOXIB 0.18 Y Y Y YPMS /CP
0242327 MYLAN-CELECOXIB 0.18 Y Y Y YMYL /CP
0242015 ACT CELECOXIB 0.18 Y Y Y YACT /CP
0241893 APO-CELECOXIB 0.18 Y Y Y YAPX /CP
0241249 MINT-CELECOXIB 0.18 Y Y Y YMNT /CP
0243629 CELECOXIB 0.17 Y Y Y YSAI /CP
0241237 RAN-CELECOXIB 0.17 Y Y Y YRAN /CP
0243563 ACCEL-CELECOXIB 0.14 Y Y Y YACC /CP
0223994 CELEBREX 0.7 Y Y Y YPHU /CP
0228891 TEVA-CELECOXIB 0.17 Y Y Y YTVM /CP
200MG
0232125 SANDOZ-CELECOXIB 0.35 Y Y Y YSDZ /CP
0241238 RAN-CELECOXIB 0.36 Y Y Y YRAN /CP
0228892 TEVA-CELECOXIB 0.35 Y Y Y YTVM /CP
0241250 MINT-CELECOXIB 0.36 Y Y Y YMNT /CP
0241894 APO-CELECOXIB 0.36 Y Y Y YAPX /CP
0242016 ACT CELECOXIB 0.36 Y Y Y YACT /CP
0243564 ACCEL-CELECOXIB 0.28 Y Y Y YACC /CP
0235545 PMS-CELECOXIB 0.36 Y Y Y YPMS /CP
0239988 MYLAN-CELECOXIB 0.35 Y Y Y YMYL /CP
0243630 CELECOXIB 0.35 Y Y Y YSAI /CP
0223994 CELEBREX 1.4 Y Y Y YPHU /CP
DICLOFENAC
1.16% GEL
0229037 VOLTAREN EMULGEL 0.07 Y N N NNVR /GM
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
104
PHRM/CHRN/CDO/F28:08.04 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
DICLOFENAC POTASSIUM
DICLOFENAC
50MG
0223935 TEVA-DIFENAC-K 0.3937 Y Y Y YTVM /TB
0224343 APO-DICLO RAPIDE 0.3937 Y Y Y YAPX /TB
0088163 VOLTAREN RAPIDE 0.95 Y Y Y YNOP /TB
0235168 SANIS-DIFENAC-K 0.3937 Y Y Y YSAN /TB
0223975 PMS-DICLOFENAC K 0.3937 Y Y Y YPHA /TB
DICLOFENAC SODIUM
100MG
0063273 VOLTAREN SUPPOS. 2 Y Y Y YNVR /SP
0223150 PMS-DICLOFENAC SUPPOS. 0.584 Y Y Y YPMS /SP
0217468 TEVA-DIFENAC SUPPOS. 0.8397 Y Y Y YTVM /SP
0059082 VOLTAREN-SR 1.74 Y Y Y YNVR /TB
0226194 SANDOZ DICLOFENAC SR 0.4048 Y Y Y YSDZ /TB
0204869 TEVA-DIFENAC SR 0.4048 Y Y Y YTVM /TB
0209119 APO-DICLO SR 0.4048 Y Y Y YAPX /TB
0223150 PMS-DICLOFENAC-SR 0.4048 Y Y Y YPMS /TB
25MG
0083917 APO-DICLO E.C. 0.0781 Y Y Y YAPX /TB
0080853 TEVA-DIFENAC E.C. 0.0781 Y Y Y YTVM /TB
0223150 PMS-DICLFENAC EC 0.1902 Y Y Y YPMS /TB
50MG
0217467 TEVA-DIFENAC SUPPOS. 0.6237 Y Y Y YTVM /SP
0063272 VOLTAREN SUPPOS. 1.49 Y Y Y YNVR /SP
0223150 PMS-DICLOFENAC SUPPOS. 0.434 Y Y Y YPMS /SP
0226196 SANDOZ-DICLOFENAC 0.2 Y Y Y YSDZ /TB
0230262 PMS-DICLOFENAC 0.2 Y Y Y YPMS /TB
0080854 TEVA-DIFENAC E.C. 0.2 Y Y Y YTVM /TB
0235239 SANIS-DICLOFENAC SODIUM E.C. 0.2 Y Y Y YSAN /TB
0083918 APO-DICLO E.C. 0.2 Y Y Y YAPX /TB
0051401 VOLTAREN 1.07 Y Y Y YNVR /TB
0223150 PMS-DICLOFENAC EC 0.38 Y Y Y YPMS /TB
75MG
0235240 SANIS-DICLOFENAC SR 0.23 Y Y Y YSAN /TB
0226190 SANDOZ-DICLOFENAC SR 0.234 Y Y Y YSDZ /TB
0223150 PMS-DICLOFENAC-SR 0.23 Y Y Y YPMS /TB
0215858 TEVA-DIFENAC SR 0.234 Y Y Y YTVM /TB
0216281 APO-DICLO SR 0.23 Y Y Y YAPX /TB
0078245 VOLTAREN-SR 1.22 Y Y Y YNVR /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
105
PHRM/CHRN/CDO/F28:08.04 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
DICLOFENAC SODIUM/MISOPROSTOL
DICLOFENAC
50/200UG
0239714 CO DICLO-MISO 0.45 Y Y Y YCOB /TB
0191705 ARTHROTEC 0.61 Y Y Y YPHU /TB
75/200UG
0239715 CO DICLO-MISO 0.62 Y Y Y YCOB /TB
0234169 GD-DICLOFENAC/MISOPROSTOL 0.43 Y Y Y YGDI /TB
0222983 ARTHROTEC 75 0.84 Y Y Y YPHU /TB
DICLOFENAC
50/200UG
0234168 GD-DICLOFENAC/MISOPROSTOL 0.31 Y Y Y YGDI /TB
DIFLUNISAL
250MG
0204849 NOVO-DIFLUNISAL 0.5647 Y Y Y YNOP /TB
0203948 APO-DIFLUNISAL 0.5647 Y Y Y YAPX /TB
500MG
0203949 APO-DIFLUNISAL 0.72 Y Y Y YAPX /TB
ETODOLAC
200MG
0223231 APO-ETODOLAC 0.76 Y Y Y YAPX /CP
300MG
0223231 APO-ETODOLAC 0.76 Y Y Y YAPX /CP
FLURBIPROFEN
100MG
0210051 NOVO-FLURPROFEN 0.3 Y Y Y YNOP /TB
0191203 APO-FLURBIPROFEN 0.3 Y Y Y YAPX /TB
50MG
0191204 APO-FLURBIPROFEN 0.22 Y Y Y YAPX /TB
0210050 NOVO-FLURPROFEN 0.22 Y Y Y YNOP /TB
IBUPROFEN
200MG
0044164 APO-IBUPROFEN 0.04 Y N N NAPX /TB
0218693 MOTRIN IB 0.07 Y N N NMCL /TB
0193355 ADVIL 0.08 Y N N NWHI /TB
0193353 ADVIL 0.1 Y N N NWHI /TB
300MG
0044165 APO-IBUPROFEN 0.14 Y N N NAPX /TB
0224263 MOTRIN IB 0.13 Y N N YMCL /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
106
PHRM/CHRN/CDO/F28:08.04 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
IBUPROFEN (continued)
400MG
0240129 JAMP-IBUPROFEN 0.09 Y N N YJPC
/TB
0224265 MOTRIN IB 0.17 Y N N YMCL /TB
0062934 NOVO-PROFEN 0.09 Y N N YTVM /TB
0050605 APO-IBUPROFEN 0.09 Y N Y NAPX /TB
600MG
0058511 APO-IBUPROFEN 0.13 Y Y Y YAPX /TB
0062935 NOVO-PROFEN 0.13 Y Y Y YNOP /TB
INDOMETHACIN
100MG
0193413 RATIO-INDOMETHACIN SUPPOS 0.89 Y N Y YRTP /SP
0223180 SANDOZ-INDOMETHACIN SUPP 0.89 Y N Y YSDZ /SP
25MG
0061115 APO-INDOMETHACIN 0.0871 Y Y Y YAPX /CP
0033742 NOVO-METHACIN 0.23 Y Y Y YNOP /CP
50MG
0061116 APO-INDOMETHACIN 0.1511 Y Y Y YAPX /CP
0033743 NOVO-METHACIN 0.45 Y Y Y YNOP /CP
0223179 SANDOZ-INDOMETHACIN SUPP 0.88 Y N Y YSDZ /SP
KETOPROFEN
100MG
0201595 PMS-KETOPROFEN SUPPOS. 1.22 Y N Y YPMS /SP
100MG EC
0084266 APO-KETO-E 0.68 Y Y Y YAPX /TB
0215082 PMS-KETOPROFEN-EC 0.3078 Y Y Y YPMS /TB
200MG SR
0217257 APO-KETOPROFEN SR 1.39 Y Y Y YAPX /TB
50MG
0079042 APO-KETO CAP 0.34 Y Y Y YAPX /CP
0215080 PMS-KETOPROFEN 0.1662 Y Y Y YPMS /CP
50MG EC
0079043 APO-KETO-E 0.34 Y Y Y YAPX /TB
KETOROLAC
30MG/ML
0223994 SDZ-KETOROLAC 30MG/ML INJ 4.41 Y N N YSDZ /ML
KETOROLAC
10MG
0216266 TORADOL 0.7 Y Y Y YHLR /TB
0222908 KETOROLAC 0.52 Y Y Y YAPX /TB
0223020 NOVO-KETOROLAC 0.41 Y Y Y YNOP /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
107
PHRM/CHRN/CDO/F28:08.04 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
MEFENAMIC ACID
MEFENAMIC ACID
250MG
0223120 PMS-MEFENAMIC ACID 0.3308 Y Y Y YPMS /CP
0222945 APO-MEFENAMIC 0.5 Y Y Y YAPX /CP
MELOXICAM
15 MG
0225832 TEVA-MELOXICAM 0.57 Y Y Y YTVM /TB
0235315 SANIS-MELOXICAM 0.57 Y Y Y YSAN /TB
0224278 MOBICOX 0.92 Y Y Y YBOE /TB
0224803 RATIO-MELOXICAM 0.567 Y Y Y YRTP /TB
0225002 CO-MELOXICAM 0.57 Y Y Y YCOB /TB
0224897 APO-MELOXICAM 0.57 Y Y Y YAPX /TB
0224826 PMS-MELOXICAM 0.57 Y Y Y YPMS /TB
7.5 MG
0224788 RATIO-MELOXICAM 0.4914 Y Y Y YRTP /TB
0225831 TEVA-MELOXICAM 0.49 Y Y Y YTVM /TB
0225001 CO-MELOXICAM 0.49 Y Y Y YCOB /TB
0224278 MOBICOX 0.8 Y Y Y YBOE /TB
0224897 APO-MELOXICAM 0.49 Y Y Y YAPO /TB
0235314 SANIS-MELOXICAM 0.49 Y Y Y YSAN /TB
0224826 PMS-MELOXICAM 0.49 Y Y Y YPMS /TB
NABUMETONE
500MG
0224086 NOVO-NABUMETONE 0.36 Y Y Y YNOP /TB
0223863 APO-NABUMETONE 0.36 Y Y Y YAPX /TB
750MG
0224086 NOVO-NABUMETONE 0.92 Y Y Y YNOP /TB
NAPROXEN
125MG
0052267 APO-NAPROXEN 0.08 Y Y Y YAPX /TB
25MG/ML
0216243 NAPROSYN SUSP 0.06 Y Y Y YHLR /ML
250MG
0052265 APO-NAPROXEN 0.107 Y Y Y YAPX /TB
0056535 NOVO-NAPROX 0.107 Y Y Y YNOP /TB
0235075 SANIS-NAPROXEN 0.107 Y Y Y YSAN /TB
250MG/ECT
0216279 NAPROSYN E 0.42 Y Y Y YHLR /TB
0224669 APO-NAPROXEN EC 0.2 Y Y Y YAPX /TB
0224331 NOVO-NAPROX EC 0.11 Y Y Y YNOP /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
108
PHRM/CHRN/CDO/F28:08.04 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
NAPROXEN (continued)
325MG/ECT
0216241 NAPROSYN E 0.56 Y Y Y YHLR /TB
375MG
0060080 APO-NAPROXEN 0.15 Y Y Y YAPX /TB
0235076 SANIS-NAPROXEN 0.15 Y Y Y YSAN /TB
0062709 NOVO-NAPROX 0.15 Y Y Y YNOP /TB
375MG/ECT
0224343 GEN-NAPROXEN EC 0.15 Y Y Y YGPM /TB
0235079 NAPROXEN EC 0.15 Y Y Y YSAI /TB
0224670 APO-NAPROXEN EC 0.15 Y Y Y YAPX /TB
0224331 NOVO-NAPROX EC 0.15 Y Y Y YNOP /TB
500MG
0201723 PMS-NAPROXEN SUPPOS. 0.94 Y N Y YPMS /SP
0235077 SANIS-NAPROXEN 0.21 Y Y Y YSAN /TB
0059227 APO-NAPROXEN 0.21 Y Y Y YAPX /TB
0058986 NOVO-NAPROX 0.21 Y Y Y YNOP /TB
500MG/ECT
0235080 NAPROXEN EC 0.21 Y Y Y YSAI /TB
0224331 NOVO-NAPROX EC 0.21 Y Y Y YNOP /TB
0224670 APO-NAPROXEN EC 0.21 Y Y Y YAPX /TB
0229471 PMS-NAPROXEN EC 0.21 Y Y Y YPMS /TB
0224102 GEN-NAPROXEN EC 0.21 Y Y Y YGPM /TB
0216242 NAPROSYN E 1 Y Y Y YHLR /TB
750MG
0217707 APO-NAPROXEN SR 1.0048 Y Y N YAPX /TB
0216246 NAPROSYN-S.R. 1.48 Y Y N YHLR /TB
NAPROXEN SODIUM
275MG
0078435 APO-NAPRO-NA 0.34 Y Y Y YAPX /TB
0077838 NOVO-NAPROX 0.34 Y Y Y YNOP /TB
0235101 SANIS-NAPROXEN SODIUM 0.34 Y Y Y YSAN /TB
550MG
0235102 SANIS-NAPROXEN SODIUM 0.67 Y Y Y YSAN /TB
0194030 APO-NAPROXEN DS 0.67 Y Y Y YAPX /TB
0202660 NOVO-NAPROX DS 0.67 Y Y Y YNOP /TB
PIROXICAM
10MG
0064288 APO-PIROXICAM 0.44 Y Y Y YAPX /CP
0069571 NOVO-PIROCAM 0.44 Y Y Y YNOP /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
109
PHRM/CHRN/CDO/F28:08.04 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
PIROXICAM (continued)
20MG
0064289 APO-PIROXICAM 0.74 Y Y Y YAPX /CP
0083623 PMS-PIROXICAM 0.74 Y Y Y YPMS /CP
0069569 NOVO-PIROCAM 0.74 Y Y Y YNOP /CP
0215446 PMS-PIROXICAM SUPPOS. 2.21 Y Y Y YPMS /SP
SULINDAC
150MG
0074558 NOVO-SUNDAC 0.3824 Y Y Y YNOP /TB
0077835 APO-SULIN 0.3824 Y Y Y YAPX /TB
200MG
0074559 NOVO-SUNDAC 0.39 Y Y Y YNOP /TB
0077836 APO-SULIN 0.39 Y Y Y YAPX /TB
TIAPROFENIC ACID
200MG
0223082 PMS-TIAPROFENIC 0.3437 Y Y Y YPMS /TB
0213611 APO-TIAPROFENIC 0.3437 Y Y Y YAPX /TB
0217967 NOVO-TIAPROFENIC 0.49 Y Y Y YNOP /TB
300MG
0223082 PMS-TIAPROFENIC 0.4104 Y Y Y YPMS /TB
0217968 NOVO-TIAPROFENIC 0.68 Y Y Y YNOP /TB
0213612 APO-TIAPROFENIC 0.33 Y Y Y YAPX /TB
28:08.08 OPIATE AGONISTS ----------------------------------------------------------------
ACETAMINOPHEN/CAFFE
15MG COD
0065324 RATIO-LENOLTEC NO.2 (15MG 0.1 Y Y N YRTP /TB
0216393 TYLENOL WITH CODEINE NO.2 0.1 Y Y N YJAN /TB
0029350 ATASOL-15 'WITH 15MG CODEINE 0.091 Y Y N YHOR /TB
30MG COD
0065327 RATIO-LENOLTEC NO.3 (30MG 0.11 Y Y Y YRTP /TB
0223238 EXDOL-30 (W 30MG CODEINE) 0.1594 Y Y N YLIH /TB
0216392 TYLENOL WITH CODEINE NO.3 0.11 Y Y N YJAN /TB
325/15/30MG
0029351 ATASOL-30 WITH 30MG CODEINE 0.061 Y Y N YHOR /TB
8MG COD
0218106 TYLENOL WITH CODEINE NO.1 8MG 0.14 Y N N NMCL /TB
0223742 ACETAMINOPHEN 8MG CODEINE 0.0342 Y N N NCAN /TB
0202533 ACETAMINOPHEN 8 MG CODEINE 0.02 Y N N NPMS /TB
0029349 ATASOL 8 WITH 8MG CODEINE 0.07 Y N N NHOR /TB
0070622 ACETAMINOPHEN 8MG CODEINE 0.0342 Y N N NVTH /TB
0065323 LENOLTEC NO.1( 8MG COD) 0.14 Y N N NRTP /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
110
PHRM/CHRN/CDO/F28:08.08 OPIATE AGONISTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
ACETAMINOPHEN/CODEINE
ACETAMINOPHEN/CODEI
300MG/30MG
0060888 RATIO-EMTEC 0.17 E E N YRTP /TB
300MG/60MG
0216391 TYLENOL WITH CODEINE NO.4 0.23 Y Y N YJAN /TB
0062146 RATIO-LENOLTEC NO.4 0.23 Y Y N YRTP /TB
ASA/CAFFEINE/CODEINE
325/15/8MG
0010816 222 0.14 Y N N NJJM
/TB
375/30/15
0223451 282 MG 0.0655 Y Y N YLIH /TB
375/30/30
0223864 292 MG 0.18 Y Y N YLIH /TB
CODEINE
100MG
0216374 CODEINE CONTIN 0.68 Y E N YPFR /TB
150MG
0216378 CODEINE CONTIN 1.02 Y E N YPFR /TB
200MG
0216379 CODEINE CONTIN 1.36 Y E N YPFR /TB
50MG
0223030 CODEINE CONTIN 0.31 Y E N YPFR /TB
CODEINE PHOSPHATE
15MG
0224397 PMS-CODEINE 0.0641 Y Y N YPHA /TB
0077945 CODEINE PHOSPHATE 0.0618 Y Y N YROG /TB
0059343 RATIO-CODEINE 0.08 Y Y N YRTP /TB
30MG
0059345 RATIO-CODEINE 0.13 Y Y N YRTP /TB
0224397 PMS-CODEINE 0.0773 Y Y N YPMS /TB
5MG/ML
0005002 CODEINE PHOSPHATE SYRUP 0.05 Y Y N YLAB /ML
0077947 RATIO-CODEINE SYRUP 0.03 Y Y N YRTP /ML
FENTANYL
100MCG
0239674 MYLAN-FENTANYL MATRIX PATCH 12.05 Y Y N YMYL /PT
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
111
PHRM/CHRN/CDO/F28:08.08 OPIATE AGONISTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
FENTANYL (continued)
100UG/HR
0228298 RATIO-FENTANYL 100 PATCH 12.05 Y Y N YRPH /PT
0233015 RAN-FENTANYL 100 MATRIX 12.05 Y Y N YRAN /PT
0231466 TEVA-FENTANYL 100 PATCH 12.05 Y Y N YTVM /PT
0238689 CO FENTANYL 12.05 Y Y N YCOB /PT
0234141 PMS-FENTANYL 100 PATCH 12.05 Y Y N YPMS /PT
0232716 SDZ-FENTANYL 100 PATCH 12.05 Y Y N YSDZ /PT
12MCG
0239669 MYLAN-FENTANYL MATRIX PATCH 2.23 Y Y N YMYL /PT
12UG/HR
0234137 PMS-FENTANYL 12 PATCH 2.23 Y Y N YPMS /PT
0231192 RATIO-FENTANYL 12 UG PATCH 2.23 Y Y N YRPH /PT
0238684 CO FENTANYL 2.23 Y Y N YCOB /PT
0232711 SDZ-FENTANYL 12 PATCH 2.23 Y Y N YSDZ /PT
0233010 RAN-FENTANYL 12 MATRIX PATCH 2.23 Y Y N YRAN /PT
25MCG
0239671 MYLAN-FENTANYL MATRIX PATCH 3.66 Y Y N YMYL /PT
25UG/HR
0233011 RAN-FENTANYL 25 MATRIX PATCH 3.66 Y Y N YRAN /PT
0231463 TEVA-FENTANYL 25 PATCH 3.66 Y Y N YTVM /PT
0228294 RATIO-FENTANYL 25 PATCH 3.66 Y Y N YRPH /PT
0234138 PMS-FENTANYL 25 PATCH 3.66 Y Y N YPMD /PT
0232712 SDZ-FENTANYL 25 PATCH 3.66 Y Y N YSDZ /PT
37UG/HR
0232713 SDZ-TENTANYL PATCH 8.5 Y Y N YSDZ /PT
50 UG/HR
0239672 MYLAN-FENTANYL MATRIX PATCH 6.88 Y Y N YMYL /PT
50UG/HR
0232714 SDZ-FENTANYL 50 PATCH 6.88 Y Y N YSDZ /PT
0228296 RATIO-FENTANYL 50 PATCH 6.88 Y Y N YRPH /PT
0234139 PMS-FENTANYL 50 PATCH 6.88 Y Y N YPMS /PT
0231464 TEVA-FENTANYL 50 PATCH 6.88 Y Y N YTVM /PT
0233012 RAN-FENTANYL 50 MATRIX PATCH 6.88 Y Y N YRAN /PT
75UG/HR
0231465 TEVA-FENTANYL 75 PATCH 9.68 Y Y N YTVM /PT
0234140 PMS-FENTANYL 75 PATCH 9.68 Y Y N YPMS /PT
0233014 RAN-FENTANYL 75 MATRIX PATCH 9.68 Y Y N YRAN /PT
0232715 SDZ-FENTANYL 75 PATCH 9.68 Y Y N YSDZ /PT
0239673 MYLAN-FENTANYL 75 MATRIX 9.68 Y Y N YMYL /PT
0238688 CO FENTANYL 9.68 Y Y N YCOB /PT
0228297 RATIO-FENTANYL 75 PATCH 9.68 Y Y N YRPH /PT
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
112
PHRM/CHRN/CDO/F28:08.08 OPIATE AGONISTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
FENTANYL CITRATE
FENTANYL CITRATE
100MCG S/L
0236417 ABSTRAL 10.9 N N N YPAL /TB
200MCG S/L
0236418 ABSTRAL 12.34 N N N YPAL /TB
300MCG S/L
0236419 ABSTRAL 14.79 N N N YPAL /TB
400MCG S/L
0236420 ABSTRAL 16.81 N N N YPAL /TB
600MCG S/L
0236421 ABSTRAL 22.42 N N N YPAL /TB
800MCG S/L
0236422 ABSTRAL 28.02 N N N YPAL /TB
HYDROMORPHONE
1MG/ML
0191658 HYCODAN ORAL LIQUID 0.13 Y N N YBMY /ML
HYDROMORPHONE HCL
1MG
0231940 TEVA-HYDROMORPHONE 0.1 Y Y N YTVM /TB
0070543 DILAUDID 0.1 Y Y N YABB /TB
0088544 PMS-HYDROMORPHONE 0.1 Y Y N YPMS /TB
0236411 APO-HYDROMORPHONE 0.1 Y Y N YAPX /TB
1MG/ML
0191638 PMS-HYDROMORPHONE ORAL LQ 0.07 Y Y N YPMS /ML
0078653 DILAUDID ORAL LIQUID 0.08 Y Y N YABB /ML
10MG/ML
0062213 DILAUDID-HP (1ML) INJ 2.651 Y Y N YABB /ML
0214592 HYDROMORPHONE HP 10 (1ML)INJ 3.78 Y Y N YSAB /ML
12MG
0212536 HYDROMORPH CONTIN 1.86 Y Y N YPFR /CP
18MG
0224356 HYDROMORPH CONTIN 2.68 Y Y N YPUR /CP
2MG
0231941 TEVA-HYDROMORPHONE 0.14 Y Y N YTVM /TB
0088543 PMS-HYDROMORPHONE 0.14 Y Y N YPMS /TB
0012508 DILAUDID 0.13 Y Y N YABB /TB
0236412 APO-HYDROMORPHONE 0.14 Y Y N Ynull /TB
2MG/ML
0214590 HYDROMORPHONE HCL (1ML)INJ 1.78 Y Y N YSAB /ML
0062710 DILAUDID (1ML) INJ 1.0832 Y Y N YABB /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
113
PHRM/CHRN/CDO/F28:08.08 OPIATE AGONISTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
HYDROMORPHONE HCL (continued)
20MG/ML
0214593 HYDROMORPHONE HP 20 (1ML)INJ 6.4 Y Y N YSAB /ML
24MG
0212538 HYDROMORPH CONTIN 3.31 Y Y N YPFR /CP
3MG
0212532 HYDROMORPH CONTIN 0.69 Y Y N YPFR /CP
0191639 PMS-HYDROMORPHONE SUPP 3.15 Y Y N YPMS /SP
30MG
0212539 HYDROMORPH CONTIN 3.96 Y Y N YPFR /CP
4MG
0088540 PMS-HYDROMORPHONE 0.22 Y Y N YPMS /TB
0231943 TEVA-HYDROMORPHONE 0.22 Y Y N YTVM /TB
0012512 DILAUDID 0.22 Y Y N YABB /TB
4.5MG
0235950 HYDROMORPH CONTIN 0.84 Y Y N YPFR /CP
50MG/ML
0214612 HYDROMORPHONE HP 50 (1ML)INJ 15.91 Y Y N YSAB /ML
6MG
0212533 HYDROMORPH CONTIN 1.03 Y Y N YPFR /CP
8MG
0088542 PMS-HYDROMORPHONE 0.35 Y Y N YPMS /TB
0231944 TEVA-HYDROMORPHONE 0.35 Y Y N YTVM /TB
0078654 DILAUDID 0.35 Y Y N YABB /TB
9MG
0235951 HYDROMORPH CONTIN 1.41 Y Y N YPFR /CP
MEPERIDINE HCL
100MG/ML
0072574 MEPERIDINE 100 (1ML) INJ 1.34 Y Y N YSAB /ML
50MG
0213801 DEMEROL 0.15 Y Y Y YSAW /TB
50MG/ML
0072576 MEPERIDINE 50 (1ML) INJ 1.2 Y Y N YSAB /ML
75MG/ML
0072575 MEPERIDINE 75 (1ML) INJ 1.26 Y Y N YSAB /ML
METHADONE
10MG/ML
0239459 METHADOSE 0.15 Y N N YMAL /ML
0239461 METHADOSE 0.15 Y N N YMAL /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
114
PHRM/CHRN/CDO/F28:08.08 OPIATE AGONISTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
MORPHINE
MORPHINE
1MG/ML
0048658 M.O.S. 1MG/ML (ORAL SOLN) 0.02 Y Y Y YICN /ML
0060776 RATIO-MORPHINE 1MG/ML SOLN 0.02 Y Y Y YRTP /ML
0059146 STATEX 1MG/ML (ORAL SOLN) 0.02 Y Y Y YPMS /ML
10MG
0063220 STATEX SUPPOS. 1.9 Y Y N YPMS /SP
0069019 M.O.S. 10MG TAB 0.17 Y Y Y YICN /TB
0200976 MOS-SULFATE 0.18 Y Y Y YICN /TB
0201421 MSIR 0.19 Y Y Y YPFR /TB
0059464 STATEX 0.17 Y Y Y YPMS /TB
10MG/ML
0063250 M.O.S.10MG/ML (ORAL SOLN) 0.1988 Y Y Y YICN /ML
0069078 RATIO-MORPHINE 10MG/ML SOLN 0.2 Y Y Y YRTP /ML
10MG ER
0201993 M-ESLON 0.3 Y Y N YAVT /CP
10MG SR
0224216 KADIAN 10MG 0.38 Y Y N YFAU /CP
100MG SR
0218445 KADIAN SR 2.73 Y Y N YABB /CP
0201996 M-ESLON 2.06 Y Y N YAVT /CP
0230279 NOVO-MORPHINE SR 2.68 Y Y N YNOP /TB
0201431 MS CONTIN 2.83 Y Y N YPFR /TB
15MG ER
0217774 M-ESLON ER CAP 0.35 Y Y N YAVT /CP
15MG SR
0235081 SANIS-MORPHINE 0.23 Y Y N YSAI /TB
0224479 RATIO-MORPHINE SR 0.23 Y Y N YRTP /TB
0230276 TEVA-MORPHINE SR 0.23 Y Y N YTEV /TB
0201543 MS CONTIN 0.7 Y Y N YPFR /TB
20MG
0059696 STATEX SUPPOS 2.26 Y Y N YPMS /SP
0201423 MSIR 0.34 Y Y Y YPFR /TB
0069020 M.O.S. 20MG TAB 0.3243 Y Y Y YICN /TB
20MG/ML
0069079 RATIO-MORPHINE 20MG/ML SOLN 0.55 Y Y Y YRTP /ML
0063248 M.O.S.20MG/ML (ORAL SOLN) 0.524 Y Y Y YICN /ML
0062193 STATEX 20MG/ML (ORAL SOLN) 0.51 Y Y Y YPMS /ML
20MG SR
0218443 KADIAN SR 0.81 Y Y N YABB /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
115
PHRM/CHRN/CDO/F28:08.08 OPIATE AGONISTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
MORPHINE (continued)
200MG ER
0217775 M-ESLON ER CAP 3.99 Y Y N YAVT /CP
200MG SR
0230280 NOVO-MORPHINE SR 4.62 Y Y N YNOP /TB
0201432 MS CONTIN 5.26 Y Y N YPFR /TB
25MG
0059463 STATEX 0.23 Y Y Y YPMS /TB
0200974 MOS-SULFATE 0.23 Y Y Y YICN /TB
30MG
0063938 STATEX SUPPOS. 2.48 Y Y N YPMS /SP
0201425 MSIR 0.44 Y Y N YPFR /TB
30MG ER
0201994 M-ESLON 0.52 Y Y N YAVT /CP
30MG SR
0224479 RATIO-MORPHINE SR 0.35 Y Y N YRTP /TB
0230277 NOVO-MORPHINE SR 0.35 Y Y N YNOP /TB
0235089 MORPHINE SR 0.35 Y Y N YSAI /TB
0201429 MS CONTIN 1.05 Y Y N YPFR /TB
0077618 M.O.S.-S.R. 0.48 Y Y N YICN /TB
40MG
0069022 M.O.S. 40MG TAB 0.4214 Y Y N YICN /TB
5MG
0063222 STATEX SUPPOS. 1.7 Y Y N YPMS /SP
0059465 STATEX 0.11 Y Y Y YPMS /TB
0201420 MSIR 0.12 Y Y Y YPFR /TB
0200977 MOS-SULFATE 0.11 Y Y Y YICN /TB
5MG/ML
0051421 M.O.S. 5MG/ML (ORAL SOLN) 0.0842 Y Y Y YICN /ML
0059147 STATEX 5MG/ML (ORAL SOLN ) 0.08 Y Y Y YPMS /ML
0060777 RATIO-MORPHINE 5MG/ML SOLN 0.06 Y Y Y YRTP /ML
50MG
0200970 MOS-SULFATE 0.36 Y Y N YICN /TB
0067596 STATEX 0.35 Y Y N YPMS /TB
50MG/ML
0069023 MOS-50 ORAL CONCENTRATE 1.2426 Y Y N YICN /ML
50MG SR
0218444 KADIAN SR 1.48 Y Y N YABB /CP
60MG
0069024 M.O.S. 60MG TAB 0.5851 Y Y N YICN /TB
60MG ER
0201995 M-ESLON 0.93 Y Y N YAVT /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
116
PHRM/CHRN/CDO/F28:08.08 OPIATE AGONISTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
MORPHINE (continued)
60MG SR
0235091 MORPHINE SR 0.62 Y Y N YSAI /TB
0230278 NOVO-MORPHINE SR 0.62 Y Y N YNOP /TB
0201430 MS CONTIN 1.86 Y Y N YPFR /TB
0224479 RATIO-MORPHINE SR 0.62 Y Y N YRTP /TB
0077620 M.O.S.-S.R. 0.84 Y Y N YICN /TB
MORPHINE INJ
10MG/ML
0039258 MORPHINE SO4 (1ML) INJ 2.07 Y Y N YSAB /ML
15MG/ML
0039256 MORPHINE SO4 (1ML) INJ 1.26 Y Y N YSAB /ML
2MG/ML
0224248 MORPHINE SULPHATE INJ. 2.14 Y Y N YSAB /ML
50MG/ML
0061728 MORPHINE HP 50 (1ML) INJ 5.05 Y Y N YSAB /ML
OXYCODONE
10MG
0231998 PMS-OXYCODONE 0.19 Y Y Y YPMS /TB
0044394 SUPEUDOL 0.19 Y Y Y YSAB /TB
0224013 OXY-IR 0.39 Y Y Y YPUR /TB
20MG
0224013 OXY-IR 0.67 Y Y Y YPUR /TB
0226298 SUPEUDOL 0.3 Y Y Y YSDZ /TB
0231999 PMS-OXYCODONE 0.3 Y Y Y YPMS /TB
5MG
0223193 OXY-IR 0.262 Y Y Y YPUR /TB
0078973 SUPEUDOL 0.13 Y Y Y YSAB /TB
0231997 PMS-OXYCODONE 0.13 Y Y Y YPMS /TB
OXYCODONE
5MG/325MG
0236136 OXYCODONE/ACET 0.13 Y Y Y YSAI /TB
0060816 RATIO-OXYCOCET 0.13 Y Y Y YRTP /TB
OXYCODONE
5MG/325MG
0191654 ENDOCET 0.1285 Y Y Y YLIN /TB
0224575 PMS-OXYCODONE- 0.1285 Y Y Y YPMS /TB
0191647 PERCOCET 0.85 Y Y Y YBMY /TB
0232462 APO-OXYCODONE HCL/ACET 0.1285 Y Y Y YAPX /TB
0230789 NOVO-OXYCODONE ACET 0.1285 Y Y Y YNOP /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
117
PHRM/CHRN/CDO/F28:08.08 OPIATE AGONISTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
OXYCODONE/ACETYLSALICYLIC ACID
OXYCODONE/ACETYLSA
5MG/325MG
0060815 OXYCODAN COMPRIMES 0.4 Y Y N YTEC /TB
PROPOXYPHENE
100MG
0026143 DARVON-N 0.6268 Y Y Y YPMS /CP
28:08.12 OPIATE PARTIAL AGONISTS --------------------------------------------------------
BUPRENORPHINE/NALOX
2/0.5MG
0242485 TEVA-BUPRENORPHINE/NALOXONE 1.34 Y E N YTVM /TB
0240809 MYLAN- 1.34 Y E N YMYL /TB
8/2MG
0242487 TEVA-BUPRENORPHINE/NALOXONE 2.37 Y E N YTVM /TB
0240810 MYLAN- 2.37 Y E N YMYL /TB
PENTAZOCINE
50 MG
0213798 TALWIN 0.46 Y N N YAVT /TB
28:08.92 MISCELLANEOUS ANALGESICS AND ANTIPYRETICS --------------------------------------
ACETAMINOPHEN
325MG
0193808 ACETAMINOPHEN 0.012 Y N N NJPC
/TB
0236234 ACETAMINOPHEN CAPLETS 325MG 0.03 Y N N NAPX /TB
0223741 ACETAMINOPHEN 0.0359 Y N N NCAN /TB
0055939 TYLENOL REGULAR STRENGTH 0.07 Y N N NMCL /TB
0054498 APO-ACETAMINOPHEN 0.03 Y N N NAPX /TB
0074354 ACETAMINOPHEN USP 0.0138 Y N N NWHL /TB
0225280 ACETAMINOPHEN 325MG TABLETS 0.02 Y N N NPHM /TB
0060575 ACETAMINOPHEN TAB 0.0237 Y N N NVTH /TB
0038921 NOVO-GESIC 0.03 Y N N NNOP /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
118
PHRM/CHRN/CDO/F28:08.92 MISCELLANEOUS ANALGESICS AND ANTIPYRETICS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
ACETAMINOPHEN (continued)
500MG
0222997 APO-ACETAMINOPHEN 0.03 Y N N NAPX /CAPLE
0224281 ACETAMINOPHEN EXTRA 0.257 Y N N NWHL /CP
0048232 NOVO-GESIC FORTE 500 0.07 Y N N NNOP /TB
0060577 ACETAMINOPHEN EXTRA STREN 0.031 Y N N NVTH /TB
0072390 TYLENOL EXTRA STRENGTH 0.07 Y N N NMCL /TB
0055940 TYLENOL EXTRA STRENGTH 0.07 Y N N NMCL /TB
0054970 ACETAMINOPHEN 0.03 Y N N NSDM /TB
0054500 APO ACETAMINOPHEN 0.03 Y N N NAPX /TB
0225525 ACETAMINOPHEN EXTRA 0.257 Y N N NWHL /TB
0225281 ACETAMINOPHEN (LIFE BRAND) 0.03 Y N N NSDM /TB
0228579 ACETAMINOPHEN 500 MG 0.095 Y N N NVIT /TB
0223741 ACETAMINOPHEN EXTRA STREN 0.03 Y N N NCAN /TB
0089250 PMS-ACETAMINOPHEN 0.03 Y N N NPMS /TB
0078979 ACETAMINOPHEN TAB 0.03 Y N N NTRA /TB
0193912 JAMP-ACETAMINOPHEN 0.03 Y N N NJPC
/TB
80MG/5ML
0190584 ACETAMINOPHEN 0.031 Y N N NLAB /ML
ACETAMINOPHEN
160/5ML
0202779 PEDIATRIX 0.02 Y N N NTVM /ML
0079269 PMS-ACETAMINOPHEN LIQUID 0.03 Y N N NPMS /ML
0222687 ACETAMINOPHEN LIQ 160MG/5ML 0.03 Y N N NRIV /ML
ASA/CAFF/CODEINE/BU
15MG COD
0017619 FIORINAL C1/4 1.84 Y N N YNVR /CP
30MG COD
0060818 RATIO-TECNAL C1/2 2.2 Y N N YRPH /CP
0017620 FIORINAL C1/2 2.2 Y N N YSAN /CP
330//40MG
0022632 FIORINAL 1.72 Y N N YNVR /CP
FLOCTAFENINE
200MG
0224468 APO-FLOCTAFENINE 0.42 Y N Y YAPX /TB
400MG
0224468 APO-FLOCTAFENINE 0.81 Y N Y YAPX /TB
28:10.00 OPIATE ANTAGONISTS -------------------------------------------------------------
NALTREXONE HCL
50MG
0244427 APO-NALTREXONE 7.3 Y E N YAPX /TB
0221382 REVIA 14.32 Y E Y YBMY /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
119
PHRM/CHRN/CDO/F28:12.04 BARBITURATES
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
PHENOBARBITAL
28:12.04 BARBITURATES -------------------------------------------------------------------
100MG
0017882 PHENOBARBITAL 0.2 Y Y Y YPMS /TB
15MG
0017879 PHENOBARBITAL 0.09 Y Y Y YPMS /TB
30MG
0017880 PHENOBARBITAL 0.11 Y Y Y YPMS /TB
5MG/ML
0064557 PHENOBARBITAL ELIXIR 0.12 Y Y Y YPMS /ML
60MG
0017881 PHENOBARBITAL 0.15 Y Y Y YPMS /TB
PHENOBARBITAL
120MG/ML
0230409 PHENOBARBITAL SODIUM INJ 13 N N N YSDZ /ML
PRIMIDONE
125MG
0039931 APO-PRIMIDONE 0.06 Y Y N YAPX /TB
250MG
0039676 APO-PRIMIDONE 0.09 Y Y N YAPX /TB
28:12.08 BENZODIAZEPINES ----------------------------------------------------------------
CLOBAZAM
10MG
0223833 NOVO-CLOBAZAM 0.22 Y Y N YNOP /TB
0224447 PMS-CLOBAZAM 0.22 Y Y N YPMS /TB
0224463 APO-CLOBAZAM 0.22 Y Y Y YAPX /TB
0222179 FRISIUM 0.4393 Y Y N YHLR /TB
CLONAZEPAM
0.25MG
0217966 PMS-CLONAZEPAM 0.08 Y Y N YPMS /TB
0.5MG
0223036 CLONAPAM 0.1166 Y Y N YICN /TB
0217788 APO-CLONAZEPAM 0.05 Y Y N YAPX /TB
0220781 PMS-CLONAZEPAM-R 0.05 Y Y N YPMS /TB
0223095 GEN-CLONAZEPAM 0.05 Y Y N YGPM /TB
0223396 SANDOZ-CLONAZEPAM 0.05 Y Y N YSDZ /TB
0227064 CO-CLONAZEPAM 0.05 Y Y N YCOB /TB
0223902 NOVO-CLONAZEPAM 0.05 Y Y N YNOP /TB
0204870 PMS-CLONAZEPAM 0.05 Y Y N YPMS /TB
0210365 RATIO-CLONAZEPAM 0.1166 Y Y N YRTP /TB
0038282 RIVOTRIL 0.2 Y Y N YHLR /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
120
PHRM/CHRN/CDO/F28:12.08 BENZODIAZEPINES (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
CLONAZEPAM (continued)
1MG
0223036 CLONAPAM 0.186 Y Y N YICN /TB
0204872 PMS-CLONAZEPAM 0.15 Y Y N YPMS /TB
0214523 CLONAZEPAM 0.186 Y Y N YPHL /TB
0227066 CO-CLONAZEPAM 0.15 Y Y N YCOB /TB
0223398 SANDOZ-CLONAZEPAM 0.15 Y Y N YSDZ /TB
2MG
0038284 RIVOTRIL 0.35 Y Y N YHLR /TB
0223398 SANDOZ-CLONAZEPAM 0.09 Y Y N YSDZ /TB
0223902 NOVO-CLONAZEPAM 0.09 Y Y N YNOP /TB
0210373 RATIO-CLONAZEPAM 0.201 Y Y N YRTP /TB
0227067 CO-CLONAZEPAM 0.13 Y Y N YCOB /TB
0204873 PMS-CLONAZEPAM 0.09 Y Y N YPMS /TB
0217789 APO-CLONAZEPAM 0.09 Y Y N YAPX /TB
0223095 GEN-CLONAZEPAM 0.09 Y Y N YGPM /TB
0223036 CLONAPAM 0.201 Y Y N YICN /TB
NITRAZEPAM
10MG
0224523 APO-NITRAZEPAM 0.05 Y Y N YAPX /TB
0223400 SANDOZ-NITRAZEPAM 0.05 Y Y N YSDZ /TB
0222965 NITRAZADON 0.11 Y Y N YICN /TB
0051153 MOGADON 0.23 Y Y N YICN /TB
5MG
0224523 APO-NITRAZEPAM 0.04 Y Y N YAPX /TB
0223400 SANDOZ-NITRAZEPAM 0.04 Y Y N YSDZ /TB
0222965 NITRAZADON 0.07 Y Y N YICN /TB
0051152 MOGADON 0.15 Y Y N YICN /TB
28:12.12 HYDANTOINS ---------------------------------------------------------------------
LEVOCARNITINE
100MG/ML
0214433 CARNITOR ORAL SOLN 0.4 N E N YSIG /ML
330MG
0214432 CARNITOR 330MG TAB 1.31 N E N YSIG /TB
PHENYTOIN
100MG
0002278 DILANTIN 0.08 Y Y N YPFI /CP
25MG/ML
0225089 TARO-PHENYTOIN ORAL SUSP 0.03 Y Y N YTAR /ML
0002345 DILANTIN ORAL SUSP 0.05 Y Y N YPFI /ML
30MG
0002277 DILANTIN 0.05 Y Y N YPFI /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
121
PHRM/CHRN/CDO/F28:12.12 HYDANTOINS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
PHENYTOIN (continued)
50MG
0002369 DILANTIN 0.07 Y Y N YPFI /TB
6MG/ML
0002344 DILANTIN ORAL SUSP 0.04 Y Y N YPFI /ML
28:12.20 SUCCINIMIDES -------------------------------------------------------------------
ETHOSUXIMIDE
250MG
0002279 ZARONTIN 0.34 Y Y N YPFI /CP
50MG/ML
0002348 ZARONTIN ORAL SYRUP 0.06 Y Y N YPFI /ML
METHSUXIMIDE
300MG
0002280 CELONTIN 1.08 Y Y N YPFI /CP
28:12.92 MISCELLANEOUS ANTICONVULSANTS --------------------------------------------------
CARBAMAZEPINE
100MG CH
0224440 TARO-CARBAMAZEPINE CHEWTAB 0.12 Y Y N YTAR /TB
0223154 PMS-CARBAMAZEPINE CHEWTAB 0.038 Y Y N YPMS /TB
0036981 TEGRETOL CHEW TAB 0.18 Y Y N YNVR /TB
20MG/ML
0219433 TEGRETOL ORAL SUSP 0.09 Y Y N YNVR /ML
200MG
0040269 APO-CARBAMAZEPINE 0.15 Y Y N YAPX /TB
0240751 TARO-CARBAMAZEPINE 0.15 Y Y N YTAR /TB
0001040 TEGRETOL 0.43 Y Y N YNVR /TB
0078271 NOVO-CARBAMAZ 0.23 Y Y N YNOP /TB
200MG CH
0223154 PMS-CARBAMAZEPINE CHEWTAB 0.0749 Y Y N YPMS /TB
0066508 TEGRETOL CHEW TAB 0.36 Y Y N YNVR /TB
0224440 TARO-CARBAMAZEPINE CHEWTAB 0.24 Y Y N YTAR /TB
200MG CR
0077361 TEGRETOL CR 0.45 Y Y N YNVR /TB
0223790 TARO-CARBAMAZEPINE CR 0.1887 Y Y N YTAR /TB
0224188 GEN-CARBAMAZEPINE CR 0.09 Y Y N YGPM /TB
0223154 PMS-CARBAMAZEPINE CR 0.093 Y Y N YPMS /TB
0226183 SDZ-CARBAMAZEPINE CR 0.09 Y Y N YSDZ /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
122
PHRM/CHRN/CDO/F28:12.92 MISCELLANEOUS ANTICONVULSANTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
CARBAMAZEPINE (continued)
400MG CR
0226184 SDZ-CARBAMAZEPINE CR 0.19 Y Y N YSDZ /TB
0075558 TEGRETOL CR 0.89 Y Y N YNVR /TB
0224188 GEN-CARBAMAZEPINE CR 0.19 Y Y N YGPM /TB
0223790 TARO-CARBAMAZEPINE CR 0.3775 Y Y N YTAR /TB
0223154 PMS-CARBAMAZEPINE CR 0.19 Y Y N YPMS /TB
DIVALPROEX SODIUM
125MG
0059641 EPIVAL EC 0.31 Y Y N YABB /TB
0226513 GEN-DIVALPROEX EC 0.1377 Y Y N YGPM /TB
0240049 DIVALPROEX 0.07 Y Y N YSAI /TB
0223970 NOVO-DIVALPROEX EC 0.07 Y Y N YNOP /TB
0223969 APO-DIVALPROEX EC 0.07 Y Y N YAPX /TB
250MG
0223970 NOVO-DIVALPROEX EC 0.13 Y Y N YNOP /TB
0223969 APO-DIVALPROEX EC 0.1301 Y Y N YAPX /TB
0226514 GEN-DIVALPROEX EC 0.2475 Y Y N YGPM /TB
0240050 DIVALPROEX 0.13 Y Y N YSAI /TB
0059642 EPIVAL EC 0.55 Y Y N YABB /TB
500MG
0226516 GEN-DIVALPROEX EC 0.4952 Y Y N YGPM /TB
0223970 APO-DIVALPROEX EC 0.2604 Y Y N YAPX /TB
0059643 EPIVAL EC 1.11 Y Y N YABB /TB
0240051 DIVALPROEX 0.26 Y Y N YSAI /TB
0223970 NOVO-DIVALPROEX EC 0.2604 Y Y N YNOP /TB
ESLICARBAZEPINE
200MG
0242686 APTIOM 9.56 E E N YSUN /TB
400MG
0242687 APTIOM 9.56 E E N YSUN /TB
600MG
0242688 APTIOM 9.56 E E N YSUN /TB
800MG
0242689 APTIOM 9.56 E E N YSUN /TB
GABAPENTIN
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
123
PHRM/CHRN/CDO/F28:12.92 MISCELLANEOUS ANTICONVULSANTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
GABAPENTIN (continued)
100MG
0235324 SANIS-GABAPENTIN 0.07 Y Y N YSAN /CP
0225614 CO-GABAPENTIN 0.07 Y Y N YCOB /CP
0208426 NEURONTIN 0.43 Y Y N YPFI /CP
0224344 PMS-GABAPENTIN 0.07 Y Y N YPMS /CP
0224825 MYLAN-GABAPENTIN 0.07 Y Y N YMYL /CP
0224451 TEVA-GABAPENTIN 0.07 Y Y N YTVM /CP
0224430 APO-GABAPENTIN 0.07 Y Y N YAPX /CP
0231905 RAN-GABAPENTIN 0.07 Y Y N YRAN /CP
300MG
0224344 PMS-GABAPENTIN 0.18 Y Y N YPMS /CP
0224451 TEVA-GABAPENTIN 0.18 Y Y N YTVM /CP
0225615 CO-GABAPENTIN 0.18 Y Y N YCOB /CP
0224430 APO-GABAPENTIN 0.18 Y Y N YAPX /CP
0208427 NEURONTIN 1.04 Y Y N YPFI /CP
0231906 RAN-GABAPENTIN 0.18 Y Y N YRAN /CP
0235325 SANIS-GABAPENTIN 0.18 Y Y N YSAN /CP
0224826 MYLAN-GABAPENTIN 0.18 Y Y N YMYL /CP
400MG
0224826 MYLAN-GABAPENTIN 0.22 Y Y N YMYL /CP
0235326 SANIS-GABAPENTIN 0.22 Y Y N YSAN /CP
0231907 RAN-GABAPENTIN 0.22 Y Y N YRAN /CP
0208428 NEURONTIN 1.24 Y Y N YPFI /CP
0224430 APO-GABAPENTIN 0.22 Y Y N YAPX /CP
0224344 PMS-GABAPENTIN 0.22 Y Y N YPMS /CP
0225616 CO-GABAPENTIN 0.22 Y Y N YCOB /CP
0224451 TEVA-GABAPENTIN 0.22 Y Y N YTVM /CP
600MG
0225589 PMS-GABAPENTIN 0.33 Y Y N YPMS /TB
0224845 TEVA-GABAPENTIN 0.33 Y Y N YTVM /TB
0243128 GABAPENTIN 0.33 Y Y N YSAI /TB
0223971 NEURONTIN 1.86 Y Y N YPFI /TB
0228584 GD-GABAPENTIN 0.33 Y Y N YGDI /TB
0229335 APO-GABAPENTIN 0.33 Y Y N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
124
PHRM/CHRN/CDO/F28:12.92 MISCELLANEOUS ANTICONVULSANTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
GABAPENTIN (continued)
800MG
0226092 RATIO-GABAPENTIN 1.7393 Y Y N YRAT /TB
0243129 GABAPENTIN 0.43 Y Y N YSAI /TB
0223971 NEURONTIN 2.49 Y Y N YPFI /TB
0228585 GD-GABAPENTIN 1.74 Y Y N YGDI /TB
0229336 APO-GABAPENTIN 0.43 Y Y N YAPX /TB
0224734 TEVA-GABAPENTIN 0.43 Y Y N YTVM /TB
0225590 PMS-GABAPENTIN 0.43 Y Y N YPMS /TB
LACOSAMIDE
100MG
0235762 VIMPAT 3.46 E E N YUCB /TB
150MG
0235763 VIMPAT 4.59 E E N YUCB /TB
200MG
0235765 VIMPAT 5.66 E E N YUCB /TB
50MG
0235761 VIMPAT 2.47 E E N YUCB /TB
LAMOTRIGINE
100MG
0224689 PMS-LAMOTRIGINE 0.37 Y Y N YPMS /TB
0214210 LAMICTAL 1.55 Y Y N YGSK /TB
0224823 TEVA-LAMOTRIGINE 0.37 Y Y N YNVO /TB
0226550 GEN-LAMOTRIGINE 0.37 Y Y N YGPM /TB
0234302 SANIS-LAMOTRIGINE 0.37 Y Y N YSAN /TB
0224520 APO-LAMOTRIGINE 0.37 Y Y N YAPX /TB
0224335 RATIO-LAMOTRIGINE 0.37 Y Y N YRPH /TB
150MG
0234303 SANIS-LAMOTRIGINE 0.55 Y Y N YSAN /TB
0224696 RATIO-LAMOTRIGINE 0.55 Y Y N YRAT /TB
0226551 GEN-LAMOTRIGINE 0.55 Y Y N YGPM /TB
0224689 PMS-LAMOTRIGINE 0.55 Y Y N YPMS /TB
0224823 TEVA-LAMOTRIGINE 0.55 Y Y N YTVM /TB
0224521 APO-LAMOTRIGINE 0.55 Y Y N YAPX /TB
0214211 LAMICTAL 2.28 Y Y N YGSK /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
125
PHRM/CHRN/CDO/F28:12.92 MISCELLANEOUS ANTICONVULSANTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
LAMOTRIGINE (continued)
25MG
0224823 TEVA-LAMOTRIGINE 0.09 Y Y N YTVM /TB
0224520 APO-LAMOTRIGINE 0.09 Y Y N YAPX /TB
0234301 SANIS-LAMOTRIGINE 0.09 Y Y N YSAN /TB
0214208 LAMICTAL 0.39 Y Y N YGSK /TB
0224335 RATIO-LAMOTRIGINE 0.09 Y Y N YRAT /TB
0226549 GEN-LAMOTRIGINE 0.09 Y Y N YGPM /TB
0224689 PMS-LAMOTRIGINE 0.09 Y Y N YPMS /TB
5MG
0224011 LAMICTAL CHEW TAB 0.17 Y Y N YGSK /TB
LEVETIRACETAM
250MG
0228592 APO-LEVETIRACETAM 0.45 Y Y N YAPX /TB
0239610 RAN-LEVETIRACETAM 0.4 Y Y N YRAN /TB
0227418 CO-LEVETIRACETAM 0.8 Y Y N YCOB /TB
0235334 SANIS-LEVETIRACETAM 0.8 Y Y N YSAN /TB
0224702 KEPPRA 1.76 Y Y N YUCB /TB
500MG
0237525 AURO-LEVETIRACETAM 0.98 Y Y N YAUR /TB
0229612 PMS-LEVETIRACETAM 0.54 Y Y N YPMS /TB
0224702 KEPPRA 2.14 Y Y N YUCB /TB
0235335 SANIS-LEVETIRACETAM 0.98 Y Y N YSAN /TB
0227419 CO-LEVETIRACETAM 0.54 Y Y N YCOB /TB
0228593 APO-LEVETIRACETAM 0.54 Y Y N YAPX /TB
0239611 RAN-LEVETIRACETAM 0.49 Y Y N YRAN /TB
750MG
0239612 RAN-LEVETIRACETAM 0.68 Y Y N YRAN /TB
0227420 CO-LEVETIRACETAM 1.35 Y Y N YCOB /TB
0228594 APO-LEVETIRACETAM 1.35 Y Y N YAPX /TB
0224702 KEPPRA 2.96 Y Y N YUCB /TB
0235336 SANIS-LEVETIRACETAM 1.35 Y Y N YSAN /TB
OXCARBAZEPINE
150 MG
0228429 APO-OXCARBAZEPINE 0.62 Y Y N YAPX /TB
0224206 TRILEPTAL 0.8278 Y Y N YNVR /TB
300 MG
0228430 APO-OXCARBAZEPINE 0.91 Y Y N YAPX /TB
0224206 TRILEPTAL 0.91 Y Y N YNVR /TB
60MG/ML
0224467 TRILEPTAL ORAL SUSP 0.331 E E N YNVR /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
126
PHRM/CHRN/CDO/F28:12.92 MISCELLANEOUS ANTICONVULSANTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
OXCARBAZEPINE (continued)
600 MG
0224206 TRILEPTAL 1.82 Y Y N YNVR /TB
0228431 APO-OXCARBAZEPINE 1.82 Y Y N YAPX /TB
PERAMPANEL
6MG
0240453 FYCOMPA 9.45 E E N YEIS /TB
8MG
0240454 FYCOMPA 9.45 E E N YEIS /TB
PREGABALIN
150MG
0235963 PMS-PREGABALIN 1.727 Y Y N YPMS /CP
0239284 RAN-PREGABALIN 1.73 Y Y N YRAN /CP
0239084 SANDOZ-PREGABALIN 1.727 Y Y N YSDZ /CP
0240295 CO-PREGABALIN 1.73 Y Y N YCOB /CP
0226845 LYRICA 2.302 Y Y N YPFI /CP
0239427 APO-PREGABALIN 1.73 Y Y N YAPX /CP
0242420 MINT-PREGABALIN 1.73 Y Y N YMNT /CP
0236017 GD-PREGABALIN 1.73 Y Y N YGDI /CP
0236120 TEVA-PREGABALIN 1.727 Y Y N YTVM /CP
0240556 PREGABALIN 1.73 Y Y N YSAI /CP
225MG
0236122 TEVA-PREGABALIN 1.727 Y Y N YTVM /CP
0236019 GD-PREGABALIN 1.73 Y Y N YGDI /CP
0240297 CO-PREGABALIN 1.73 Y Y N YCOB /CP
0226847 LYRICA 2.3 Y Y N YPFI /CP
0239807 PMS-PREGABALIN 1.727 Y Y N YPMS /CP
0239428 APO-PREGABALIN 1.73 Y Y N YAPX /CP
0239285 RAN-PREGABALIN 1.73 Y Y N YRAN /CP
25MG
0236115 TEVA-PREGABALIN 0.617 Y Y N YTVM /AP
0240291 CO-PREGABALIN 0.62 Y Y N YCOB /CP
0239423 APO-PREGABALIN 0.62 Y Y N YAPX /CP
0236013 GD-PREGABALIN 0.62 Y Y N YGDI /CP
0235959 PMS-PREGABALIN 0.617 Y Y N YPMS /CP
0239280 RAN-PREGABALIN 0.62 Y Y N YRAN /CP
0239081 SANDOZ-PREGABALIN 0.617 Y Y N YSDZ /CP
0240553 PREGABALIN 0.617 Y Y N YSAI /CP
0242380 MINT-PREGABALIN 0.62 Y Y N YMNT /CP
0226841 LYRICA 0.82 Y Y N YPFI /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
127
PHRM/CHRN/CDO/F28:12.92 MISCELLANEOUS ANTICONVULSANTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
PREGABALIN (continued)
300MG
0226848 LYRICA 2.3 Y Y N YPFI /CP
0239429 APO-PREGABALIN 1.73 Y Y N YAPX /CP
0240559 PREGABALIN 1.73 Y Y N YSAI /CP
0236020 GD-PREGABALIN 1.73 Y Y N YGDI /CP
0239286 RAN-PREGABALIN 1.73 Y Y N YRAN /CP
0236124 TEVA-PREGABALIN 1.727 Y Y N YTVM /CP
0235964 PMS-PREGABALIN 1.727 Y Y N YPMS /CP
0239086 SANDOZ-PREGABALIN 1.727 Y Y N YSDZ /CP
0240299 CO-PREGABALIN 1.73 Y Y N YCOB /CP
50MG
0239424 APO-PREGABALIN 0.97 Y Y N YAPX /CP
0240292 CO-PREGABALIN 0.97 Y Y N YCOB /CP
0242381 MINT-PREGABALIN 0.97 Y Y N YMNT /CP
0239082 SANDOZ-PREGABALIN 0.968 Y Y N YSDZ /CP
0239282 RAN-PREGABALIN 0.97 Y Y N YRAN /CP
0240554 PREGABALIN 0.968 Y Y N YSAI /CP
0236014 GD-PREGABALIN 0.97 Y Y N YGDI /CP
0236117 TEVA-PREGABALIN 0.968 Y Y N YTVM /CP
0235961 PMS-PREGABALIN 0.968 Y Y N YPMS /CP
0226842 LYRICA 1.29 Y Y N YPFI /CP
75MG
0239083 SANDOZ-PREGABALIN 1.252 Y Y N YSDZ /CP
0236118 TEVA-PREGABALIN 1.252 Y Y N YTVM /CP
0242418 MINT-PREGABALIN 1.25 Y Y N YMNT /CP
0240555 PREGABALIN 1.25 Y Y N YSAI /CP
0239283 RAN-PREGABALIN 1.25 Y Y N YRAN /CP
0239425 APO-PREGABALIN 1.25 Y Y N YAPX /CP
0236015 GD-PREGABALIN 1.25 Y Y N YGDI /CP
0226843 LYRICA 1.671 Y Y N YPFI /CP
0240293 CO-PREGABALIN 1.25 Y Y N YCOB /CP
0235962 PMS-PREGABALIN 1.252 Y Y N YPMS /CP
TOPIRAMATE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
128
PHRM/CHRN/CDO/F28:12.92 MISCELLANEOUS ANTICONVULSANTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
TOPIRAMATE (continued)
100MG
0243534 ACCEL-TOPIRAMATE 0.47 Y Y N YACC /TB
0224886 TEVA-TOPIRAMATE 0.59 Y Y N YTVM /TB
0223089 TOPAMAX 2.46 Y Y N YJAN /TB
0227963 APO-TOPIRAMATE 0.59 Y Y N YAPX /TB
0228777 CO-TOPIRAMATE 0.59 Y Y N YCOB /TB
0231565 MINT-TOPIRAMATE 0.59 Y Y N Ynull /TB
0234583 AURO-TOPIRAMATE 0.59 Y Y N YAUR /TB
0226337 GEN-TOPIRAMATE 0.59 Y Y N YGPM /TB
0226300 PMS-TOPIRAMATE 0.59 Y Y N YPMS /TB
0226006 SANDOZ TOPIRAMATE 0.59 Y Y N YSDZ /TB
0235686 SANIS-TOPIRAMATE 0.59 Y Y N YSAN /TB
15MG
0223990 TOPAMAX SPRINKLE CAP 1.2 E E N YJAN /CP
200MG
0235687 SANIS-TOPIRAMATE 0.89 Y Y N YSAN /TB
0224886 TEVA-TOPIRAMATE 0.89 Y Y N YTVM /TB
0223089 TOPAMAX 3.67 Y Y N YJAN /TB
0226783 SANDOZ TOPIRAMATE 0.89 Y Y N YSDZ /TB
0226301 PMS-TOPIRAMATE 0.89 Y Y N YPMS /TB
0243535 ACCEL-TOPIRAMATE 0.69 Y Y N YACC /TB
0227964 APO-TOPIRAMATE 0.89 Y Y N YAPX /TB
0228778 CO-TOPIRAMATE 0.89 Y Y N YCOB /TB
0231566 MINT-TOPIRAMATE 0.93 Y Y N YMNT /TB
0226338 GEN-TOPIRAMATE 0.89 Y Y N YGPM /TB
25MG
0223990 TOPAMAX SPRINKLE CAP 1.26 E E N YJAN /CP
0235685 SANIS-TOPIRAMATE 0.31 Y Y N YSAN /TB
0228776 CO-TOPIRAMATE 0.31 Y Y N YCOB /TB
0243533 ACCEL-TOPIRAMATE 0.25 Y Y N YACC /TB
0226005 SANDOZ TOPIRAMATE 0.31 Y Y N YSDZ /TB
0226299 PMS-TOPIRAMATE 0.31 Y Y N YPMS /TB
0223089 TOPAMAX 1.3 Y Y N YJAN /TB
0231564 MINT-TOPIRAMATE 0.31 Y Y N YMNT /TB
0227961 APO-TOPIRAMATE 0.31 Y Y N YAPX /TB
0234580 AURO-TOPIRAMATE 0.31 Y Y N YAUR /TB
0224886 TEVA-TOPIRAMATE 0.31 Y Y N YTVM /TB
0226335 GEN-TOPIRAMATE 0.31 Y Y N YGPM /TB
50MG
0231208 PMS-TOPIRAMATE 1.13 Y Y N YPMS /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
129
PHRM/CHRN/CDO/F28:12.92 MISCELLANEOUS ANTICONVULSANTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
VALPROIC ACID
VALPROIC ACID
250MG
0044384 DEPAKENE 0.58 Y Y N YABB /CP
0223804 APO-VALPROIC 0.29 Y Y N YAPX /CP
0214004 RATIO-VALPROIC 0.29 Y Y N YRTP /CP
0223076 PMS-VALPROIC 0.29 Y Y N YPMS /CP
50MG/ML
0223680 PMS-VALPROIC ACID ORAL SYRUP 0.04 Y Y N YPMS /ML
0214006 RATIO-VALPROIC ORAL SYRUP 0.04 Y Y N YRTP /ML
0044383 DEPAKENE ORAL SYRUP 0.12 Y Y N YABB /ML
0223837 APO-VALPROIC ORAL SYRUP 0.06 Y Y N YAPX /ML
500MG
0221832 NOVO-VALPROIC EC 0.5197 Y Y N YNOP /CP
0222962 PMS-VALPROIC ACID E.C. 0.55 Y Y N YPMS /CP
VIGABATRIN
500MG
0206803 SABRIL SACHET 0.911 Y Y N YHLR /DS
0206581 SABRIL 0.911 Y Y N YHLR /TB
28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS) -------------------------------------
AMITRIPTYLINE
10MG
0232604 TEVA-AMITRIPTYLINE 0.07 Y Y Y YTVM /TB
0033505 ELAVIL (AA) AMITRIPTYLINE 0.066 Y Y Y YAA /TB
0065452 PMS-AMITRIPTYLINE TABLETS 0.07 Y Y Y YPMS /TB
0240313 APO-AMITRIPTYLINE 0.066 Y Y Y YAPX /TB
25MG
0232605 TEVA-AMITRIPTYLINE 0.12 Y Y Y YTVM /TB
0240314 APO-AMITRIPTYLINE 0.1211 Y Y Y YAPX /TB
0033506 ELAVIL (AA) AMITRIPTYLINE 0.1211 Y Y Y YAA /TB
0065451 PMS-AMITRIPTYLINE TABLETS 0.12 Y Y Y YPMS /TB
50MG
0065450 PMS-AMITRIPTYLINE 0.23 Y Y Y YPMS /TB
0033508 ELAVIL (AA) AMITRIPTYLINE 0.23 Y Y Y YAA /TB
0240315 APO-AMITRIPTYLINE 0.23 Y Y Y YAPX /TB
0232607 TEVA-AMITRIPTYLINE 0.23 Y Y Y YTVM /TB
75MG
0240316 APO-AMITRIPTYLINE 0.36 Y Y Y YAPX /TB
0075412 ELAVIL 0.3634 Y Y Y YAA /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
130
PHRM/CHRN/CDO/F28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
BUPROPION HYDROCHLORIDE
BUPROPION
100MG
0232537 PMS-BUPROPION SR 0.15 Y Y Y YPMS /TB
0239156 SANIS-BUPROPION SR 0.15 Y Y Y YSAI /TB
0227507 SANDOZ BUPROPION SR 0.15 Y Y Y YSDZ /TB
0228565 RATIO-BUPROPION SR 0.15 Y Y Y YRPH /TB
150MG
0227508 SANDOZ BUPROPION SR 0.23 Y Y Y YSDZ /TB
0228566 RATIO-BUPROPION SR 0.23 Y Y Y YRPH /TB
0223782 WELLBUTRIN SR 0.98 Y Y Y YBVL /TB
0239157 SANIS-BUPROPION 0.23 Y Y Y YSAI /TB
0231342 PMS-BUPROPION SR 0.23 Y Y Y YPMS /TB
0226023 NOVO-BUPROPION SR 0.504 Y Y Y YNOP /TB
150MG XL
0243965 ACT BUPROPION XL 0.29 Y Y Y YACT /TB
0238207 MYLAN-BUPROPION 0.4 Y Y Y Ynull /TB
0227509 WELLBUTRIN XL 0.57 Y Y Y YBVL /TB
300MG XL
0227510 WELLBUTRIN XL 1.13 Y Y Y Ynull /TB
0238208 MYLAN-BUPROPION 0.8 Y Y Y YMYL /TB
0243966 ACT BUPROPION XL 0.59 Y Y Y YACT /TB
CITALOPRAM
10MG
0231233 TEVA-CITALOPRAM 0.14 Y Y Y YTVM /TB
0237007 MINT-CITALOPRAM 0.14 Y Y Y YMNT /TB
0244571 CITALOPRAM 0.14 Y Y Y YSAI /TB
0235524 ACCEL-CITALOPRAM TABLETS 0.14 Y Y Y YACC /TB
0242969 MINT-CITALOPRAM 0.14 Y Y Y YMNT /TB
0227060 PMS-CITALOPRAM 0.14 Y Y Y YPMS /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
131
PHRM/CHRN/CDO/F28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
CITALOPRAM (continued)
20MG
0223960 CELEXA 1.37 Y Y Y YLUD /TB
0229321 TEVA-CITALOPRAM 0.24 Y Y Y YTVM /TB
0230468 MINT-CITALOPRAM 0.24 Y Y Y YMNT /TB
0224659 MYLAN-CITALOPRAM 0.24 Y Y Y YMYL /TB
0224605 APO-CITALOPRAM 0.24 Y Y Y YAPX /TB
0224817 SDZ-CITALOPRAM 0.24 Y Y Y YSDZ /TB
0224805 CO CITALOPRAM 0.24 Y Y Y YCOB /TB
0224801 PMS-CITALOPRAM 0.24 Y Y Y YPMS /TB
0228562 RAN-CITALO 0.24 Y Y Y YRAN /TB
0242970 MINT-CITALOPRAM 0.24 Y Y Y YMNT /TB
0235525 ACCEL-CITALOPRAM 0.23 Y Y Y YACC /TB
0235366 SANIS-CITALOPRAM 0.24 Y Y Y YSAN /TB
30MG
0229615 CTP 30 0.88 Y Y Y YSEP
/TB
40MG
0235367 SANIS-CITALOPRAM 0.24 Y Y Y YSAN /TB
0224659 MYLAN-CITALOPRAM 0.24 Y Y Y YMYL /TB
0224801 PMS-CITALOPRAM 0.24 Y Y Y YPMS /TB
0235526 ACCEL-CITALOPRAM 0.23 Y Y Y YACC /TB
0224605 APO-CITALOPRAM 0.24 Y Y Y YAPX /TB
0228563 RAN-CITALO 0.24 Y Y Y YRAN /TB
0242971 MINT-CITALOPRAM 0.24 Y Y Y YMNT /TB
0224817 SDZ-CITALOPRAM 0.24 Y Y Y YSDZ /TB
0230469 MINT-CITALOPRAM 0.24 Y Y Y YMNT /TB
0229322 TEVA-CITALOPRAM 0.24 Y Y Y YTVM /TB
0224805 CO CITALOPRAM 0.24 Y Y Y YCOB /TB
0223960 CELEXA 1.37 Y Y Y YLUD /TB
CLOMIPRAMINE HCL
10MG
0033056 ANAFRANIL 0.29 Y Y Y YNVR /TB
0204078 APO-CLOMIPRAMINE 0.13 Y Y Y YAPX /TB
0224481 CO-CLOMIPRAMINE 0.13 Y Y Y YCOB /TB
25MG
0224481 CO-CLOMIPRAMINE 0.18 Y Y Y YCOB /TB
0032401 ANAFRANIL 0.39 Y Y Y YNVR /TB
0204077 APO-CLOMIPRAMINE 0.18 Y Y Y YAPX /TB
50MG
0224481 CO-CLOMIPRAMINE 0.32 Y Y Y YCOB /TB
0204075 APO-CLOMIPRAMINE 0.32 Y Y Y YAPX /TB
0040259 ANAFRANIL 0.73 Y Y Y YNVR /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
132
PHRM/CHRN/CDO/F28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
DESIPRAMINE HCL
DESIPRAMINE HCL
10MG
0221624 APO-DESIPRAMINE 0.3804 Y Y Y YAPX /TB
0194625 PMS-DESIPRAMINE 0.1905 Y Y Y YPMS /TB
100MG
0221628 APO-DESIPRAMINE 0.8915 Y Y Y YAPX /TB
25MG
0221625 APO-DESIPRAMINE 0.3804 Y Y Y YAPX /TB
0194626 PMS-DESIPRAMINE 0.2544 Y Y Y YPMS /TB
50MG
0194627 PMS-DESIPRAMINE 0.411 Y Y Y YPMS /TB
0221626 APO-DESIPRAMINE 0.68 Y Y Y YAPX /TB
75MG
0194624 PMS-DESIPRAMINE 0.6334 Y Y Y YPMS /TB
0221627 APO-DESIPRAMINE 0.8915 Y Y Y YAPX /TB
DOXEPIN HCL
10MG
0204999 APO-DOXEPIN 0.25 Y Y Y YAPX /CP
0002432 SINEQUAN 0.08 Y Y Y YPFI /CP
100MG
0205004 APO-DOXEPIN 1.34 Y Y Y YAPX /CP
0191346 NOVO-DOXEPIN 0.345 Y Y Y YNOP /CP
0032692 SINEQUAN 0.345 Y Y Y YPFI /CP
150MG
0191347 NOVO-DOXEPIN 1.2 Y Y Y YNOP /CP
25MG
0205000 APO-DOXEPIN 0.31 Y Y Y YAPX /CP
0002433 SINEQUAN 0.1 Y Y Y YPFI /CP
0191342 NOVO-DOXEPIN 0.1 Y Y Y YNOP /CP
50MG
0002434 SINEQUAN 0.1827 Y Y Y YPFI /CP
0191343 NOVO-DOXEPIN 0.1827 Y Y Y YNOP /CP
0205001 APO-DOXEPIN 0.57 Y Y Y YAPX /CP
75MG
0191344 NOVO-DOXEPIN 0.3673 Y Y Y YNOP /CP
0205002 APO-DOXEPIN 0.81 Y Y Y YAPX /CP
0040075 SINEQUAN 0.3967 Y Y Y YPFI /CP
DULOXETINE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
133
PHRM/CHRN/CDO/F28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
DULOXETINE (continued)
30MG
0230148 CYMBALTA 1.93 Y Y N YLIL /CP
0243994 SANDOZ DULOXETINE 0.48 Y Y N YSDZ /CP
0244042 APO-DULOXETINE 0.48 Y Y N YAPX /CP
0243664 AURO-DULOXETINE 0.48 Y Y N YAUR /CP
0243898 MINT-DULOXETINE 0.48 Y Y N YMNT /CP
60MG
0243995 SANDOZ DULOXETINE 0.98 Y Y N YSDZ /CP
0243899 MINT-DULOXETINE 0.98 Y Y N YMNT /CP
0230149 CYMBALTA 3.86 Y Y N YLIL /CP
0244043 APO-DULOXETINE 0.98 Y Y N YAPX /CP
0243665 AURO-DULOXETINE 0.98 Y Y N YAUR /CP
ESCITALOPRAM
10MG
0226323 CIPRALEX 1.73 Y Y N YLUN /TB
0229501 APO-ESCITALOPRAM 0.43 Y Y N YAPX /TB
0240741 MINT-ESCITALOPRAM 0.43 Y Y N YMNT /TB
0243011 ESCITALOPRAM 0.43 Y Y N YSAN /TB
0242978 JAMP-ESCITALOPRAM 0.43 Y Y N YJAM /TB
0236407 SANDOZ ESCITALOPRAM 0.43 Y Y N YSDZ /TB
0238548 RAN-ESCITALOPRAM 0.35 Y Y N YRAN /TB
0231356 CO ESCITALOPRAM 0.43 Y Y Y YCOB /TB
0230946 MYLAN-ESCITALOPRAM 0.43 Y Y N YMYL /TB
0230394 PMS-ESCITALOPRAM 0.43 Y Y N YPMS /TB
0231818 TEVA-ESCITALOPRAM 0.43 Y Y N YTEV /TB
20MG
0229502 APO-ESCITALOPRAM 0.46 Y Y N YAPX /TB
0240743 MINT-ESCITALOPRAM 0.46 Y Y N YMNT /TB
0231358 CO ESCITALOPRAM 0.46 Y Y N YCOB /TB
0236408 SANDOZ ESCITALOPRAM 0.46 Y Y N Ynull /TB
0230947 MYLAN-ESCITALOPRAM 0.46 Y Y N YMYL /TB
0226325 CIPRALEX 1.84 Y Y N YLUN /TB
0230396 PMS-ESCITALOPRAM 0.46 Y Y N YPMS /TB
0238550 RAN-ESCITALOPRAM 0.37 Y Y N YRAN /TB
0231820 TEVA-ESCITALOPRAM 0.46 Y Y N YTEV /TB
0243012 ESCITALOPRAM 0.46 Y Y N YSAN /TB
0242979 JAMP-ESCITALOPRAM 0.46 Y Y N YJAM /TB
FLUOXETINE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
134
PHRM/CHRN/CDO/F28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
FLUOXETINE (continued)
10MG
0240039 ACCEL-FLUOXETINE 0.37 Y Y Y YACC /CP
0217757 PMS-FLUOXETINE 0.46 Y Y Y YPMS /CP
0224348 SDZ-FLUOXETINE 0.87 Y Y Y YSDZ /CP
0224217 CO FLUOXETINE 0.46 Y Y Y YCOB /CP
0201898 PROZAC 1.85 Y Y Y YLIL /CP
0221658 TEVA-FLUOXETINE 0.46 Y Y Y YTVM /CP
0223781 GEN-FLUOXETINE 0.46 Y Y Y YGPM /CP
0224137 RATIO-FLUOXETINE 0.46 Y Y Y YRTP /CP
0221635 APO-FLUOXETINE 0.46 Y Y Y YAPX /CP
0238056 MINT-FLUOXETINE 0.46 Y Y Y YMNT /CP
0228606 SANIS-FLUOXETINE 0.46 Y Y Y YSAN /CP
20MG
0217758 PMS-FLUOXETINE 0.46 Y Y Y YPMS /CP
0221659 TEVA-FLUOXETINE 0.46 Y Y Y YTVM /CP
0221636 APO-FLUOXETINE 0.46 Y Y Y YAPX /CP
0223781 GEN-FLUOXETINE 0.46 Y Y Y YGPM /CP
0063662 PROZAC 1.85 Y Y Y YLIL /CP
0224348 SDZ-FLUOXETINE 0.46 Y Y Y YSDZ /CP
0238057 MINT-FLUOXETINE 0.46 Y Y Y YMNT /CP
0228607 SANIS-FLUOXETINE 0.46 Y Y Y YSAN /CP
0224137 RATIO-FLUOXETINE 0.46 Y Y Y YRTP /CP
0224217 CO FLUOXETINE 0.46 Y Y Y YCOB /CP
0240040 ACCEL-FLUOXETINE 0.37 Y Y Y YACC /CP
4MG/ML
0223132 APO-FLUOXETINE ORAL SOLN 0.59 Y Y Y YAPX /ML
FLUVOXAMINE MALEATE
100MG
0223133 APO-FLUVOXAMINE 0.38 Y Y Y YAPX /TB
0191936 LUVOX 1.61 Y Y Y YSLV /TB
0224068 PMS-FLUVOXAMINE 0.605 Y Y Y YPMS /TB
0225553 CO-FLUVOXAMINE 0.38 Y Y Y YCOB /TB
0223995 NOVO-FLUVOXAMINE 0.55 Y Y Y YNOP /TB
0224705 SANDOZ FLUVOXAMINE 0.38 Y Y Y YSDZ /TB
0221846 RATIO-FLUVOXAMINE 0.38 Y Y Y YRTP /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
135
PHRM/CHRN/CDO/F28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
FLUVOXAMINE MALEATE (continued)
50MG
0224068 PMS-FLUVOXAMINE 0.337 Y Y Y YPMS /TB
0223995 NOVO-FLUVOXAMINE 0.21 Y Y Y YNOP /TB
0221845 RATIO-FLUVOXAMINE 0.21 Y Y Y YRTP /TB
0191934 LUVOX 0.9 Y Y Y YSLV /TB
0225552 CO-FLUVOXAMINE 0.21 Y Y Y YCOB /TB
0223132 APO-FLUVOXAMINE 0.21 Y Y Y YAPX /TB
IMIPRAMINE
10MG
0036020 APO-IMIPRAMINE 0.14 Y Y Y YAPX /TB
25MG
0031279 APO-IMIPRAMINE 0.25 Y Y Y YAPX /TB
50MG
0032685 APO-IMIPRAMINE 0.48 Y Y Y YAPX /TB
75MG
0064457 APO-IMIPRAMINE 0.63 Y Y Y YAPX /TB
L-TRYPTOPHAN
1000MG
0065453 TRYPTAN 1.54 Y Y N YICN /TB
0223020 TRYPTOPHAN 0.858 Y Y N YPMS /TB
MAPROTILINE
25MG
0215861 NOVO-MAPROTILINE 0.6 Y Y Y YNOP /TB
50MG
0215862 NOVO-MAPROTILINE 1.13 Y Y Y YNOP /TB
75MG
0215863 NOVO-MAPROTILINE 1.54 Y Y Y YNOP /TB
MIRTAZAPINE
15MG
0227394 PMS-MIRTAZAPINE 0.1 Y Y N YPMS /TB
0228661 APO-MIRTAZAPINE 0.38 Y Y N YAPX /TB
0225609 GEN-MIRTAZAPINE 0.1 Y Y N YGPM /TB
0241169 AURO-MIRTAZAPINE 0.38 Y Y N YAUR /TB
0225059 SANDOZ-MIRTAZAPINE 0.38 Y Y N YSDZ /TB
15 MG ODT
0224854 REMERON RD 0.44 Y Y N YORG /TB
0227989 NOVO-MIRTAZAPINE OD 0.27 Y Y N YNOP /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
136
PHRM/CHRN/CDO/F28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
MIRTAZAPINE (continued)
30MG
0224391 REMERON 1.51 Y Y N YORG /TB
0227092 RATIO-MIRTAZAPINE 0.69 Y Y N YRPH /TB
0237068 SANIS-MIRTAZAPINE 0.2 Y Y N YSAI /TB
0225611 GEN-MIRTAZAPINE 0.2 Y Y N YGPM /TB
0225060 SANDOZ-MIRTAZAPINE 0.2 Y Y N YSDZ /TB
0224876 PMS-MIRTAZAPINE 0.2 Y Y N YPMS /TB
0228662 APO-MIRTAZAPINE 0.2 Y Y N YAPX /TB
0225935 NOVO-MIRTAZAPINE 0.2 Y Y N YNOP /TB
0241170 AURO-MIRTAZAPINE 0.2 Y Y N YAUR /TB
30 MG ODT
0227990 NOVO-MIRTAZAPIINE OD 0.55 Y Y N YNOP /TB
0229982 AURO-MIRTAZAPINE OD 0.55 Y Y N YAUR /TB
0224854 REMERON RD 0.88 Y Y N YORG /TB
45MG
0241171 AURO-MIRTAZAPINE 1.13 Y Y N YAUR /TB
0225612 GEN-MIRTAZAPINE 1.16 Y Y N YGPM /TB
0228663 APO-MIRTAZAPINE 1.13 Y Y N YAPX /TB
45 MG ODT
0227991 NOVO-MIRTAZAPINE OD 0.82 Y Y N YNOP /TB
0224854 REMERON RD 1.32 Y Y N YORG /TB
MOCLOBEMIDE
100MG
0223214 APO-MOCLOBEMIDE 0.25 Y Y Y YAPX /TB
150MG
0223974 NOVO-MOCLOBEMIDE 0.31 Y Y Y YNOP /TB
0223215 APO-MOCLOBEMIDE 0.31 Y Y Y YAPX /TB
0089935 MANERIX 0.64 Y Y Y YHLR /TB
300MG
0224045 APO-MOCLOBEMIDE 0.61 Y Y Y YAPX /TB
0216674 MANERIX 1.26 Y Y Y YHLR /TB
0223974 NOVO-MOCLOBEMIDE 0.61 Y Y Y YNOP /TB
NORTRIPTYLINE
10MG
0217769 PMS-NORTRIPTYLINE 0.05 Y Y Y YPMS /CP
0001522 AVENTYL 0.25 Y Y Y YMM /CP
0223178 NOVO-NORTRIPTYLINE 0.05 Y Y Y YNOP /CP
0223036 NORVENTYL 0.126 Y Y Y YVAL /CP
0222351 APO-NORTRIPTYLINE 0.05 Y Y Y YAPX /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
137
PHRM/CHRN/CDO/F28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
NORTRIPTYLINE (continued)
25MG
0001523 AVENTYL 0.51 Y Y Y YMM /CP
0223178 NOVO-NORTRIPTYLINE 0.1 Y Y Y YNOP /CP
0222353 APO-NORTRIPTYLINE 0.1 Y Y Y YAPX /CP
0223036 NORVENTYL 0.2547 Y Y Y YVAL /CP
0217770 PMS-NORTRIPTYLINE 0.1 Y Y Y YPMS /CP
PAROXETINE
10MG
0224781 RATIO-PAROXETINE 1.043 Y Y Y YRPH /TB
0226274 CO PAROXETINE 1.04 Y Y Y YCOB /TB
0224775 PMS-PAROXETINE 1.043 Y Y Y YPMS /TB
0224855 TEVA-PAROXETINE 1.04 Y Y Y YTEV /TB
0202788 PAXIL 1.692 Y Y Y YGSK /TB
0224090 APO-PAROXETINE 1.043 Y Y Y YAPX /TB
0228284 SANIS-PAROXETINE 1.043 Y Y Y YSAN /TB
0224801 GEN-PAROXETINE 1.043 Y Y Y YGPM /TB
20MG
0224775 PMS-PAROXETINE 0.45 Y Y Y YPMS /TB
0224090 APO-PAROXETINE 0.45 Y Y Y YAPX /TB
0226275 CO PAROXETINE 0.45 Y Y Y YCOB /TB
0224781 RATIO-PAROXETINE 0.45 Y Y Y YRPH /TB
0224855 NOVO-PAROXETINE 0.45 Y Y Y YNOP /TB
0228285 SANIS-PAROXETINE 0.45 Y Y Y YSAN /TB
0194048 PAXIL 1.81 Y Y Y YGSK /TB
0224801 GEN-PAROXETINE 0.45 Y Y Y YGPM /TB
30MG
0224801 GEN-PAROXETINE 0.48 Y Y Y YGPM /TB
0228286 SANIS-PAROXETINE 0.48 Y Y Y YSAN /TB
0226276 CO PAROXETINE 0.48 Y Y Y YCOB /TB
0242139 MINT-PAROXETINE 0.48 Y Y Y YMNT /TB
0224855 NOVO-PAROXETINE 0.48 Y Y Y YNOP /TB
0194047 PAXIL 1.92 Y Y Y YGSK /TB
0224090 APO-PAROXETINE 0.48 Y Y Y YAPX /TB
0224781 RATIO-PAROXETINE 0.48 Y Y Y YRPH /TB
0224775 PMS-PAROXETINE 0.48 Y Y Y YPMS /TB
PHENELZINE SO4
15MG
0047655 NARDIL 0.38 Y Y Y YPFI /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
138
PHRM/CHRN/CDO/F28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
SERTRALINE HYDROCHLORIDE
SERTRALINE
100MG
0224252 MYLAN-SERTRALINE 0.42 Y Y Y YMYL /CP
0224484 PMS-SERTRALINE 0.42 Y Y Y YPMS /CP
0224578 RATIO-SERTRALINE 1.1025 Y Y Y YRPH /CP
0223828 APO-SERTRALINE 0.42 Y Y Y YAPX /CP
0224048 TEVA-SERTRALINE 0.42 Y Y Y YTVM /CP
0196277 ZOLOFT 1.79 Y Y Y YPFI /CP
0240240 MINT-SERTALINE 0.42 Y Y Y YMNT /CP
0235354 SANIS-SERTRALINE 0.42 Y Y Y YSAN /CP
0228741 CO-SERTRALINE 0.42 Y Y Y YCOB /CP
25MG
0228739 CO-SERTRALINE 0.2 Y Y Y YCOB /CP
0224251 MYLAN-SERTRALINE 0.2 Y Y Y YMYL /CP
0235352 SANIS-SERTRALINE 0.2 Y Y Y YSAN /CP
0223828 APO-SERTRALINE 0.2 Y Y Y YAPX /CP
0224578 RATIO-SERTRALINE 0.504 Y Y Y YRPH /CP
0213270 ZOLOFT 0.84 Y Y Y YPFI /CP
0224483 PMS-SERTRALINE 0.2 Y Y Y YPMS /CP
0224048 TEVA-SERTRALINE 0.2 Y Y Y YTVM /CP
0240237 MINT-SERTRALINE 0.2 Y Y Y YMNT /CP
50MG
0235353 SANIS-SERTRALINE 0.4 Y Y Y YSAN /CP
0240239 MINT-SERTRALINE 0.4 Y Y Y YMNT /CP
0196281 ZOLOFT 1.68 Y Y Y YPFI /CP
0224048 TEVA-SERTRALINE 0.4 Y Y Y YTVM /CP
0223828 APO-SERTRALINE 0.4 Y Y Y YAPX /CP
0224578 RATIO-SERTRALINE 1.008 Y Y Y YRPH /CP
0224483 PMS-SERTRALINE 0.4 Y Y Y YPMS /CP
0228740 CO-SERTRALINE 0.4 Y Y Y YCOB /CP
0224252 MYLAN-SERTRALINE 0.4 Y Y Y YMYL /CP
TRANYLCYPROMINE SO4
10MG
0191959 PARNATE 0.38 Y Y Y YGSK /TB
TRAZODONE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
139
PHRM/CHRN/CDO/F28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
TRAZODONE (continued)
100MG
0214764 APO-TRAZODONE 0.1 Y Y Y YAPX /TB
0223168 GEN-TRAZODONE 0.13 Y Y Y YGPM /TB
0227735 RATIO TRAZODONE 0.3956 Y Y Y YRTP /TB
0234878 SANIS-TRAZODONE 0.1 Y Y Y YSAN /TB
0214427 TEVA-TRAZODONE 0.1 Y Y Y YTVM /TB
0223028 TRAZOREL 0.4 Y Y Y YICN /TB
0193723 PMS-TRAZODONE 0.1 Y Y Y YPMS /TB
150MG
0234879 SANIS-TRAZODONE 0.15 Y Y Y YSAN /TB
0214429 TEVA-TRAZODONE 0.15 Y Y Y YTVM /TB
0227736 RATIO-TRAZODONE 0.5812 Y Y Y YRTP /TB
0214765 APO-TRAZODONE D 0.15 Y Y Y YAPX /TB
50MG
0223168 GEN-TRAZODONE 0.06 Y Y Y YGPM /TB
0227734 RATIO-TRAZODONE 0.2214 Y Y Y YRTP /TB
0223028 TRAZOREL 0.2214 Y Y Y YICN /TB
0193722 PMS-TRAZODONE 0.06 Y Y Y YPMS /TB
0234877 SANIS-TRAZODONE 0.06 Y Y Y YSAN /TB
0214763 APO-TRAZODONE 0.06 Y Y Y YAPX /TB
0214426 TEVA-TRAZODONE 0.06 Y Y Y YTVM /TB
68.25MG
0223733 PMS-TRAZODONE 0.37 Y Y Y YPMS /TB
TRIMIPRAMINE
100MG
0074082 APO-TRIMIP 0.9273 Y Y Y YAPX /TB
12.5MG
0074079 APO-TRIMIP 0.22 Y Y Y YAPX /TB
25MG
0074080 APO-TRIMIP 0.2776 Y Y Y YAPX /TB
50MG
0074081 APO-TRIMIP 0.5434 Y Y Y YAPX /TB
75MG
0207098 APO-TRIMIP 0.73 Y Y Y YAPX /CP
TRYPTOPHAN
500MG
0071814 TRYPTAN 0.77 Y Y N YICN /CP
0224033 TEVA-TRYPTOPHAN 0.36 Y Y N YTVM /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
140
PHRM/CHRN/CDO/F28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
VENLAFAXINE HYDROCHLORIDE
VENLAFAXINE
150MG
0227505 NOVO-VENLAFAXINE XR 0.35 Y Y Y YNOP /CP
0231029 MYLAN-VENLAFAXINE XR 0.35 Y Y Y YMYL /CP
0223728 EFFEXOR XR 1.98 Y Y Y YWYA /CP
0230433 CO-VENLAFAXINE XR 0.35 Y Y Y YCOB /CP
0227398 RATIO-VENLAFAXINE 0.35 Y Y Y YRTP /CP
0235474 SANIS-VENLAFAXINE XR 0.35 Y Y Y YSAN /CP
0227856 PMS-VENLAFAXINE XR 0.35 Y Y Y YPMS /CP
0233170 APO-VENLAFAXINE XR 0.35 Y Y Y YAPX /CP
0238009 RAN-VENLAFAXINE XR 0.35 Y Y Y YRAN /CP
0231033 SDZ-VENLAFAXINE XR 0.35 Y Y Y YPMS /CP
37.5MG
0235471 SANIS-VENLAFAXINE XR 0.16 Y Y Y YSAN /CP
0230431 CO-VENLAFAXINE XR 0.16 Y Y Y YCOB /CP
0223727 EFFEXOR XR 0.94 Y Y Y YWYA /CP
0227854 PMS-VENLAFAXINE XR 0.16 Y Y Y YPMS /CP
0231031 SDZ-VENLAFAXINE XR 0.16 Y Y Y YSDZ /CP
0227396 RATIO-VENLAFAXINE XR 0.1643 Y Y Y YRTP /CP
0231027 MYLAN-VENLAFAXINE XR 0.16 Y Y Y YMYL /CP
0227502 NOVO-VENLAFAXINE XR 0.16 Y Y Y YNOP /CP
75MG
0227503 NOVO-VENLAFAXINE XR 0.33 Y Y Y YNOP /CP
0231032 SDZ-VENLAFAXINE XR 0.33 Y Y Y YSDZ /CP
0231028 MYLAN-VENLAFAXINE XR 0.33 Y Y Y YMYL /CP
0230432 CO-VENLAFAXINE XR 0.33 Y Y Y YCOB /CP
0235472 SANIS-VENLAFAXINE XR 0.33 Y Y Y YSAN /CP
0223728 EFFEXOR XR 1.88 Y Y Y YWYA /CP
0227397 RATIO-VENLAFAXINE XR 0.33 Y Y Y YRTP /CP
0227855 PMS-VENLAFAXINE XR 0.33 Y Y Y YPMS /CP
VENLAFAXINE
75MG
0238008 RAN-VENLAFAXINE XR 0.33 Y Y Y YRAN /CP
28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS) --------------------------------
ARIPIPRAZOLE
10MG
0232239 ABILIFY 3.87 E E N YBMY /TB
15MG
0232240 ABILIFY 3.97 E E N YBMY /TB
2MG
0232237 ABILIFY 3.03 E E N YBMY /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
141
PHRM/CHRN/CDO/F28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
ARIPIPRAZOLE (continued)
20MG
0232241 ABILIFY 4.01 E E N YBMY /TB
30MG
0232245 ABILIFY 4.01 E E N YBMY /TB
300MG
0242086 ABILIFY MAINTENA 456.18 E E N YOTS /EA
400MG
0242087 ABILIFY MAINTENA 456.18 E E N YOTS /EA
5MG
0232238 ABILIFY 3.41 E E N YBMY /TB
ASENAPINE
10MG
0237481 SAPHRIS 1.43 E E N YMSD /TB
5MG
0237480 SAPHRIS 1.43 E E N YMSD /TB
CHLORPROMAZINE
100MG
0023283 NOVO-CHLORPROMAZINE 0.68 Y Y N YNOP /TB
25MG
0023282 NOVO-CHLORPROMAZINE 0.2206 Y Y N YNOP /TB
50MG
0023280 NOVO-CHLORPROMAZINE 0.2524 Y Y N YNOP /TB
CLOZAPINE
100MG
0089474 CLOZARIL 3.78 Y Y N YNVR /TB
0224803 APO-CLOZAPINE 2.6446 Y Y N YAPX /TB
0224724 GEN-CLOZAPINE 2.6446 Y Y N YGPM /TB
25MG
0224724 GEN-CLOZAPINE 0.6594 Y Y N YGPM /TB
0224803 APO-CLOZAPINE 0.6594 Y Y N YAPX /TB
0089473 CLOZARIL 0.94 Y Y N YNVR /TB
50MG
0230500 GEN-CLOZAPINE 1.32 Y Y N YGEN /TB
FLUPENTHIXOL
100MG/ML
0215604 FLUANXOL DEPOT (2ML) INJ 35.93 Y Y N YLUD /ML
20MG/ML
0215603 FLUANXOL DEPOT (10ML) INJ 7.186 Y Y N YLUD /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
142
PHRM/CHRN/CDO/F28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
FLUPENTHIXOL DIHYDROCHLORIDE
FLUPENTHIXOL
0.5MG
0215600 FLUANXOL 0.26 Y Y N YLUD /TB
3MG
0215601 FLUANXOL 0.55 Y Y N YLUD /TB
FLUPHENAZINE
100MG/ML
0075557 MODECATE CONC. (1ML) INJ 29.78 Y Y N YSQU /ML
0224192 PMS-FLUPHENAZINE (1ML) INJ 29.78 Y Y N YPMS /ML
25MG/ML
0223963 FLUPHENAXINE OMEGA 4.98 Y Y N YOME /ML
0209127 PMS-FLUPHENAZINE DECAN.5ML 4.632 Y Y N YPMS /ML
FLUPHENAZINE HCL
1MG
0040534 APO-FLUPHENAZINE 0.17 Y Y N YAPX /TB
2MG
0041063 APO-FLUPHENAZINE 0.23 Y Y N YAPX /TB
5MG
0040536 APO-FLUPHENAZINE 0.17 Y Y N YAPX /TB
0072635 PMS-FLUPHENAZINE HCL 0.17 Y Y N YPMS /TB
HALOPERIDOL
0.5MG
0036368 NOVO-PERIDOL 0.12 Y Y N YNOP /TB
0039679 APO-HALOPERIDOL 0.12 Y Y N YAPX /TB
1MG
0039681 APO-HALOPERIDOL 0.18 Y Y N YAPX /TB
0036367 NOVO-PERIDOL 0.19 Y Y N YNOP /TB
10MG
0071344 NOVO-PERIDOL 0.64 Y Y N YNOP /TB
0046369 APO-HALOPERIDOL 0.64 Y Y N YAPX /TB
2MG
0039682 APO-HALOPERIDOL 0.275 Y Y N YAPX /TB
0036366 NOVO-PERIDOL 0.28 Y Y N YNOP /TB
2MG/ML
0075950 PMS-HALOPERIDOL ORAL SOLN 0.1073 Y Y N YPMS /ML
5MG
0039683 APO-HALOPERIDOL 0.44 Y Y N YAPX /TB
0036365 NOVO-PERIDOL 0.44 Y Y N YNOP /TB
5MG/ML
0080865 HALOPERIDOL (1ML) INJ 4.83 Y Y N YSAB /ML
0236601 HALOPERIDOL (1ML) INJ 4.9 Y Y N YOMG /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
143
PHRM/CHRN/CDO/F28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
HALOPERIDOL DECANOATE
HALOPERIDOL
100MG/ML
0213030 HALOPERIDOL LA (5ML) INJ 16.92 Y Y N YSAB /ML
50MG/ML
0213029 HALOPERIDOL LA (5ML) INJ 8.46 Y Y N YSAB /ML
LOXAPINE SUCCINATE
10MG
0223083 PMS-LOXAPINE 0.29 Y Y N YPMS /TB
25MG
0223083 PMS-LOXAPINE 0.44 Y Y N YPMS /TB
5MG
0223083 PMS-LOXAPINE 0.17 Y Y N YPMS /TB
50MG
0223084 PMS-LOXAPINE 0.59 Y Y N YPMS /TB
50MG/ML
0216999 LOXAPAC IM INJ 9.46 Y Y N YWYA /ML
LURASIDONE HCL
120MG
0238778 LATUDA 4.08 E E N YSUN /TB
20MG
0242205 LATUDA 4.08 E E N YSUN /TB
40MG
0238775 LATUDA 4.08 E E N YSUN /TB
60MG
0241336 LATUDA 4.08 E E N YSUN /TB
80MG
0238777 LATUDA 4.08 E E N YSUN /TB
METHOTRIMEPRAZINE
2MG
0223840 APO-METHOPRAZINE 0.07 Y Y N YAPX /TB
25MG
0223840 APO-METHOPRAZINE 0.25 Y Y N YAPX /TB
25MG/ML
0192769 NOZINAN INJ 3.53 Y Y N YAVT /ML
5MG
0223840 APO-METHOPRAZINE 0.1 Y Y N YAPX /TB
50MG
0223840 APO-METHOPRAZINE 0.39 Y Y N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
144
PHRM/CHRN/CDO/F28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
OLANZAPINE
OLANZAPINE
10MG
0240309 RAN-OLANZAPINE 1.28 Y Y N YRAN /TB
0237284 SANIS-OLANZAPINE 1.28 Y Y N YSAI /TB
0228182 APO-OLANZAPINE 1.28 Y Y N YAPX /TB
0227674 NOVO-OLANZAPINE 1.28 Y Y N YNOP /TB
0222928 ZYPREXA 7.19 Y Y N YLIL /TB
0230317 PMS-OLANZAPINE 1.28 Y Y N YPMS /TB
0232568 ACT OLANZAPINE 1.28 Y Y N YACT /TB
10 MG ODT
0236062 APO-OLANZAPINE ODT 1.29 Y Y N YAPX /TB
10MG ODT
0232757 CO-OLANZAPINE ODT 1.29 Y Y N YCOB /TB
0224308 ZYPREXA ZYDIS 7.14 Y Y N YLIL /TB
0232135 TEVA-OLANZAPINE 1.29 Y Y N YTVM /TB
0235298 SANIS-OLANZAPINE 1.29 Y Y N YSAI /TB
0230320 PMS-OLANZAPINE 1.29 Y Y N YPMS /TB
0232778 SDZ-OLANZAPINE ODT 1.29 Y Y N YSDZ /TB
15MG
0230318 PMS-OLANZAPINE 1.91 Y Y N YPMS /TB
0223885 ZYPREXA 10.78 Y Y N YLIL /TB
0228184 APO-OLANZAPINE 1.91 Y Y N YAPX /TB
0227675 NOVO-OLANZAPINE 1.91 Y Y N YNOP /TB
0237285 SANIS-OLANZAPINE 1.91 Y Y N YSAI /TB
15MG ODT
0232779 SDZ-OLANZAPINE ODT 1.93 Y Y N YSDZ /ODT
0224308 ZYPREXA ZYDIS 10.71 Y Y N YLIL /TB
0232758 CO-OLANZAPINE ODT 1.93 Y Y N YCOB /TB
0236063 APO-OLANZAPINE ODT 1.93 Y Y N YAPX /TB
0235299 SANIS-OLANZAPINE 1.93 Y Y N YSAI /TB
0232137 TEVA-OLANZAPINE 1.93 Y Y N YTVM /TB
2.5MG
0237281 SANIS-OLANZAPINE 0.32 Y Y N YSAI /TB
0227671 NOVO-OLANZAPINE 0.32 Y Y N YNOP /TB
0232565 ACT OLANZAPINE 0.32 Y Y N YACT /TB
0230311 PMS-OLANZAPINE 0.32 Y Y N YPMS /TB
0222925 ZYPREXA 1.8 Y Y N YLIL /TB
0228179 APO-OLANZAPINE 0.32 Y Y N YAPX /TB
20MG
0235970 TEVA-OLANZAPINE 2.59 N Y N YTVM /TB
0233301 APO-OLANZAPINE 2.59 Y Y N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
145
PHRM/CHRN/CDO/F28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
OLANZAPINE (continued)
20MG ODT
0224308 ZYPREXA ZYDIS 14.14 Y Y N YLIL /TB
0232759 CO-OLANZAPINE ODT 2.54 Y Y N YCOB /TB
0232780 SDZ-OLANZAPINE ODT 2.54 Y Y N YSDZ /TB
0236064 APO-OLANZAPINE ODT 2.54 Y Y N YAPX /TB
0232138 TEVA-OLANZAPINE 2.54 Y Y N YTVM /TB
20MGODT
0241412 RAN-OLANZAPINE ODT 2.54 Y Y N YRAN /TB
5MG
0222926 ZYPREXA 3.59 Y Y N YLIL /TB
0240307 RAN-OLANZAPINE 0.64 Y Y N YRAN /TB
0237282 SANIS-OLANZAPINE 0.64 Y Y N YSAI /TB
0228180 APO-OLANZAPINE 0.64 Y Y N YAPO /TB
0227672 NOVO-OLANZAPINE 0.64 Y Y N YNOP /TB
0230315 PMS-OLANZAPINE 0.64 Y Y N YPMS /TB
0232566 ACT OLANZAPINE 0.64 Y Y N YACT /TB
5 MG ODT
0236061 APO-OLANZAPINE ODT 0.64 Y Y N YAPX /TB
5MG ODT
0224308 ZYPREXA ZYDIS 3.57 Y Y N YLIL /TB
0235297 SANIS-OLANZAPINE 0.64 Y Y N YSAI /TB
0232756 CO-OLANZAPINE ODT 0.64 Y Y N YCOB /TB
0232777 SDZ-OLANZAPINE ODT 0.64 Y Y N YSDZ /TB
0232134 TEVA-OLANZAPINE 0.64 Y Y N YTVM /TB
0230319 PMS-OLANZAPINE 0.64 Y Y N YPMS /TB
7.5MG
0222927 ZYPREXA 5.39 Y Y N YLIL /TB
0237283 SANIS-OLANZAPINE 0.96 Y Y N YSAI /TB
0228181 APO-OLANZAPINE 0.96 Y Y N YAPX /TB
0227673 NOVO-OLANZAPINE 0.96 Y Y N YNOP /TB
0230316 PMS-OLANZAPINE 0.96 Y Y N YPMS /TB
PALIPERIDONE
100MG/ML
0235423 INVEGA SUSTENNA 476.87 E E N YJAN /EA
150MG/1.5ML
0235424 INVEGA SUSTENNA 635.83 E E N YJAN /EA
3MG
0230027 INVEGA 3.72 E E N YJAN /TB
50MG/0.5ML
0235421 INVEGA SUSTENNA 317.91 E E N YJAN /EA
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
146
PHRM/CHRN/CDO/F28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
PALIPERIDONE (continued)
6MG
0230028 INVEGA 5.57 E E N YJAN /TB
75MG/0,75ML
0235422 INVEGA SUSTENNA 476.87 E E N YJAN /EA
9MG
0230030 INVEGA 7.42 E E N YJAN /TB
PERICYAZINE
10MG
0192677 NEULEPTIL 0.41 Y Y N YAVT /CP
10MG/ML
0192675 NEULEPTIL ORAL DROPS 0.41 Y Y N YAVT /ML
20MG
0192676 NEULEPTIL 0.58 Y Y N YAVT /CP
5MG
0192678 NEULEPTIL 0.24 Y Y N YAVT /CP
PERPHENAZINE
16MG
0033509 APO-PERPHENAZINE 0.13 Y Y N YAPX /TB
2MG
0033513 APO-PERPHENAZINE 0.06 Y Y N YAPX /TB
4MG
0033512 APO-PERPHENAZINE 0.08 Y Y N YAPX /TB
8MG
0033511 APO-PERPHENAZINE 0.08 Y Y N YAPX /TB
PIMOZIDE
2MG
0031381 ORAP 0.3186 Y Y N YPHL /TB
0224543 APO-PIMOZIDE 0.309 Y Y N YAPX /TB
4MG
0031382 ORAP 0.48 Y Y N YPHL /TB
0224543 APO-PIMOZIDE 0.41 Y Y N YAPX /TB
PROCHLORPERAZINE
10MG
0078972 PROCHLORPERAZINE SUPP 1.38 Y Y Y YSDZ /SP
0075368 PMS-PROCHLORPERAZINE SUPP 0.83 Y Y Y YPMS /SP
0088643 APO-PROCHLORAZINE 0.2 Y Y Y YAPX /TB
0075363 PMS-PROCHLORPERAZINE 0.2 Y Y Y YPMS /TB
5MG
0075366 PMS-PROCHLORPERAZINE 0.166 Y Y Y YPMS /TB
0088644 APO-PROHCHLORAZINE 0.17 Y Y Y YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
147
PHRM/CHRN/CDO/F28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
PROCHLORPERAZINE (continued)
5MG/ML
0078974 PROCHLORPERAZINE (2ML) INJ 13.06 Y Y Y YSAB /ML
QUETIAPINE
100MG
0235317 SANIS-QUETIAPINE 0.24 Y Y N YSAN /TB
0230781 MYLAN-QUETIAPINE 0.24 Y Y N YMYL /TB
0231171 RATIO-QUETIAPINE 0.24 Y Y N YRTP /TB
0231392 APO-QUETIAPINE 0.24 Y Y N YAPX /TB
0223695 SEROQUEL 1.39 Y Y N YAST /TB
0243801 MINT-QUETIAPINE 0.24 Y Y N YMNT /TB
0240035 ACCEL-QUETIAPINE 0.24 Y Y N YACC /TB
0231400 SDZ-QUETIAPINE 0.24 Y Y N YSDZ /TB
0228424 TEVA-QUETIAPINE 0.24 Y Y N YTVM /TB
0229657 PMS-QUETIAPINE 0.24 Y Y N YPMS /TB
0231609 CO-QUETIAPINE 0.23 Y Y N YCOB /TB
150MG XR
0239545 TEVA-QUETIAPINE XR 0.78 Y Y N YTVM /TB
0240769 SANDOX QUETIAPINE XRT 0.78 Y Y N YSDZ /TB
200MG
0230783 MYLAN-QUETIAPINE 0.48 Y Y N YMYL /TB
0229659 PMS-QUETIAPINE 0.48 Y Y N YPMS /TB
0223695 SEROQUEL 2.78 Y Y N YAST /TB
0228427 TEVA-QUETIAPINE 0.48 Y Y N YNOP /TB
0231393 APO-QUETIAPINE 0.48 Y Y N YAPX /TB
0231611 CO-QUETIAPINE 0.48 Y Y N YCOB /TB
0235319 SANIS-QUETIAPINE 0.48 Y Y N YSAN /TB
0240037 ACCEL-QUETIAPINE 0.48 Y Y N YACC /TB
0231401 SDZ-QUETIAPINE 0.48 Y Y N YSDZ /TB
0231174 RATIO-QUETIAPINE 0.48 Y Y N YRTP /TB
200MG XR
0240770 SANDOZ QUETIAPINE XRT 1.05 Y Y N YSDZ /TB
0230019 SEROQUEL XR 2.62 Y Y N YAST /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
148
PHRM/CHRN/CDO/F28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
QUETIAPINE (continued)
25MG
0231608 CO-QUETIAPINE 0.09 Y Y N YCOB /TB
0231170 RATIO-QUETIAPINE 0.09 Y Y N YRTP /TB
0230780 MYLAN-QUETIAPINE 0.09 Y Y N YMYL /TB
0228423 TEVA-QUETIAPINE 0.09 Y Y N YTVM /TB
0231390 APO-QUETIAPINE 0.09 Y Y N YAPX /TB
0235316 SANIS-QUETIAPINE 0.09 Y Y N YSAN /TB
0223695 SEROQUEL 0.52 Y Y N YAST /TB
0240034 ACCEL-QUETIAPINE 0.09 Y Y N YACC /TB
0229655 PMS-QUETIAPINE 0.09 Y Y N YPMS /TB
0243800 MINT-QUETIAPINE 0.09 Y Y N YMNT /TB
0231399 SDZ-QUETIAPINE 0.09 Y Y N YSDZ /TB
300MG
0235320 SANIS-QUETIAPINE 0.7 Y Y N YSAN /TB
0240038 ACCEL-QUETIAPINE 0.7 Y Y N YACC /TB
0230784 MYLAN-QUETIAPINE 0.7 Y Y N YMYL /TB
0228428 TEVA-QUETIAPINE 0.7 Y Y N YTVM /TB
0231402 SDZ-QUETIAPINE 0.7 Y Y N YSDZ /TB
0231612 CO-QUETIAPINE 0.7 Y Y N YCOB /TB
0231394 APO-QUETIAPINE 0.7 Y Y N YAPX /TB
0229660 PMS-QUETIAPINE 0.7 Y Y N YPMS /TB
0224410 SEROQUEL 4.06 Y Y N YAST /TB
0231175 RATIO-QUETIAPINE 0.7 Y Y N YRTP /TB
300MG XR
0230020 SEROQUEL XR 3.86 Y Y N YAST /TB
0240772 SANDOZ QUETIAPINE XRT 1.54 Y Y N YSDZ /TB
50MG XR
0240767 SANDOZ QUETIAPINE XRT 0.4 Y Y N YSDZ /TB
0239544 TEVA-QUETIAPINE XR 0.4 Y Y N YTVM /TB
RISPERIDONE
0.25MG
0235688 SANIS-RISPERIDONE 0.13 Y Y N YSAN /TB
0226475 RATIO-RISPERIDONE 0.2615 Y Y N YRTP /TB
0235979 MINT-RISPERIDON 0.13 Y Y N YMNT /TB
0232830 RBX-RISPERIDONE 0.13 Y Y N YRAN /TB
0225200 PMS-RISPERIDONE 0.13 Y Y N YPMS /TB
0228211 APO-RISPERIDONE 0.13 Y Y N YAPX /TB
0224055 RISPERDAL 0.25MG 0.58 Y Y N YJAN /TB
0228269 TEVA-RISPERIDONE 0.13 Y Y N YTVM /TB
0228258 CO RISPERIDONE 0.13 Y Y N YCOB /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
149
PHRM/CHRN/CDO/F28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
RISPERIDONE (continued)
0.5MG
0226418 TEVA-RISPERIDONE 0.21 Y Y N YTVM /TB
0225201 PMS-RISPERIDONE 0.21 Y Y N YPMS /TB
0228259 CO RISPERIDONE 0.21 Y Y N YCOB /TB
0228212 APO-RISPERIDONE 0.21 Y Y N YAPX /TB
0235980 MINT-RISPERIDON 0.21 Y Y N YMNT /TB
0235689 SANIS-RISPERIDONE 0.21 Y Y N YSAN /TB
0232831 RBX-RISPERIDONE 0.21 Y Y N YRAN /TB
0224055 RISPERDAL 0.5MG 0.96 Y Y N YJAN /TB
0226476 RATIO-RISPERIDONE 0.4379 Y Y N YRTP /TB
0.5 MG ODT
0241348 MYLAN-RISPERIDONE ODT 0.56 Y Y N YMNT /TB
0224770 RISPERDAL M-TAB 0.75 Y Y N YJAN /TB
1MG
0228260 CO RISPERIDONE 0.29 Y Y N YCOB /TB
0202528 RISPERDAL 1.33 Y Y N YJAN /TB
0228226 MYLAN-RISPERIDONE 0.29 Y Y N YMYL /TB
0235954 JAMP-RISPERIDONE 0.29 Y Y N YJPC
/TB
0235981 MINT-RISPERIDONE 0.29 Y Y N YMNT /TB
0225202 PMS-RISPERIDONE 0.29 Y Y N YPMS /TB
0226477 RATIO-RISPERIDONE 0.6048 Y Y N YRTP /TB
0228213 APO-RISPERIDONE 0.29 Y Y N YAPX /TB
0226419 TEVA-RISPERIDONE 0.29 Y Y N YTVM /TB
0235690 SANIS-RISPERIDONE 0.29 Y Y N YSAN /TB
0232832 RBX-RISPERIDONE 0.29 Y Y N YRAN /TB
1MG/ML
0227926 PMS-RISPERIDONE ORAL SOLN 0.71 Y Y N YPMS /ML
0223695 RISPERDAL ORAL SOLN 1.42 Y Y N YJAN /ML
1 MG ODT
0229178 PMS-RISPERIDONE ODT 0.52 Y Y N YPMS /TB
0224770 RISPERDAL M-TAB 1.03 Y Y N YJAN /TB
0241349 MYLAN-RISPERIDONE ODT 0.52 Y Y N YMYL /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
150
PHRM/CHRN/CDO/F28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
RISPERIDONE (continued)
2MG
0235691 SANIS-RISPERIDONE 0.58 Y Y N YSAN /TB
0235955 JAMP-RISPERIDONE 0.58 Y Y N YJPC
/TB
0235982 MINT-RISPERIDON 0.58 Y Y N YMNT /TB
0232834 RBX-RISPERIDONE 0.58 Y Y N YRAN /TB
0228214 APO-RISPERIDONE 0.58 Y Y N YAPX /TB
0228261 CO RISPERIDONE 0.58 Y Y N YCOB /TB
0225203 PMS-RISPERIDONE 0.58 Y Y N YPMS /TB
0226421 TEVA-RISPERIDONE 0.58 Y Y N YTVM /TB
0226478 RATIO-RISPERIDONE 1.2075 Y Y N YRTP /TB
0202529 RISPERDAL 2.66 Y Y N YJAN /TB
2 MG ODT
0229179 PMS-RISPERIDONE ODT 1.02 Y Y N YPMS /TB
0224770 RISPERDAL M-TAB 2.04 Y Y N YJAN /TB
0241350 MYLAN-RISPERIDONE ODT 1.02 Y Y N YMYL /null
25MG
0225570 RISPERDAL CONSTA INJ 161.09 E E N YJOI /KT
3 MG
0228262 CO RISPERIDONE 0.87 Y Y N YCOB /TB
0226422 TEVA-RISPERIDONE 0.87 Y Y N YTVM /TB
0226480 RATIO-RISPERIDONE 1.8113 Y Y N YRTP /TB
0202530 RISPERDAL 3.99 Y Y N YJAN /TB
0228215 APO-RISPERIDONE 0.87 Y Y N YAPX /TB
0235983 MINT-RISPERIDON 0.87 Y Y N YMNT /TB
3MG
0235692 SANIS-RISPERIDONE 0.87 Y Y N YSAN /TB
0225205 PMS-RISPERIDONE 0.87 Y Y N YPMS /TB
0232836 RBX-RISPERIDONE 0.87 Y Y N YRAN /TB
3 MG ODT
0237069 PMS-RISPERIDONE ODT 1.53 Y Y N YPMS /TB
0241351 MYLAN-RISPERIDONE ODT 1.53 Y Y N YMYL /TB
0226808 RISPERDAL M 3.06 Y Y N YJAN /TB
37.5MG
0225572 RISPERDAL CONSTA INJ 244.75 E E N YJOI /KT
4 MG
0226423 TEVA-RISPERIDONE 1.16 Y Y N YTVM /TB
0228263 CO RISPERIDONE 1.16 Y Y N YCOB /TB
0226481 RATIO-RISPERIDONE 2.415 Y Y N YRTP /TB
0228217 APO-RISPERIDONE 1.16 Y Y N YAPX /TB
0202531 RISPERDAL 5.32 Y Y N YJAN /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
151
PHRM/CHRN/CDO/F28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
RISPERIDONE (continued)
4MG
0232837 RBX-RISPERIDONE 1.16 Y Y N YRAN /TB
0235693 SANIS-RISPERIDONE 1.16 Y Y N YSAN /TB
0225206 PMS-RISPERIDONE 1.16 Y Y N YPMS /TB
4 MG ODT
0241352 MYLAN-RISPERIDONE ODT 2.04 Y Y N YMYL /TB
0226809 RISPERDAL M 4.09 Y Y N YJAN /TB
0237070 PMS-RISPERIDONE ODT 2.04 Y Y N YPMS /null
50MG
0225575 RISPERDAL CONSTA INJ 336.13 E E N YJOI /KT
THIOTHIXENE
10MG
0002445 NAVANE 0.56 Y Y N YPFI /CP
2MG
0002443 NAVANE 0.32 Y Y N YPFI /CP
5MG
0002444 NAVANE 0.46 Y Y N YPFI /CP
TRIFLUOPERAZINE
1MG
0034553 APO-TRIFLUOPERAZINE 0.13 Y Y N YAPX /TB
10MG
0032683 APO-TRIFLUOPERAZINE 0.279 Y Y N YAPX /TB
2MG
0031275 APO-TRIFLUOPERAZINE 0.18 Y Y N YAPX /TB
5MG
0031274 APO-TRIFLUOPERAZINE 0.2328 Y Y N YAPX /TB
ZIPRASIDONE
20MG
0229859 ZELDOX 1.8 Y Y N YPFI /CP
40MG
0229860 ZELDOX 1.99 Y Y N YPFI /CP
60MG
0229861 ZELDOX 1.99 Y Y N YPFI /CP
80MG
0229862 ZELDOX 1.99 Y Y N YPFI /CP
ZUCLOPENTHIXOL
50MG/ML
0223040 CLOPIXOL ACUPHASE (1ML)INJ 14.914 Y Y N YLUD /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
152
PHRM/CHRN/CDO/F28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS) (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
ZUCLOPENTHIXOL DECANOATE
ZUCLOPENTHIXOL
200MG/ML
0223040 CLOPIXOL DEPOT (10ML) INJ 14.91 Y Y N YLUD /ML
ZUCLOPENTHIXOL
10MG
0223040 CLOPIXOL 0.4 Y Y N YLUD /TB
25MG
0223040 CLOPIXOL 0.99 Y Y N YLUD /TB
28:20.00 ANOREXIGENIC AGENTS & RESPIRATORY AND CEREBRAL STIMULANTS ----------------------
BUPROPION
150MG
0223844 ZYBAN SR 0.96 Y N Y YBVL /TB
DEXTROAMPHETAMINE
10MG
0192455 DEXEDRINE SPANSULE 0.96 E E N YGSK /CP
15MG
0192456 DEXEDRINE SPANSULE 1.18 E E N YGSK /CP
5MG
0244323 APO-DEXTROAMPHETAMINE 0.51 E E N YAPX /TB
0192451 DEXEDRINE 0.67 E E N YGSK /TB
METHYLPHENIDATE HCL
10MG
0058499 PMS-METHYLPHENIDATE 0.08 E E N YPMS /TB
0000560 RITALIN 0.4 E E N YNVR /TB
0224932 APO-METHYLPHENIDATE 0.08 E E N YAPX /TB
10 MG ER
0227716 BIPHENTIN 0.7 E E N YPFR /CP
15 MG ER
0227713 BIPHENTIN 0.99 E E N YPFR /CP
18MG ER
0224773 CONCERTA 2.1 E E N YJAN /TB
0231506 NOVO-METHYLPHENIDATE ER-C 1.43 E E N YNOP /TB
0241372 PMS-METHYLPHENIDATE ER 1.43 E E N YPMS /TB
20MG
0058500 PMS-METHYLPHENIDATE 0.23 E E N YPMS /TB
0000561 RITALIN 0.71 E E N YNVR /TB
0224933 APO-METHYLPHENIDATE 0.23 E E N YAPX /TB
20 MG ER
0227715 BIPHENTIN 1.29 E E N YPFR /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
153
PHRM/CHRN/CDO/F28:20.00 ANOREXIGENIC AGENTS & RESPIRATORY AND CEREBRAL STIMULANTS
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
METHYLPHENIDATE HCL (continued)
20MG SR
0063277 RITALIN SR 0.71 E E N YNVR /TB
0226668 APO-METHYLPHENIDATE 0.28 E E N YAPX /TB
0232031 SDZ-METHYLPHENIDATE 0.28 E E N YSDZ /TB
27MG ER
0225024 CONCERTA 2.42 E E N YJAN /TB
0241373 PMS-METHYLPHENIDATE 1.65 E E N YPMS /TB
0231507 NOVO-METHYLPHENIDATE ER-C 1.65 E E N YNOP /TB
30 MG ER
0227717 BIPHENTIN 1.76 E E N YPFR /CP
36MG ER
0224773 CONCERTA 2.75 E E N YJAN /TB
0231508 NOVO-METHYLPHENIDATE ER-C 1.87 E E N YNOP /TB
0241374 PMS-METHYLPHENIDATE ER 1.87 E E N YPMS /TB
40 MG ER
0227718 BIPHENTIN 2.25 E E N YPFR /CP
5MG
0227395 APO-METHYLPHENIDATE 0.1 E E N YAPX /TB
0223474 PMS-METHYLPHENIDATE 0.1 E E N YPMS /TB
50 MG ER
0227719 BIPHENTIN 2.72 E E N YPFR /CP
54MG ER
0231509 NOVO-METHYLPHENIDATE ER-C 2.31 E E N YNOP /TB
0233037 APO-METHYLPHENIDATE ER 2.31 E E N YAPX /TB
0241375 PMS-METHYLPHENIDATE ER 2.31 E E N YPMS /TB
0224773 CONCERTA 3.39 E E N YJAN /TB
60 MG ER
0227720 BIPHENTIN 3.17 E E N YPFR /CP
80 MG ER
0227721 BIPHENTIN 4.18 E E N YPFR /CP
MODAFINIL
100MG
0223966 ALERTEC 1.37 E E N YDPY /TB
0228539 APO-MODAFINIL 1 E E N YAPX /TB
28:20.04 AMPHETAMINES -------------------------------------------------------------------
LISDEXAMFETAMINE
10MG
0243960 VYVANSE 2.18 E E N YSCI /CP
30MG
0232295 VYVANSE 3.25 E E N YSCI /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
154
PHRM/CHRN/CDO/F28:20.04 AMPHETAMINES (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
LISDEXAMFETAMINE DIMESYLATE (continued)
40MG
0234716 VYVANSE 3.78 E E N YSCI /CP
50MG
0232297 VYVANSE 4.31 E E N YSCI /CP
60MG
0234717 VYVANSE 4.85 E E N YSCI /CP
LISDEXAMFETAMINE
20MG
0234715 VYVANSE 2.72 E E N YSCI /CP
28:24.08 BENZODIAZEPINES ----------------------------------------------------------------
ALPRAZOLAM
0.25MG
0054835 XANAX 0.249 Y N Y YPHU /TB
0234919 SANIS-ALPRAZOLAM 0.061 Y N Y YSAN /TB
0213753 MYLAN-ALPRAZOLAM 0.061 Y N Y YMYL /TB
0191348 TEVA-ALPRAZOL 0.061 Y N Y YTVM /TB
0086539 APO-ALPRAZ 0.061 Y N Y YAPX /TB
0.5MG
0191349 TEVA-ALPRAZOL 0.073 Y N Y YTVM /TB
0086540 APO-ALPRAZ 0.073 Y N Y YAPX /TB
0234920 SANIS-ALPRAZOLAM 0.073 Y N Y YSAN /TB
0213754 MYLAN-ALPRAZOLAM 0.073 Y N Y YMYL /TB
0054836 XANAX 0.3 Y N Y YPHU /TB
1MG
0224361 APO-ALPRAZ 0.3099 Y N Y YAPX /TB
0222981 MYLAN-ALPRAZOLAM 0.55 Y N Y YMYL /TB
0072377 XANAX 0.55 Y N Y YPHU /TB
2MG
0224361 APO-ALPRAZ TS 0.55 Y N Y YAPX /TB
0222981 MYLAN-ALPRAZOLAM 0.55 Y N Y YMYL /TB
BROMAZEPAM
1.5MG
0217715 APO-BROMAZEPAM 0.1 Y N Y YAPX /TB
3MG
0051812 LECTOPAM 0.15 Y N Y YHLR /TB
0217716 APO-BROMAZEPAM 0.08 Y N Y YAPX /TB
0223058 NOVO-BROMAZEPAM 0.08 Y N Y YNOP /TB
6MG
0217718 APO-BROMAZEPAM 0.11 Y N Y YAPX /TB
0223058 NOVO-BROMAZEPAM 0.11 Y N Y YNOP /TB
0051813 LECTOPAM 0.23 Y N Y YHLR /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
155
PHRM/CHRN/CDO/F28:24.08 BENZODIAZEPINES (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
CHLORDIAZEPOXIDE
CHLORDIAZEPOXIDE
10MG
0052298 APO-CHLORDIAZEPOXIDE 0.107 Y N Y YAPX /CP
25MG
0052299 APO-CHLORDIAZEPOXIDE 0.1659 Y N Y YAPX /CP
5MG
0052272 APO-CHLORDIAZEPOXIDE 0.07 Y N Y YAPX /CP
CLORAZEPATE
15MG
0086069 APO-CLORAZEPATE 0.39 Y N N YAPX /CP
0062821 NOVO-CLOPATE 0.3856 Y N N YNOP /CP
3.75MG
0062819 NOVO-CLOPATE 0.0694 Y N N YNOP /CP
0086068 APO-CLORAZEPATE 0.15 Y N N YAPX /CP
7.5MG
0086070 APO-CLORAZEPATE 0.1926 Y N N YAPX /CP
0062820 NOVO-CLOPATE 0.1926 Y N N YNOP /CP
DIAZEPAM
1MG/ML
0089179 PMS-DIAZEPAM SOLUTION 1MG/ML 0.12 N N N YPMS /ML
10MG
0040533 APO-DIAZEPAM 0.09 Y N Y YAPX /TB
0224749 PMS-DIAZEPAM 0.09 Y N Y YPMS /TB
2MG
0040532 APO-DIAZEPAM 0.0508 Y N Y YAPX /TB
0224749 PMS-DIAZEPAM 0.051 Y N Y YPMS /TB
5MG
0001328 VALIUM 0.16 Y N Y YHLR /TB
0036215 APO-DIAZEPAM 0.07 Y N Y YAPX /TB
0224749 PMS-DIAZEPAM 0.07 Y N Y YPMS /TB
5MG/ML
0238614 DIAZEPAM INJ SDZ 1.24 Y E N YSDZ /ML
0039972 DIAZEPAM INJ 1.24 Y E N YSAB /ML
0223816 DIASTAT 76.79 N Y N YN/A /SP
FLURAZEPAM HCL
15MG
0052169 APO-FLURAZEPAM 0.12 Y N Y YAPX /CP
30MG
0052170 APO-FLURAZEPAM 0.14 Y N Y YAPX /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
156
PHRM/CHRN/CDO/F28:24.08 BENZODIAZEPINES (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
LORAZEPAM
LORAZEPAM
0.5MG
0065574 APO-LORAZEPAM 0.04 Y N Y YAPX /TB
0235107 SANIS-LORAZEPAM 0.04 Y N Y YSAN /TB
0071110 TEVA-LORAZEPAM 0.04 Y N Y YTVM /TB
0204141 ATIVAN 0.04 Y N Y YWYA /TB
0.5MG SL
0241074 APO-LORAZEPAM SUBLINGUAL 0.0875 Y N Y YAPX /TB
0204145 ATIVAN SUBLINGUAL 0.11 Y N Y YWYA /TB
1MG
0235108 SANIS-LORAZEPAM 0.4 Y N Y YSAN /TB
0072819 PMS-LORAZEPAM 0.04 Y N Y YPMS /TB
0065575 APO-LORAZEPAM 0.04 Y N Y YAPX /TB
0063774 TEVALORAZEPAM 0.04 Y N Y YTVM /TB
0204142 ATIVAN 0.05 Y N Y YWYA /TB
1MG SL
0204146 ATIVAN SUBLINGUAL 0.14 Y N Y YWYA /TB
0241075 APO-LORAZEPAM SUBLINGUAL 0.11 Y N Y YAPX /TB
2MG
0204144 ATIVAN 0.07 Y N Y YWYA /TB
0235109 SANIS-LORAZEPAM 0.07 Y N Y YSAN /TB
0065576 APO-LORAZEPAM 0.07 Y N Y YAPX /TB
0063775 TEVA-LORAZEPAM 0.07 Y N Y YTVM /TB
2MG SL
0241076 APO-LORAZEPAM SUBLINGUAL 0.171 Y N Y YAPX /TB
0204147 ATIVAN SUBLINGUAL 0.21 Y N Y YWYA /TB
4MG/ML
0224327 LORAZEPAM INJ 21.2 Y E N YSAB /ML
OXAZEPAM
10MG
0040268 APO-OXAZEPAM 0.04 Y N Y YAPX /TB
15MG
0040274 APO-OXAZEPAM 0.07 Y N Y YAPX /TB
30MG
0040273 APO-OXAZEPAM 0.09 Y N Y YAPX /TB
TEMAZEPAM
15MG
0222596 APO-TEMAZEPAM 0.13 Y N Y YAPX /CP
0224481 CO TEMAZEPAM 0.04 Y N Y YCOB /CP
0060445 RESTORIL 0.2 Y N Y YNVR /CP
0223009 NOVO-TEMAZEPAM 0.04 Y N Y YNOP /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
157
PHRM/CHRN/CDO/F28:24.08 BENZODIAZEPINES (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
TEMAZEPAM (continued)
30MG
0222597 APO-TEMAZEPAM 0.16 Y N Y YAPX /CP
0060446 RESTORIL 0.24 Y N Y YNVR /CP
0223010 NOVO-TEMAZEPAM 0.05 Y N Y YNOP /CP
0224481 CO TEMAZEPAM 0.05 Y N Y YCOB /CP
TRIAZOLAM
0.125MG
0080856 APO-TRIAZO 1.5 Y N Y YAPX /TB
0.25MG
0080857 APO-TRIAZO 0.25 Y N Y YAPX /TB
ZOPICLONE
5MG
0224342 PMS-ZOPICLONE 0.18 Y N Y YPMS /TB
0224507 APO-ZOPICLONE 0.18 Y N Y YAPX /TB
0224653 RATIO-ZOPICLONE 0.18 Y N Y YRPH /TB
0221616 IMOVANE 1.06 Y N Y YAVT /TB
0239171 MINT-ZOPICLONE 0.18 Y N Y YMNT /TB
0234412 SANIS ZOPICLONE 0.18 Y N Y YSAN /TB
0225757 SANDOZ ZOPICLONE 0.18 Y N Y YSDZ /TB
0226791 RAN-ZOPICLONE 0.18 Y N Y YRAP /TB
0227193 CO ZOPICLONE 0.18 Y N Y YCOB /TB
7.5MG
0227195 CO ZOPICLONE 0.23 Y N Y YC0B /TB
0226792 RAN-ZOPICLONE 0.23 Y N Y YRAN /TB
0224248 RATIO-ZOPICLONE 0.23 Y N Y YRTP /TB
0192679 IMOVANE 1.34 Y N Y YAVT /TB
0224060 PMS-ZOPICLONE 0.23 Y N Y YPMS /TB
0228244 SANIS ZOPICLONE 0.23 Y N Y YSAN /TB
0239172 MINT-ZOPICLONE 0.23 Y N Y YMNT /TB
0238691 SEPTA-ZOPICLONE 0.23 Y N Y YWHL /TB
0221831 APO-ZOPICLONE 0.23 Y N Y YAPX /TB
0200820 RHOVANE 0.31 Y N Y YROP /TB
0223859 GEN-ZOPICLONE 0.31 Y N Y YGPM /TB
28:24.92 MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS ------------------------------
BUSPIRONE
10MG
0223094 PMS-BUSPIRONE 0.352 Y Y Y YPMS /TB
0223149 NOVO-BUSPIRONE 0.352 Y Y Y YNOP /TB
0221107 APO-BUSPIRONE 0.352 Y Y Y YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
158
PHRM/CHRN/CDO/F28:24.92 MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
CHLORAL HYDRATE
CHLORAL HYDRATE
100MG/ML
0079265 PMS-CHLORAL HYDRATE SYRUP 0.05 Y E Y YPMS /ML
HYDROXYZINE
10MG
0064605 APO-HYDROXYZINE 0.11 Y Y Y YAPX /CP
0073882 NOVO-HYDROXYZIN 0.11 Y Y Y YNOP /CP
2MG/ML
0002469 ATARAX ORAL SYRUP 0.05 Y Y Y YPFI /ML
0074181 PMS-HYDROXYZINE ORAL SYRUP 0.05 Y Y Y YPMS /ML
25MG
0073883 NOVO-HYDROXYZIN 0.14 Y Y Y YNOP /CP
0064602 APO-HYDROXYZINE 0.14 Y Y Y YAPX /CP
50MG
0073884 NOVO-HYDROXYZIN 0.21 Y Y Y YNOP /CP
0064601 APO-HYDROXYZINE 0.21 Y Y Y YAPX /CP
28:28.00 ANTIMANIC AGENTS ---------------------------------------------------------------
LITHIUM CARBONATE
150MG
0221613 PMS-LITHIUM CARBONATE 0.04 Y Y N YPMS /CP
0224283 APO-LITHIUM CARBONATE 0.07 Y Y N YAPX /CP
0046173 CARBOLITH 0.12 Y Y N YICN /CP
300MG
0224283 APO-LITHIUM CARBONATE 0.07 Y Y N YAPX /CP
0221614 PMS-LITHIUM CARBONATE 0.04 Y Y N YPMS /CP
0040677 LITHANE 0.1 Y Y N YPFI /CP
0023668 CARBOLITH 0.1 Y Y N YICN /CP
300MG SR
0226669 LITHMAX 0.25 Y Y N YAA /TB
600MG
0201123 CARBOLITH 0.18 Y Y N YICN /CP
0221615 PMS-LITHIUM CARBONATE 0.16 Y Y N YPMS /CP
28:36.16 DOPAMINE PRECURSORS ------------------------------------------------------------
CARBIDOPA/LEVODOPA
5MG/20MG/ML
0229216 DUODOPA 1.66 E E N YABV /ML
28:92.00 MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS ------------------------------------
ACAMPROSATE CALCIUM
333MG
0229326 CAMPRAL 0.8 Y E N YMYL /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
159
PHRM/CHRN/CDO/F28:92.00 MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
ATOMOXETINE
ATOMOXETINE
10MG
0226280 STRATTERA 2.69 E E N YLIL /CP
0231802 APO-ATOMOXETINE 2.314 E E N YAPX /CP
0231454 TEVA-ATOMOXETINE 2.69 E E N YTVM /CP
100MG
0231808 APO-ATOMOXETINE 4.35 E E N YAPX /CP
18MG
0226281 STRATTERA 3.07 E E N YLIL /CP
0231803 APO-ATOMOXETINE 2.652 E E N YAPX /CP
0231456 TEVA-ATOMOXETINE 2.652 E E N YTVM /CP
0238642 SANDOZ ATOMOXETINE 2.65 E E N YSDZ /CP
25MG
0231804 APO-ATOMOXETINE 2.928 E E N YAPX /CP
0231457 TEVA-ATOMOXETINE 2.928 E E N YTVM /CP
40MG
0231458 TEVA-ATOMOXETINE 3.337 E E N YTVM /CP
0238644 SANDOZ ATOMOXETINE 3.337 E E N YSDZ /CP
0226283 STRATTERA 3.87 E E N YLIL /CP
0231805 APO-ATOMOXETINE 3.337 E E N YAPX /CP
60MG
0231459 TEVA-ATOMOXETINE 4.34 E E N YTVM /CP
0231806 APO-ATOMOXETINE 3.7 E E N YAPX /CP
0238645 SANDOZ ATOMOXETINE 3.7 E E N YSDZ /CP
0226284 STRATTERA 4.34 E E N YLIL /CP
80MG
0231807 APO-ATOMOXETINE 4 E E N YAPX /CP
0238646 SANDOZ ATOMOXETINE 4 E E N YSDZ /CP
CARBIDOPA/ENTACAPO
18.75/200/75MG
0233782 STALEVO 1.68 Y Y N YNVR /TB
25/200/100MG
0230594 STALEVO (100) 1.68 Y Y N YNVR /TB
37.5/200/150MG
0230596 STALEVO (150) 1.68 Y Y N YNVR /TB
DIMETHYL FUMARATE
120MG
0240450 TECFIDERA 16.52 E E N YBGN /CP
240MG
0242020 TECFIDERA 33.03 E E N YBGN /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
160
PHRM/CHRN/CDO/F28:92.00 MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
ENTACAPONE
ENTACAPONE
200MG
0238000 SANDOZ-ENTACAPONE 0.4 Y Y N YSDZ /TB
0237555 TEVA-ENTACAPONE 0.4 Y Y N YTEV /TB
0224376 COMTAN 1.65 Y Y N YNVR /TB
LEVODOPA/BENZERAZID
100/25MG
0038646 PROLOPA 0.47 Y Y N YHLR /CP
200/50MG
0038647 PROLOPA 0.78 Y Y N YHLR /CP
50/12.5MG
0052259 PROLOPA 0.28 Y Y N YHLR /CP
LEVODOPA/CARBIDOPA
100/10MG
0035565 SINEMET 0.53 Y Y N YMSD /TB
0219593 APO-LEVOCARB 0.19 Y Y N YAPX /TB
0224449 NOVO-LEVOCARBIDOPA 0.19 Y Y N YNOP /TB
100/25MG
0219594 APO-LEVOCARB 0.28 Y Y N YAPX /TB
0051399 SINEMET 0.79 Y Y N YMSD /TB
0224449 NOVO-LEVOCARBIDOPA 0.28 Y Y N YNOP /TB
0242148 PMS-LEVOCARB CR 0.39 Y Y N YPMS /TB
0227287 APO-LEVOCARB CR 0.39 Y Y N YAPX /TB
100/25MG X
0202878 SINEMET CR 0.82 Y Y N YMSD /TB
200/50MG
0242149 PMS-LEVOCARB CR 0.71 Y Y N YPMS /TB
0224521 APO-LEVOCARB CR 0.71 Y Y N YAPX /TB
0087093 SINEMET CR 1.51 Y Y N YMSD /TB
250/25MG
0224449 NOVO-LEVOCARBIDOPA 0.31 Y Y N YNOP /TB
0032821 SINEMET 0.89 Y Y N YMSD /TB
0219596 APO-LEVOCARB 0.31 Y Y N YAPX /TB
PRAMIPEXOLE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
161
PHRM/CHRN/CDO/F28:92.00 MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
PRAMIPEXOLE DIHYDROCHLORIDE (continued)
0.25MG
0229011 PMS-PRAMIPEXOLE 0.26 Y Y N YPMS /TB
0226930 NOVO-PRAMIPEXOLE 0.26 Y Y N YNOP /TB
0223714 MIRAPEX 1.08 Y Y N YBOE /TB
0237635 MYLAN-PRAMIPEXOLE 0.26 Y Y N YMYL /TB
0236760 PRAMIPEXOLE 0.26 Y Y N YSAI /TB
0231526 SANDOZ PRAMIPEXOLE 0.26 Y Y N YSDZ /TB
0229237 APO-PRAMIPEXOLE 0.26 Y Y N YAPX /TB
0229730 CO-PRAMIPEXOLE 0.26 Y Y N YCOB /TB
0.5MG
0237636 MYLAN-PRAMIPEXOLE 1.05 Y Y N YMYL /TB
0229731 CO-PRAMIPEXOLE 1.386 Y Y N YCOB /TB
0226931 NOVO-PRAMIPEXOLE 1.386 Y Y N YNOP /TB
0229013 PMS-PRAMIPEXOLE 1.39 Y Y N YPMS /TB
0229238 APO-PRAMIPEXOLE 1.386 Y Y N YAPX /TB
0224159 MIRAPEX 2.17 Y Y N YBOE /TB
0231527 SANDOZ PRAMIPEXOLE 1.39 Y Y N YSDZ /TB
0236761 PRAMIPEXOLE 1.386 Y Y N YSAI /TB
1MG
0226932 NOVO-PRAMIPEXOLE 0.53 Y Y N YNOP /TB
0229014 PMS-PRAMIPEXOLE 0.53 Y Y N YPMS /TB
0229732 CO-PRAMIPEXOLE 0.53 Y Y N YCOB /TB
0229239 APO-PRAMIPEXOLE 0.53 Y Y N YAPX /TB
0231528 SANDOZ PRAMIPEXOLE 0.53 Y Y N YSDZ /TB
0236762 PRAMIPEXOLE 0.53 Y Y N YSAI /TB
0223714 MIRAPEX 2.17 Y Y N YBOE /TB
1.5MG
0229240 APO-PRAMIPEXOLE 0.53 Y Y N YAPX /TB
0229733 CO-PRAMIPEXOLE 0.53 Y Y N YCOB /TB
0231529 SANDOZ PRAMIPEXOLE 0.53 Y Y N YSDZ /TB
0223714 MIRAPEX 2.17 Y Y N YBOE /TB
0226933 NOVO-PRAMIPEXOLE 0.53 Y Y N YNOP /TB
0229015 PMS-PRAMIPEXOLE 0.53 Y Y N YPMS /TB
RASAGILINE
1MG
0228465 AZILECT 7.21 E E N YTVM /TB
0240469 APO-RASAGILINE 6.13 E E N YAPX /TB
0241844 TEVA-RASAGILINE 6.13 E E N YTVM /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
162
PHRM/CHRN/CDO/F28:92.00 MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS (continued)
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
RILUZOLE
RILUZOLE
50MG
0224276 RILUTEK 10.05 E E N YAVT /TB
ROPINIROLE
0.25MG
0223256 REQUIP 0.29 Y Y N YGSK /TB
0235304 SANIS-ROPINIROLE 0.07 Y Y N YSAN /TB
0232659 PMS-ROPINIROLE 0.07 Y Y N YPMS /TB
0231684 CO-ROPINIROLE 0.07 Y Y N YCOB /TB
0231403 RAN-ROPINIROLE 0.07 Y Y N YRAN /TB
0.5MG
0231404 RAN-ROPINIROLE 0.2838 Y Y N YRAN /TB
1MG
0231685 CO-ROPINIROLE 0.28 Y Y N YCOB /TB
0231405 RAN-ROPINIROLE 0.28 Y Y N YRAN /TB
0235305 SANIS-ROPINIROLE 0.28 Y Y N YSAN /TB
0223256 REQUIP 1.15 Y Y N YGSK /TB
0232661 PMS-ROPINIROLE 0.28 Y Y N YPMS /TB
2MG
0231686 CO-ROPINIROLE 0.31 Y Y N YCOB /TB
0235306 SANIS-ROPINIROLE 0.31 Y Y N YSAN /TB
0232662 PMS-ROPINIROLE 0.31 Y Y N YPMS /TB
0223256 REQUIP 1.27 Y Y N YGSK /TB
0231406 RAN-ROPINIROLE 0.31 Y Y N YRAN /TB
5MG
0232663 PMS-ROPINIROLE 0.86 Y Y N YPMS /TB
0231406 RAN-ROPINIROLE 1.7192 Y Y N YRAN /TB
0235307 SANIS-ROPINIROLE 0.86 Y Y N YSAN /TB
0231687 CO-ROPINIROLE 0.86 Y Y N YCOB /TB
0223256 REQUIP 3.49 Y Y N YGSK /TB
SELEGILINE HCL
5MG
0223810 PMS-SELEGILINE 1.265 Y Y N YPMS /TB
0206808 NOVO-SELEGILINE 0.5 Y Y N YNOP /TB
0223103 GEN-SELEGILINE 0.5 Y Y N YGPM /TB
0223064 APO-SELEGILINE 0.5 Y Y N YAPX /TB
28::0.4. null -------------------------------------------------------------------------------
KETAMINE HCL
10MG/ML
0224679 KETAMINE HCL INJ 1.65 Y N N YSDZ /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
163
PHRM/CHRN/CDO/F28::0.4. null
28:00 CENTRAL NERVOUS SYSTEM DRUGS (continued)
KETAMINE HCL (continued)
50MG/ML
0224679 KETAMINE HCL INJ 4.95 Y N N YSDZ /ML
40:00 ELECTROLYTIC, CALORIC AND WATER BALANCE
40:12.00 REPLACEMENT PREPARATIONS -------------------------------------------------------
MAGNESIUM
100MG/ML
0002669 ROUGIER MAGNESIUM ORAL SOLN 0.02 E E N YROU /ML
MAGNESIUM
500MG
0055512 MAGLUCATE 0.118 E N N NPMS /TB
MAGNESIUM OXIDE
420 MG
0029944 MAGNESIUM OXIDE (SWISS) 0.033 E N Y NSWI /TB
PHOSPHORUS
500MG
8002720 PHOSPHATE NOVARTIS EFFERV. 0.85 Y E N YNVR /TB
POTASSIUM CHLORIDE
1.3MMOL/ML
0223860 PMS-POTASSIUM CHL.ORAL SOLN 0.015 Y N N YPMS /ML
0191830 K-10 ORAL SOLN 0.016 Y N N YGSK /ML
100MG/ML
8002436 K10 ORAL SOLUTION 0.02 Y N N YGSK /ML
1500MG
8001300 JAMP-K-20 0.199 Y N N YJPC
/TB
2.1GM
0208599 K-LYTE S (OR.F) 0.555 Y N N YWEL /TB
20MMOL
0224226 EURO-K 0.2 Y N N YWHL /TB
0071337 K-DUR 0.21 Y N N YSCH /TB
8MMOL
0204230 MICRO-K EXTENCAPS 0.093 Y N N YWYA /CP
8001300 JAMP-K-8 0.089 Y N N YJAM /TB
0060288 APO-K 0.0899 Y N N YAPX /TB
8004022 SLOW-K 0.12 Y N N YNVR /TB
POTASSIUM CITRATE
1080MG
0224376 K-CITRA 0.29 Y N N NWHL /TB
SODIUM CHLORIDE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
164
PHRM/CHRN/CDO/F40:12.00 REPLACEMENT PREPARATIONS (continued)
40:00 ELECTROLYTIC, CALORIC AND WATER BALANCE (continued)
SODIUM CHLORIDE (continued)
0.9%
0215020 SODIUM CHLORIDE 0.9% INJ 3.25 Y N N NOME /ML
0205823 DEY-PAK INH SOLN (100X3ML ) 3.4 Y N N NDEY /ML
0003781 BACTERIOSTATIC NACI INJ 2.73 Y N N NABB /ML
0230434 SODIUM CHLORIDE INJ USP 0.9% 0.23 Y Y N NALV /ML
0006020 NORMAL SALINE IV BAG 500ML 1.86 Y N N YBAX /ML
0003779 SODIUM CHLORIDE 0.9% INJ 4.06 Y N N NABB /ML
SODIUM CHLORIDE NEBS
15M
0221597 SODIUM CHLORIDE NEBS 15M 0.25 Y Y N NWHL /ML
40:18.00 POTASSIUM-REMOVING RESINS ------------------------------------------------------
CALCIUM POLYSTYRENE
999MG/G
0201774 RESONIUM CALCIUM (CALC 0.36 Y N N YAVT /G
SOD POLYSTYRENE
250 MG/ML
0076954 SOLYSTAT 0.14 Y N N YPMS /ML
SODIUM POLYSTYRENE
1G/1MMOL K
0075533 PMS-SOD POLYSTYRENE SULF PDR 0.17 Y N N YPMS /GM
0202696 KAYEXALATE POWDER 0.19 Y N N YSAW /GM
40:28.00 DIURETICS ----------------------------------------------------------------------
BUMETANIDE
1MG
0072828 BURINEX 0.77 E E N YLEO /TB
CHLORTHALIDONE
100MG
0036028 APO-CHLORTHALIDONE 0.094 Y Y N YAPX /TB
50MG
0036027 APO-CHLORTHALIDONE 0.1242 Y Y N YAPX /TB
FUROSEMIDE
10MG/ML
0052703 FUROSEMIDE INJ 0.87 Y N N YSDZ /ML
0222472 LASIX ORAL SOLN 0.28 Y Y N YHLR /ML
20MG
0235142 SANIS-FUROSEMIDE 0.04 Y Y N YSAN /TB
0222469 LASIX 0.087 Y Y N YHLR /TB
0039678 APO-FUROSEMIDE 0.04 Y Y N YAPX /TB
0224749 PMS-FUROSEMIDE 0.04 Y Y N YPMS /TB
0033773 TEVA-FUROSEMIDE 0.04 Y Y N YTVM /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
165
PHRM/CHRN/CDO/F40:28.00 DIURETICS (continued)
40:00 ELECTROLYTIC, CALORIC AND WATER BALANCE (continued)
FUROSEMIDE (continued)
40MG
0235143 SANIS-FUROSEMIDE 0.07 Y Y N YSAN /TB
0033774 TEVA-FUROSEMIDE 0.07 Y Y N YTVM /TB
0036216 APO-FUROSEMIDE 0.07 Y Y N YAPX /TB
0222470 LASIX 0.131 Y Y N YHLR /TB
0224749 PMS-FUROSEMIDE 0.07 Y Y N YPMS /TB
500 MG
0222475 LASIX SPECIAL 3.09 E E N YAVT /TB
80MG
0076595 TEVA-FUROSEMIDE 0.12 Y Y N YTVM /TB
0235144 SANIS-FUROSEMIDE 0.12 Y Y N YSAN /TB
0070757 APO-FUROSEMIDE 0.12 Y Y N YAPX /TB
HYDROCHLOROTHIAZID
12.5MG
0232785 APO-HYDRO 0.034 Y Y Y YAPX /TB
0227408 PMS-HYDROCHLOROTHIAZIDE 0.034 Y Y Y YPMS /TB
25MG
0236059 SANIS-HYDROCHLOROTHIAZIDE 0.02 Y Y Y YSAN /TB
0002147 TEVA-HYDROCHLOROTHIAZIDE 0.02 Y Y Y YTVM /TB
0032684 APO-HYDRO 0.02 Y Y Y YAPX /TB
0224738 PMS-HYDROCHLOROTHIAZIDE 0.04 Y Y Y YPMS /TB
50MG
0002148 TEVA-HYDROCHLOROTHIAZIDE 0.02 Y Y Y YTVM /TB
0236060 SANIS-HYDROCHLOROTHIAZIDE 0.02 Y Y Y YSAN /TB
0031280 APO-HYDRO 0.02 Y Y Y YAPX /TB
INDAPAMIDE
1.25MG
0224006 GEN-INDAPAMIDE 0.0745 Y Y N YGPM /TB
0223961 PMS-INDAPAMIDE 0.0745 Y Y N YPMS /TB
0244582 INDAPAMIDE 0.0745 Y Y N YSAI /TB
0224524 APO-INDAPAMIDE 0.0745 Y Y N YAPX /TB
0217970 LOZIDE 0.3 Y Y N YSEV /TB
2.5MG
0244583 INDAPAMIDE 0.12 Y Y N YSAI /TB
0056496 LOZIDE 0.49 Y Y N YSEV /TB
0223118 NOVO-INDAPAMIDE 0.12 Y Y N YNOP /TB
0223962 PMS-INDAPAMIDE 0.12 Y Y N YPMS /TB
0222367 APO-INDAPAMIDE 0.12 Y Y N YAPX /TB
0215348 GEN-INDAPAMIDE 0.12 Y Y N YGPM /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
166
PHRM/CHRN/CDO/F40:28.00 DIURETICS (continued)
40:00 ELECTROLYTIC, CALORIC AND WATER BALANCE (continued)
METOLAZONE
METOLAZONE
2.5MG
0088840 ZAROXOLYN 0.2 Y Y N YAVT /TB
SPIRONOLAC/HYDROCH
25/25MG
0018040 ALDACTAZIDE-25 0.13 Y Y N YPHU /TB
0061323 NOVO-SPIROZINE 0.12 Y Y N YNOP /TB
50/50MG
0065718 NOVO-SPIROZINE 0.26 Y Y N YNOP /TB
0059437 ALDACTAZIDE-50 0.28 Y Y N YPHU /TB
40:28.10 POTASSIUM SPARING DIURETICS ----------------------------------------------------
AMILORIDE HCL
5MG
0224951 APO-AMILORIDE 0.2717 Y Y N YAPX /TB
AMILORIDE/HYDROCHL
5/50MG
0078440 APO-AMILZIDE 0.084 Y Y N YAPX /TB
0193721 NOVAMILOR 0.084 Y Y N YNOP /TB
SPIRONOLACTONE
100MG
0028545 ALDACTONE 0.31 Y Y Y YPHU /TB
0061322 NOVO-SPIROTON 0.28 Y Y Y YNOP /TB
25MG
0002860 ALDACTONE 0.13 Y Y Y YPHU /TB
0061321 NOVO-SPIROTON 0.12 Y Y Y YNOP /TB
40:40.00 URICOSURIC AGENTS --------------------------------------------------------------
SULFINPYRAZONE
200MG
0044176 APO-SULFINPYRAZONE 0.2997 Y Y N YAPX /TB
40::2.8. null -------------------------------------------------------------------------------
FUROSEMIDE
10MG/ML
0040163 FUROSEMIDE SPECIAL 0.87 Y N N YSDZ /ML
48:00 COUGH PREPARATIONS
48:02.00 null -------------------------------------------------------------------------------
NINTEDANIB
100MG
0244306 OFEV 27.18 E E N YBOE /CP
150MG
0244307 OFEV 54.36 E E N YBOE /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
167
PHRM/CHRN/CDO/F48:08.00 ANTITUSSIVES
48:00 COUGH PREPARATIONS (continued)
CODEINE PHOSPHATE
48:08.00 ANTITUSSIVES -------------------------------------------------------------------
10MG/5ML
0216912 RATIO-COTRIDIN 0.05 Y N N YRTP /ML
0006859 COACTIFED SYRUP 0.16 Y N N YGSK /ML
0205340 RATIO-COTRIDIN EXPECTNT 0.06 Y N N YRTP /ML
CODEINE/GUAIFENES/PH
2MG COD/ML
0193474 ROBITUSSIN A-C SYR 0.0995 Y N N YWHI /ML
HYDROCODONE
5/10MG
0191696 TUSSIONEX SRT 1.63 Y N Y YRHO /TB
5/10MG/5ML
0191697 TUSSIONEX SRS 0.33 Y N Y YRHO /ML
5/20MG/5ML
0204948 NOVAHISTEX DH SYR 0.17 Y N Y YAVT /ML
48:14.12 null -------------------------------------------------------------------------------
IVACAFTOR
150MG
0239741 KALYDECO 420 E E N YVER /TB
48:24.00 MUCOLYTIC AGENTS ---------------------------------------------------------------
ACETYLCYSTEINE
200MG/ML
0230043 ACETYLCYSTEINE INJECTION 6.5 E N N YALV /ML
0224309 ACETYLCYSTEINE SOLN 6.5 E N N YSDZ /ML
0209152 MUCOMYST (30ML) SOLN 0.59 E N N YRBP /ML
DORNASE ALFA
1MG/ML
0204673 PULMOZYME (2.5ML) INH SOLN 37.99 E E N YHLR /ML
48:92.00 RESPIRATORY AGENTS, MISCELLANEOUS ----------------------------------------------
OMALIZUMAB
150MG/VL
0226056 XOLAIR 624.24 E N N YNVO /EA
52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS
52:04.04 ANTIBACTERIALS -----------------------------------------------------------------
CHLORAMPHENICOL
10MG/GM
0198056 PENTAMYCETIN OPHT OINT 1.497 Y N Y YSAB /GM
5MG/ML
0216405 PENTAMYCETIN OPHT SOLN 0.442 Y N Y YSAB /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
168
PHRM/CHRN/CDO/F52:04.04 ANTIBACTERIALS (continued)
52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS (continued)
CHORAMPHENICOL/HC
CHORAMPHENICOL/HC
10MG/GM
0198058 PENTAMYCETIN/HC 2.829 Y N Y YSDZ /GM
ERYTHROMYCIN
5MG/GM
0232666 ERYTHROMYCIN OPH OINT 1.21 Y N Y YSTR /GM
0191275 PMS ERYTHROMYCIN OPH OINT 2.86 Y N Y YPMS /GM
0214157 DIOMYCIN OPHT OINT 1.1514 Y N Y YDIO /GM
GATIFLOXACIN
0.3%
0225727 ZYMAR OPHT SOLN 2.6 Y N N YALL /ML
GENTAMICIN SO4
.3%
0202377 DIOGENT OPHTHALMIC OINTMENT 1.2429 Y N Y YSDZ /GM
0223088 SAB-GENTAMICIN OPHT OINTMENT 1.1429 Y N Y YSAB /GM
0077652 PMS-GENTAMYCIN OPHTH SOLN 0.406 Y N Y YPMS /ML
0051219 GARAMYCIN OPHTHALMIC SOLN 0.406 Y N Y YSCH /ML
0051218 GARAMYCIN OTIC SOLN 1.032 Y N Y YSCH /ML
0202382 DIOGENT OPHTHALMIC SOLN 0.428 Y N Y YSDZ /ML
0223088 PMS-GENTAMICIN OTIC SOLN 1.032 Y N Y YPMS /ML
0222944 GENTAMICIN SO4 OTIC SOLN 1.032 Y N Y YSAB /ML
0222944 SANDOZ GENTAMICIN OPHT SOLN 0.406 Y N Y YSDZ /ML
MOXIFLOXACIN
0.5%
0240637 APO-MOXIFLOXACIN 3.76 Y N Y YAPX /ML
0240465 ACT MOXIFLOXACIN 3.98 Y N Y YACA /ML
0241152 SANDOZ MOXIFLOXACIN 3.76 Y N Y YSDZ /ML
0225226 VIGAMOX OPHT SOLN 4.35 Y N Y YALC /ML
POLYMIXIN
1MG/ML
0223923 SANDOZ POLYTRIMETHOPRIM 2.51 Y N Y Ynull /ML
POLYMYXIN
1MG/ML
0224036 PMS-POLYTRIMETHOPRIM OPHT 2.388 Y N Y YPMS /ML
0201195 POLYTRIM OPHTHALMIC SOLN 3.29 Y N Y YALL /ML
POLYMYXIN/NEOMYCIN/
/2.5MG/ML
0080743 OPTIMYXIN PLUS E/E SOLN 0.725 Y N Y YSAB /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
169
PHRM/CHRN/CDO/F52:04.04 ANTIBACTERIALS (continued)
52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS (continued)
TOBRAMYCIN
TOBRAMYCIN
0.3%
0061425 TOBREX OPHTHALMIC OINT (4G) 2.511 Y N Y YALC /GM
0224175 SAB-TOBRAMYCIN OPHT SOLN 1.05 Y N Y YSAB /ML
0051396 TOBREX 5ML OPHTHALMIC SOLN 1.79 Y N Y YALC /ML
0223957 PMS-TOBRAMYCIN OPHT SOLN 0.656 Y N Y YPMS /ML
52:04.06 ANTI-INFECTIVES (ANTIVIRALS) ---------------------------------------------------
TRIFLURIDINE
1%
0068745 VIROPTIC OPHT SOLN 3.084 Y N Y YGSK /ML
0224852 SANDOZ TRIFLURIDINE OPHT SOLN 3.039 Y N Y YSDZ /ML
52:04.08 SULFONAMIDES -------------------------------------------------------------------
SULFACETAMIDE
10%
0002805 SODIUM SULAMYD OPHT SOLN 0.493 Y N Y YSCH /ML
0062296 DIOSULF OPHT SOLN 0.0789 Y N Y YAKN /ML
52:04.12 ANTI-INFECTIVES (MISCELLANEOUS) ------------------------------------------------
CIPROFLOXACIN
0.3%
0220086 CILOXAN OPHT OINTMENT 2.946 Y N Y YALC /GM
0226313 APO-CIPROFLOX OPHT SOLN 1.76 Y N Y YAPX /ML
0238713 SANDOZ CIPROFLOXACIN 1.86 Y N Y YSDZ /ML
0194527 CILOXAN OPHT SOLN 2.1 Y N Y YALC /ML
FUSIDIC ACID
10MG/GM
0224386 FUCITHALMIC VISCOUS DROPS 2.06 Y N Y YLEO /GM
OFLOXACIN
0.3%
0214329 OCUFLOX OPHT SOLN 2.5 Y N Y YALL /ML
0224839 APO-OFLOXACIN OPHT SOLN 1.47 Y N Y YAPX /ML
0225257 PMS-OFLOXACIN OPHT SOLN 0.978 Y N Y YPMS /ML
52:08.00 ANTI-INFLAMMATORY AGENTS -------------------------------------------------------
BECLOMETHASONE
50UG/DS
0217271 GEN-BECLO AQ. NASAL SPR 0.06 Y N Y YGPM /DS
0223879 APO-BECLOMETHASONE AQ.NASAL 0.06 Y N Y YAPX /DS
BUDESONIDE
100UG/DS
0203532 RHINOCORT TURBUHALER 0.12 Y N Y YAST /DS
0223064 GEN-BUDESONIDE AQ NASAL SPR 0.1 Y N Y YGPM /DS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
170
PHRM/CHRN/CDO/F52:08.00 ANTI-INFLAMMATORY AGENTS (continued)
52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS (continued)
BUDESONIDE (continued)
64UG/DS
0223192 RHINOCORT AQUA NASAL SPR 0.089 Y N Y YAST /DS
0224100 GEN-BUDESONIDE NASAL SPR 0.084 Y N Y YGPM /DS
CIPROFLOXACIN/DEXAM
0.3%/0.1%
0225271 CIPRODEX OTIC SOLUTION 3.61 Y N Y YALC /ML
DEXAMETHASONE
0.1%
0004257 MAXIDEX OPHTH OINTMENT (4G) 2.73 Y E Y YALC /GM
0004256 MAXIDEX OPHTHALMIC SUSP 1.65 Y E Y YALC /ML
0202386 DIODEX E/E SOLN 0.712 Y E Y YAKN /ML
0078526 PMS-DEXAMETHASONE E/E SOLN 0.676 Y E Y YPMS /ML
0073983 DEXAMETHASONE E/E SOLN 1.38 Y E Y YSAB /ML
FLUNISOLIDE
0.025%
0223928 APO-FLUNISOLIDE NASAL SOLN 0.75 Y N Y YAPX /DS
0216268 RHINALAR NASAL SOLN 0.792 Y N Y YHLR /DS
FLUOROMEHTOLONE
0.1%
0043281 SANDOZ FLUOROMETHOLONE 1.788 Y N Y YSDZ /ML
FLUOROMETHOLONE
.25%
0070751 FML FORTE OPHT SUSP 2.76 Y E Y YALL /ML
0.1%
0223856 PMS-FLUOROMETHOLONE OPHT 1.79 Y N Y YPMS /ML
0024785 FML OPHTHALMIC SUSP 3.21 Y N Y YALL /ML
FLUOROMETHOLONE
0.1%
0075678 FLAREX OPHT SUSP 1.87 Y N Y YALC /ML
FLUTICASONE FUROATE
27.5UG/DS
0229858 AVAMYS 0.209 Y N Y YGCH /DS
FLUTICASONE
50UG/DS
0229607 RATIO- FLUTICASONE NASAL 0.18 Y N Y YRTP /DS
0221367 FLONASE AQ NASAL SPR 120DS 0.26 Y N Y YGSK /DS
0229474 APO-FLUTICASONE NASAL SPRAY 0.18 Y N Y YAPX /DS
FRAMYCETIN/GRAMICIDI
12.5MG/ML
0222486 SOFRAMYCIN E/E SOLN 2.7 Y N Y YERF /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
171
PHRM/CHRN/CDO/F52:08.00 ANTI-INFLAMMATORY AGENTS (continued)
52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS (continued)
FRAMYCETIN/GRAMICIDIN/DEXAMETH (continued)
5MG//ML
0222462 SOFRACORT E/E SOLN 1.91 Y N Y YAVT /ML
0224792 SANDOZ OPTICORT E/E SOLN 0.98 Y N Y YSDZ /ML
GENTAMICIN/BETAMETH
0.3%/0.1%
0058670 GARASONE OPHT OINT 2.8943 Y N Y YSCH /GM
0224499 SAB-PENTASONE E/E SOLN 1.2813 Y N Y YSAB /ML
0068221 GARASONE E/E SOLN 1.2813 Y N Y YSCH /ML
IODOCHLORHYDROXYQ
1%/0.02%
0007445 LOCACORTEN-VIOFORM OTIC 1.58 Y N Y YNVR /ML
KETOROLAC
0.5%
0224746 RATIO-KETOROLAC OPHT SOLN 1.6 Y N Y YRAT /ML
0196830 ACULAR OPHT SOLN 3.46 Y N Y YALL /ML
0224582 APO-KETOROLAC OPHT SOLN 2.6 Y N Y YAPO /ML
MOMETASONE FUROATE
50MCG/MD
0223846 NASONEX NASAL SPR 0.21 Y N Y YSCH /DS
0244981 SANDOZ MOMETASONE 0.11 Y N Y YSDZ /DS
0240358 APO-MOMETASONE FUROATE 0.15 Y N Y YAPX /DS
POLYMYX/NEOMYC/HYD
5/10MG/ML
0223038 SAB-CORTIMYXIN OTIC SOLN 1.14 Y N Y YSAB /ML
POLYMYX/NEOMYCIN/D
5MG/1MG/G
0035817 MAXITROL OPHT OINT 2.6543 Y N Y YALC /GM
5MG/1MG/ML
0004267 MAXITROL OPHT SOLN 2.04 Y N Y YALC /ML
PREDNISOLONE
0.12%
0029940 PRED MILD OPHTHALMIC SUSP 1.83 Y N Y YALL /ML
0191618 PREDNISOLONE OPHT SUSP 1.345 Y N Y YSAB /ML
1.0%
0030117 PRED FORTE OPHTHALMIC SUSP 5.288 Y E Y YALL /ML
0191620 PREDNISOLONE OPHT SUSP 1.94 Y E Y YSDZ /ML
0070040 RATIO-PREDNISOLONE OPHT SUSP 4.13 Y E Y YRTP /ML
PREDNISOLONE SODIUM
0.5%
0214849 PREDNISOLONE MINIMS 0.5% 2 E N N YCHA /EA
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
172
PHRM/CHRN/CDO/F52:08.00 ANTI-INFLAMMATORY AGENTS (continued)
52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS (continued)
RIMEXOLONE
RIMEXOLONE
1%
0216369 VEXOL OPHTHALMIC SUSP 1% 3.56 Y N N YALC /ML
SULFACETAMIDE/PREDNI
0.2%;10%
0080778 BLEPHAMIDE OPHT SUSP 2.8 Y N Y YALL /ML
0.5%;10%
0202381 DIOPTIMYD OPHT SUSP 1.25 Y N Y YAKN /ML
100MG/2MG
0030724 BLEPHAMIDE S.O.P. OPH OINT 3.457 Y N Y YALL /GM
TOBRAMYCIN/DEXAMET
0.3%/0.1%
0077891 TOBRADEX (4GM) OPHT OINT 3.05 Y N Y YALC /GM
0077890 TOBRADEX OPHTHALMIC SUSP 2.09 Y N Y YALC /ML
TRIAMCINOLONE
55MCG/DS
0243763 APO-TRIAMCINOLONE AQ 0.17 Y N Y YAPX /DS
0221383 NASACORT AQ NASAL SPR 0.2 Y N Y YAVT /DS
52:08.08 CORTICOSTEROIDS ----------------------------------------------------------------
FLUTIASONE FUROATE
200MCG
0244658 ARNUITY ELLIPTA 2.54 Y Y Y YGSK /DS
FLUTICASONE FUROATE
100MCG
0244656 ARNUITY ELLIPTA 1.27 Y Y Y YGSK /DS
52:10.00 CARBONIC ANHYDRASE INHIBITORS --------------------------------------------------
ACETAZOLAMIDE
250MG
0054501 APO-ACETAZOLAMIDE 0.12 Y Y N YAPX /TB
BRINZOLAMIDE
1%
0223887 AZOPT OPHTHALMIC SUSP 3.37 Y Y N YALC /ML
DORZOLAMIDE HCL
2%
0231630 SANDOZ-DORZOLAMIDE OPHTH 3.16 Y Y N YSDZ /ML
0221620 TRUSOPT OPHT SOLN 4.09 Y Y N YMSD /ML
METHAZOLAMIDE
50MG
0224588 APO-METHAZOLAMIDE 0.48 Y Y N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
173
PHRM/CHRN/CDO/F52:20.00 MIOTICS
52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS (continued)
PILOCARPINE HCL
52:20.00 MIOTICS ------------------------------------------------------------------------
1%
0000084 ISOPTO CARPINE OPHT SOLN 0.22 Y Y Y YALC /ML
2%
0000086 ISOPTO CARPINE OPHT SOLN 0.25 Y Y Y YALC /ML
0202374 DIOCARPINEOPHTHALMIC SOLN 0.204 Y Y Y YAKN /ML
4%
0202373 DIOCARPINE OPHTHALMIC SOLN 0.2327 Y Y Y YAKN /ML
0000088 ISOPTO CARPINE OPHT SOLN 0.29 Y Y Y YALC /ML
52:24.00 MYDRIATICS ---------------------------------------------------------------------
ATROPINE SO4
1%
0003501 ISOPTO ATROPINE OPHT SOLN 0.64 Y N Y YALC /ML
CYCLOPENTOLATE HCL
1%
0025250 CYCLOGYL OPHTHALMIC DROPS 0.87 Y N Y YALC /ML
DIPIVEFRIN HCL
0.1%
0223786 PMS-DIPIVEFRIN OPHT SOLN 0.996 Y N Y YPMS /ML
HOMATROPINE
2%
0000077 ISOPTO HOMATROPINE OPHT SOLN 0.65 Y E Y YALC /ML
5%
0000078 ISOPTO HOMATROPINE OPHT SOLN 0.78 Y E Y YALC /ML
52:28.00 MOUTHWASHES AND GARGLES --------------------------------------------------------
BENZYDAMINE
0.15%
0222979 NOVO-BENZYDAMINE RINSE 0.029 Y E Y YNOP /ML
0222977 PHARIXIA 0.08 Y E Y YPMS /ML
0223904 APO-BENZYDAMINE RINSE 0.029 Y E Y YAPX /ML
0196606 TANTUM LIQ 0.133 Y E Y YMDA /ML
CHLORHEXIDINE
0.12%
0224043 PERICHLOR 0.0181 Y N Y YPMS /ML
0223745 PERIDEX ORAL RINSE 0.0218 Y N Y YZIL /ML
0238427 GUM PAROEX 0.015 Y N Y YSUN /ML
0220779 PERIOGARD 0.0164 Y N Y YCOL /ML
52:36.00 MISCELLANEOUS E.E.N.T. DRUGS ---------------------------------------------------
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
174
PHRM/CHRN/CDO/F52:36.00 MISCELLANEOUS E.E.N.T. DRUGS
52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS (continued)
APRACLONIDINE HCL
APRACLONIDINE HCL
0.5%
0207630 IOPIDINE OPHTHALMIC SOLN (5ML) 4.56 Y Y Y YALC /ML
1%
0088835 IOPIDINE OPHTHALMIC (12X0.1ML) 134.4 Y Y Y YALC /KT
BETAXOLOL HCL
0.25%
0190844 BETOPTIC S OPHTHALMIC SUSP 2.36 Y Y N YALC /ML
0.5%
0223597 SANDOZ BETAXOLOL 1X 1.822 Y Y N YSDZ /ML
BIMATOPROST
0.01%
0232499 LUMIGAN RC OPHTHALM SOLN 10.976 Y Y N YALL /ML
0.03%
0242906 VISTITAN 9.52 Y Y N YSDZ /ML
BRIMONIDINE TARTRATE
0.15%
0230133 APO-BRIMONIDINE P 2.43 Y Y N YAPX /ML
0224815 ALPHAGAN P OPHT SOLN 2.43 Y Y N YALL /ML
0.2%
0224628 PMS-BRIMONIDINE OPHT SOLN 1.16 Y Y N YPMS /ML
0226007 APO-BRIMONIDINE 1.16 Y Y N YAPX /ML
0224302 RATIO-BRIMONIDINE OPHT SOLN 3.44 Y Y N YRAT /ML
0223687 ALPHAGAN OPHTHALMIC SOLN 3.44 Y Y N YALL /ML
0230542 SANDOZ BRIMONIDINE 1.15 Y Y N YSDZ /ML
BRIMONIDINE
0.2%/0.5%
0224834 COMBIGAN OPHT SOLN 4.19 Y Y N YALL /ML
BRINZOLAMIDE/TIMOLO
1%/0.5%
0233162 AZARGA(1%/0.5%) 4.39 Y Y N YALC /ML
DICLOFENAC SODIUM
0.1%
0245480 SANDOZ DICLOFENAC OPHTHA 2.66 Y N Y YSDZ /ML
0194041 VOLTAREN OPTHA SOLN 2.58 Y N Y YNVO /ML
DORZOLAMIDE
20/5MG
0225869 COSOPT (2%/0.5%) OPHT SOLN (UD 0.51 E E N YMSD /EA
0229961 APO-DORZO-TIMOP OPT SOLN 1.99 Y Y N YAPX /ML
0234435 SANDOZ-DORZOLAMIDE/TIMOLOL 2.33 Y Y N YSDZ /ML
0224011 COSOPT (2%/0.5%) OPHT SOLN 6.35 Y Y N YMSD /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
175
PHRM/CHRN/CDO/F52:36.00 MISCELLANEOUS E.E.N.T. DRUGS (continued)
52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS (continued)
DORZOLAMIDE HCL/TIMOLOL (continued)
20/5MG/ML
0232052 TEVA-DORZOLAMIDE/TIMOLOL 1.989 Y Y N YTVM /ML
DORZOLAMIDE/TIMOLO
20/5MG
0240438 CO DORZOTIMOLOL 2.33 Y Y N YCOB /ML
LATANOPROST
50MCG/ML
0236733 SANDOZ LATANOPROST 3.63 Y Y N YSDZ /ML
0223149 XALATAN OPHT SOLN 11.18 Y Y N YPMS /ML
0229652 APO-LATANOPROST 3.63 Y Y N YAPX /ML
0225478 CO-LATANOPROST 3.63 Y Y N YCOB /ML
LATANOPROST/TIMOLO
50MCG/5MG
0224661 XALACOM 12.65 Y Y N YPFI /ML
0239468 SANDOZ-LATANOPROST/TIMOLOL 4.428 Y Y N YSDZ /ML
0243625 ACT LATANOPROST/TIMOLOL 4.428 Y Y N YACT /null
LEVOBUNOLOL HCL
0.25%
0203115 RATIO-LEVOBUNOLOL OPHT SOLN 3.9 Y Y N YRTP /ML
0075128 BETAGAN OPHTHALMIC SOLN 2.127 Y Y N YALL /ML
0.5%
0203116 RATIO-LEVOBUNOLOL OPHT SOLN 1.15 Y Y N YRTP /ML
0063766 BETAGAN OPHTHALMIC SOLN 3.36 Y Y N YALL /ML
0223799 PMS-LEVOBUNOLOL OPHT SOLN 1.32 Y Y N YPMS /ML
LEVOCABASTINE
0.5MG/ML
0202001 LIVOSTIN SUS NASAL SPR 1.79 Y N Y YJAN /ML
LODOXAMIDE
0.1%
0089356 ALOMIDE OPHTHALMIC SOLN 1.12 Y N Y YALC /ML
NEPAFENAC
0.1%
0230898 NEVANAC OPHTHALMIC 3.99 Y N N YALC /ML
RANIBIZUMAB
10MG/ML
0229681 LUCENTIS INTRAVITREAL INJ 1575 E E N YNVO /VL
SODIUM
2%
0223139 APO-CROMOLYN NASAL MIST 0.5292 Y N Y YAPX /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
176
PHRM/CHRN/CDO/F52:36.00 MISCELLANEOUS E.E.N.T. DRUGS (continued)
52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS (continued)
TIMOLOL MALEATE
TIMOLOL MALEATE
0.25%
0075582 APO-TIMOP OPHTHALMIC SOLN 0.97 Y Y N YAPX /ML
0216671 SANDOZ TIMOLOL 0.97 Y Y N YSDZ /ML
0208335 PMS-TIMOLOL OPHTHALMIC SOLN 0.97 Y Y N YPMS /ML
0.25%GEL
0217188 TIMOPTIC-XE OPHT GELLAN SOLN 4.5 Y Y N YMSD /ML
0224227 TIMOLOL MALEATE-EX GEL SOLN 3.22 Y Y N YALC /ML
0.5%
0045120 TIMOPTIC OPHTHALMIC SOLN 4.22 Y Y N YMSD /ML
0075583 APO-TIMOP OPHTHALMIC SOLN 1.21 Y Y N YAPX /ML
0208334 PMS-TIMOLOL OPHTHALMIC SOLN 1.21 Y Y N YPMS /ML
0216672 SAB-TIMOLOL OPHT SOLN 1.21 Y Y N YSAB /ML
0.5%GEL
0224227 TIMOLOL MALEATE-EX GEL SOLN 3.85 Y Y N YALC /ML
0217189 TIMOPTIC-XE OPHT GELLAN SOLN 5.39 Y Y N YMSD /ML
TIMOLOL/TRAVOPROST
0.5%/0.004%
0227825 DUOTRAV 13.28 Y Y N YALC /ML
TRAVOPROST
0.004%
0241316 SANDOZ TRAVOPROST 4.03 Y Y N YSDZ /ML
0241206 TEVA-TRAVOPROST Z OPHT SOLN 4.03 Y Y N YTVM /ML
0231800 TRAVATAN Z OPHT SOLN 11.36 Y Y N YALC /ML
0.5%/0.004%
0241573 APO-TRAVOPROST Z 4.03 Y Y N YAPX /ML
52:40.04 ALPHA-ADRENERGIC AGONISTS ------------------------------------------------------
BRIMONIDINE/BRINZOLA
0.2/1%
0243541 SIMBRINZA 4.57 Y Y N YALC /ML
52:92.00 EENT DRUGS, MISCELLANEOUS ------------------------------------------------------
AFLIBERCEPT
40MG/ML
0241599 EYLEA 1418 E E N YBAY /ML
56:00 GASTROINTESTINAL DRUGS
56:08.00 ANTIDIARRHEA AGENTS ------------------------------------------------------------
DIPHENOXYLATE HCL
2.5MG
0003632 LOMOTIL 0.45 Y Y Y YPHU /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
177
PHRM/CHRN/CDO/F56:14.00 CHOLELITHOLYTIC AGENTS
56:00 GASTROINTESTINAL DRUGS (continued)
URSODIOL
56:14.00 CHOLELITHOLYTIC AGENTS ---------------------------------------------------------
250MG
0227349 PMS-URSODIOL C 0.99 Y Y N YPMS /TB
0223898 URSO 1.45 Y Y N YAXC /TB
500MG
0224589 URSO DS 2.76 Y Y N YAXC /TB
0227350 PMS-URSODIOL C 1.88 Y Y N YPMS /TB
56:16.00 DIGESTANTS ---------------------------------------------------------------------
PANCRELIPASE
10000U//
0220010 CREON 10 0.2723 Y Y N YSLV /CP
10000U/ EC
0078943 PANCREASE MT 10 1.5 Y Y N YJAN /CP
16000U//
0078942 PANCREASE MT 16 2.17 Y Y N YJAN /CP
0224193 VIOKASE 0.37 Y Y N YAXC /TB
20000U/ EC
0082137 COTAZYM ECS 20 0.96 Y Y N YORG /CP
25000U//
0198520 CREON 25 0.8507 Y Y N YSLV /CP
4000U//
0078944 PANCREASE MT 4 0.54 Y Y N YJAN /CP
5000U//
0223900 CREON 5 MINIMICROSPHERES 0.1703 Y Y N YSLV /CP
8000U//
0026381 COTAZYM' 0.2 Y Y N YORG /CP
0223001 VIOKASE 0.24 Y Y N YAXC /TB
8000U// EC
0050279 COTAZYM ECS 8 0.36 Y Y N YORG /CP
56:16.01 null -------------------------------------------------------------------------------
PANCRELIPASE
12000//
0204583 ULTRASE MT12 0.46 Y Y N YAXC /CP
20000U//
0204586 ULTRASE MT20 0.79 Y Y N YAXC /CP
56:22.00 ANTI-EMETICS -------------------------------------------------------------------
APREPITANT
125MG
0229880 EMEND 31.55 E E N YMSD /CP
125MG/80MG/80MG
0229881 EMEND TRI-PACK 93.24 E E N YMSD /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
178
PHRM/CHRN/CDO/F56:22.00 ANTI-EMETICS (continued)
56:00 GASTROINTESTINAL DRUGS (continued)
APREPITANT (continued)
80MG
0229879 EMEND 31.55 E E N YMSD /CP
DOLASETRON
100MG
0223137 ANZEMET 29.6 E E N YSAW /TB
DOXYLAMINE
10/10MG
0060912 DICLECTIN 1.27 N N Y YDUI /TB
GRANISETRON
1MG
0230889 APO-GRANISETRON 9 E E N YAPX /TB
0218588 KYTRIL 18 E E N YHLR /TB
MECLIZINE HCL
25MG
0236883 BONAMINE 0.442 Y N N NMCN /TB
NABILONE
0.5MG
0238488 TEVA-NABILONE 0.78 E E N YTVM /CP
0238090 PMS-NABILONE 0.78 E E N YPMS /CP
0225619 CESAMET 3.29 E E N YVAE /CP
0235808 RAN-NABILONE 0.78 E E N YRAN /CP
1MG
0239360 ACT NABILONE 1.55 E E N YACT /CP
0054837 CESAMET 6.58 E E N YVAE /CP
0238489 TEVA-NABILONE 1.551 E E N YTVM /CP
0235809 RAN-NABILONE 1.55 E E N YRAN /CP
0238091 PMS-NABILONE 1.55 E E N YPMS /CP
ONDANSETRON
2MG/ML
0227942 ONDANSETRON INJ (PRESERV FREE) 5.94 E E N YSDZ /ML
0227943 ONDANSETRON INJ- SANDOZ 3.46 E E N YSDZ /ML
0227441 ONDANSETRON HCL INJ 3.46 E E N YSDZ /ML
0226552 ONDANSETRON INJ- NOVO 6.8 E E N YNOP /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
179
PHRM/CHRN/CDO/F56:22.00 ANTI-EMETICS (continued)
56:00 GASTROINTESTINAL DRUGS (continued)
ONDANSETRON (continued)
4MG
0225818 PMS-ONDANSETRON 3.27 E E N YPMS /TB
0230621 ONDANSETRON-ODAN 3.35 E E N YODN /TB
0227431 SANDOZ ONDANSETRON 3.27 E E N YSDZ /TB
0227852 RATIO-ONDANSETRON 3.35 E E N Ynull /TB
0226405 NOVO-ONDANSETRON 3.27 E E N YNOP /TB
0242140 ONDANSETRON 3.35 E E N YSAI /TB
0221356 ZOFRAN 13.6 E E N YGSK /TB
0228818 APO-ONDANSETRON 3.27 E E N YAPX /TB
0229634 CO-ONDANSETRON 3.27 E E N YCOB /TB
0229786 MYLAN-ONDANSETRON 3.27 E E N YMYL /TB
0230525 MINT-ONDANSETRON 3.27 E E N YMNT /TB
0231224 RAN-ONDANSETRON 3.27 E E N YRAN /TB
4MG ODT
0238998 ONDISSOLVE 3.27 E E N YTAK /TB
0244467 SANDOZ ONDANSETRON ODT 3.27 E E N YSDZ /TB
0223937 ZOFRAN ODT 13.089 E E N YGSK /TB
4MG/5ML
0222963 ZOFRAN (50ML) ORAL LIQ 2.04 E E N YGSK /ML
8MG
0221357 ZOFRAN 20.75 E E N YGSK /TB
0226406 NOVO-ONDANSETRON 4.99 E E N YNOP /TB
0230622 ONDANSETRON-ODAN 5.11 E E N YODN /TB
0228819 APO-ONDANSETRON 4.99 E E N YAPX /TB
0230526 MINT-ONDANSETRON 4.99 E E N YMNT /TB
0227853 RATIO-ONDANSETRON 5.11 E E N YRPH /TB
0242141 ONDANSETRON 5.11 E E N YSAI /TB
0231225 RAN-ONDANSETRON 4.99 E E N YRAN /TB
0227432 SANDOZ ONDANSETRON 4.99 E E N YSDZ /TB
0225819 PMS-ONDANSETRON 4.99 E E N YPMS /TB
8MG ODT
0238999 ONDISSOLVE ODF 4.99 E E N YTAK /TB
0223937 ZOFRAN ODT 19.972 E E N YGSK /TB
56:40.00 MISCELLANEOUS GASTROINTESTINAL DRUGS -------------------------------------------
5-AMINOSALICYLIC
1GM ER
0239946 PENTASA 1.11 Y Y Y YFEI /TB
1.0G SUP
0224214 SALOFALK 1.85 Y Y Y YAXC /SP
1.0G SUPP
0215356 PENTASA SUPP 1.65 Y Y Y YFEI /SP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
180
PHRM/CHRN/CDO/F56:40.00 MISCELLANEOUS GASTROINTESTINAL DRUGS (continued)
56:00 GASTROINTESTINAL DRUGS (continued)
5-AMINOSALICYLIC ACID (continued)
1.0G/100ML
0215352 QUINTASA RET.ENEMA 0.27 Y Y Y YFEI /ML
1.2G ER
0229755 MEZAVANT 1.63 Y Y N YSCI /TB
2.0G/60G
0211279 SALOFALK RET.ENEMA 0.47 Y Y Y YAXC /GM
4.0G/100ML
0215355 PENTASA RET.ENEMA 0.32 Y Y Y YFEI /ML
4.0G/60G
0211280 SALOFALK RET.ENEMA 0.8 Y Y Y YAXC /GM
400MG EC
0217192 NOVO-5-ASA EC 0.47 Y Y Y YNOP /TB
400MG ECT
0199758 ASACOL EC 0.552 Y Y Y YPGA /TB
500MG CR
0209968 PENTASA (DELAYED REL) 0.57 Y Y Y YFEI /TB
500MG EC
0211278 SALOFALK EC 0.57 Y Y Y YAXC /TB
500MG ECT
0191403 MESASAL EC 0.64 Y Y Y YGSK /TB
500MG SUPP
0211276 SALOFALK SUPP 1.26 Y Y Y YAXC /SP
800MG EC
0226721 ASACOL EC 1.08 Y Y Y YPGA /TB
BETAMETHASONE
5MG/100ML
0206088 BETNESOL ENEMA (100ML) 0.71 Y Y Y YRBP /ML
BUDESONIDE
0.02MG/ML
0205243 ENTOCORT ENEMA (100ML) 0.52 Y Y Y YAST /ML
3MG
0222929 ENTOCORT CONTR ILEAL RELEASE 1.63 Y Y N YAST /CP
CIMETIDINE
300MG
0048787 APO-CIMETIDINE 0.18 Y N Y YAPX /TB
0222971 PMS-CIMETIDINE 0.086 Y N Y YPMS /TB
0222744 GEN-CIMETIDINE 0.086 Y N Y YGPM /TB
0058241 NOVO-CIMETINE 0.086 Y N Y YNOP /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
181
PHRM/CHRN/CDO/F56:40.00 MISCELLANEOUS GASTROINTESTINAL DRUGS (continued)
56:00 GASTROINTESTINAL DRUGS (continued)
CIMETIDINE (continued)
400MG
0060005 APO-CIMETIDINE 0.29 Y N Y YAPX /TB
0222971 PMS-CIMETIDINE 0.135 Y N Y YPMS /TB
0060367 NOVO-CIMETINE 0.135 Y N Y YNOP /TB
0222745 GEN-CIMETIDINE 0.14 Y N Y YGPM /TB
600MG
0060006 APO-CIMETIDINE 0.34 Y N Y YAPX /TB
0060368 NOVO-CIMETINE 0.172 Y N Y YNOP /TB
0222746 GEN-CIMETIDINE 0.172 Y N Y YGPM /TB
0222972 PMS-CIMETIDINE 0.172 Y N Y YPMS /TB
0086583 NU-CIMET 0.172 Y N Y YNXP /TB
DOMPERIDONE MALEATE
10MG
0215719 NOVO-DOMPERIDONE 0.06 Y Y Y YNOP /TB
0223646 PMS-DOMPERIDONE 0.06 Y Y Y YPMS /TB
0226807 RAN-DOMPERIDONE 0.06 Y Y Y YRAP /TB
0210361 APO-DOMPERIDONE 0.06 Y Y Y YAPX /TB
0235044 DOMPERIDONE 0.06 Y Y Y YSAI /TB
0191207 RATIO-DOMPERIDONE 0.06 Y Y Y YRTP /TB
FAMOTIDINE
20MG
0219601 GEN-FAMOTIDINE 0.27 Y N Y YGPM /TB
0195384 APO-FAMOTIDINE 0.27 Y N Y YAPX /TB
0235110 SANIS-FAMOTIDINE 0.27 Y N Y YSAN /TB
0202213 TEVA-FAMOTIDINE 0.27 Y N Y YTVM /TB
40MG
0202214 TEVA-FAMOTIDINE 0.48 Y N Y YTVM /TB
0235111 SANIS-FAMOTIDINE 0.48 Y N Y YSAN /TB
0195383 APO-FAMOTIDINE 0.48 Y N Y YAPX /TB
0219602 GEN-FAMOTIDINE 0.48 Y N Y YGPM /TB
HYDROCORTISONE
100MG/60ML
0023031 HYCORT ENEMA (60ML) 0.09 Y Y Y YICN /EA
0211273 CORTENEMA ENEMA (60ML) 0.12 Y Y Y YAXC /ML
LANSOPRAZOLE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
182
PHRM/CHRN/CDO/F56:40.00 MISCELLANEOUS GASTROINTESTINAL DRUGS (continued)
56:00 GASTROINTESTINAL DRUGS (continued)
LANSOPRAZOLE (continued)
15MG
0216550 PREVACID 2 Y E Y YABB /CP
0243300 LANSOPRAZOLE 0.5 Y E Y YPMS /CP
0240261 RAN-LANSOPRAZOLE 0.5 Y E Y YRAN /CP
0235768 SANIS-LANSOPRAZOLE 0.5 Y E Y YSAN /CP
0235383 MYLAN-LANSOPRAZOLE 0.5 Y E Y YMYL /CP
0229381 APO-LANSOPRAZOLE 0.5 Y E Y YAPX /CP
0228051 TEVA-LANSOPRAZOLE 0.5 Y E Y YTVM /CP
30MG
0240262 RAN-LANSOPRAZOLE 0.5 Y E Y YRAN /CP
0243302 LANSOPRAZOLE 0.5 Y E Y YPMS /CP
0235769 SANIS-LANSOPRAZOLE 0.5 Y E Y YSAN /CP
0229383 APO-LANSOPRAZOLE 0.5 Y E Y YAPX /CP
0216551 PREVACID 2 Y E Y YABB /CP
0239526 PMS-LANSOPRAZOLE 0.5 Y E Y YPMS /CP
0228052 TEVA-LANSOPRAZOLE 0.5 Y E Y YTVM /CP
0235384 MYLAN-LANSOPRAZOLE 0.5 Y E Y YMYL /CP
LANSOPRAZOLE/CLARIT
30/500/500
0223852 HP-PAC (30/500/500MG 7-DAY 12.15 Y N Y YABB /PK
METOCLOPRAMIDE HCL
1MG/ML
0223043 PMS-METOCLOPRAMIDE ORAL 0.05 Y Y Y YPMS /ML
10MG
0084283 APO-METOCLOP 0.0583 Y Y Y YAPX /TB
0223043 PMS-METOCLOPRAMIDE 0.06 Y Y Y YPMS /TB
5MG
0223043 PMS-METOCLOPRAMIDE 0.06 Y Y Y YPMS /TB
0084282 APO-METOCLOP 0.0556 Y Y Y YAPX /TB
5MG/ML
0218543 METOCLOPRAMIDE HCL INJ 3.14 Y Y Y YSAB /ML
MISOPROSTOL
100MCG
0224402 APO-MISOPROSTOL 0.26 Y Y Y YAPX /TB
200MCG
0224402 APO-MISOPROSTOL 0.43 Y Y Y YAPX /TB
0224412 PMS-MISOPROSTOL 0.4303 Y Y Y YPMS /TB
NIZATIDINE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
183
PHRM/CHRN/CDO/F56:40.00 MISCELLANEOUS GASTROINTESTINAL DRUGS (continued)
56:00 GASTROINTESTINAL DRUGS (continued)
NIZATIDINE (continued)
150MG
0224045 NOVO-NIZATIDINE 0.21 Y N Y YNOP /CP
0217771 PMS-NIZATIDINE 0.21 Y N Y YPMS /CP
0222015 APO-NIZATIDINE 0.21 Y N Y YAPX /CP
0077833 AXID 1.01 Y N Y YPHL /CP
300MG
0222016 APO-NIZATIDINE 0.38 Y N Y YAPX /CP
0224045 NOVO-NIZATIDINE 0.38 Y N Y YNOP /CP
0077834 AXID 1.5206 Y N Y YPHL /CP
0217772 PMS-NIZATIDINE 0.38 Y N Y YPMS /CP
OLSALAZINE SODIUM
250MG
0206380 DIPENTUM 0.56 Y Y Y YPHU /CP
OMEPRAZOLE
10MG
0223073 LOSEC TAB 1.86 Y E Y YAST /CP
0232942 MYLAN-OMEPRAZOLE 0.82 Y E Y YMYL /CP
0229643 SANDOZ-OMEPRAZOLE 0.82 Y E N YSDZ /CP
0229540 TEVA-OMEPRAZOLE 0.82 Y E N YTEV /TB
20MG
0232085 PMS-OMEPRAZOLE 0.41 Y E Y YPMS /CP
0224505 APO-OMEPRAZOLE 0.41 Y E Y YAPX /CP
0229644 SANDOZ-OMEPRAZOLE 0.41 Y E Y YSDZ /CP
0232943 MYLAN-OMEPRAZOLE 0.41 Y E Y YMYL /CP
0234869 SANIS-OMEPRAZOLE 0.41 Y E Y YSAN /CP
0241654 OMEPRAZOLE MAGNESIUM DR 0.41 Y E Y YACC /TB
0237487 RAN-OMEPRAZOLE 0.41 Y E Y YRAN /TB
0226086 RATIO-OMEPRAZOLE 0.41 Y E Y YRPH /TB
0229541 TEVA-OMEPRAZOLE 0.41 Y E Y YTEV /TB
0219091 LOSEC TAB 2.34 Y E Y YAST /TB
0231026 PMS-OMEPRAZOLE 0.41 Y E Y YPMS /TB
PANTOPRAZOLE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
184
PHRM/CHRN/CDO/F56:40.00 MISCELLANEOUS GASTROINTESTINAL DRUGS (continued)
56:00 GASTROINTESTINAL DRUGS (continued)
PANTOPRAZOLE (continued)
40MG
0222945 PANTOLOC 2.08 Y E Y YATA /TB
0228548 TEVA-PANTOPRAZOLE 0.36 Y E Y YTVM /TB
0229292 APO-PANTOPRAZOLE 0.36 Y E Y YAPX /TB
0229958 MYLAN-PANTOPRAZOLE 0.36 Y E Y YMYL /TB
0230048 CO-PANTOPRAZOLE 0.36 Y E Y YCOB /TB
0230108 SANDOZ-PANTOPRAZOLE 0.36 Y E Y YSDZ /TB
0226723 TECTA 0.75 Y E Y YNYC /TB
0230787 PMS-PANTOPRAZOLE 0.36 Y E Y YPMS /TB
0230870 RATIO-PANTOPRAZOLE 0.36 Y E Y YRTP /TB
0230504 RAN-PANTOPRAZOLE 0.36 Y E Y YRAN /TB
0237080 SANIS-PANTOPRAZOLE 0.36 Y E Y YSAN /TB
0240857 MYLAN-PANTOPRAZOLE T 0.19 Y E Y YMYL /TB
0241744 MINT-PANTOPRAZOLE 0.36 Y E Y YMNT /TB
PANTOPRAZOLE
40MG
0244062 TEVA-PANTOPRAZOLE MAGNESIUM 0.19 Y E Y YTVM /TB
RABEPRAZOLE
10MG
0235651 SANIS-RABEPRAZOLE 0.12 Y E Y YSAN /TB
0231417 SANDOZ RABEPRAZOLE 0.12 Y E Y YSDZ /TB
0224379 PARIET ECT 0.69 Y E Y YJAN /TB
0231080 PMS-RABEPRAZOLE 0.1204 Y E Y YPMS /TB
0229807 RAN-RABEPRAZOLE 0.12 Y E Y YRAN /TB
0229663 TEVA-RABEPRAZOLE 0.12 Y E Y YTVM /TB
20MG
0238174 PAT-RABEPRAZOLE 0.24 Y E Y YPAT /TB
0235653 SANIS-RABEPRAZOLE 0.24 Y E Y YSAN /TB
0234558 APO-RABEPRAZOLE 0.24 Y E Y YAPX /TB
0231418 SANDOZ RABEPRAZOLE 0.24 Y E Y YSDZ /TB
0229664 TEVA-RABEPRAZOLE 0.24 Y E Y YTVM /TB
0231081 PMS-RABEPRAZOLE 0.2408 Y E Y YPMS /TB
0229808 RAN-RABEPRAZOLE 0.24 Y E Y YRAN /TB
0224379 PARIET ECT 1.37 Y E Y YJAN /TB
RANITIDINE
15MG/ML
0228083 APO-RANITIDINE 0.15 Y N Y YAPX /ML
0224294 NOVO-RANIDINE ORAL SOLN 0.15 Y N Y YNVP /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
185
PHRM/CHRN/CDO/F56:40.00 MISCELLANEOUS GASTROINTESTINAL DRUGS (continued)
56:00 GASTROINTESTINAL DRUGS (continued)
RANITIDINE (continued)
150MG
0235301 SANIS-RANITIDINE 0.18 Y N Y NSAN /TB
0233648 RAN-RANITIDINE 0.18 Y N Y NRAN /TB
0224322 SANDOZ RANITIDINE 0.18 Y N Y NSDZ /TB
0073305 APO-RANITIDINE 0.18 Y N Y NAPX /TB
0224245 PMS-RANITIDINE 0.18 Y N Y NPMS /TB
0224159 SCHEINPHARM RANITIDINE 0.4042 Y N Y NSCN /TB
0221233 ZANTAC 0.18 Y N Y NGSK /TB
0224857 CO RANITIDINE 0.18 Y N Y NCOB /TB
0082882 RATIO-RANITIDINE 0.18 Y N Y NRTP /TB
0082856 TEVA-RANIDINE 0.18 Y N Y NTVM /TB
0220776 MYLAN-RANITIDINE 0.18 Y N Y NMYL /TB
25MG/ML
0225671 SDZ-RANITIDINE INJ 1.4 Y N Y YSDZ /ML
300MG
0235302 SANIS-RANITIDINE 0.36 Y N Y YSAN /TB
0224857 CO RANITIDINE 0.36 Y N Y YCOB /TB
0224245 PMS-RANITIDINE 0.36 Y N Y YPMS /TB
0082868 RATIO-RANITIDINE 0.36 Y N Y YRTP /TB
0082855 TEVA-RANIDINE 0.36 Y N Y YTVM /TB
0220778 MYLAN-RANITIDINE 0.36 Y N Y YMYL /TB
0073306 APO-RANITIDINE 0.36 Y N Y YAPX /TB
SUCRALFATE
1G
0212525 APO-SUCRALFATE 0.31 Y Y Y YAPX /TB
0204570 NOVO-SUCRALATE 0.31 Y Y Y YNOP /TB
0210062 SULCRATE 0.61 Y Y Y YHLR /TB
200MG/ML
0210356 SULCRATE PLUS ORAL SUSP 0.11 Y Y Y YHLR /ML
SULFASALAZINE
500MG
0206448 SALAZOPYRIN 0.32 Y Y Y YPHU /TB
0059846 PMS-SULFASALAZINE 0.23 Y Y Y YPMS /TB
500MG EC
0206447 SALAZOPYRIN EC 0.39 Y Y Y YPHU /TB
0059848 PMS-SULFASALAZINE EC 0.36 Y Y Y YPMS /TB
60:00 GOLD COMPOUNDS
60:00.00 GOLD COMPOUNDS -----------------------------------------------------------------
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
186
PHRM/CHRN/CDO/F60:00.00 GOLD COMPOUNDS
60:00 GOLD COMPOUNDS
AURANOFIN
AURANOFIN
3MG
0191682 RIDAURA 6.01 Y Y N YXED /CP
SODIUM
10MG/ML
0192762 MYOCHRYSINE (1ML) INJ 12.07 Y Y N YAVT /ML
0224545 SODIUM AUROTHIOMALATE(1ML) 9.66 Y Y N YSAB /ML
25MG/ML
0224545 SODIUM AUROTHIOMALATE(1ML) 14.05 Y Y N YSAB /ML
0192761 MYOCHRYSINE (1ML) INJ 14.67 Y Y N YAVT /ML
50MG/ML
0224545 SODIUM AUROTHIOMALATE(1ML) 18.21 Y Y N YSAB /ML
0192760 MYOCHRYSINE (1ML) INJ 23.01 Y Y N YAVT /ML
64:00 HEAVY METAL ANTAGONISTS
64:00.00 HEAVY METAL ANTAGONISTS --------------------------------------------------------
DEFERIPRONE
100MG/ML
0243652 FERRIPROX 3.036 E E N YAPX /ML
1000MG
0243655 FERRIPROX 30.36 E E N YAPP /TB
DEFEROXAMINE
500MG
0224205 PMS-DEFEROXAMINE VIAL 5.031 Y N N YPMS /VL
0198124 DESFERAL VIAL 15.19 Y N N YNVO /VL
PENICILLAMINE
250MG
0001605 CUPRIMINE 3.5 Y N N YMSD /CP
66:00 null
66:16.12 null -------------------------------------------------------------------------------
RALOXIFENE
60MG
0235884 COBALT-RALOXIFENE 0.458 Y E N YCOB /TB
68:00 HORMONES AND SUBSTITUTES
68:04.00 ADRENALS -----------------------------------------------------------------------
BECLOMETHASONE
100UG
0224203 QVAR INH 0.31 Y Y Y YMDA /DS
50UG
0224202 QVAR INH 0.15 Y Y Y YMDA /DS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
187
PHRM/CHRN/CDO/F68:04.00 ADRENALS (continued)
68:00 HORMONES AND SUBSTITUTES (continued)
BUDESONIDE
BUDESONIDE
0.125MG/ML
0222909 PULMICORT NEBUAMP (2ML) 0.44 Y Y N YAST /ML
0.25MG/ML
0197891 PULMICORT NEBUAMP (2ML) 0.87 Y Y N YAST /ML
0.5MG/ML
0197892 PULMICORT NEBUAMP (2ML) 1.74 Y Y N YAST /ML
100UG
0085207 PULMICORT TURBUHALER 0.16 Y Y Y YAST /DS
200UG
0085175 PULMICORT TURBUHALER 0.3158 Y Y Y YAST /DS
400UG
0085176 PULMICORT TURBUHALER 0.47 Y Y Y YAST /DS
CICLESONIDE
100UG/DS
0228560 ALVESCO 0.3795 Y Y N YNYC /DS
200UG/DS
0228561 ALVESCO 0.63 Y Y N YNYC /DS
50UG/DS
0230367 OMNARIS 0.21 Y N N YNYC /DS
0241731 APO-CICLESONIDE 0.18 Y N N YAPX /DS
CORTISONE ACETATE
25MG
0028043 CORTISONE 0.33 Y Y Y YICN /TB
DESAMETHASONE
0.5MG/5ML
0194689 PMS-DEXAMETHASONE ELIXER 0.38 Y Y Y YPMS /ML
DEXAMETHASONE
0.5MG
0224068 RATIO-DEXAMETHASONE 0.0782 Y Y Y YRTP /TB
0196497 PMS-DEXAMETHASONE 0.0782 Y Y Y YPMS /TB
0226108 APO-DEXAMETHASONE 0.0782 Y Y Y YAPX /TB
0.75MG
0196496 PMS-DEXAMETHASONE 0.48 Y Y Y YPMS /TB
0028547 DEXASONE 0.45 Y Y Y YICN /TB
2MG
0227936 PMS-DEXAMETHASONE 0.46 Y Y Y YPMS /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
188
PHRM/CHRN/CDO/F68:04.00 ADRENALS (continued)
68:00 HORMONES AND SUBSTITUTES (continued)
DEXAMETHASONE (continued)
4MG
0225005 APO-DEXAMETHASONE 0.3046 Y Y Y YAPX /TB
0048915 DEXASONE 0.81 Y Y Y YICN /TB
0196407 PMS-DEXAMETHASONE 0.3046 Y Y Y YPMS /TB
0224068 RATIO-DEXAMETHASONE 0.3046 Y Y Y YRTP /TB
DEXAMETHASONE 21-
4MG/ML
0197754 DEXAMETHASONE SOD PHO INJ 1.69 Y Y Y YCYT /ML
0220426 DEXAMETHASONE SOD PHO INJ 1.61 Y Y N YOME /ML
0066422 DEXAMETHASONE SOD PHO INJ 1.69 Y Y Y YSAB /ML
DEXAMETHASONE
10MG/ML
0078390 PMS-DEXAMETHASONE INJ 1.28 Y Y N YPMS /ML
DEXAMETHASONE
10MG/ML
0087458 SANDOZ-DEXAMETHASONE SOD 4.56 Y Y N YSDZ /ML
FLUDROCORTISONE
0.1MG
0208602 FLORINEF 0.26 Y Y Y YRBP /TB
FLUTICASONE
100UG/DS
0223724 FLOVENT DISKUS 0.4 Y Y Y YGSK /DS
125UG
0224429 FLOVENT HFA INHALER 0.34 Y Y Y YGSK /DS
250UG
0224429 FLOVENT HFA INHALER 0.69 Y Y Y YGSK /DS
250UG/DS
0223724 FLOVENT DISKUS 0.69 Y Y Y YGSK /DS
50UG
0224429 FLOVENT HFA INHALER 0.2 Y Y Y YGSK /DS
500UG/DS
0223724 FLOVENT DISKUS 1.17 Y Y Y YGSK /DS
HYDROCORTISONE
10MG
0003091 CORTEF 0.2 Y Y Y YPHU /TB
20MG
0003092 CORTEF 0.35 Y Y Y YPHU /TB
METHYLPREDNISOLONE
16MG
0003612 MEDROL 1 Y Y Y YPHU /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
189
PHRM/CHRN/CDO/F68:04.00 ADRENALS (continued)
68:00 HORMONES AND SUBSTITUTES (continued)
METHYLPREDNISOLONE (continued)
4MG
0003098 MEDROL 0.35 Y Y Y YPHU /TB
METHYLPREDNISOLONE
10MG/ML
0026042 DEPO-MEDROL W LIDOCANE INJ 6.13 Y Y N YPMS /ML
40MG/ML
0003075 DEPO-MEDROL (1ML) INJ 5.82 Y Y N YPHU /ML
0224540 METHYLPREDNISOLONE(1ML)INJ 4.1 Y Y N YSAB /ML
0224540 SDZ- METHYLPREDNISOLONE 40 4.1 Y Y N YSDZ /ML
80MG/ML
0224540 METHYLPREDNISOLONE(5ML)INJ 6.99 Y Y N YSDZ /ML
0003076 DEPO-MEDROL (1ML) INJ 9.7 Y Y N YPHU /ML
0224540 METHYLPREDNISOLONE(1ML)INJ 8.2 Y Y N YSAB /ML
80MG/ML PR
0193434 DEPO-MEDROL W PRESERV.(5ML)INJ 8.09 Y Y N YPHU /ML
METHYLPREDNISOLONE
1GM
0224122 METHYLPREDNISOLONE SOD INJ 34.41 Y Y N YNOP /VL
0003613 SOLU-MEDROL INJ 55.09 Y Y N YPHU /VL
0236797 SOLU-MEDROL 60.19 Y Y N YPFI /VL
0223275 METHYLPREDNISOLONE 1GM INJ 18.99 Y Y N YFAU /VL
PREDNISOLONE SODIUM
1MG/ML
0223061 PEDIAPRED ORAL LIQ 0.13 Y Y Y YAVT /ML
0224553 PMS-PREDNISOLONE ORAL SOLN 0.1 Y Y Y YPMS /ML
PREDNISONE
1MG
0027137 WINPRED 0.11 Y Y Y YICN /TB
0059819 APO-PREDNISONE 0.104 Y Y Y YAPX /TB
5MG
0002169 NOVO-PREDNISONE 0.04 Y Y Y YNOP /TB
0031277 APO-PREDNISONE 0.0401 Y Y Y YAPX /TB
50MG
0055095 APO-PREDNISONE 0.17 Y Y Y YAPX /TB
0023237 NOVO-PREDNISONE 0.17 Y Y Y YNOP /TB
TRIAMCINOLONE
20MG/ML
0219415 ARISTOSPAN INJ SUSP 6.17 Y Y Y YSTI /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
190
PHRM/CHRN/CDO/F68:04.00 ADRENALS (continued)
68:00 HORMONES AND SUBSTITUTES (continued)
TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE
10MG/ML
0199976 KENALOG 10 (5ML) INJ 3.29 Y Y Y YWSD /ML
0222954 TRIAMCINOLONE ACET. (5ML) INJ 2.68 Y Y Y YSAB /ML
40MG/ML
0222955 TRIAMCINOLONE ACET. (1ML) 4.38 Y Y Y YSAB /ML
0197756 TRIAMCINOLONE ACET. (1ML) INJ 5.5 Y Y Y YCYT /ML
0199986 KENALOG 40 (1ML) INJ 7.65 Y Y Y YWSD /ML
68:08.00 ANDROGENS ----------------------------------------------------------------------
DANAZOL
100MG
0201815 CYCLOMEN 1.37 Y N Y YSAW /CP
200MG
0201816 CYCLOMEN 2.2 Y N Y YSAW /CP
50MG
0201814 CYCLOMEN 0.93 Y N Y YSAW /CP
TESTOSTERONE
100MG/ML
0003078 DEPO-TESTOSTERONE OILY(10ML) 4.2 Y N N YPHU /ML
0224606 TESTOSTERONE CYP. OILY(10ML)IN 2.36 Y N N YSAB /ML
TESTOSTERONE
200MG/ML
0002924 DELATESTRYL OILY (ML)INJ 10.13 Y E N YPPZ /ML
TESTOSTERONE
40MG
0232249 PMS-TESTOSTERONE 0.47 Y N N YPMS /CP
0078232 ANDRIOL 0.94 Y N N YORG /CP
0242118 TARO-TESTOSTERONE 0.71 Y N N YTAR /CP
68:12.00 CONTRACEPTIVES -----------------------------------------------------------------
ETHINYL ESTRADIOL &
2.6/11.4MG
0225318 NUVARING 15.15 N N Y YSCP /EA
ETHINYL ESTRADIOL
.02/3MG
0232115 YAZ 0.57 N N Y YBAY /TB
ETHINYL
0.03/0.15MG
0241025 MIRVALA 28 0.28 N N Y YAPX /TB
21
0242081 RECLIPSEN 0.37 N N Y YACV /TB
0204248 MARVELON 0.84 N N Y YORG /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
191
PHRM/CHRN/CDO/F68:12.00 CONTRACEPTIVES (continued)
68:00 HORMONES AND SUBSTITUTES (continued)
ETHINYL ESTRADIOL/DESOGESTREL (continued)
28
0241746 RECLIPSEN 0.28 N N Y YACV /TB
0204253 ORTHO-CEPT 0.79 N N Y YJAN /TB
0204247 MARVELON 0.63 N N Y YORG /TB
ETHINYL
.02/3MG
0241538 MYA 0.42 N N Y YAPO /TB
21
0226172 YASMIN 21 0.57 N N Y YBAY /TB
28
0226173 YASMIN 28 0.43 N N Y YBAY /TB
ETHINYL
21
0046932 DEMULEN 30 0.6 N N Y YPHU /TB
28
0047152 DEMULEN 30 0.48 N N Y YPHU /TB
ETHINYL ESTRADIOL/L-
20/100MCG
0229854 AVIANE 28 0.27 N N Y YBAR /TB
0238788 ALYSENA 28 0.27 N N Y YBAR /TB
0223697 ALESSE 21 S 0.71 N N Y YWYA /TB
0223697 ALESSE 28 S 0.54 N N Y YWYA /TB
0229853 AVIANE 21 0.36 N N Y YBAR /TB
21
0204232 MIN-OVRAL 0.71 N N Y YWYA /TB
0229594 PORTIA 21 0.35 N N Y YAPX /TB
0070760 TRIQUILAR 0.74 N N Y YBEX /TB
28
0229595 PORTIA 28 0.26 N N Y YAPX /TB
0204233 MIN-OVRAL 0.53 N N Y YWYA /TB
0070750 TRIQUILAR 0.55 N N Y YBEX /TB
ETHINYL
21
0196844 CYCLEN 1.05 N N Y YJAN /TB
0202870 TRI-CYCLEN 1.05 N N Y YJAN /TB
28
0202942 TRI-CYCLEN 0.79 N N Y YJAN /TB
0199287 CYCLEN 0.79 N N Y YJAN /TB
0225858 TRI-CYCLEN LO 0.45 N N Y YJAN /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
192
PHRM/CHRN/CDO/F68:12.00 CONTRACEPTIVES (continued)
68:00 HORMONES AND SUBSTITUTES (continued)
ETHINYLESTRADIOL/LEVONORGESTRE
ETHINYLESTRADIOL/LEV
28(0.03/0.15)MG
0229665 SEASONALE 0.62 N N Y YTVM /TB
ETHINYLESTRADIOL/NO
21
0218710 SYNPHASIC 0.5 N N Y YPHU /TB
21 (0.5/35
0031704 ORTHO 0.5/35 1.05 N N Y YJAN /TB
0218708 BREVICON 0.55 N N Y YPHU /TB
21 (1.5/30
0029714 LOESTRIN 1.5/30 0.64 N N Y YPFI /TB
21 (1/20)
0031596 MINESTRIN 1/20 0.64 N N Y YPFI /TB
21 (1/35)
0218905 BREVICON 1/35 0.55 N N Y YPHU /TB
0037284 ORTHO 1/35 1.05 N N Y YJAN /TB
0219750 SELECT 1/35 0.37 N N Y YDIS /TB
21 (777)
0060295 ORTHO 7/7/7 1.05 N N Y YJAN /TB
28
0218711 SYNPHASIC 0.38 N N Y YPHU /TB
28 (0.5/35
0034073 ORTHO 0.5/35 0.79 N N Y YJAN /TB
0218709 BREVICON 0.41 N N Y YPHU /TB
0035302 LOESTRIN 1.5/30 0.48 N N Y YPFI /TB
28 (1/20)
0034383 MINESTRIN 1/20 0.48 N N Y YPFI /TB
28 (1/35)
0218906 BREVICON 1/35 0.41 N N Y YPHU /TB
0037283 ORTHO 1/35 0.79 N N Y YJAN /TB
0219929 SELECT 1/35 0.27 N N Y YDIS /TB
28 (777)
0060296 ORTHO 7/7/7 0.79 N N Y YJAN /TB
LEVONORGESTREL
0.75MG
0224167 PLAN B 8.6 N N Y YTEV /TB
13.5MG
0240829 JAYDESS 270.68 N N Y YBAY /EA
52MG
0224300 MIRENA INSERT 336.22 N N Y YBEX /EA
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
193
PHRM/CHRN/CDO/F68:12.00 CONTRACEPTIVES (continued)
68:00 HORMONES AND SUBSTITUTES (continued)
NORETHINDRONE
NORETHINDRONE
0.35MG
0003760 MICRONOR (28 ) 0.79 N N Y YJAN /TB
68:16.04 ESTROGENS ----------------------------------------------------------------------
CONJUGATED
0.3 MG
0204339 PREMARIN 0.3 Y N N YWYA /TB
0.3MG
0241467 PREMARIN 0.3 Y N N YPFI /TB
0.625 MG
0204340 PREMARIN 0.3 Y N N YWYA /TB
0.625MG
0026547 C.E.S. 0.1014 Y N N YICN /TB
0241468 PREMARIN 0.3 Y N N YPFI /TB
0.625MG/G
0204344 PREMARIN VAGINAL CREAM 0.64 Y N N YWYA /GM
1.25 MG
0204342 PREMARIN 0.3 Y N N YWYA /TB
1.25MG
0241469 PREMARIN 0.3 Y N N YPFI /TB
ESTRADIOL
0.39MG
0224567 ESTRADOT 25 2.67 Y N N YNVR /PT
0.585MG
0224399 ESTRADOT 37.5 2.68 Y N N YNVR /PT
0.780MG
0224696 SANDOZ-ESTRADIOL 2.41 Y N N YSDZ /PT
0224400 ESTRADOT 50 2.86 Y N N YNVR /PT
1.17MG
0224400 ESTRADOT 75 3.07 Y N N YNVR /PT
0224696 SANDOZ-ESTRADIOL 2.59 Y N N YSDZ /PT
1.56MG
0224400 ESTRADOT100 3.24 Y N N YNVR /PT
0224696 SANDOZ-ESTRADIOL 2.74 Y N N YSDZ /PT
10MCG
0232546 VAGIFEM VAG TABLET 3.72 Y N N YNOO /TB
ESTRADIOL &
0.06%
0223870 ESTROGEL TRANSDERMAL GEL SPR 0.42 Y N N YSCH /GM
0.5MG
0222519 ESTRACE 0.14 Y N N YRBP /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
194
PHRM/CHRN/CDO/F68:16.04 ESTROGENS (continued)
68:00 HORMONES AND SUBSTITUTES (continued)
ESTRADIOL & NORETHINDRONE (continued)
1MG
0214858 ESTRACE 0.26 Y N N YRBP /TB
140/50MCG
0224183 ESTALIS 3.23 Y N N YNVR /EA
2MG
0216889 ESTRING VAGINAL RING(7.5 69.73 Y N N YPHU /EA
0214859 ESTRACE 0.46 Y N N YRBP /TB
250/50MCG
0224183 ESTALIS 3.23 Y N N YNVR /EA
5UG/1MG
0224253 FEMHRT 1/5 0.74 Y N N YPFI /TB
ESTRADIOL
3.8MG
0223150 CLIMARA 50 5.25 Y N N YBAY /EA
68:16.12 ESTROGEN AGONIST-ANTAGONISTS ---------------------------------------------------
RALOXIFENE
60MG
0223902 EVISTA 1.88 Y E N YELI /TB
0227921 APO-RALOXIFENE 0.46 Y E N YAPX /TB
68:20.04 BIGUANIDES ---------------------------------------------------------------------
LINAGLIPTIN/METFORMI
2.5/1000MG
0240327 JENTADUETO 1.33 E E N YBOE /TB
2.5/500MG
0240325 JENTADUETO 1.33 E E N YBOE /TB
2.5/850MG
0240326 JENTADUETO 1.33 E E N YBOE /TB
METFORMIN/SAXAGLIPTI
1000/2.5MG
0238918 KOMBOGLYZE 1.27 E E N YAST /TB
500/2.5MG
0238916 KOMBOGLYZE 1.27 E E N YAST /TB
850/2.5MG
0238917 KOMBOGLYZE 1.27 E E N YAST /TB
68:20.05 DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS --------------------------------------
LINAGLIPTIN
5MG
0237092 TRAJENTA 2.55 E E N YBOE /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
195
PHRM/CHRN/CDO/F68:20.05 DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS
68:00 HORMONES AND SUBSTITUTES (continued)
SAXAGLIPTIN HCL
SAXAGLIPTIN HCL
2.5MG
0237584 ONGLYZA 2.4 E E N YAST /TB
5MG
0233355 ONGLYZA 2.86 E E N YAST /TB
68:20.08 INSULINS -----------------------------------------------------------------------
INSULIN LISPRO
100U/ML
0224029 HUMALOG MIX (10ML) 3.67 Y Y N YLIL /ML
INSULIN (REGULAR)
100U/ML
0222970 HUMALOG (10ML) 2.76 Y Y N YLIL /ML
0222970 HUMALOG CARTRIDGE (5X3ML) 3.63 Y Y N YLIL /ML
INSULIN ASPART
100U/ML
0224539 NOVORAPID VIAL (10ML) 2.9 Y Y N YNOO /ML
100U/ML PN
0224435 NOVORAPID PENFILL (5X3ML) 3.89 Y Y N YNOO /ML
0237720 NOVORAPID FLEXTOUCH 4.08 Y Y N YNOO /ML
INSULIN DETEMIR
100U/ML
0241282 LEVEMIR FLEXTOUCH 7.12 E E N YNOO /ML
0227184 LEVEMIR PENFILL 6.78 E E N YNOO /ML
INSULIN GLARGINE
100U/ML
0225193 LANTUS CARTRIDGE(5X3ML 6.09 E E N YAVT /ML
0224568 LANTUS INSULIN (10 ML VIAL) 6.11 E E N YAVT /ML
0229433 LANTUS SOLOSTAR (5X3ML 6.09 E E N YAVT /ML
INSULIN GLULISINE
100U/ML
0227947 APIDRA 3ML CARTRIDGE 3.28 Y Y N YSNF /ML
0227946 APIDRA 10ML VIAL 2.51 Y Y N YAVT /ML
INSULIN ISOPHANE
100U/ML
0240344 HUMULIN N KWIKPEN 3 Y Y N YLIL /ML
INSULIN ISOPHANE PORK
100 U/ML
0227586 HYPURIN NPH INSULIN 9.9 Y Y N YWHL /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
196
PHRM/CHRN/CDO/F68:20.08 INSULINS (continued)
68:00 HORMONES AND SUBSTITUTES (continued)
INSULIN LISPRO
INSULIN LISPRO
100U/ML
0240341 HUMALOG KWIKPEN 3.63 Y Y N YLIL /ML
INSULIN PORK
100 U/ML
0227587 HYPURIN REGULAR INSULIN 9.9 Y Y N YWHL /ML
INSULIN
100U/ML PN
0226543 NOVOMIX 30 PENFILL 3.66 Y Y N YNOO /ML
INSULIN(ISOPHANE)
100U/ML
0058773 HUMULIN-N (10ML) 2.25 Y Y N YLIL /ML
0202422 NOVOLIN GE NPH (10ML) 2.15 Y Y N YNOO /ML
100U/ML PN
0202426 NOVOLIN GE NPH PENFILL (5X3ML) 2.715 Y Y N YNOO /ML
0195923 HUMULIN-N CARTRIDGE (5X3ML) 3 Y Y N YLIL /ML
INSULIN(LENTE)HUMAN
100U/ML
0064614 HUMULIN-L (10ML) 1.638 Y Y N YLIL /ML
INSULIN(REG./ISOPHANE)
100U/ML
0202421 NOVOLIN GE 30/70 (10ML) 2.16 Y Y N YNOO /ML
0079587 HUMULIN 30/70 (10ML) 2.25 Y Y N YLIL /ML
0195921 HUMULIN 30/70 CARTRIDGE 3 Y Y N YLIL /ML
100U/ML PN
0202432 NOVOLIN GE 50/50 PENFILL 2.778 Y Y N YNOO /ML
0202431 NOVOLIN GE 40/60 PENFILL 2.778 Y Y N YNOO /ML
0202524 NOVOLIN GE 30/70 PENFILL 2.87 Y Y N YNOO /ML
INSULIN(REGULAR)
100U/ML
0058671 HUMULIN-R (10ML) 2.25 Y Y N YLIL /ML
0195922 HUMULIN-R CARTRIDGE (5X3ML) 3 Y Y N YLIL /ML
0202423 NOVOLIN GE TORONTO (10ML) 2.1 Y Y N YNOO /ML
100U/ML PN
0202428 NOVOLIN GE TORONTO PENFIL 2.725 Y Y N YNOO /ML
68:20.18 Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors ------------------------------
CANAGLIFLOZIN
100MG
0242548 INVOKANA 2.62 E E N YJAN /TB
300MG
0242549 INVOKANA 2.62 E E N YJAN /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
197
PHRM/CHRN/CDO/F68:20.18 Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors (continued)
68:00 HORMONES AND SUBSTITUTES (continued)
DAPAGLIFLOZIN
DAPAGLIFLOZIN
10MG
0243547 FORXIGA 2.62 E E N YAST /TB
5MG
0243546 FORXIGA 2.62 E E N YAST /TB
EMPAGLIFLOZIN
10MG
0244393 JARDIANCE 2.62 E E N YBOE /TB
25MG
0244394 JARDIANCE 2.62 E E N YBOE /TB
68:20.20 SULFONYLUREAS ------------------------------------------------------------------
ACARBOSE
100MG
0219089 GLUCOBAY 0.37 Y Y N YBAY /TB
50MG
0219088 GLUCOBAY 0.27 Y Y N YBAY /TB
CHLORPROPAMIDE
100MG
0039930 APO-CHLORPROPAMIDE 0.0745 Y Y N YAPX /TB
250MG
0031271 APO-CHLORPROPAMIDE 0.076 Y Y N YAPX /TB
GLICLAZIDE
30MG
0242976 ACT GLICLAZIDE MR 0.09 Y Y N YWHL /TB
0229779 APO-GLICLAZIDE MR 0.14 Y Y N YAPX /TB
0242328 MINT-GLICLAZIDE MR 0.14 Y Y N YMNT /TB
30MG ER
0224298 DIAMICRON MR 0.14 Y Y N YSEV /TB
60MG
0240712 APO-GLICLAZIDE MR 0.22 Y Y N YAPX /TB
0235642 DIAMICRON MR 0.25 Y Y N YSEV /TB
80MG
0224524 APO-GLICLAZIDE 0.09 Y Y N YAPX /TB
0228707 SANIS-GLICLAZIDE 0.09 Y Y N YSAN /TB
0076599 DIAMICRON 0.37 Y Y N YSEV /TB
0223810 TEVA-GLICLAZIDE 0.09 Y Y N YTVM /TB
0222951 MYLAN-GLICLAZIDE 0.09 Y Y N YMYL /TB
GLYBURIDE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
198
PHRM/CHRN/CDO/F68:20.20 SULFONYLUREAS (continued)
68:00 HORMONES AND SUBSTITUTES (continued)
GLYBURIDE (continued)
2.5MG
0191367 TEVA-GLYBURIDE 0.0321 Y Y N YTVM /TB
0080873 GEN-GLYBE 0.032 Y Y N YGPM /TB
0190092 RATIO-GLYBURIDE 0.0321 Y Y N YRTP /TB
0222455 DIABETA 0.14 Y Y N YAVT /TB
0191365 APO-GLYBURIDE 0.03 Y Y N YAPX /TB
5MG
0072094 EUGLUCON 0.0683 Y Y N YPMS /TB
0223673 PMS-GLYBURIDE 0.06 Y Y N YPMS /TB
0235046 SANIS-GLYBURIDE 0.06 Y Y N YSAN /TB
0080874 GEN-GLYBE 0.06 Y Y N YGPM /TB
0191368 TEVA-GLYBURIDE 0.06 Y Y N YTVM /TB
0191366 APO-GLYBURIDE 0.06 Y Y N YAPX /TB
0190093 RATIO-GLYBURIDE 0.057 Y Y N YRTP /TB
0222456 DIABETA 0.24 Y Y N YHLR /TB
TOLBUTAMIDE
500MG
0031276 APO-TOLBUTAMIDE 0.1089 Y Y N YAPX /TB
68:20.90 null -------------------------------------------------------------------------------
METFORMIN
850MG
0224682 SANDOZ METFORMIN FC 0.06 Y Y N YSDZ /TB
68:20.92 ANTI DIABETIC DRUGS ------------------------------------------------------------
GLUCAGON
1 MG
0224329 GLUCAGON POWDER (RDNA) 86.35 Y Y N YLIL /ML
METFORMIN
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
199
PHRM/CHRN/CDO/F68:20.92 ANTI DIABETIC DRUGS (continued)
68:00 HORMONES AND SUBSTITUTES (continued)
METFORMIN (continued)
500MG
0222951 GLYCON 0.1216 Y Y N YICN /TB
0204571 TEVA-METFORMIN 0.04 Y Y N YTVM /TB
0224682 SANDOZ-METFORMIN 0.04 Y Y N YSDZ /TB
0226903 RAN-METFORMIN 0.04 Y Y N YRAP /TB
0222356 PMS-METFORMIN 0.04 Y Y N YPMS /TB
0225772 CO METFORMIN 0.04 Y Y N YCOB /TB
0216778 APO-METFORMIN 0.04 Y Y N YAPX /TB
0214876 MYLAN-METFORMIN 0.04 Y Y N YMYL /TB
0235337 SANIS-METFORMIN 0.04 Y Y N YSAN /TB
0224297 RATIO-METFORMIN 0.04 Y Y N YRTP /TB
0209923 GLUCOPHAGE 0.25 Y Y N YHLR /TB
0237862 MAR-METFORMIN 0.04 Y Y N YMRC /TB
0238019 JAMP-METFORMIN 0.04 Y Y N YJPC
/TB
0238876 MINT-METFORMIN 0.04 Y Y N YMNT /null
850MG
0226905 RAN-METFORMIN 0.06 Y Y N YRAP /TB
0235338 SANIS-METFORMIN 0.06 Y Y N YSAN /TB
0225773 CO METFORMIN 0.06 Y Y N YCOB /TB
0224293 RATIO-METFORMIN 0.06 Y Y N YRTP /TB
0224258 PMS-METFORMIN 0.06 Y Y N YPMS /TB
0224279 METFORMIN 0.209 Y Y N YZYP /TB
0216284 GLUCOPHAGE 0.36 Y Y N YAVT /TB
0223921 GLYCON 0.209 Y Y N YVAE /TB
0223047 TEVA-METFORMIN 0.06 Y Y N YTVM /TB
0222978 APO-METFORMIN 0.06 Y Y N YAPX /TB
0222965 MYLAN-METFORMIN 850MG 0.06 Y Y N YMYL /TB
METFORMIN
850MG
0238877 MINT-METFORMIN 0.06 Y Y N YMNT /TB
PIOGLITAZONE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
200
PHRM/CHRN/CDO/F68:20.92 ANTI DIABETIC DRUGS (continued)
68:00 HORMONES AND SUBSTITUTES (continued)
PIOGLITAZONE (continued)
15MG
0232647 MINT-PIOGLITAZONE 0.58 E E N YMNT /TB
0230344 ACCEL PIOGLITAZONE 0.46 E E N YACC /TB
0224257 ACTOS 2.51 E E N YTAK /TB
0229790 SANDOZ PIOGLITAZONE 0.58 E E N YSDZ /TB
0227491 NOVO-PIOGLITAZONE 0.58 E E N YNOP /TB
0230312 PMS-PIOGLITAZONE 0.58 E E N YPMS /TB
0230294 APO-PIOGLITAZONE 0.5 E E N YAPX /TB
0230286 CO-PIOGLITAZONE 0.58 E E N YCOB /TB
0230142 RATIO-PIOGLITAZONE 0.58 E E N YRTP /TB
0239160 ACCORD-PIOGLITAZONE 0.58 E E N YWHL /TB
0237585 RAN-PIOGLITAZONE 0.58 E E N YRAN /TB
0229827 GEN-PIOGLITAZONE 0.58 E E N YGPM /TB
30MG
0232648 MINT-PIOGLITAZONE 0.81 E E N YMNT /TB
0233958 ACCORD-PIOGLITAZONE 0.81 E E N YWHL /TB
0237586 RAN-PIOGLITAZONE 0.81 E E N YRAN /TB
0227492 TEVA-PIOGLITAZONE 0.81 E E N YTVM /TB
0229791 SANDOZ PIOGLITAZONE 0.81 E E N YSDZ /TB
0229828 GEN-PIOGLITAZONE 0.81 E E N YGPM /TB
0230143 RATIO-PIOGLITAZONE 0.814 E E N YRTP /TB
0230288 CO-PIOGLITAZONE 0.81 E E N YCOB /TB
0230295 APO-PIOGLITAZONE 0.7 E E N YAPX /TB
0230313 PMS-PIOGLITAZONE 0.81 E E N YPMS /TB
0230345 ACCEL PIOGLITAZONE 0.65 E E N YACC /TB
0224257 ACTOS 3.51 E E N YTAK /TB
45MG
0224257 ACTOS 5.27 E E N YTAK /TB
0237587 RAN-PIOGLITAZONE 1.22 E E N YRAN /TB
0230297 APO-PIOGLITAZONE 1.05 E E N YAPX /TB
0230289 CO-PIOGLITAZONE 1.22 E E N YCOB /TB
0230145 RATIO-PIOGLITAZONE 1.22 E E N YRTP /TB
0229829 GEN-PIOGLITAZONE 1.22 E E N YGPM /TB
0229792 SANDOZ PIOGLITAZONE 1.22 E E N YSDZ /TB
0227493 NOVO-PIOGLITAZONE 1.22 E E N YNOP /TB
0230346 ACCEL PIOGLITAZONE 0.98 E E N YACC /TB
0230314 PMS-PIOGLITAZONE 1.22 E E N Ynull /TB
0233959 PIOGLITAZONE HYDROCHLORIDE 1.1 E E N YACD /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
201
PHRM/CHRN/CDO/F68:20.92 ANTI DIABETIC DRUGS (continued)
68:00 HORMONES AND SUBSTITUTES (continued)
REPAGLINIDE
REPAGLINIDE
0.5MG
0235492 PMS-REPAGLINIDE 0.1 Y Y N YPMS /TB
0232147 CO-REPAGLINIDE 0.1 Y Y N YCOB /TB
0235745 SDZ-REPAGLINIDE 0.1 Y Y N YSDZ /TB
0223992 GLUCONORM 0.32 Y Y N YNOO /TB
1MG
0232148 CO-REPAGLINIDE 0.1 Y Y N YCOB /TB
0223992 GLUCONORM 0.33 Y Y N YNOO /TB
0235746 SDZ-REPAGLINIDE 0.1 Y Y N YSDZ /TB
0235493 PMS-REPAGLINIDE 0.1 Y Y N YPMS /TB
2MG
0235748 SDZ-REPAGLINIDE 0.11 Y Y N YSDZ /TB
0235494 PMS-REPAGLINIDE 0.11 Y Y N YPMS /TB
0232149 CO-REPAGLINIDE 0.11 Y Y N YCOB /TB
0223992 GLUCONORM 0.34 Y Y N YNOO /TB
ROSIGLITAZONE
2MG
0224111 AVANDIA 1.3755 E E N YGSK /TB
4MG
0224111 AVANDIA 2.1584 E E N YGSK /TB
8MG
0224111 AVANDIA 3.0865 E E N YGSK /TB
SITAGLIPTIN
100MG
0230392 JANUVIA 2.98 E E N YMSD /TB
25MG
0238883 JANUVIA 2.98 E E N YMSD /TB
50MG
0238884 JANUVIA 2.98 E E N YMSD /TB
SITAGLIPTIN/METFORMI
50/1000MG
0233387 JANUMET 1.62 E E N YMDS /TB
0241679 JANUMET XR 1.62 E E N YMDS /TB
50/500MG
0233385 JANUMET 1.62 E E N YMDS /TB
50/850MG
0233386 JANUMET 1.62 E E N YMDS /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
202
PHRM/CHRN/CDO/F68:24.00 PARATHYROID
68:00 HORMONES AND SUBSTITUTES (continued)
CALCITONIN
68:24.00 PARATHYROID --------------------------------------------------------------------
200IU/ML
0192669 CALCIMAR INJ 28.29 E E N YAVT /ML
68:28.00 PITUITARY ----------------------------------------------------------------------
DESMOPRESSIN
0.1MG
0082430 D.D.A.V.P. 1.3217 E E Y YFEI /TB
0228773 NOVO-DESMOPRESSIN 0.33 E E Y YNOP /TB
0228403 APO-DESMOPRESSIN 0.33 E E Y YAPX /TB
0230436 PMS-DESMOPRESSIN 0.33 E E Y YPMS /TB
0.2MG
0082414 D.D.A.V.P. 2.6433 E E Y YFEI /TB
0228774 NOVO-DESMOPRESSIN 0.661 E E Y YNOP /TB
0228404 APO-DESMOPRESSIN 0.661 E E Y YAPX /TB
0230437 PMS-DESMOPRESSIN 0.661 E E Y YPMS /TB
10MCG/DS
0083636 D.D.A.V.P. (NASAL SPR) 1.916 E E Y YFEI /DS
0224246 AA-DESMOPRESSIN NASAL SPR 1.416 E E Y YAA /DS
0040251 D.D.A.V.P. (NASAL SOLN) 19.448 E E Y YFEI /EA
SOMATROPIN
1.6MG/SYR
0240181 GENOTROPIN 62.3 N Y N YPFI /null
10MG
0232507 OMNITROPE 207.73 N Y N YSDZ /VL
12MG
0224307 HUMATROPE INJ 560.04 N Y N YLIL /KT
12MG/PEN
0240171 GENOTROPIN 467.28 N Y N YPFI /null
24MG
0224307 HUMATROPE INJ 1120.08 N Y N YLIL /EA
3.33MG
0221513 SAIZEN (10IU) INJ KIT 147.07 N Y N YSRO /KT
5MG
0074562 HUMATROPE 1MG/ML (6X5ML)INJ 233.35 N Y N YLIL /KT
0223797 SAIZEN INJ 220.78 N Y N YSRO /KT
0232506 OMNITROPE 155.8 N Y N YSDZ /VL
6MG
0224307 HUMATROPE INJ 280.02 N Y N YLIL /EA
8.8MG
0227208 SAIZEN INJ CLK EZ 353.25 N Y N YSRO /VL
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
203
PHRM/CHRN/CDO/F68:32.00 PROGESTINS
68:00 HORMONES AND SUBSTITUTES (continued)
MEDROXYPROGESTERONE ACETATE
68:32.00 PROGESTINS ---------------------------------------------------------------------
10MG
0227729 APO-MEDROXY 0.17 Y N Y YAPX /TB
0072997 PROVERA 0.67 Y N Y YPHU /TB
0222130 NOVO-MEDRONE 0.17 Y N Y YNOP /TB
150MG/ML
0058509 DEPO-PROVERA (1ML) INJ 27.96 Y N Y YPHU /ML
2.5MG
0224472 APO-MEDROXY 0.04 Y N Y YAPX /TB
0070891 PROVERA 0.17 Y N Y YPHU /TB
0222128 NOVO-MEDRONE 0.04 Y N Y YNOP /TB
5MG
0222129 NOVO-MEDRONE 0.08 Y N Y YNOP /TB
0003093 PROVERA 0.33 Y N Y YPHU /TB
0224472 APO-MEDROXY 0.08 Y N Y YAPX /TB
50MG/ML
0003084 DEPO-PROVERA (5ML) INJ 5.42 Y N Y YPHU /ML
PROGESTERONE
100MG
0216670 PROMETRIUM 1.5 Y N N YSCH /CP
68:36.04 THYROID AGENTS -----------------------------------------------------------------
LEVOTHYROXINE
0.025MG
0217206 SYNTHROID 0.08 Y Y N YABB /TB
0.05 MG
0217207 SYNTHROID 0.06 Y Y N YABB /TB
0221319 ELTROXIN 0.03 Y Y N YGSK /TB
0.075MG
0217208 SYNTHROID 0.09 Y Y N YABB /TB
0.088MG
0217209 SYNTHROID 0.09 Y Y N YABB /TB
0.1 MG
0221320 ELTROXIN 0.04 Y Y N YGSK /TB
0217210 SYNTHROID 0.07 Y Y N YABB /TB
0.112MG
0217122 SYNTHROID 0.1 Y Y N YABB /TB
0.125MG
0217211 SYNTHROID 0.1 Y Y N YABB /TB
0.137MG
0223385 SYNTHROID 0.17 Y Y N YABB /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
204
PHRM/CHRN/CDO/F68:36.04 THYROID AGENTS (continued)
68:00 HORMONES AND SUBSTITUTES (continued)
LEVOTHYROXINE (SODIUM) (continued)
0.15 MG
0217212 SYNTHROID 0.07 Y Y N YABB /TB
0221321 ELTROXIN 0.04 Y Y N YGSK /TB
0.175MG
0217213 SYNTHROID 0.11 Y Y N YABB /TB
0.2 MG
0221322 ELTROXIN 0.04 Y Y N YGSK /TB
0217214 SYNTHROID 0.08 Y Y N YABB /TB
0.3 MG
0221323 ELTROXIN 0.064 Y Y N YGSK /TB
0.3MG
0217215 SYNTHROID 0.12 Y Y N YABB /TB
LIOTHYRONINE SODIUM
25UG
0191946 CYTOMEL 1.39 Y Y N YGSK /TB
5UG
0191945 CYTOMEL 12.82 Y Y N YGSK /TB
68:36.08 ANTITHYROID AGENTS -------------------------------------------------------------
METHIMAZOLE
10MG
0229603 TAPAZOLE 0.53 Y Y N YLIL /TB
5MG
0001574 TAPAZOLE 0.27 Y Y N YLIL /TB
PROPYLTHIOURACIL
100MG
0001021 PROPYL-THYRACIL 0.36 Y Y Y YMSD /TB
50MG
0001020 PROPYL-THYRACIL 0.23 Y Y Y YMSD /TB
68:60.00 null -------------------------------------------------------------------------------
THYROTROPIN
0.9MG/ML
0224601 THYROGEN 1715.9 Y Y N YGDI /ML
80:00 SERUMS, TOXOIDS AND VACCINES
80:12.00 VACCINES -----------------------------------------------------------------------
BACILLUS CALMETTE-
50MG/DS
0215351 ONCOTICE 260.13 E E N YMSD /MG
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
205
PHRM/CHRN/CDO/F84:04.04 ANTIBIOTICS
84:00 SKIN AND MUCOUS MEMBRANE AGENTS
BENZOYL PEROXIDE CLINDAMYCIN
84:00 SKIN AND MUCOUS MEMBRANE AGENTS
50MG/G/10M
0224847 BENACLIN 0.95 N N Y YSAV /GM
BENZOYL PEROXIDE/
50/10MG/GM
0224315 CLINDOXYL TOPICAL GEL 0.91 Y N Y YSTI /GM
BENZOYL PEROXIDE/
50MG/30MG/
0222527 BENZAMYCIN TOPICAL GEL 0.942 N N Y YSAN /GM
BENZOYL
3%/1%W/W
0238282 CLINDOXYL ADV GEL 0.86 N N Y YGSK /GM
CLINDAMYCIN
1% SOLN
0226693 TARO CLINDAMYCIN 0.2262 Y N Y YTAR /ML
0058230 DALACIN T TOPICAL 0.33 Y N Y YPHU /ML
20MG/GM
0206060 DALACIN VAGINAL CREAM 0.76 Y N Y YPMS /ML
CLINDAMYCIN/BENZOYL
1/5%
0244018 TARO-CLINDAMYCIN/BENZOYL 0.78 N N Y YTAR /GM
FRAMYCETIN SO4
1% GAUZE
0198884 SOFRA-TULLE (10CM X 10CM) 1.03 Y N Y YHLR /EA
0198768 SOFRA-TULLE (30CM X 10CM) 3.6 Y N Y YHLR /EA
FUSIDIC ACID
2% CRM
0058666 FUCIDIN TOPICAL CREAM 0.69 Y N Y YLEO /GM
2% OINT
0058667 FUCIDIN TOPICAL OINTMENT 0.69 Y N Y YLEO /GM
FUSIDIC ACID 2%
2% /1%CRM
0223857 FUCIDIN H TOPICAL CREAM 1.26 Y Y Y YLEO /GM
GENTAMICIN
1MG/GM
0080538 RATIO-GENTAMICIN CREAM 0.44 Y N Y YRTP /GM
1MG/GM OINT
0080502 RATIO-GENTAMICIN OINTMENT 0.43 Y N Y YRTP /GM
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
206
PHRM/CHRN/CDO/F84:04.04 ANTIBIOTICS (continued)
84:00 SKIN AND MUCOUS MEMBRANE AGENTS (continued)
MUPIROCIN
MUPIROCIN
2% CRM
0223975 BACTROBAN CREAM 0.55 Y N Y YGSK /GM
2% OINT
0227998 TARO-MUPIROCIN OINT 0.44 Y N Y YTAR /GM
0191694 BACTROBAN OINTMENT 0.55 Y N Y YGSK /GM
POLYMYX/NEOMYCIN/B
5000U//G
0066612 NEOSPORIN TOPICAL OINTMENT 0.47 Y N Y YGSK /GM
84:04.06 ANTIVIRALS ---------------------------------------------------------------------
ACYCLOVIR
5%
0203952 ZOVIRAX CREAM 13.18 Y N Y YGSK /GM
5% OINT
0056977 ZOVIRAX OINTMENT 13.18 Y N Y YGSK /GM
84:04.08 ANTIFUNGALS --------------------------------------------------------------------
CICLOPIROX OLAMINE
1%
0222180 LOPROX TOPICAL CREAM 0.31 Y N Y YHLR /GM
0222181 LOPROX TOPICAL LOTION 0.32 Y N Y YHLR /ML
1.5%
0224722 STIEPROX SHAMPOO 0.13 Y N Y YGSK /ML
CLOTRIMAZOLE
1%
0081238 CLOTRIMADERM TOP CRM 1% 0.22 Y N Y NTAR /GM
0081236 CLOTRIMADERM VAGINAL CREAM 0.19 Y N Y NTAR /GM
0223943 CANESTEN EXTERNAL CREAM 0.377 Y N Y NBCD /GM
0215086 CANESTEN TOPICAL CREAM 0.3 Y N Y NBCD /GM
0215089 CANESTEN-6 VAGINAL CREAM 0.24 Y N Y NBCD /GM
0222938 CLOTRIMAZOLE TOP CRM 1% 0.21 Y N Y NTAR /GM
0222937 CLOTRIMAZOLE VAG CR 1% 0.13 Y N Y NSAI /GM
2%
0215090 CANESTEN-3 VAGINAL CREAM 0.49 Y N Y NBCD /GM
0222937 CLOTRIMAZOLE VAGINAL CREAM 0.34 Y N Y NTAR /GM
0081237 CLOTRIMADERM VAGINAL CREAM 0.39 Y N Y NTAR /GM
500MG
0215094 CANESTEN-1-COMBI-PAK 12.08 Y N Y NBCD /GM
KETOCONAZOLE
2%
0224566 KETODERM TOPICAL CREAM 0.32 Y N Y YTAR /GM
0218292 NIZORAL SHAMPOO 0.09 N N Y NMCL /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
207
PHRM/CHRN/CDO/F84:04.08 ANTIFUNGALS (continued)
84:00 SKIN AND MUCOUS MEMBRANE AGENTS (continued)
MICONAZOLE NITRATE
MICONAZOLE NITRATE
100MG
0212625 MONISTAT 7 DUOPAK 13.76 Y N Y YMCL /PK
2%
0212656 MONISTAT DERM CREAM TOPICAL 0.35 Y N Y NMCL /GM
0208430 MONISTAT-7 VAGINAL CREAM 0.34 Y N Y NMCL /GM
0208585 MICATIN TOPICAL CREAM 0.3 Y N Y NMCL /GM
0223110 MICOZOLE 0.26 Y N Y NTAR /GM
4%
0224400 MONISTAT 3 VAGINAL CREAM 0.8 Y N Y NMCL /GM
400MG
0212624 MONISTAT 3 COMBINATION 13.76 Y N Y NMCL /PK
0217177 MICONAZOLE 3 DAY OVULE 4.8 Y N Y NSDM /PK
0212660 MONISTAT-3 VAGINAL OVULES 4.01 Y N Y NMCL /PK
NYSTATIN
100000U/G
0071687 NYADERM TOPICAL CREAM 0.07 Y N Y NTAR /GM
0071689 NYADERM TOPICAL OINTMENT 0.0903 Y N Y NTAR /GM
0219423 RATIO-NYSTATIN TOPICAL CREAM 0.06 Y N Y NRTP /GM
0219416 RATIO-NYSTATIN VAGINAL CREAM 0.32 Y N Y YRTP /GM
100000U/G OINT
0219422 RATIO-NYSTATIN TOPICAL 0.12 Y N Y NRTP /GM
25000U/G
0071690 NYADERM VAGINAL CREAM 0.13 Y N Y YTAR /GM
TERBINAFINE HCL
1%
0203109 LAMISIL TOPICAL CREAM 0.53 Y N Y YNVR /GM
10MG/GM
0223870 LAMISIL SPRAY 0.54 Y N Y YNVR /GM
TERCONAZOLE
0.4%
0224765 TARO-TERCONAZOLE VAG CRM 0.46 Y N Y YTAR /GM
0089472 TERAZOL-7 VAGINAL CREAM (PKG) 0.64 Y N Y YJAN /GM
80MG
0213087 TERAZOL-3 DUAL-PAK 9.21 Y N Y YJAN /EA
84:04.12 SCABICIDES AND PEDICULICIDES ---------------------------------------------------
CROTAMITON
10%
0062337 EURAX TOPICAL CREAM 0.3584 Y N Y NCLC /GM
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
208
PHRM/CHRN/CDO/F84:04.12 SCABICIDES AND PEDICULICIDES
84:00 SKIN AND MUCOUS MEMBRANE AGENTS (continued)
PERMETHRIN
PERMETHRIN
1%
0077136 NIX CREME RINSE 0.159 N N Y NINS /ML
0223148 KWELLADA-P CREME RINSE 0.2328 N N Y NGCH /ML
5%
0221990 NIX DERMAL CREAM 0.5 N N Y NGCH /GM
0223134 KWELLADA-P TOPICAL LOTION 0.5053 N N Y NGCH /ML
PETROLEUM DISTILLATE
0.33//%
0212544 R&C SHAMPOO/CONDITIONER 0.09 N N Y NGCH /ML
84:04.16 MISCELLANEOUS ANTI-INFECTIVES --------------------------------------------------
METRONIDAZOLE
0.75%
0222683 METROCREAM TOPICAL CREAM 0.66 Y N Y YGAC /GM
0209283 METROGEL TOPICAL GEL 1.26 Y N Y YGAC /GM
0212522 NIDAGEL VAGINAL GEL 0.3 Y N Y YFEI /GM
0224820 METROLOTION 0.526 Y N Y YGAC /ML
1%
0229780 METROGEL TOPICAL GEL 0.64 Y N Y YGAC /GM
0215609 NORITATE TOPICAL CREAM 0.57 Y N Y YDER /GM
10%
0192686 FLAGYL VAGINAL CREAM 0.24 Y N Y YAVT /GM
10MG/GM
0224291 ROSASOL CREAM 0.53 Y N N YSTI /GM
500MG
0192682 FLAGYSTATIN VAGINAL OVULE 3.2 Y N Y YAVT /TB
500/4.5GM
0192684 FLAGYSTATIN CRM 0.58 Y N Y YAVT /GM
SILVER SULFADIAZINE
1%
0032309 FLAMAZINE CREAM TUBE 0.13 Y N Y YSNI /GM
SULFACETAMIDE/COLLO
10%/5%
0222040 SULFACET-R TOPICAL LOTION 1.02 Y N Y YDER /GM
84:06.00 ANTI-INFLAMMATORY AGENTS -------------------------------------------------------
AMCINONIDE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
209
PHRM/CHRN/CDO/F84:06.00 ANTI-INFLAMMATORY AGENTS (continued)
84:00 SKIN AND MUCOUS MEMBRANE AGENTS (continued)
AMCINONIDE (continued)
0.1%
0224709 RATIO-AMCINONIDE TOPICAL 0.19 Y Y Y YRPH /GM
0224671 TARO-AMCINONIDE CREAM 0.1% 0.19 Y Y Y YTAR /GM
0219228 CYCLOCORT TOPICAL CREAM 0.42 Y Y Y YSTI /GM
0219227 CYCLOCORT TOPICAL LOTION 0.35 Y Y Y YSTI /ML
0224709 RATIO-AMCINONIDE LOTION 0.4 Y Y Y YRTP /ML
0.1% OINT
0219226 CYCLOCORT TOPICAL OINTMENT 0.42 Y Y Y YSTI /GM
BECLOMETHASONE
0.025%
0208960 PROPADERM TOPICAL CREAM 0.43 Y Y Y YRBP /GM
BETAMETHASONE
0.05%/1%
0061117 LOTRIDERM TOPICAL CREAM 0.92 Y Y Y YSCH /GM
0.05%/2%
0224568 RATIO-DIPROSALIC TOPICAL LOTIO 0.52 Y Y Y YRTP /ML
0057842 DIPROSALIC TOPICAL LOTION 0.52 Y Y Y YSCH /ML
0.05%/3% O
0057843 DIPROSALIC TOPICAL OINTMENT 1.05 Y Y Y YSCH /GM
BETAMETHASONE
0.05%
0068862 DIPROLENE TOPICAL GLYCOL 0.5187 Y Y Y YSCH /GM
0192535 TARO-SONE TOPICAL CREAM 0.2 Y Y Y YTAR /GM
0084965 RATIO-TOPILENE TOPICAL GLY CR 0.5187 Y Y Y YRTP /GM
0080499 RATIO-TOPISONE CRM 0.2 Y Y Y YRTP /GM
0032307 DIPROSONE TOPICAL CREAM 0.2 Y Y Y YSCH /GM
0192791 RATIO-TOPILENE TOP GLY LOT 0.27 Y Y Y YRTP /ML
0086297 DIPROLENE TOPICAL GLYCOL 0.27 Y Y Y YSCH /ML
0080918 RATIO-TOPISONE TOPICAL LOTION 0.198 Y Y Y YRTP /ML
0194444 TARO-SONE TOPICAL LOTION 0.198 Y Y Y YTAR /ML
0041724 DIPROSONE TOPICAL LOTION 0.198 Y Y Y YSCH /ML
0.05% OINT
0084966 RATIO-TOPILENE TOPICAL GYL OT 0.5187 Y Y Y YRTP /GM
0080500 RATIO-TOPISONE TOPICAL 0.22 Y Y Y YRTP /GM
0062936 DIPROLENE TOPICAL GYLCOL OINT 0.5187 Y Y Y YSCH /GM
0034492 DIPROSONE TOPICAL OINTMENT 0.22 Y Y Y YSCH /GM
BETAMETHASONE
0.05%
0071661 BETADERM TOPICAL CREAM 0.06 Y Y Y YTAR /GM
0053542 RATIO-ECTOSONE MILD TOPICAL 0.06 Y Y Y YRTP /GM
0065320 RATIO-ECTOSONE TOPICAL 0.26 Y Y Y YRTP /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
210
PHRM/CHRN/CDO/F84:06.00 ANTI-INFLAMMATORY AGENTS (continued)
84:00 SKIN AND MUCOUS MEMBRANE AGENTS (continued)
BETAMETHASONE VALERATE (continued)
0.05% OINT
0071664 BETADERM TOPICAL OINTMENT 0.06 Y Y Y YTAR /GM
0.1%
0071662 BETADERM TOPICAL CREAM 0.1 Y Y Y YTAR /GM
0053543 RATIO-ECTOSONE REG TOPICAL CR 0.1 Y Y Y YRTP /GM
0065321 RATIO-ECTOSONE SCALP LOTION 0.09 Y Y N YRTP /ML
0071663 BETADERM SCALP LOTION 0.09 Y Y Y YTAR /ML
0002794 VALISONE SCALP LOTION 0.09 Y Y Y YSCH /ML
0075005 RATIO-ECTOSONE TOPICAL 0.317 Y Y Y YRTP /ML
0.1% OINT
0071665 BETADERM TOPICAL OINTMENT 0.09 Y Y Y YTAR /GM
CLOBETASOL
0.05%
0223219 PMS-CLOBETASOL CREAM 0.3 Y Y Y YPMS /GM
0191027 RATIO-CLOBETASOL TOPICAL 0.23 Y Y Y YRTP /GM
0224552 TARO-CLOBETASOL TOPICAL CRM 0.26 Y Y Y YTAR /GM
0202418 GEN-CLOBETASOL CRM 0.05% 0.23 Y Y Y YGPM /GM
0209316 NOVO-CLOBETASOL TOPICAL 0.23 Y Y Y YNOP /GM
0191029 RATIO-CLOBETASOL SCALP APP 0.2 Y Y Y YRTP /ML
0221328 DERMOVATE SCALP APPLICATION 0.72 Y Y Y YGSK /ML
0224552 TARO-CLOBETASOL TOICAL 0.25 Y Y Y YTPM /ML
0221621 GEN-CLOBETASOL SCALP APP 0.2 Y Y Y YGPM /ML
0.05% OINT
0223219 PMS-CLOBETASOL OINTMENT 0.375 Y Y Y YPMS /GM
0212619 NOVO-CLOBETASOL TOPICAL 0.23 Y Y Y YNOP /GM
0191028 RATIO-CLOBETASOL TOPICAL 0.23 Y Y Y YRTP /GM
0224552 TARO-CLOBETASOL TOPICAL OINT 0.23 Y Y Y YTAR /GM
0202676 GEN-CLOBETASOL OINTMENT 0.23 Y Y Y YGPM /GM
CLOBETASONE
0.05%
0221441 EUMOVATE TOPICAL CREAM 0.38 Y Y Y YGSK /GM
DESONIDE
0.05%
0222931 PMS-DESONIDE TOPICAL CREAM 0.33 Y Y Y YPMS /GM
0215486 TRIDESILON TOPICAL CREAM 0.388 Y Y Y YBAY /GM
0211551 DESOCORT TOPICAL LOTION 0.25 Y Y Y YGAC /ML
0.05% OINT
0215487 TRIDESILON TOPICAL OINTMENT 0.3867 Y Y Y YBAY /GM
0222932 PMS-DESONIDE TOPICAL 0.31 Y Y Y YPMS /GM
0211552 DESOCORT TOPICAL OINTMENT 0.315 Y Y Y YGAC /GM
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
211
PHRM/CHRN/CDO/F84:06.00 ANTI-INFLAMMATORY AGENTS (continued)
84:00 SKIN AND MUCOUS MEMBRANE AGENTS (continued)
DESOXIMETASONE
DESOXIMETASONE
0.05%
0222191 TOPICORT MILD TOPICAL CREAM 0.42 Y Y Y YHLR /GM
0223906 DESOXI TOPICAL CREAM 0.2785 Y Y Y YOPT /GM
0.25%
0222189 TOPICORT TOPICAL CREAM 0.63 Y Y Y YHLR /GM
DIFLUCORTOLONE
0.1%
0058782 NERISONE TOPICAL CREAM 0.394 Y Y Y YSTI /GM
0058781 NERISONE TOPICAL OILY CREAM 0.394 Y Y Y YSTI /GM
0.1% OINT
0058783 NERISONE TOPICAL OINTMENT 0.386 Y Y Y YSTI /GM
FLUMETHASONE
3.0/0.02%
0007446 LOCACORTEN VIOFORM TOP CR 0.91 Y N Y YPAL /ML
FLUOCINOLONE
0.01%
0071678 FLUODERM TOPICAL CREAM 0.0694 Y Y Y YTAR /GM
0087329 DERMA SMOOTH/FS LIQ 0.28 Y Y Y YHIL /ML
0.01%SOL
0216250 SYNALAR TOPICAL 0.41 Y Y Y YMDC /ML
0.025%
0071679 FLUODERM TOPICAL CREAM 0.31 Y Y Y YTAR /GM
0.025% OIN
0216251 SYNALAR REG TOPICAL OINTMENT 0.43 Y Y Y YMDC /GM
0071681 FLUODERM TOPICAL OINTMENT 0.0889 Y Y Y YTAR /GM
0.1% SHP
0224273 CAPEX SHAMPOO 0.72 Y Y Y YGAC /ML
FLUOCINONIDE
0.05%
0071686 LYDERM TOPICAL CREAM 0.24 Y Y Y YTAR /GM
0216192 LIDEX TOPICAL CREAM 0.24 Y Y Y YMDC /GM
0216315 LIDEMOL IN EMOLLIENT BASE 0.2 Y Y Y YMDC /GM
0.05% GEL
0223699 LYDERM TOPICAL GEL 0.31 Y Y Y YTAR /GM
0216197 LIDEX GEL 0.05% 0.31 Y Y Y YMDC /GM
0.05% OINT
0216196 LIDEX TOPICAL OINTMENT 0.3 Y Y Y YHLR /GM
0223699 LYDERM TOPICAL OINTMENT 0.3 Y Y Y YTAR /GM
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
212
PHRM/CHRN/CDO/F84:06.00 ANTI-INFLAMMATORY AGENTS (continued)
84:00 SKIN AND MUCOUS MEMBRANE AGENTS (continued)
HALOBETASOL
HALOBETASOL
0.05%
0196270 ULTRAVATE CREAM 0.91 E E N YWSD /GM
0.05% OINT
0196272 ULTRAVATE OINTMENT 0.05% 0.88 E E N YWSD /GM
HYDROCORTISONE
0.5% CRM
0071682 HYDERM TOPICAL CREAM 0.189 Y N Y NTAR /GM
0051328 CORTATE TOPICAL CREAM 0.1333 Y N N NSCH /GM
0.5% OINT
0071668 CORTODERM TOPICAL OINTMENT 0.155 Y N Y NTAR /GM
1%
0019260 EMO-CORT TOPICAL LOTION 0.16 Y N Y NSTI /ML
0057854 SARNA HC TOPICAL LOTION 0.094 Y N Y NSTI /ML
1% CRM
0019259 EMO-CORT TOPICAL CREAM 0.17 Y N Y NSTI /GM
0071683 HYDERM TOPICAL CREAM 0.09 Y N Y NTAR /GM
1% OINT
0071669 CORTODERM TOPICAL OINTMENT 0.04 Y Y Y YTAR /GM
2%
0074983 TOPIDERM HC 2% TOPICAL CREAM 0.29 Y N Y YTPI /GM
2.5%
0059579 EMO-CORT TOPICAL CREAM 0.2 Y Y Y YSTI /GM
0059580 EMO-CORT TOPICAL LOTION 0.21 Y Y Y YSTI /ML
0085671 SARNA HC TOPICAL LOTION 0.18 Y Y Y YSTI /ML
20/50GM
0007450 VIOFORM HYDROCORTISONE 0.86 Y N Y YNVR /GM
HYDROCORTISONE
0.5/.5%ZIN
0212844 ANODAN-HC OINTMENT 0.39 Y N Y YODN /GM
0060778 HEMCORT HC OINTMENT 0.39 Y N Y YTEC /GM
0224769 SANDOZ ANUZINC HC 0.38 Y N Y YSDZ /GM
0050577 ANUSOL HC OINTMENT 0.76 Y N Y YPFI /GM
0.5/1/0.5%ZINC
0223446 PROCTODAN-HC OINTMENT 0.73 Y N Y YODN /GM
0050578 ANUGESIC HC OINTMENT 0.91 Y N Y YPFI /GM
10%
0057933 CORTIFOAM 6.54 Y Y Y YGSK /GM
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
213
PHRM/CHRN/CDO/F84:06.00 ANTI-INFLAMMATORY AGENTS (continued)
84:00 SKIN AND MUCOUS MEMBRANE AGENTS (continued)
HYDROCORTISONE ACETATE (continued)
10/10MG ZINC
0047628 ANUSOL HC SUPOSITORIES 1 Y N Y YPFI /SP
0223639 ANODAN-HC SUPPOSITORIES 0.58 Y N Y YODN /SP
0060779 HEMCORT HC SUPPOSITORIES 0.58 Y N Y YTEC /SP
0224279 SAB-ANUZINC HC SUPPOSITORIES 0.58 Y N Y YSDZ /SP
10/20/10MG
0224085 PROCTODAN-HC SUPP 0.78 Y N Y YODA /SP
0047624 ANUGESIC HC SUPP 1.37 Y N Y YPFI /SP
1%/1%
0036301 PROCTOFOAM-HC 1.71 Y N Y YGCH /GM
5/5/10/10MG FRAMYC
0222325 PROCTOSEDYL OINTMENT 0.83 Y N Y YAVT /GM
0224732 PROCTOL OINTMENT 0.4 Y N Y YODN /GM
0224252 SAB-PROCTOMYXIN HC OINT 0.4 Y N Y YSAB /GM
0222638 RATIO-PROCTOSONE OINTMENT 0.4 Y N Y YRPH /GM
0224788 PROCTOL SUPPOS 0.6 Y N Y YODN /SP
0222326 PROCTOSEDYL SUPPOS 1.09 Y N Y YAVT /SP
0224252 SAB-PROCTOMYXIN HC SUPPOS 0.6 Y N Y YSAB /SP
0222639 RATIO-PROCTOSONE SUPPOS 0.6 Y N Y YRPH /SP
HYDROCORTISONE
0.2%
0224298 HYDROVAL CR TOPICAL CREAM 0.17 Y Y Y YOPT /GM
0.2% OINT
0224298 HYDROVAL OINTMENT TOP OINT 0.17 Y Y Y YOPT /GM
HYDROCORTISONE/PRA
1%/1%
0077095 PRAMOX HC TOPICAL CREAM 0.44 N N Y NDPL /GM
MOMETASONE FUROATE
0.1%
0085174 ELOCOM TOPICAL CREAM 0.68 Y Y Y YSCH /GM
0236715 TARO-MOMETASONE TOPICAL 0.57 Y Y Y YTAR /GM
0226638 TARO-MOMETASONE LOTION 0.34 Y Y Y YTAR /ML
0087109 ELOCOM TOPICAL LOTION 0.48 Y Y Y YSCH /ML
0.1% OINT
0224476 PMS-MOMETASONE TOPICAL 0.3493 Y Y Y YPMS /GM
0226474 TARO-MOMETASONE TOPICAL 0.28 Y Y Y YTAR /GM
0085173 ELOCOM TOPICAL OINTMENT 0.61 Y Y Y YSCH /GM
0224813 RATIO-MOMETASONE TOPICAL 0.57 Y Y Y YRPH /GM
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
214
PHRM/CHRN/CDO/F84:06.00 ANTI-INFLAMMATORY AGENTS (continued)
84:00 SKIN AND MUCOUS MEMBRANE AGENTS (continued)
NEOMYC/GRAM/NYS/TRIAMCINOLONE
NEOMYC/GRAM/NYS/TR
2.5//G CRM
0071700 VIADERM-KC 0.24 Y N Y YTAR /GM
2.5//G OINT
0071702 VIADERM-KC 0.47 Y N Y YTAR /GM
0055050 RATIO-TRIACOMB REG CRM 0.226 Y N Y YRTP /GM
POLYMYX/BACIT/NEOM/
5000U//G
0066624 CORTISPORIN TOPICAL OINT 0.79 Y N Y YGSK /GM
TRIAMCINOLONE
0.025%
0071695 TRIADERM TOPICAL CREAM 0.0464 Y Y Y YTAR /GM
0.1%
0071696 TRIADERM TOPICAL CREAM 0.05 Y Y Y YTAR /GM
0219405 ARISTOCORT R TOPICAL CREAM 0.05 Y Y Y YSTI /GM
0.1% OINT
0071698 TRIADERM TOPICAL OINTMENT 0.0716 Y Y Y YTAR /GM
0219403 ARISTOCORT R TOPICAL OINTMENT 0.13 Y Y Y YSTI /GM
0.1% PASTE
0196405 ORACORT DENTAL PASTE 1.23 Y N Y YTAR /GM
0.5%
0219406 ARISTOCORT C TOPICAL CREAM 1.152 Y Y Y YSTI /GM
84:12.00 ASTRINGENTS AND DEODORANTS -----------------------------------------------------
ALUMINUM
0.35/.023%
0057994 BURO-SOL POWDER (2.36G PK) 0.751 N N Y NSTI /EA
84:16.00 CELL STIMULANTS AND PROLIFERANTS -----------------------------------------------
ERYTHROMYCIN
0.01%
0201599 STIEVAMYCIN MILD TOPICAL GEL 0.84 N N Y YSTI /GM
4%;025%
0190511 STIEVAMYCIN GEL 0.84 N N Y YSTI /GM
TRETINOIN
0.01%
0065720 STIEVA-A TOPICAL CREAM 0.3 N N Y YSTI /GM
0089732 RETIN A TOPICAL CREAM 0.356 N N Y YJAN /GM
0.01% GEL
0087001 RETIN A TOPICAL GEL 0.3737 N N Y YJAN /GM
0192646 VITAMIN A ACID TOPICAL GEL 0.31 N N Y YDER /GM
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
215
PHRM/CHRN/CDO/F84:16.00 CELL STIMULANTS AND PROLIFERANTS (continued)
84:00 SKIN AND MUCOUS MEMBRANE AGENTS (continued)
TRETINOIN (continued)
0.025%
0057857 STIEVA-A TOPICAL CREAM 0.3 N N Y YSTI /GM
0089731 RETIN A TOPICAL CREAM 0.356 N N Y YJAN /GM
0.025% GEL
0044381 RETIN A TOPICAL GEL 0.4 N N Y YJAN /GM
0192647 VITAMIN A ACID TOPICAL GEL 0.31 N N Y YDER /GM
0.05%
0051818 STIEVA-A TOPICAL CREAM 0.3 N N Y YSTI /GM
0044379 RETIN A TOPICAL CREAM 0.4 N N Y YJAN /GM
0.05% GEL
0192648 VITAMIN A ACID TOPICAL GEL 0.31 N N Y YDER /GM
0.1%
0066234 STIEVA-A FORTE TOPICAL CREAM 0.3 N N Y YSTI /GM
0087002 RETIN A TOPICAL CREAM 0.3737 N N Y YJAN /GM
84:24.04 BASIC LOTIONS AND LINIMENTS ----------------------------------------------------
CAPSAICIN
0.025%
0215710 CAPSAICIN REGULAR(STIEFEL 0.179 Y N N NSTI /GM
0074030 ZOSTRIX CREAM 0.2192 Y N N NMED /GM
0.075%
0215712 CAPSAICIN FORTE (STIEFEL) 0.225 Y N N NSTI /GM
0200424 ZOSTRIX HP CREAM 0.28 Y N N NMED /GM
84:28.00 KERATOLYTIC AGENTS -------------------------------------------------------------
ADAPALENE
0.1%
0223159 DIFFERIN CR 1.86 N N Y YGAC /GM
0214874 DIFFERIN TOPICAL GEL 1.71 N N Y YGAL /GM
BENZOYL PEROXIDE
10%
0026369 PANOXYL-10 TOPI GEL (ALCOH BS) 0.1458 Y N Y YSTI /GM
0191243 BENZAC AC GEL (AQUEOUS BASE) 0.333 Y N Y YGAC /GM
0043293 OXYDERM TOPICAL LOTION 0.1545 Y N Y YICN /ML
10% BAR
0052766 PANOXYL BAR 0.1123 Y N Y YSTI /GM
10% WASH
0192519 BENZAC W WASH 0.31 Y N Y YGAC /GM
20%
0037303 PANOXYL-20 TOP GEL (ALCO BASE) 0.19 Y N Y YSTI /GM
0037431 OXYDERM TOPICAL LOTION 0.2005 Y N Y YICN /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
216
PHRM/CHRN/CDO/F84:28.00 KERATOLYTIC AGENTS (continued)
84:00 SKIN AND MUCOUS MEMBRANE AGENTS (continued)
COAL TAR/JUNIPER TAR/PINE TAR
COAL TAR/JUNIPER
1.0%
0024986 POLYTAR SHAMPOO 0.04 N N Y NSTI /ML
DITHRANOL
0.1%
0053759 ANTHRANOL TOPICAL CREAM 0.5616 Y N N NMED /GM
0.2%
0053760 ANTHRANOL TOPICAL CREAM 0.592 Y N N NMED /GM
0.4%
0069535 ANTHRASCALP LOTION 0.7 Y N N NMED /ML
1% OINT
0056675 ANTHRAFORTE-1 OINTMENT 0.7646 Y N N NMED /GM
2% OINT
0056674 ANTHRAFORTE-2 OINTMENT 0.81 Y N N NMED /GM
LACTIC ACID/SALICYLIC
16.7/16.7%
0037057 DUOFILM 0.54 N N Y NSTI /ML
PODOPHYLLOTOXIN
0.5%
0194514 CONDYLINE TOPICAL (PACKAGE) 11.089 Y N Y YCDX /ML
0207478 WARTEC TOPICAL (PACKAGE) 16.1 Y N Y YPMS /ML
84:36.00 MISCELLANEOUS SKIN & MUCOUS MEMBRANE AGENTS ------------------------------------
ACITRETIN
10MG
0207084 SORIATANE 2.04 E E N YHLR /CP
25MG
0207086 SORIATANE 3.59 E E N YHLR /CP
ALITRETINOIN
10MG
0233763 TOCTINO 21.99 N E N YGSK /CP
30MG
0233764 TOCTINO 21.99 N E N YGSK /CP
CALCIPOTRIOL
50UG/G
0215095 DOVONEX TOPICAL CREAM 0.8 Y Y N YLEO /GM
50UG/G OIN
0197613 DOVONEX TOPICAL OINTMENT 0.76 Y Y N YLEO /GM
50UG/ML
0219434 DOVONEX 0.8 Y Y N YLEO /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
217
PHRM/CHRN/CDO/F84:36.00 MISCELLANEOUS SKIN & MUCOUS MEMBRANE AGENTS (continued)
84:00 SKIN AND MUCOUS MEMBRANE AGENTS (continued)
CALCIPOTRIOL/BETAMETHASONE DIP
CALCIPOTRIOL/BETAMET
0.5MG/50UG/G
0224412 DOVOBET OINTMENT 1.46 Y Y N YLEO /GM
50UG/0.5MG/G
0231901 DOVOBET GEL 1.54 Y Y N YLEO /GM
CYPROTERONE/ESTROGE
2MG/35MCG
0223354 DIANE-35 1.61 N N Y YBEX /TB
FLUOROURACIL
5%
0033058 EFUDEX TOPICAL CREAM 0.84 Y N N YICN /GM
IMIQUIMOD
5%
0240782 APO-IMIQUIMOD 11.03 E E N YAPX /EA
0223950 ALDARA 5% CREAM 50.13 E E N YVAE /EA
ISOTRETINOIN
10MG
0058234 ACCUTANE 0.93 N N Y YHLR /CP
40MG
0058235 ACCUTANE 1.9 N N Y YHLR /CP
PODOPHYLLIN
250MG/ML
0059820 PODOFILM LIQ (25%) 1.26 Y N Y YPAL /ML
TAZAROTENE
0.05%
0223078 TAZORAC TOPICAL GEL 1.36 N Y N YALL /GM
0.1%
0223078 TAZORAC TOPICAL GEL 1.36 N Y N YALL /GM
84:50.06 PIGMENTING AGENTS --------------------------------------------------------------
METHOXSALEN
1%
0190747 OXSORALEN TOPICAL LOTION 1.51 N E N YICN /ML
10MG
0000726 OXSORALEN 0.884 N E N YICN /CP
84:92.00 MISC. SKIN AND MUCOUS MEMBRANE AGENTS ------------------------------------------
AZELAIC ACID
15%
0227081 FINACEA 0.6 Y N Y YBAY /GM
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
218
PHRM/CHRN/CDO/F84:92.00 MISC. SKIN AND MUCOUS MEMBRANE AGENTS
84:00 SKIN AND MUCOUS MEMBRANE AGENTS (continued)
SECUKINUMAB
SECUKINUMAB
150MG/ML
0243807 COSENTYX 1645 E E N YNVR /KT
86:00 SMOOTH MUSCLE RELAXANTS
86:12.00 GENITOURINARY SMOOTH MUSCLE RELAXANTS ------------------------------------------
DARIFENACIN
15MG ER
0227322 ENABLEX 1.55 E E N YNVR /TB
7.5MG ER
0227321 ENABLEX 1.5 E E N YNVR /TB
FLAVOXATE HCL
200MG
0072817 URISPAS 0.494 Y Y Y YPMS /TB
0224484 APO-FLAVOXATE 0.727 Y Y Y YAPX /TB
OXYBUTYNIN CHLORIDE
1MG/ML
0223108 APO-OXYBUTYNIN SYRUP 0.0622 Y N Y YAPX /ML
0222337 PMS-OXYBUTYNIN SYRUP 0.134 Y N Y YPMS /ML
10 MG ER
0224396 DITROPAN XL 10MG 2.28 E N N YJAN /TB
2.5MG
0224054 PMS-OXYBUTYNIN 0.15 Y N Y YPMS /TB
5MG
0235023 SANIS-OXYBUTYNIN 0.1 Y N Y YSAI /TB
0223080 GEN-OXYBUTYNIN 0.1 Y N Y YGPM /TB
0216354 APO-OXYBUTYNIN 0.1 Y N Y YAPX /TB
0224055 PMS-OXYBUTYNIN 0.1 Y N Y YPMS /TB
0223039 NOVO-OXYBUTYNIN 0.1 Y N Y YNOP /TB
5 MG ER
0224396 DITROPAN XL 2.28 E N N YJAN /TB
SOLIFENACIN
10MG
0242224 ACT SOLIFENACIN 0.42 Y N N YACA /TB
0239904 SANDOZ SOLIFENACIN 0.42 Y N N YSDZ /TB
0227727 VESICARE 1.5 Y N N YAST /TB
5MG
0242223 ACT SOLIFENACIN 0.42 Y N N YACA /TB
0239903 SANDOZ SOLIFENACIN 0.42 Y N N YSDZ /TB
0227726 VESICARE 1.5 Y N N YAST /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
219
PHRM/CHRN/CDO/F86:12.00 GENITOURINARY SMOOTH MUSCLE RELAXANTS (continued)
86:00 SMOOTH MUSCLE RELAXANTS (continued)
TOLTERODINE
TOLTERODINE
1MG
0223906 DETROL 0.98 Y N N YPMS /TB
0242330 MINT-TOLTERODINE 0.49 Y N N YMNT /TB
2MG
0240418 MYLAN-TOLTERODINE ER 1.47 E N N YMYL /CP
0241219 TEVA-TOLTERODINE LA 0.49 E N N YTVM /CP
0224461 DETROL LA 1.96 E N N YPHU /CP
0223906 DETROL 0.98 Y N N YPMS /TB
0242331 MINT-TOLTERODINE 0.49 Y N N YMNT /TB
4MG
0241220 TEVA-TOLTERODINE LA 0.49 E N N YTVM /CP
0240419 MYLAN-TOLTERODINE ER 1.47 E N N YMYL /CP
0224461 DETROL LA 1.96 E N N YPHU /CP
86:12.04 null -------------------------------------------------------------------------------
SOLIFENACIN
5MG
0239790 TEVA-SOLIFENACIN 0.42 Y N N YTVM /TB
86:12.08 null -------------------------------------------------------------------------------
MIRABEGRON
25MG
0240287 MYRBETRIQ 1.46 E N N YASL /TB
50MG
0240288 MYRBETRIQ 1.46 E N N YASL /TB
86:16.00 RESPIRATORY SMOOTH MUSCLE RELAXANTS --------------------------------------------
OXTRIPHYLLINE
100MG
0044172 APO-OXTRIPHYLLINE 0.0475 Y Y N YAPX /TB
20MG/ML
0047636 CHOLEDYL ELIXIR 0.03 Y Y N YPFI /ML
0079294 PMS-OXTRIPHYLLINE ELIXIR 0.03 Y Y N YPMS /ML
200MG
0044173 APO-OXTRIPHYLLINE 0.0675 Y Y N YAPX /TB
300MG
0051169 APO-OXTRIPHYLLINE 0.095 Y Y N YAPX /TB
OXTRIPHYLLINE/GUAIFE
20/10MG/ML
0047637 CHOLEDYL EXPECTORANT 0.1 Y Y N YPFI /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
220
PHRM/CHRN/CDO/F86:16.00 RESPIRATORY SMOOTH MUSCLE RELAXANTS (continued)
86:00 SMOOTH MUSCLE RELAXANTS (continued)
THEOPHYLLINE (ANHYDROUS)
THEOPHYLLINE
100MG
0223008 NOVO-THEOPHYL SR 0.13 Y Y N YNOP /TB
0069268 APO-THEO-LA 0.13 Y Y N YAPX /TB
200MG
0069269 APO-THEO-LA 0.14 Y Y N YAPX /TB
0223008 NOVO-THEOPHYL SR 0.14 Y Y N YNOP /TB
300MG
0069270 APO-THEO-LA 0.18 Y Y N YAPX /TB
0223008 NOVO-THEOPHYL SR 0.14 Y Y Y YNOP /TB
400MG
0201416 UNIPHYL 0.5 Y Y N YPFR /TB
400MG ER
0236010 THEO ER 0.3735 Y Y N YAA /TB
5.33MG/ML
0196621 THEOLAIR LIQUID 0.03 Y Y N YMDA /ML
600MG
0201418 UNIPHYL 0.61 Y Y N YPFR /TB
600MG ER
0236012 THEO ER 0.452 Y Y N YAA /TB
88:00 VITAMINS
88:08.00 VITAMIN B COMPLEX --------------------------------------------------------------
CYANOCOBALAMIN
1MG/ML
0198700 CYANOCOBALAMIN (10ML) 0.45 Y E N YCYT /ML
0052151 VITAMIN B12 (10ML) 0.3 Y E N YSAB /ML
0205271 CYANOCOBALAMIN (10ML) 0.31 Y E N YTAR /ML
0062611 VITAMIN B12 (10ML) 0.31 Y E N YOMG /ML
100MCG
0033101 VITAMIN B12 0.0548 Y E N NJAM /TB
100MCG/ML
0224150 VITAMIN B12 (1ML) 1.49 Y E N YSAB /ML
1000MCG
8000357 VITAMIN B12 0.056 Y E N NSDM /TB
0223773 VITAMIN B12 0.08 Y E N NSWI /TB
250MCG
0033594 VITAMIN B12 0.0625 Y E N NJAM /TB
8000405 VITAMIN B12 0.04 Y N N NSAI /TB
500MCG
0068972 VITAMIN B12 0.0686 Y E N NWHL /TB
8000079 VITAMIN B12 (NATURES) 0.06 Y E N NNAT /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
221
PHRM/CHRN/CDO/F88:08.00 VITAMIN B COMPLEX (continued)
88:00 VITAMINS (continued)
CYANOCOBALMIN
CYANOCOBALMIN
250MCG
0223969 VITAMIN B12 0.0594 Y E N NWHL /TB
FOLIC ACID
5MG
0236606 JAMP-FOLIC 0.04 Y N Y YJPC
/TB
0228567 EURO-FOLIC ACID 0.02 Y N Y YWHL /TB
0042684 APO-FOLIC 0.04 Y N Y YAPX /TB
LEUCOVORIN CALC.
5 MG
0217049 LEUCOVORIN LEDERLE 6.82 Y E N YWYA /TB
NIACIN
100MG
0026858 NIACIN 0.031 Y N N NICN /TB
0023245 NIACIN 0.0257 Y N N NLEA /TB
50MG
0026859 NIACIN 0.0141 Y N N NICN /TB
500MG
0055741 NIACIN 0.023 Y N N NVIT /TB
0023244 NIACIN 0.0546 Y N N NLEA /TB
0029495 NIACIN 0.0496 Y N N NICN /TB
0030973 NIACIN 0.055 Y N N NJAM /TB
PYDIROXINE HCL
100MG
8000366 VITAMIN B6 0.05 Y E Y NWEB /TB
PYRIDOXINE HCL
100MG
0032918 VITAMIN B6 0.0625 Y E Y NJAM /TB
0223934 VITAMIN B6 0.059 Y E Y NPMS /TB
25MG
0023247 PYRIDOXINE HCL 0.0245 Y E Y NLEA /TB
0026860 VITAMIN B6 0.0258 Y E Y NICN /TB
250MG
0033103 VITAMIN B6 0.102 Y E Y NJAM /TB
VITAMIN B12
100MCG
0045064 VITAMIN B12 0.06 Y E N NWHL /TB
1000MCG
8000693 LIFE BRAND VITAMIN B12 0.059 Y N N NWHL /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
222
PHRM/CHRN/CDO/F88:08.08 null
88:00 VITAMINS (continued)
VITAMIN B COMPLEX &VITAMIN C
88:08.08 null -------------------------------------------------------------------------------
MULTI
8000143 RENAVITE 0.064 E E N NMAC /TB
88:16.00 VITAMIN D ----------------------------------------------------------------------
ALFACALCIDOL
0.25UG
0047451 ONE-ALPHA 0.47 Y E N YLEO /CP
1.0UG
0047452 ONE ALPHA 1.42 Y E N YLEO /CP
CALCIFEROL
8288IU/ML
0201759 DRISDOL 0.4268 Y N N NSAW /ML
CALCITRIOL
0.25UG
0048182 ROCALTROL 0.93 Y E N YHLR /CP
0243163 CALCITRIOL-ODAN 0.7 Y E N YODN /CP
0.5UG
0048181 ROCALTROL 1.48 Y E N YHLR /CP
0243164 CALCITRIOL-ODAN 1.11 Y E N YODN /CP
VITAMIN D
10,000IU
0082177 D-TABS 10,000 0.21 Y N N YRIV /TB
0237900 JAMP-VITAMIN D 0.21 Y N N YJAM /TB
1000IU
8001220 VITAMIN D 0.02 Y N Y NLIF /CP
8000366 LIFE BRAND VITAMIN D 0.031 Y N N NWHL /TB
0224584 VITAMIN D 0.0362 Y N N NWHL /TB
0032317 VITAMIN D 0.028 Y N Y NSWI /TB
8000043 VITAMIN D 0.03 Y N N NJAM /TB
8000013 VITAMIN D EQUATE 0.023 Y N Y NWHL /TB
400IU
0224387 VITAMIN D DROPS 0.14 N N Y NWHL /ML
8001593 JAMIESON-VITAMIN D 0.04 N N Y NWHL /TB
8000879 VITAMIN D 0.064 N N Y NWHL /TB
0223872 VITAMIN D .. 0.0209 Y N Y NVTH /TB
0224085 VITAMIN D 0.039 Y N Y NPMS /TB
8000245 LIFE BRAND VITAMIN D 0.02 Y N N NWHL /TB
50000IU
0223745 D-FORTE 0.1986 Y E N YEUR /CP
0230191 OSTO-D2 0.2 Y E N YTRI /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
223
PHRM/CHRN/CDO/F88:28.01 VITAMINS AND MINERALS
88:00 VITAMINS (continued)
PRENATAL VITAMINS
88:28.01 VITAMINS AND MINERALS ----------------------------------------------------------
MULTI
0223188 MATERNA 0.125 N N Y NWYA /TB
88:29.00 CALCIUM ------------------------------------------------------------------------
CALCIUM 500MG
500MG
0224604 JAMP-CALCIUM 500MG 0.02 Y N Y NJPC
/TB
CALCIUM CARBONATE
500MG
0224024 CALCIUM 500MG 0.026 Y N Y NPHM /TB
0062244 O-CALCIUM 500 0.027 Y N Y NVTH /TB
8001367 O-CALCIUM 500 0.02 Y N Y NBMD /TB
8001096 CALCIUM 500MG 0.027 Y N Y NWHL /TB
0068203 APO-CAL 500 0.029 Y N Y NAPX /TB
600MG
0197914 CALCIUM CARBONATE 0.0187 Y N Y NPHM /TB
650MG
8003124 EXACT CALCIUM CARBONATE 650 0.02 Y N Y NEXA /TB
CALCIUM CARBONATE
350MG
0204088 CHEWABLE CALCIUM 0.0446 Y N Y NJAM /TB
400 MG
0215113 TUMS ULTRA STRENGTH 0.0419 Y N Y NGSK /TB
500MG
0070537 CHEWABLE CALCIUM 0.056 Y N Y NWAM /TB
CALCIUM
500MG/125
0207418 CALCIUM CARB W/VIT D3 0.0321 Y N N NVTH /TB
0077568 O CALCIUM 500 PLUS D 0.0287 Y N N NVTH /TB
0073059 CALCIUM CARB W/VIT D3 0.0264 Y N N NPHM /TB
500MG/200
8000028 CALCIUM 500MG W/VIT D 200 0.038 Y N N NWEB /TB
500MG/400IU
8000212 CALCIUM CARBONATE/VITAMIN D 0.17 Y N N NJPC
/TB
92:00 MISCELLANEOUS THERAPEUTIC AGENTS
92:00.00 MISCELLANEOUS THERAPEUTIC AGENTS -----------------------------------------------
ADALIMUMAB
40MG/0.8ML
0225859 HUMIRA 1525.14 E E N YABB /KT
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
224
PHRM/CHRN/CDO/F92:00.00 MISCELLANEOUS THERAPEUTIC AGENTS
92:00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
ALENDRONATE
ALENDRONATE
10MG
0238148 ACH-ALENDRONATE 0.5 Y E N YACH /TB
0224737 TEVA-ALENDRONATE 0.5 Y E N YTVM /TB
0240112 ACCEL-ALENDRONATE 0.4 Y E N YACC /TB
0224872 APO-ALENDRONATE 0.5 Y E N YAPX /TB
40MG
0225810 CO ALENDRONATE 3.08 Y E N YCOB /TB
5MG
0224872 APO-ALENDRONATE 1.04 Y E N YAPX /TB
0224825 TEVA-ALENDRONATE 1.04 Y E N YTVM /TB
70MG
0227527 RATIO-ALENDRONATE 2.52 Y E N YRTP /TB
0224873 APO-ALENDRONATE 2.52 Y E N YAPX /TB
0225811 CO ALENDRONATE 2.51 Y E N YCOB /TB
0228400 PMS-ALENDRONATE 2.51 Y E N YPMS /TB
0226171 TEVA-ALENDRONATE 2.51 Y E N YTVM /TB
0240113 ACCEL-ALENDRONATE 2.01 Y E N YACC /TB
0235296 SANIS-ALENDRONATE 2.52 Y E N YSAN /TB
0224532 FOSAMAX 10.55 Y E N YMSD /TB
0239487 MINT-ALENDRONATE 2.52 Y E N YMNT /TB
ALENDRONATE/CHOLEC
70MG/5600IU
0240364 TEVA- 2.31 Y E N YTVM /TB
0245447 APO-ALENDRONATE/VITAMIN D3 1.22 Y E N YAPX /TB
ALFUZOSIN
10MG
0230467 SDZ-ALFUZOSIN 0.26 Y N N YSDZ /TB
0224556 XATRAL 1.04 Y N N YSAN /TB
0231428 TEVA-ALFUZOSIN 0.5 Y N N YTVM /TB
0231586 APO-ALFUZOSIN 0.5 Y N N YAPX /TB
ALLOPURINOL
100MG
0239632 MAR-ALLOPURINOL 0.08 Y Y N YWHL /TB
0040281 ZYLOPRIM 0.078 Y Y N YAAA /TB
0240276 APO-ALLOPURINOL 0.078 Y Y N YAPX /TB
200MG
0047979 ZYLOPRIM 0.13 Y Y N YAAA /TB
0240277 APO-ALLOPURINOL 0.13 Y Y N YAPX /TB
0239633 MAR-ALLOPURINOL 0.13 Y Y N YWHL /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
225
PHRM/CHRN/CDO/F92:00.00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
92:00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
ALLOPURINOL (continued)
300MG
0040279 ZYLOPRIM 0.213 Y Y N YAAA /TB
0240278 APO-ALLOPURINOL 0.21 Y Y N YAPX /TB
0239634 MAR-ALLOPURINOL 0.21 Y Y N YWHL /TB
ANAKINRA
150MG/ML
0224591 KINERET 48.06 E E N YSOB /EA
AZATHIOPRINE
50MG
0224290 APO-AZATHIOPRINE 0.24 Y Y N YAPX /TB
0223681 NOVO-AZATHIOPRINE 0.24 Y Y N YNOP /TB
0000459 IMURAN 1.01 Y Y N YGSK /TB
0223149 GEN-AZATHIOPRINE 1.01 Y Y N YGPM /TB
0234300 SANIS-AZATHIOPRINE 0.24 Y Y N YSAN /TB
BETAHISTINE
16MG
0233021 PMS-BETAHISTINE 0.177 Y N N YPMS /TB
0228019 TEVA-BETAHISTINE 0.18 Y N N YTVM /TB
0244915 AURO-BETAHISTINE 0.12 Y N N YAUR /TB
0224387 SERC 16 MG 0.47 Y N N YSLV /TB
0237475 CO-BETAHISTINE 0.177 Y N N YCOB /TB
24MG
0233023 PMS-BETAHISTINE 0.49 Y N N YPMS /TB
0228020 TEVA-BETAHISTINE 0.49 Y N N YTVM /TB
0224799 SERC 0.7 Y N N YSLV /TB
0237476 CO-BETAHISTINE 0.49 Y N N YCOB /TB
8MG
0228018 TEVA-BETAHISTINE 0.21 Y N N YTVM /TB
BOTULINUM TOXIN TYPE
100U
0198150 BOTOX 357 E E N YALL /VL
BROMOCRIPTINE
2.5MG
0223170 PMS-BROMOCRIPTINE 0.4328 Y Y N YPMS /TB
0208732 APO-BROMOCRIPTINE 0.9782 Y Y N YAPX /TB
5MG
0223694 PMS-BROMOCRIPTINE 0.917 Y Y N YPMS /CP
0223045 APO-BROMOCRIPTINE 1.46 Y Y N YAPX /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
226
PHRM/CHRN/CDO/F92:00.00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
92:00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
BUSERELIN ACETATE
BUSERELIN ACETATE
9.45MG/IMP
0224074 SUPREFACT DEPOT 3 MONTHS 1137.26 Y Y N YAVT /EA
CERTOLIZUMAB PEGOL
200MG/ML
0233167 CIMZIA 1329.02 E E N YUCB /KT
CLODRONATE DISODIUM
400MG
0198484 BONEFOS 1.96 Y Y N YAVT /CP
0224582 CLASTEON 1.21 Y Y N YSUN /CP
60MG/ML
0198483 BONEFOS 63.51 Y Y N YBEX /ML
COLCHICINE
0.6MG
0028787 COLCHICINE 0.2565 Y Y N YWHL /TB
0240218 PMS-COLCHICINE 0.26 Y Y N YPMS /TB
0057234 COLCHICINE-ODAN 0.2565 Y Y N YODN /TB
COMPOUNDED
CPD INJ
0099002 COMPOUNDED INJECTABLES 100 E E N YCPD /ML
COMPOUNDED ORAL
CPD ORAL
0099002 COMPOUNDED ORAL PREPS 100 E E Y YCPD /EA
COMPOUNDED
CPD TOP
0099001 COMPOUNDED TOPICALS 100 Y E Y YCPD /GM
CYCLOSPORINE
10MG
0223767 NEORAL 0.6238 Y Y N YNVR /CP
100MG
0224282 SANDOZ CYCLOSPORINE 5.09 Y Y N YSDZ /CP
0215067 NEORAL 5.656 Y Y N YNVR /CP
100MG/ML
0215069 NEORAL 5.0276 Y Y N YNVR /ML
25MG
0215068 NEORAL 1.45 Y Y N YNVR /CP
0224707 SANDOZ CYCLOSPORINE 1.31 Y Y N YSDZ /CP
50MG
0224707 SANDOZ CYCLOSPORINE 2.55 Y Y N YSDZ /CP
0215066 NEORAL 2.827 Y Y N YNVR /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
227
PHRM/CHRN/CDO/F92:00.00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
92:00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
DENOSUMAB
DENOSUMAB
60MG/ML
0234354 PROLIA 354.09 E E N YAMG /ML
DICITRATE SOLN
66.8/100MG
0072134 CITRIC ACID - SODIUM CITRATE 0.046 E N N NPMS /ML
DUTASTERIDE
0.5MG
0240420 APO-DUTASTERIDE 0.42 Y N N YAPX /CP
0244305 DUTASTERIDE 0.42 Y N N YSAI /CP
0241269 ACT DUTASTERIDE 0.42 Y N N YACT /CP
0224781 AVODART 1.68 Y N N YGCH /CP
ETANERCEPT
25MG/ML
0224290 ENBREL (4 VIALS) 776.98 E E N YIMM /KT
50MG/ML
0227472 ENBREL 405.99 E E N YIMM /KT
ETIDRONATE /CALCIUM
400/500MG
0224732 GEN-ETI-CAL CAREPAC 19.99 Y E N YGPM /KT
0217601 DIDROCAL 44.48 Y E N YPRO /KT
0226386 CO-ETIDROCAL COMBO KIT 29.99 Y E N YCOB /KT
0235321 SANIS-ETIDROCAL COMBO KIT 19.99 Y E N YSAN /KT
ETIDRONATE DISODIUM
200MG
0224533 GEN-ETIDRONATE 0.36 Y E N YGEN /TB
0224868 CO-ETIDRONATE 0.36 Y E N YCOB /TB
FEBUXOSTAT
80MG
0235738 ULORIC 1.59 E E N YTAK /TB
FINASTERIDE
5MG
0230690 RATIO-FINASTERIDE 0.46 Y N N YRPH /TB
0231011 PMS-FINASTERIDE 0.46 Y N N YPMS /TB
0232257 SANDOZ FINASTERIDE 0.46 Y N N YSDZ /TB
0238987 MINT-FINASTERIDE 0.463 Y N N YMNT /TB
0235446 ACT FINASTERIDE 0.46 Y N N YACT /TB
0244507 FINASTERIDE 0.46 Y N N YSAI /TB
0201090 PROSCAR 2.06 Y N N YMSD /TB
0234850 TEVA-FINASTERIDE 0.46 Y N N YTVM /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
228
PHRM/CHRN/CDO/F92:00.00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
92:00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
FINGOLIMOD
FINGOLIMOD
0.5MG
0236548 GILENYA 85.17 E E N YNVR /CP
GLATIRAMER ACETATE
20MG/1.0ML
0224561 COPAXONE (30X1ML) 45.21 E E N YN/A /EA
GOLIMUMAB
100 MG/ML
0241318 SIMPONI 1555.17 E E N YJAN /KT
50 MG/ML
0232478 SIMPONI 1555.17 E E N Ynull /KT
GOSERELIN ACETATE
10.8MG/IMP
0222590 ZOLADEX LA INJ 1157.95 Y Y N YAST /EA
3.6MG
0204932 ZOLADEX 398.3 Y Y N YAST /EA
INCOBOTULINUMTOXIN
100U/VIAL
0232403 XEOMIN 330 E E N YMER /EA
50U/VIAL
0237108 XEOMIN 165 E E N YMER /EA
INFLIXIMAB
100 MG
0224401 REMICADE 987.56 E E N YCEN /EA
0241947 INFLECTRA 525 E E N YHOS /EA
INTERFERON BETA-1A
22UG
0223731 REBIF (6MILLION IU) 122.28 E E N YSRO /EA
22UG (3DOSES)
0231825 REBIF (66UG/1.5ML) CART 3X4 366.82 E E N YSRO /KT
30IU/0.5ML
0226920 AVONEX 395.97 E E N YBGN /KT
44UG
0223732 REBIF (12 MILLION IU) 148.85 E E N YSRO /EA
44UG (3DOSES)
0231826 REBIF (132UG/1.5ML) CART 3X4 470.55 E E N YSRO /KT
INTERFERON BETA-1B
0.3MG
0216964 BETASERON 99.33 E E N YBEX /KT
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
229
PHRM/CHRN/CDO/F92:00.00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
92:00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
LEFLUNOMIDE
LEFLUNOMIDE
10MG
0235166 SANIS-LEFLUNOMIDE 2.64 E E N YSAN /TB
0225649 APO-LEFLUNOMIDE 2.64 E E N YAPX /TB
0224188 ARAVA 11.07 E E N YAVT /TB
0226125 NOVO-LEFLUNOMIDE 2.64 E E N YNOP /TB
20MG
0224188 ARAVA 11.07 E E N YAVT /TB
0235167 SANIS-LEFLUNOMIDE 2.64 E E N YSAN /TB
0226127 NOVO-LEFLUNOMIDE 2.64 E E N YNOP /TB
0225650 APO-LEFLUNOMIDE 2.64 E E N YAPX /TB
0228397 SANDOZ LEFLUNOMIDE 2.64 E E N YSDZ /TB
MONTELUKAST SODIUM
10MG
0237460 APO-MONTELUKAST 0.82 E E N YAPX /TB
0240864 MINT-MONTELUKAST 0.82 E E N YMNT /TB
0237394 PMS-MONTELUKAST 0.82 E E N YPMS /TB
0235552 TEVA-MONTELUKAST 0.82 E E N YTVM /TB
0239142 JAMP-MONTELUKAST 0.82 E E N YJAM /TB
0238951 RAN-MONTELUKAST 1.77 E E N YRAN /TB
0237933 SANIS-MONTELUKAST SODIUM 0.82 E E N YSAI /TB
0232859 SDZ-MONTELUKAST 0.82 E E N YSDZ /TB
0223821 SINGULAIR 2.48 E E N YMSD /TB
0236822 MYLAN-MONTELUKAST 0.82 E E N YMYL /TB
4MG CH
0237931 MONTELUKAST 0.36 E E N YSAI /TB
0224360 SINGULAIR 1.53 E E N YMSD /TB
0233038 SDZ-MONTELUKAST 0.36 E E N YSDZ /TB
0235550 TEVA-MONTELUKAST 0.36 E E N YTVM /TB
0235497 PMS-MONTELUKAST 0.36 E E N YPMS /TB
4/500MG
0224799 SINGULAIR 1.532 E E N YMSD /PK
0235861 SDZ-MONTELUKAST GRANULES 0.84 E E N YSDZ /PK
5MG CH
0235551 TEVA-MONTELUKAST 0.56 E E N YTVM /TB
0235498 PMS-MONTELUKAST 0.56 E E N YPMS /TB
0233039 SDZ-MONTELUKAST 0.56 E E N YSDZ /TB
0223821 SINGULAIR 1.7 E E N YMSD /TB
0240280 RAN-MONTELUKAST 0.56 E E N YRAN /TB
0237932 MONTELUKAST 0.56 E E N YSAI /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
230
PHRM/CHRN/CDO/F92:00.00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
92:00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
MYCOPHENOLATE
MYCOPHENOLATE
500MG
0238038 JAMP-MYCOPHENOLATE 2.06 Y Y N YJPC
/TB
MYCOPHENOLATE
250MG
0237115 MYLAN-MYCOPHENOLATE 1.03 Y Y N YMYL /CP
0219274 CELLCEPT 2.06 Y Y N YHLR /CP
0232063 SDZ-MYCOPHENOLATE 1.03 Y Y N YSDZ /CP
0236488 TEVA-MYCOPHENOLATE 1.03 Y Y N YTVM /CP
0235255 APO-MYCOPHENOLATE 1.03 Y Y N YAPX /CP
500MG
0237054 MYLAN-MYCOPHENOLATE 2.06 Y Y N YMYL /CP
0237999 CO-MYCOPHENOLATE 2.06 Y Y N YCOB /CP
0234867 TEVA-MYCOPHENOLATE 2.06 Y Y N YTVM /CP
0231385 SDZ-MYCOPHENOLATE 2.06 Y Y N YSDZ /CP
0235256 APO-MYCOPHENOLATE 2.06 Y Y N YAPX /CP
0223748 CELLCEPT 4.12 Y Y N YHLR /TB
MYCOPHENOLIC ACID
180MG
0237273 APO-MYCOPHENOLIC ACID 1.69 Y Y N YAPX /TB
360MG
0237274 APO-MYCOPHENOLIC ACID 3.4 Y Y N YAPX /TB
NATALIZUMAB
20MG/ML
0228638 TYSABRI 3392.84 E E N YBGN /VL
OCRIPLASMIN
2.5MG/ML
0241081 JETREA 3950 E E N YALC /ML
OCTREOTIDE
100UG
0224864 OCTREOTIDE ACETATE OMEGA 4.03 Y N N YOMG /ML
0241320 OCPHYL 3.3 Y N N YPED /ML
0083920 SANDOSTATIN (1ML) 10.09 Y N N YNVR /ML
200UG/ML
0204939 SANDOSTATIN (5ML) 19.41 Y N N YNVR /ML
50UG
0241319 OCPHYL 8.75 Y N N YPED /ML
0083919 SANDOSTATIN (1ML) 5.146 Y N N YNVR /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
231
PHRM/CHRN/CDO/F92:00.00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
92:00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
OCTREOTIDE (continued)
500UG
0224864 OCTREOTIDE ACETATE OMEGA 52.3 Y N N YOME /ML
0241321 OCPHYL 16.17 Y N N YPED /ML
0083921 SANDOSTATIN (1ML) 45.65 Y N N YNVR /ML
OCTREOTIDE ACETATE
10MG
0223932 SANDOSTATIN LAR VIAL IM INJEC. 1315.74 Y E N YNVR /KT
20MG
0223932 SANDOSTATIN LAR VIAL IM INJEC. 1699.89 Y E N YNVR /KT
30MG
0223932 SANDOSTATIN LAR VIAL IM INJEC. 2180.94 Y E N YNVR /KT
PAMIDRONATE
30MG
0224455 PAMIDRONATE DISODIUM 3.01 Y Y N YDBU /ML
0205976 AREDIA 166.93 Y Y N YNVR /VL
0224599 PMS-PAMIDRONATE 99.98 Y Y N YPMS /VL
6MG/ML
0224967 PAMIDRONATE DISODIUM OMEGA 17.67 Y Y N YOMG /ML
90MG
0224455 PAMIDRONATE DISODIUM 9.02 Y Y N YDBU /ML
0205978 AREDIA 500.79 Y Y N YNVR /VL
0224599 PMS-PAMIDRONATE 315 Y Y N YPMS /VL
PENTOSAN
100MG
0202944 ELMIRON 2.17 Y N Y YJAN /CP
PIMECROLIMUS
1.0%
0224723 ELIDEL OINTMENT 2.28 E E N YNVO /GM
RISEDRONATE
35MG
0235798 MYLAN-RISEDRONATE 2.43 Y E N YMYL /TB
RISEDRONATE SODIUM
30MG
0223914 ACTONEL 12.36 Y N N YPGA /TB
0229838 TEVA-RISEDRONATE 10.12 Y E N YTVM /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
232
PHRM/CHRN/CDO/F92:00.00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
92:00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
RISEDRONATE SODIUM (continued)
35MG
0230220 PMS-RISEDRONATE 2.43 Y E N YPMS /TB
0224689 ACTONEL 10.44 Y E N YPGA /TB
0229839 TEVA-RISEDRONATE 2.43 Y E N YTVM /TB
0237025 SANIS-RISEDRONATE SODIUM 2.43 Y E N YSAI /TB
0231986 RATIO-RISEDRONATE 2.43 Y E N YRTP /TB
0232729 SANDOZ-RISEDRONATE 2.43 Y E N YSDZ /TB
0235368 APO-RISEDRONATE 2.43 Y E N YAPX /TB
5MG
0224251 ACTONEL 2.01 Y E N YPGA /TB
0229837 TEVA-RISEDRONATE 1.56 Y E N YTVM /TB
SEVELAMER
800MG
0224431 RENAGEL 1.64 E E N YGPM /MG
SIROLIMUS
1 MG
0224711 RAPAMUNE 7.91 Y Y N YWYA /TB
1.0MG/ML
0224323 RAPAMUNE ORAL 7.91 Y Y N YWYA /ML
SODIUM
10MG/ML
0204611 PMS-SODIUM CROMOGLYCATE 0.79 Y N N YPMS /ML
0223143 APO-CROMOLYN (2ML) 0.2423 Y N N YAPX /ML
100MG
0050089 NALCROM 1.46 Y N Y YAVT /CP
TACROLIMUS
0.5MG
0241681 SANDOZ TACROLIMUS 1.48 Y Y N YSDZ /CP
0224314 PROGRAF 1.97 Y Y N YFUJ /CP
0229646 ADVAGRAF 1.97 Y Y N YASL /CP
1MG
0241682 SANDOZ TACROLIMUS 1.89 Y Y N YSDZ /CP
0217599 PROGRAF 2.52 Y Y N YFUJ /CP
0229647 ADVAGRAF 2.52 Y Y N YASL /CP
3MG
0233166 ADVAGRAF 7.56 Y Y N YASL /CP
5MG
0229648 ADVAGRAF 12.62 Y Y N YASL /CP
0217598 PROGRAF 12.62 Y Y N YFUJ /CP
0241683 SANDOZ TACROLIMUS 9.47 Y Y N YSDZ /CP
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
233
PHRM/CHRN/CDO/F92:00.00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
92:00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
TACROLIMUS (continued)
5MG/ML
0217600 PROGRAF AMPOULE (10X1ML) 124.5 Y Y N YFUJ /KT
TACROLIMUS TOPICAL
0.03%
0224414 PROTOPIC 2.15 E E N YFUJ /GM
0.1%
0224414 PROTOPIC 2.3 E E N YFUJ /GM
TAMSULOSIN HCL
0.4MG
0231921 SANDOZ TAMSULOSIN 0.15 Y N N Ynull /CP
0229857 MYLAN-TAMSULOSIN 0.24 Y N N YMYL /CP
0236240 APO-TAMSULOSIN HCL 0.15 Y N N YAPX /TB
0242711 TAMSULOSIN CR 0.15 Y N Y YSAN /TB
0.4MG SR
0229426 RATIO-TAMSULOSIN 0.15 Y N N YRPH /CP
0228139 NOVO-TAMSULOSIN 0.15 Y N N YNOP /CP
0229512 SANDOZ-TAMSULOSIN 0.15 Y N N YSDZ /CP
0234020 SDZ-TAMSULOSIN CR 0.15 Y N N YSDZ /TB
0227010 FLOMAX CR 0.62 Y N N YBOE /TB
TERIFLUNOMIDE
14MG
0241632 AUBAGIO 53.97 E E N YGNZ /TB
TETRABENAZINE
25MG
0219927 NITOMAN 6.87 Y Y N YBVL /TB
TIZANIDINE
4MG
0227205 GEN-TIZANIDINE 0.37 Y Y N YGPM /TB
0225989 APO-TIZANIDINE 0.6884 Y Y N YAPX /TB
0223917 ZANAFLEX 0.81 Y Y N YELA /TB
TOCILIZUMAB
162MG/0.9ML
0242477 ACTEMRA 355 E E N YHLR /EA
200MG/10ML
0235010 ACTEMRA 45.2 E E N YHLR /VL
400MG/20ML
0235011 ACTEMRA 45.2 E E N YHLR /VL
80MG/4ML
0235009 ACTEMRA 45.2 E E N YHLR /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
234
PHRM/CHRN/CDO/F92:00.00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
92:00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
TRANEXAMIC ACID
TRANEXAMIC ACID
500MG
0240123 TRANEXAMIC ACID TABLETS 0.58 Y N N YSTE /TB
0206440 CYKLOKAPRON 1.16 Y N N YPHU /TB
USTEKINUMAB
45MG/0.5ML
0232067 STELARA 4593.14 E E N YJAN /KT
90MG/ML
0232068 STELARA 4593.14 E E N YJAN /KT
VALGANCICLOVIR
50MG/ML
0230608 VALCYTE 2.56 E E N YHLR /ML
ZAFIRLUKAST
20MG
0223660 ACCOLATE 0.77 E E N YAST /TB
ZOLEDRONIC ACID
5MG/100ML
0241510 TARO-ZOLEDRONIC ACID 3.35 E E N YTAR /ML
0240808 ZOLEDRONIC ACID INJECTION 3.35 E E N YTEV /ML
92:24.00 BONE RESORPTION INHIBITORS -----------------------------------------------------
DENOSUMAB
120MG/1.7ML
0236815 XGEVA 558.79 E E N YAMG /KT
92:32.00 COMPLEMENT INHIBITORS ----------------------------------------------------------
ICATIBANT ACETATE
10MG/ML
0242569 FIRAZYR 2700 E N N YSCI /EA
92:36.00 DISEASE-MODIFYING ANTIRHEUMATIC AGENTS -----------------------------------------
TOFACITINIB
5MG
0242389 XELJANZ 23.56 E E N YPFI /TB
92:44.00 IMMUNOSUPPRESSIVE AGENTS -------------------------------------------------------
PIRFENIDONE
267MG
0239375 ESBRIET 13.0302 E E N YINT /CP
92:92.00 OTHER MISCELLANEOUS THERAPEUTIC AGENTS -----------------------------------------
CINACALCET
30MG
0245269 APO-CINACALCET 10.19 E E N YAPX /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
235
PHRM/CHRN/CDO/F92:92.00 OTHER MISCELLANEOUS THERAPEUTIC AGENTS
92:00 MISCELLANEOUS THERAPEUTIC AGENTS (continued)
CINACALCET HYDROCHLORIDE
CINACALCET
30MG
0225713 SENSIPAR 11.4 E E N YAMG /TB
99:00 PALLIATIVE CARE
99:00.00 PALLIATIVE CARE ----------------------------------------------------------------
ALGINIC
313/63MG
0223153 GAVISCON 0.19 Y N N NGSK /TB
99:00.98 CD PALLIATIVE RX ---------------------------------------------------------------
ACETYLCYSTEINE
200MG/ML
0230043 ACETYLCYSTEINE INJECTION 6.5 Y Y N YALV /ML
CIPROFLOXACIN/DEXAM
0.3%/0.1%
0225271 CIPRODEX OTIC SOLUTION 3.61 Y Y N YALC /ML
CITALOPRAM
20MG
0224801 PMS-CITALOPRAM 0.24 Y Y N YPMS /TB
CLINDAMYCIN
20MG/GM
0206060 DALACIN VAGINAL CREAM 0.76 Y Y N YPMS /ML
CLONAZEPAM
0.25MG
0217966 PMS-CLONAZEPAM 0.08 Y Y N YPMS /TB
CONJUGATED
0.3 MG
0204339 PREMARIN 0.3 Y Y N YWYA /TB
DIAZEPAM
1MG/ML
0089179 PMS-DIAZEPAM SOLUTION 1MG/ML 0.12 Y Y N YPMS /ML
DULOXETINE
30MG
0243898 MINT-DULOXETINE 0.48 Y Y N YMNT /CP
FENTANYL CITRATE
100MCG S/L
0236417 ABSTRAL 10.9 Y Y N YPAL /TB
200MCG S/L
0236418 ABSTRAL 12.34 Y Y N YPAL /TB
300MCG S/L
0236419 ABSTRAL 14.79 Y Y N YPAL /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
236
PHRM/CHRN/CDO/F99:00.98 CD PALLIATIVE RX (continued)
99:00 PALLIATIVE CARE (continued)
FENTANYL CITRATE (continued)
400MCG S/L
0236420 ABSTRAL 16.81 Y Y N YPAL /TB
600MCG S/L
0236421 ABSTRAL 22.42 Y Y N YPAL /TB
800MCG S/L
0236422 ABSTRAL 28.02 Y Y N YPAL /TB
FLUCONAZOLE
50MG
0224564 PMS-FLUCONAZOLE 1.29 Y Y N YPMS /TB
FUROSEMIDE
10MG/ML
0040163 FUROSEMIDE SPECIAL 0.87 Y Y N YSDZ /ML
0052703 FUROSEMIDE INJ 0.87 Y Y N YSDZ /ML
HALOPERIDOL
5MG/ML
0080865 HALOPERIDOL (1ML) INJ 4.83 Y Y N YSAB /ML
HYOSCINE
10MG
0036381 BUSCOPAN 0.34 Y Y N YBOE /TB
KETAMINE HCL
10MG/ML
0224679 KETAMINE HCL INJ 1.65 Y Y N YSDZ /ML
50MG/ML
0224679 KETAMINE HCL INJ 4.95 Y Y N YSDZ /ML
KETOCONAZOLE
2%
0224566 KETODERM TOPICAL CREAM 0.32 Y Y N YTAR /GM
LORAZEPAM
0.5MG SL
0241074 APO-LORAZEPAM SUBLINGUAL 0.0875 Y Y N YAPX /TB
1MG SL
0241075 APO-LORAZEPAM SUBLINGUAL 0.11 Y Y N YAPX /TB
0204146 ATIVAN SUBLINGUAL 0.14 Y Y N YWYA /TB
MEDROXYPROGESTERON
2.5MG
0224472 APO-MEDROXY 0.04 Y Y N YAPX /TB
METHADONE
1MG
0224769 METADOL 0.18 E E N YPMS /TB
1MG/ML
0224769 METADOL SOLN 0.11 N N N YPMS /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
237
PHRM/CHRN/CDO/F99:00.98 CD PALLIATIVE RX (continued)
99:00 PALLIATIVE CARE (continued)
METHADONE (continued)
10MG
0224770 METADOL 0.98 E E N YPMS /TB
10MG/ML
0224137 METADOL SOLN 0.39 Y N N YPMS /ML
25MG
0224770 METADOL 1.73 E E N YPMS /TB
5MG
0224769 METADOL 0.61 E E N YPMS /TB
METHOTRIMEPRAZINE
25MG/ML
0192769 NOZINAN INJ 3.53 Y Y N YAVT /ML
METHYLPHENIDATE HCL
5MG
0223474 PMS-METHYLPHENIDATE 0.1 Y Y N YPMS /TB
MIDAZOLAM
1MG/ML
0224290 MIDAZOLAM INJECTION 5.8 Y N N YPPC /ML
5MG/ML
0224290 MIDAZOLAM INJECTION 3 Y N N YFMC /ML
0224028 MIDAZOLAM INJECTION 2.53 Y N N YSDZ /ML
OCTREOTIDE
100UG
0241320 OCPHYL 3.3 Y Y N YPED /ML
500UG
0083921 SANDOSTATIN (1ML) 45.65 Y Y N YNVR /ML
0224864 OCTREOTIDE ACETATE OMEGA 52.3 Y Y N YOME /ML
0241321 OCPHYL 16.17 Y Y N YPED /ML
OLANZAPINE
5MG ODT
0232777 SDZ-OLANZAPINE ODT 0.64 Y Y N YSDZ /TB
ONDANSETRON
4MG ODT
0238998 ONDISSOLVE 3.27 Y Y N YTAK /TB
OXYCODONE
10MG
0044394 SUPEUDOL 0.19 Y Y N YSAB /TB
PANTOPRAZOLE
40MG
0237080 SANIS-PANTOPRAZOLE 0.36 Y Y N YSAN /TB
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
238
PHRM/CHRN/CDO/F99:00.98 CD PALLIATIVE RX (continued)
99:00 PALLIATIVE CARE (continued)
PENTAZOCINE
PENTAZOCINE
50 MG
0213798 TALWIN 0.46 Y Y N YAVT /TB
PHENOBARBITAL
120MG/ML
0230409 PHENOBARBITAL SODIUM INJ 13 Y Y N YSDZ /ML
POLYMIXIN
1MG/ML
0223923 SANDOZ POLYTRIMETHOPRIM 2.51 Y Y N Ynull /ML
POTASSIUM CHLORIDE
1.3MMOL/ML
0223860 PMS-POTASSIUM CHL.ORAL SOLN 0.015 Y Y N YPMS /ML
8MMOL
8004022 SLOW-K 0.12 Y Y N YNVR /TB
8001300 JAMP-K-8 0.089 Y Y N YJAM /TB
PROPOXYPHENE
100MG
0026143 DARVON-N 0.6268 Y Y N YPMS /CP
RANITIDINE
25MG/ML
0225671 SDZ-RANITIDINE INJ 1.4 Y Y N YSDZ /ML
SALBUTAMOL
100MCG/DS
0224566 APO-SALVENT CFC FREE INHALER 0.03 Y Y N YAPX /DS
0241985 SALBUTAMOL HFA 0.03 Y Y N YSAI /DS
SODIUM CHLORIDE
0.9%
0006020 NORMAL SALINE IV BAG 500ML 1.86 Y Y N YBAX /ML
SODIUM POLYSTYRENE
1G/1MMOL K
0202696 KAYEXALATE POWDER 0.19 Y Y N YSAW /GM
TIMOLOL MALEATE
0.5%GEL
0224227 TIMOLOL MALEATE-EX GEL SOLN 3.85 Y Y N YALC /ML
ZOPICLONE
7.5MG
0238691 SEPTA-ZOPICLONE 0.23 Y Y N YWHL /TB
99:00.99 CD PALLIATIVE OTC --------------------------------------------------------------
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
239
PHRM/CHRN/CDO/F99:00.99 CD PALLIATIVE OTC
99:00 PALLIATIVE CARE (continued)
ACETAMINOPHEN
ACETAMINOPHEN
325MG
0225280 ACETAMINOPHEN 325MG TABLETS 0.02 Y Y N NPHM /TB
0236234 ACETAMINOPHEN CAPLETS 325MG 0.03 Y Y N NAPX /TB
0193808 ACETAMINOPHEN 0.012 Y Y N NJPC
/TB
0038921 NOVO-GESIC 0.03 Y Y N NNOP /TB
500MG
0193912 JAMP-ACETAMINOPHEN 0.03 Y Y N NJPC
/TB
ACETAMINOPHEN
160/5ML
0202779 PEDIATRIX 0.02 Y Y N NTVM /ML
0222687 ACETAMINOPHEN LIQ 160MG/5ML 0.03 Y Y N NRIV /ML
ACETYLSALICYLIC ACID
81MG
0224389 EXACT ASA 81 MG EC 0.0725 Y Y N NEXA /TB
ARTIFICIAL SALIVA
N/A
9123456 ARTIFICIAL SALIVA 0.2 Y Y N NN/A /null
FERROUS GLUCONATE
300MG
8000043 NOVO-FERROUS GLUCONATE 0.025 Y Y N NNOP /TB
IBUPROFEN
400MG
0050605 APO-IBUPROFEN 0.09 Y Y N NAPX /TB
NYSTATIN
100000U/G
0219423 RATIO-NYSTATIN TOPICAL CREAM 0.06 Y Y N NRTP /GM
SODIUM CHLORIDE
0.9%
0003779 SODIUM CHLORIDE 0.9% INJ 4.06 Y Y N NABB /ML
VITAMIN D
1000IU
0032317 VITAMIN D 0.028 Y Y N NSWI /TB
99:01.00 ANALGESICS ---------------------------------------------------------------------
ACETAMINOPHEN
650MG
0223043 PMS-ACETAMIN SUPP 0.85 Y N N NPMS /SUPP
FENTANYL
50MCG/ML
0238412 FENTANYL CITRATE INJ SDZ 2.6 Y N N YSDZ /ML
0224043 FENTANYL INJECTION 2.6 Y N N YSDZ /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
240
PHRM/CHRN/CDO/F99:01.00 ANALGESICS (continued)
99:00 PALLIATIVE CARE (continued)
IBUPROFEN
IBUPROFEN
100MG/5ML
0223229 CHILDRENS ADVIL 0.06 Y N N NPFI /ML
0224236 MOTRIN 0.05 Y N N NMCL /ML
SUFENTANIL
50MCG/ML
0224414 SANDOZ SUFENTANIL INJ 8.538 Y N N YSDZ /ML
99:03.00 STOOL SOFTENERS ----------------------------------------------------------------
SODIUM DIOCTYL
10MG/ML
0209016 COLACE DROPS 0.177 Y N N NWEL /ML
99:04.00 LAXATIVES ----------------------------------------------------------------------
BISACODYL
10MG
0058288 PMS-BISACODYL 0.4681 Y N N NPMS /SP
0075459 APO-BISACODYL 0.72 Y N N NAPX /SP
0040480 RATIO-BISACODYL 0.72 Y N N NRTP /SP
0000387 DULCOLAX SUPP 0.57 Y N N NBOE /SP
5MG
0054502 APO-BISACODYL 0.05 Y N N NAPX /TB
0058727 PMS-BISACODYL 0.05 Y N N NPMS /TB
GLYCERINE
2.6 G/SUP
0087346 GLYCERINE (ADULT SIZE) 0.0821 Y N N NMCT /SP
KCL/SOD.
4L
0067744 COLYTE 4.82 Y N N YZYP /ML
0065251 G0LYTELY GI LAVAGE 3.37 Y N N YWHL /ML
LACTULOSE
667 MG/ML
0070348 PMS-LACTULOSE SYR 0.01 Y N N NPMS /ML
0241226 LACTULOSE 0.01 Y N N NSAI /ML
667MG/ML
0224281 APO-LACTULOSE SYRUP 0.01 Y N N NAPX /ML
0085440 RATIO-LACTULOSE SYRUP 0.01 Y N N NRTP /ML
MAG OXIDE/CITRIC
3.5G/12G/10MG
0231796 PURG-ODAN 4.8 Y N N NODA /EA
0225479 PICO-SALEX 6 Y N N NFER /EA
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
241
PHRM/CHRN/CDO/F99:04.00 LAXATIVES (continued)
99:00 PALLIATIVE CARE (continued)
MAGNESIUM CITRATE
MAGNESIUM CITRATE
15GM/300ML
0026260 CITRO MAG 0.014 Y N N NROU /ML
MAGNESIUM
60MG/ML
0020204 MAGNOLAX 0.01 Y N N NWAM /ML
MINERAL OIL
100%
0010787 FLEET MINERAL OIL ENEMA 0.04 Y N N NJJM
/ML
POLYETHYLENE GLYCOL
3350
0235803 PEG 3350 LAXATIVE 0.03 Y N N NWHL /GM
0231768 LAX-A-DAY 0.04 Y N N NPEN /GM
0231816 RESTORALAX 0.04 Y N N NSCH /GM
SENNA
1.7MG/ML
8002439 SENNAQUIL LIQUID 0.032 Y N N NJPC
/ML
0036772 SENOKOT 0.044 Y N N NPUR /ML
12MG
0089640 PMS-SENNOSIDES 0.074 Y N N NPMS /TB
187MG
0002615 SENOKOT 0.157 Y N N NPFR /TB
8.6MG
0206810 SENNATAB 0.266 Y N N NPMS /TB
0223710 SENNA LAXATIVE 0.054 Y N N NVTH /TB
0195739 SENNA LAXATIVE 0.052 Y N N NTAN /TB
0089641 PMS-SENNOSIDES 0.063 Y N N NPMS /TB
0224623 SENNA LAXATIVE 0.0528 Y N N NPMS /TB
SENNA/SOD DIOCT.
187MG
0002612 SENOKOT S 0.117 Y N N NPFR /TB
SENNOSIDES
25MG
0224500 LB LAXATIVE X-STRENGTH 0.108 Y N N NSAI /TB
SOD
90/9/625ML
0206390 MICROLAX MICRO-ENEMA 2.89 Y N N NPMS /ML
SOD PHOSPHATE DI- &
180/480MG
0223039 PHOSPHATES 0.086 Y N N NPMS /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
242
PHRM/CHRN/CDO/F99:04.00 LAXATIVES (continued)
99:00 PALLIATIVE CARE (continued)
SOD PHOSPHATE DI- & MONOBASIC (continued)
6GM/100ML
0209690 ENEMOL LIQ RT 0.023 Y N N NPMS /ML
0000991 FLEET ENEMA 0.0298 Y N N NJJM
/ML
900MG/2.4G
0220621 FLEET PHOSPHO-SODA ORAL 0.0838 Y N N NJJ
/ML
99:05.00 ANTIEMETICS --------------------------------------------------------------------
DIMENHYDRINATE
100MG
0001360 GRAVOL 0.538 Y N N NHOR /SP
0039254 SAB-DIMENHYDRINATE 0.56 Y N N NSAB /SP
15MG/5ML
0023019 GRAVOL ORAL LIQUID 0.0708 Y N N YHOR /ML
25MG
0078359 GRAVOL 0.496 Y N N NHOR /SUPP
50MG
0060578 TRAVEL AID 0.01 Y N N NVTH /TB
0036376 APO-DIMENHYDRINATE 0.02 Y N N NAPX /TB
0002142 NOVO-DIMENATE 0.06 Y N N NNOP /TB
0001380 GRAVOL 0.13 Y N N NHOR /TB
0224526 DIMENHYDRINATE 0.0135 Y N N NPRO /TB
0237717 ANTI-NAUSEANT 0.02 Y N N NAPX /TB
50MG/ML
0039253 DIMENHYDRINATE IM (5ML) 1.38 Y N N YSAB /ML
0001357 GRAVOL (5ML) 1.151 Y N N YHOR /ML
LANSOPRAZOLE
15MG
0224946 PREVACID FASTAB 2 Y N N YTAP /TB
30MG
0224947 PREVACID FASTAB 2 Y N N YTAP /TB
99:06.00 ARTIFICIAL SALIVA & TEARS ------------------------------------------------------
CARBOXYMETHYL
10MG/ML
0224465 REFRESH LIQUIGEL 0.42 Y N N NALL /ML
CHLORHEXIDINE
0.12%
0220905 ORO-CLENSE RINSE 0.0165 Y N Y YWHL /ML
99:07.00 ANTISPASMOTICS -----------------------------------------------------------------
ATROPINE SULFATE
0.4MG/ML
0039278 ATROPINE SULFATE INJ 2.29 Y N N YSDZ /ML
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
243
PHRM/CHRN/CDO/F99:07.00 ANTISPASMOTICS
99:00 PALLIATIVE CARE (continued)
ATROPINE SULFATE (continued)
0.6 MG/ML
0039269 ATROPINE SULFATE INJ 2.49 Y N N YSDZ /ML
GLYCOPYRROLATE
0.2MG/ML
0203950 GLYCOPYRROLATE INJECTION 3.98 Y N N YSDZ /ML
SCOPOLAMINE N-
0.6MG/ML
0054187 HYOSCINE BUTYLBROMIDE INJ 5.36 Y N N YHOS /ML
20MG/ML
0222986 HYOSCINE BUTYLBROMIDE INJ 4.52 Y N N YSAB /ML
99:09.00 VITAMIN SUPPLEMENTS/FOOD SUPPLEMENTS -------------------------------------------
CALCIUM
100MG/5ML
8000687 CALCIUM LIQUID 0.1066 Y N N NWAM /ML
99:10.00 ANTI-INFECTIVES ----------------------------------------------------------------
SECURA
NA
8000862 EXTRA PROTECTIVE CR 0.08 Y N N NSEC /GM
99:11.00 APPETITE STIMULANTS ------------------------------------------------------------
CYPROHEPTADINE
4 MG
0075771 PMS-CYPROHEPTADINE HCL 0.23 Y N N NPMS /TB
99:13.00 ANTIPRURITICS AND LOCAL ANESTHETICS --------------------------------------------
DIPHENHYDRAMINE
2%
0201970 BENADRYL CREAM 2% 0.27 Y N N NPFC /GM
LIDOCAINE
10MG/ML
0229619 XYLOCAINE 1% INJ 1.6 Y N N NALV /ML
20MG/ML
0000169 XYLOCAINE 2% JELLY 0.47 Y N N NAST /ML
LIDOCAINE 1%-50 ML
10MG/ML
0000173 XYLOCAINE 1% INJ-50 ML 0.93 Y N N NAST /ML
LIDOCAINE/PRILOCAINE
25MG
0088685 EMLA 1.3 Y N N NAST /GM
99:14.00 PARENTERAL/IV SOLUTIONS --------------------------------------------------------
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
244
PHRM/CHRN/CDO/F99:14.00 PARENTERAL/IV SOLUTIONS
99:00 PALLIATIVE CARE (continued)
DEXTROSE/SODIUM CHLORIDE
DEXTROSE/SODIUM
3.3%.3%
0006071 DEXTROSE/SOD.CHLORIDE IV 0.09 Y N N YBAX /ML
5%/0.45%
0003890 DEXTROSE 5% IN 0.45% NACL 0.002 Y N N YHOS /ML
99:15.00 MISC.GASTROINTESTINAL DRUGS ----------------------------------------------------
ALUMINUM/MAGNESIUM
200/200/20MG
0224468 MAALOX ANTACID PLUS 0.01 Y N N NNVR /ML
LOPERAMIDE
2MG
0213259 NOVO-LOPERAMIDE 0.15 Y N N NTVM /TB
0225756 SANDOZ LOPERAMIDE 0.27 Y N N NSDZ /TB
0224899 DIARRHEA RELIEF 0.2466 Y N N NPMS /TB
0222835 PMS-LOPERAMIDE 0.15 Y N N NPMS /TB
RANITIDINE
25MG/ML
0221236 ZANTAC 1.421 Y N N YGSK /ML
99:16.00 ANTIHISTAMINE ------------------------------------------------------------------
CETIRIZINE
10MG
0224026 ALLERGY - RELIEF 0.5 Y N N NAPX /TB
0223160 APO-CETIRIZINE 0.4083 Y N N NAPX /TB
0222355 REACTINE 0.39 Y N N NPFC /TB
20MG
0190097 REACTINE 0.8595 Y N N NPFI /TB
DIPHENHYDRAMINE
25MG
0075768 PMS-DIPHENHYDRAMINE 0.09 Y N N NPMS /CP
0222949 ALLERGY FORUMULA - 0.1186 Y N N NVIT /TB
50MG
0075769 PMS-DIPHENHYDRAMINE CAP 0.11 Y N N NWHL /CP
0201967 BENADRYL S 0.2514 Y N N NPFI /CP
50MG/ML
0059661 DIPHENHYDRAMINE INJECTION 4.04 Y N N NSDZ /ML
Exception Drug Status TableChronic Disease Program (CHRN)
Pharmacare Program (PHRM)
08.00 ANTI-INFECTIVE AGENTS
08:12.02 -AMINOGLYCOSIDES
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
245
TOBRAMYCIN CHRNPHRM
For Cystic Fibrosis patients who cannot tolerate injectable, preservative-free tobramycin when used for inhalation. Specialist's consult to beprovided.
TOBRAMYCIN SULFATE CHRNPHRM
For Cystic Fibrosis patients who cannot tolerate injectable, preservative-free tobramycin when used for inhalation. Specialist's consult to beprovided.
TOBRAMYCIN SULFATE CHRNPHRM
For inhalation therapy for the treatment of cystic fibrosis.
GENTAMICIN S04 CHRNPHRM
For treatment of resistant organisms or other special circumstances.
08:12.04 - ANTIBIOTICS(ANTIFUNGALS)ITRACONAZOLE CHRN
PHRMFor severe systemic fungal infections or severe or resistant fungalinfections in immunocompromised patients, or for the treatment of severeonychomycosis caused by dermatophyte fungi as confirmed by labratoryresults. (secondary to approved chronic condition for patients on theChronic Disease Program).
VORICONAZOLE CHRNPHRM
For severe systemic fungal infections or severe or resistant fungalinfections in immunocompromised patients, or for the treatment of severeonychomycosis caused by dermatophyte fungi as confirmed by labratoryresults. (secondary to approved chronic condition for patients on theChronic Disease Program).
NYSTATIN CHRN Treatment of a serious fungal infection in immuno-compromised patients.Treatment of a condition secondary to an approved chronic disease. Pleaseprovide a description of the infection.
FLUCONAZOLE CHRN Treatment of a serious fungal infection in immuno-compromized patientssecondary to an approved chronic condition. Please provide description ofinfection.
KETOCONAZOLE CHRN Treatment of a serious fungal infection in immuno-compromized patientssecondary to an approved chronic condition. Please provide description ofinfection.
NYSTATIN CHRN Treatment of a serious fungal infection in immuno-compromized patientssecondary to an approved chronic condition. Please provide description ofinfection.
TERBINAFINE CHRN Treatment of a serious fungal infection in immuno-compromized patientssecondary to an approved chronic condition. Please provide description ofinfection.
08:12.06 -CEPHALOSPORINSCEFACLOR CHRN Case-by-case basis: For treatment of chronic infections secondary to an
approved chronic condition. (Please include anticipated duration oftherapy).
CEFAZOLIN SODIUM CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
CEFIXIME CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
CEFPROZIL CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
CEFTAZIDIME CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
CEFTRIAXONE CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
246
CEFUROXIME AXETIL CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
CEPHALEXIN MONOHYDRATE CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
08:12.12 - MACROLIDES
AZITHROMYCIN CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
CLARITHROMYCIN CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
ERYTHROMYCIN BASE CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
ERYTHROMYCIN ESTOLATE CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
ERYTHROMYCINETHYLSUCCINATE
CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
ERYTHROMYCIN STEARATE CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
08:12.16 - PENICILLINS
AMOXICILLIN (AMOXYCILLIN) CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
AMOXICILLIN/CLAVULANICACID
CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
AMPICILLIN CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
CLOXACILLIN CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
PENICILLIN V (POTASSIUM) CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
PIPERACILLIN/TAZOBACTAM CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
08:12.24 - TETRACYCLINES
DOXYCYCLINE CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
MINOCYCLINE HCL CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
TETRACYCLINE CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
MINOCYCLINE HCL CHRN For treatment of RA - recommendation of Rheumatologist. Consult fromspecialist to be provided.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
247
08:12.28 - ANTIBIOTICS(MISCELLANEOUSANTIBIOTICS)CLINDAMYCIN HCL CHRN Case-by-case basis: For treatment of chronic infections secondary to an
approved chronic condition. (Please include anticipated duration oftherapy).
CLINDAMYCIN PALMITATEHCL
CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
RIFABUTIN CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
RIFAMPIN CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
VANCOMYCIN HCL CHRN Case-by-case basis: For treatment of chronic infections secondary to anapproved chronic condition. (Please include anticipated duration oftherapy).
RIFAXIMIN CHRNPHRM
For reducing the risk of overt hepatic encephalopathy (HE) recurrence(after 2 or more episodes), if the following criteria are met:-patient is unable to achieve adequate control of HE recurrence withmaximal tolerated dose of lactulose alone -must be used in combination with a maximal dose of lactulose-for patients not maintained on lactulose, details are required regardingthe nature of the patient's intolerance to lactulose
08:18.00 - ANTIVIRALS
ACYCLOVIR CHRN Case-by-case basis: Treatment of immuno-compromised patients,secondary to an approved condtion.
AMANTADINE CHRN Case-by-case basis: Treatment of immuno-compromised patients,secondary to an approved condtion.
FAMCICLOVIR CHRN Case-by-case basis: Treatment of immuno-compromised patients,secondary to an approved condtion.
GANCICLOVIR SO4 CHRN Case-by-case basis: Treatment of immuno-compromised patients,secondary to an approved condtion.
VALACYCLOVIR CHRN Case-by-case basis: Treatment of immuno-compromised patients,secondary to an approved condtion.
VALGANCICLOVIR CHRNPHRM
Case-by-case basis: Treatment of immuno-compromised patients.Approval x 6 months.
RIBAVIRIN/PEGINTERFERONALFA2A
CHRNPHRM
Positive Hepatitis C serology and ALT > 1.5 times normal for 6 months andon recommendation of Gastroenterologist or Infectious Disease Specialist.Specialists consult to be provided. Review on case-by-case basis.COVERAGE WILL BE PROVIDED FOR 1 YEAR. Coverage for one course oftreatment only.
RIBAVIRIN/PEGINTERFERONALFA2B
CHRNPHRM
Positive Hepatitis C serology and ALT > 1.5 times normal for 6 months andon recommendation of Gastroenterologist or Infectious Disease Specialist.Specialists consult to be provided. Review on case-by-case basis.COVERAGE WILL BE PROVIDED FOR 1 YEAR. Coverage for one course oftreatment only.
08:18.08 -ANTIRETROVIRAL AGENTSCOBICISTAT/EMTRICITABINE/ELVIT
CHRNPHRM
As a complete regimen for antiretroviral treatment-naïve HIV-1 infectedpatients in whom efavirenz is not indicated.
EMTRICITABINE/RILPIVIRINE/TENO
CHRNPHRM
As a complete regimen for antiretroviral treatment-naïve HIV-1 infectedpatients in whom efavirenz is not indicated.
EFAVIRENZ/TENOFOVIR/EMTRICITAB
CHRNPHRM
Case-by-case basis: On recommendation of Specialist.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
248
ENTECAVIR CHRNPHRM
Case-by-case basis: On recommendation of Specialist.
RALTEGRAVIR CHRNPHRM
Case-by-case basis: On recommendation of Specialist.
TENOFOVIR CHRNPHRM
Case-by-case basis: On recommendation of Specialist.
TENOFOVIR/EMTRICITABINE CHRNPHRM
Case-by-case basis: On recommendation of Specialist.
ADEFOVIR DIPIVOXIL CHRNPHRM
For chronic hepatitis B patients who developed resistance or failed a 3month trial of lamivudine when prescribed by a specialist.
DOLUTEGRAVIR CHRNPHRM
For the treatment of HIV in both treatment-naive and treatment-experienced adults and children 12 years of age and older weighing atleast 40kg, in combination with other antiretrovirals.
COBICISTAT/DARUNAVIR CHRNPHRM
For treatment of human immunodeficiency virus (HIV) infection intreatment-naive and treatment-experienced patients without darunavir(DRV) resistance-associated mutations, when prescribed by an infectiousdisease specialist.
ABACAVIR/DOLUTEGRAVIR/LAMIVUDI
CHRNPHRM
When prescribed by an infectious disease specialist.
DARUNAVIR CHRNPHRM
When prescribed by an infectious disease specialist.
RILPIVIRINE HCL CHRNPHRM
When prescribed by an infectious disease specialist.
08:18.32 - NUCLEOSIDESAND NUCLEOTIDESRIBAVIRIN CHRN
PHRMOn recommendation of an infectious disease specialist for use within acombination therapy regimen for the treatment of chronic hepatitis C, inaccordance with the specific eligibility criteria for approved agents, used totreat this condition.
08:18.40 - HCV ProteaseInhibitors
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
249
OMBITASVIR/PARITAPREVIR/RITONA
CHRNPHRM
For patients that meet the eligibility criteria below clinicians areencouraged to use Holkira Pak as one of the preferred therapeutic optionsover other covered therapies (eg: interferon-based regimens with NS3/4Aprotease inhibitors or polymerase inhibitors). This recommendation isbased on Holkira Pak's advantages in some patient populations, includingpotentially higher SVR rates, improved tolerability, no need forconcommitant interferon, and a shorter course of therapy.For treatment-naive and treatment-experienced adult patients withchronic hepatitis C genotype 1 infection, with compensated liver disease(including compensated cirrhosis*) according to the following criteria:-prescribed by an infectious disease specialist or hepatologist. Consult tobe provided.-lab-confirmed hepatitis C genotype 1, subtype 1a and 1b required-patient has quantitative HCV RNA value within the last 6 months-fibrosis stafe F2 or greater (Metavir scale or equivalent)DURATION OF THERAPY REIMBURSED:12 weeks for treatment naive & experienced # genotype 1b, non-cirrhotic12 weeks in combination with ribavirin for:treatment naive & experienced genotype 1a, non-cirrhotic;OR for treatment naive & expereinced genotype 1b, cirrhoticOR for treatment naive & expereinced (prior relapsers & prior partialresponders) genotype 1a, cirrhotic24 weeks in combination with ribavirin for treatment experiencedgenotype 1a, with cirrhosis & who have had a previous null response topegIFN and RBVEXCLUSION CRITERIA;-patients currently being treated with another HCV antiviral agent-patients who have received a previous trial of Holkira Pak (re-treatmentrequests will NOT be considered)-decompensated patients-no funding for other genotypes except as noted above for genotype 1-patients who have received previous NS3/4A protease inhibitor-basedregimens (ie:boceprevir, telaprevir & simeprevir based regimens)-patients who have received previous sofosbuvir-based regimensCommentsHIV-HCV co-infected patients with genotype 1 may be considered as percriteria listed aboveHolkira Pak is recommended in patients with unknown genotype 1 subtypeor with mixed genotype 1 infection * compensated cirrhosis is defined as cirrhosis with a Child Pugh Score =A(5-6)# treatment experienced patients are defined as those who have previouslybeen treated with PegINF/RBV and did NOT receive adequate response
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
250
LEDIPASVIR/SOFOSBUVIR CHRNPHRM
For patients that meet the eligibility criteria outlined below clinicians areencouraged to use Harvoni as one of the preferred therapeutic option overother covered therapies(eg: interferon-based regimens with NS3/4Aprotease inhibitors or polymerase inhibitors). This recommendation isbased on Harvoni's advantages in some patient populations, includingpotentially higher SVR rates, improved tolerability, no need forconcomitant interferon or ribavirin therapy, shorter course of therapy, andonce daily dosing.For treatment-naive and treatment-experienced adult patients withchronic hepatitis C genotype 1 infection, with compensated liver disease,(including compensated cirrhosis*) according to the following criteria:-Prescribed by an infectious disease specilaist or hepatologist. Consult tobe provided.-Lab-confirmed hepatitis C genotype 1-Patient has quantitative HCV RNA value within the last 6 months-Fibrosis stage F2 or greater (Metavir scale or equivalent)Duration of therapy reimbursed:8 weeks for treatment-naive, non-cirrhotic patients, with viral load <6 MIU/ml#12 weeks for treatment-naive, non-cirrhotic patients, with viral load 6 MIU/ml, treatment naive cirrhotic patients OR treatment- experienced non-cirrhotic patients@24 weeks for treatment-experienced cirrhotic patientsExclusion criteria:-Patients currently being treated with another HCV antiviral agent-Patients who have received a previous trial of Harvoni (Re-treatmentrequests will NOT be considered)Notes:* Compensated cirrhosis is defined as cirrhosis with a Child Pugh Score =A(5-6)# Treatment regimens of up to 12 weeks may be considered for patientswith borderline or severe fibrosis (F3-4) or if they are co-infected with HIV.@ Treatment experinced is defined as those who failed prior therapy withan interferon-based regimen, including regimens containing an HCVprotease inhibitorTreatment of decompensated HCV may be considered for coverage on anexceptional case-by-case basis.
SIMEPREVIR CHRNPHRM
In combination with peginterferon alfa and ribavirin, for the treatment ofchronic hepatitis C genotype 1 infection in adults with compensated liverdisease if the following clinical criteria & conditions are met:Detectable levels of hepatitis C virus (HCV) RNA in the last 6 months; ANDA fibrosis stage of F2, F3 or F4Conditions:Patients should have their HCV strain tested for NS3 Q80K polymorphismDosage: 150mg once daily for 12 weeks in combination with peginterferonalfa & ribavirinResponse-guided therapy (RGT) for treatment naive patients or treatmentexperienced patients as per Product Monograph & Treatment Futility Ruleas per Product MonographRenewals ar not consideredExclusion Criteria:Patients with the NS3 Q80K polymorphismPatients who have received a prior treatment with boceprevir or telaprevirin combination with pegINF/RBV and did NOT receive an adequateresponsePatients not genotype 1Fibrosis stage less than F2 (metavir scale or equivalent)Decompensated liver diseasePatients less than 18 years of ageSimeprevir monotherapySimeprevir in combination with sofosbuvir
08:18.92 - MISCELLANEOUSANTIVIRALS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
251
BOCEPREVIR CHRNPHRM
For hepatitis c patients with detectable levels of Hepatitis C virus RNA inthe last 6 months and a fibrosis stage of F2, F3, or F4. One course of treatment only (up to 44 weeks)
BOCEPREVIR/RIBAVIRIN/PEGINTERF
CHRNPHRM
For hepatitis c patients with detectable levels of Hepatitis C virus RNA inthe last 6 months and a fibrosis stage of F2, F3, or F4. One course of treatment only (up to 44 weeks)
SOFOSBUVIR CHRNPHRM
For the treatment of adult patients with chronic hepatitis C infection withcompensated liver disease, (including compensated cirrhosis)(1) asfollows:Genotype 1 (for 12 weeks in combination with Pegylated interferon(pegIFN)/Ribavirin (RBV)): treatment-naive patients ORGenotype 2 (for 12 weeks in combination with RBV): treatment-naivepatients in whom interferon (IFN) is medically contraindicated(2) ORPegIFN/RBV treatment-experienced(3) patients ORGenotype 3 (for 24 weeks in combination with RBV): treatment-naivepatients in whom IFN is medically contraindicated OR PegIFN/RBVtreatment-experienced patientsAND who meet ALL of the following:A. Prescribed by a hepatologist, gastroenterologist or infectious diseasespecialist. Consult to be provided.B. Lab-confirmed hepatitis C genotype 1, 2 or 3C. Patient has a quantitative HCV RNA value within the last 6 monthsD. Fibrosis stage F2 or greater (Metavir scale or equivalent)Exclusion criteria:-patients currently being treated with another HCV antiviral agent-patients who have previously received a treatment course of Sovaldi (Re-treatment requests will NOT be considered).Notes:(1) Compensated cirrhosisis is defined as cirrhosis with a Child Pugh Score= A (5-6)(2) Medical contraindication to IFN is defined as hypersensitivity toperinterferon or interferon alfa-2a or 2b, polyethylene glycol or anycomponent of the formulation resulting in discontinuation of therapy; ORpresence of significant clinical co-morbidities which are deemed to have ahigh risk of worsening with IFN treatment. Details are required regardingpatient's contraindications or risk of worsening comorbidities. (3) Treatment-experienced patients (with genotype 2 or 3) are defined aspatients who have previously been treated with PegIFN/RBV and did NOTreceive adequate response.HIV-HCV co-infected patients may be considered as per above criteria.Treatment of decompensated HCV may be considered for coverage on anexceptional case-by-case basis. Provide complete documentation.
TELAPREVIR CHRNPHRM
For the treatment of chronic hepatitis C with detectable levels of HepatitisC virus in the last 6 months and a fibrosis stage of F2, F3, or F4. Not to beused in patients co-infected with HIVOne course of treatment only.
08:22.00 - QUINOLONES
CIPROFLOXACIN CHRNCHRNPHRM
For treatment of resistant organisms or those not responding toalternative agents. (Please put anticipated duration entered on applicationform).
LEVOFLOXACIN CHRNCHRNPHRM
For treatment of resistant organisms or those not responding toalternative agents. (Please put anticipated duration entered on applicationform).
MOXIFLOXACIN CHRNCHRNPHRM
For treatment of resistant organisms or those not responding toalternative agents. (Please put anticipated duration entered on applicationform).
NORFLOXACIN CHRNCHRNPHRM
For treatment of resistant organisms or those not responding toalternative agents. (Please put anticipated duration entered on applicationform).
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
252
MOXIFLOXACIN CHRNPHRM
For treatment of resistant organisms and when alternate agents cannot beused.
LEVOFLOXACIN IV CHRNPHRM
When unable to tolerate oral form.
08:26.00 - SULFONES
DAPSONE CHRN On recommendation of a specialist. Specialists consult to be provided.
08:36.00 - URINARY ANTI-INFECTIVESNITROFURANTOIN CHRN For treatment secondary to an appproved chronic condition.
NITROFURANTOINMONOHYDRATE
CHRN For treatment secondary to an appproved chronic condition.
TRIMETHOPRIM CHRN For treatment secondary to an appproved chronic condition.
NITROFURANTOIN CHRN For treatments secondary to an approved chronic condition.
08:40.00 - MISCELLANEOUSANTI-INFECTIVESATOVAQUONE CHRN For treatment of resistant organisms or other special circumstances.
Treatment of a condition secondary to an approved chronic disease.
METRONIDAZOLE CHRN For treatment of resistant organisms or other special circumstances.Treatment of a condition secondary to an approved chronic disease.
SULFA/TRIMETH(CO-TRIMOXAZOLE)
CHRN For treatment of resistant organisms or other special circumstances.Treatment of a condition secondary to an approved chronic disease.
10.00 ANTINEOPLASTIC AGENTS
10:00.00 -ANTINEOPLASTIC AGENTSLENALIDOMIDE CHRN
PHRMA) Any newly identified Multiple Myeloma patient who has failed at leastone prior therapy, including transplant,B)Any patient with transfusion-dependent anemia due to low orintermediate-1-risk MDS associated with a deletion 5q cytogeneticabnormality with or without additional cytogenetic abnormalities,C) Any newly diagnosed Multiple Myeloma patient following autologousstem-cell transplantation & the patient's disease is stable or better with noevidence of disease progression i) the patient will continue to be eligible provided that the patient'sdisease is not progressing & that the patient is not experiencingunacceptable toxicity ii) the recommended dosage is 10mg daily. Dosage adjustments in therange of 5mg to 15mg may be necessary based on individual patientcharacteristics/responsesD) Any newly diagnosed Multiple Myeloma patient as an option for first linetreatment who are not eligible for autologous stem-cell transplantation(TNE). Treatment should be in combination with dexamethasone forpatients with an ECOG performance status less than or equal to 2 & untildisease progression.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
253
EVEROLIMUS CHRNPHRM
Advanced Breast Cancer: For the treatment of hormone-receptor positive,HER2 negative advanced breast cancer, in postmenopausal women withECOG performance status 2 after recurrence or progression following anon-steroidal aromatase inhibitor (NSAI), if the treating oncologist wouldconsider using exemestane. Dosing 10mg dailyPancreatic Neuroendocrine Tumours: For the treatment of patients withprogressive, unresectable, well or moderately differentiated locallyadvanced or metastatic pancreatic neuroendocrine tumours (pNET) withgood performance status (ECOG o-2), until disease profression. NOTE:Patients whose disease progresses on everolimus are not eligible forfunded treatment with sunitinib for pNET. Dosing: 10mg dailyMetastatic Renal Cell Carcinoma: For the treatment of metastatic renal cellcarcinoma with clear cell morphology, in patients previously treated with afunded tyrosine kinase inhibitor. Dosing 10mg daily
TRASTUZUMAB EMTANSINE CHRNPHRM
As a second line therapy for patients with HER2-positive, unresectablelocally advanced or metastatic breast cancer with an ECOG statusperformance of 0 or 1, who have received prior treatment withtrastuzumab plus chemotherapy in the metastatic setting or have diseaserecurrence during or within 6 months of completing adjuvant therapy withtrastuzumab plus chemotherapy.
IPILIMUMAB CHRNPHRM
First line treatment of adult patients with advanced (unresectable ormetastatic) melanoma: for a dosing schedule of 3mg/kg, every 3 weeks for4 doses as a first-line therapy for patients with primary cutaneousunresectable state IIIC or IV melanoma, regardless of BRAF mutationstatus, who have an ECOG PS 1 and are not currently receivingimmunosuppressive therapy. If brain metastases are present, patientsshould be asymptomatic or stable.ANDFor the treatment of advanced melanoma (unresectable or metastatic StageIII or Stage IV) in patients who have received prior systemic therapy.
BEVACIZUMAB CHRNPHRM
For cervical cancer in combination with chemotherapy for the treatment ofpatients with metastatic (Stage IVB), persistent, or recurrent carcinoma ofthe cervix of all histologic subtypes (except small cell) AND patient hasECOG 1.For ovarian cancer in combination with paclitaxel and carboplatin for thefront-line treatment of epithelial ovarian, fallopian tube or primaryperitoneal cancer patients with high risk of relapse (stage III sub-optimallydebulked, or stage III unresectable, or stage IV patients); AND patient hasECOG 2.For colorectal cancer as per BCCA protocol.
AFATINIB CHRNPHRM
For first line treatment of patients with EGFR mutation positive advancedor metastatic adenocarcinoma of the lung and with an ECOG performancestatus of 0 or1.
RUXOLITINIB PHRM For patients with intermediate to high risk symptomatic Myelofibrosis (MF)as assessed using the Dynamic International Prognostic Scoring System(DIPSS) Plus or patients with symptomatic splenomegaly. Patients shouldhave ECOG performance status 3 and be either previously untreated orrefractory to other treatment. Dosing 5 to 25 mg bid
REGORAFENIB CHRNPHRM
For patients with metastatic and/or unresectable gastrointensintal stromaltumours (GIST) who have had disease progression on, or intolerance to,imatinib and sunitinib; ANDPatient has ECOG less than or equal to 1
VISMODEGIB CHRNPHRM
For patients with metastatic basal cell carcinoma (BCC) or with locallyadvanced BCC (including patients with basal cell nevus syndrome, ie.Gorlin Syndrome) who have measurable metastatic disease or locallyadvanced disease, which is considered inoperable or inappropriate forsurgery and inappropriate for radiotherapy; ANDPatient is 18 years or older; ANDPatient has ECOG less than or equal to 2
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
254
POMALIDOMIDE CHRNPHRM
For patients with relapsed and/or refractory multiple myeloma who havepreviously failed at least two treatments, including both bortezomib &lenalidomide & demonstrated disease progression on the last treatment.Pomalidomide is also be an option in rare instances where bortezimib iscontraindicated or when patients are intolerant to it; however in all casespatients should have failed lenalidomide which they may have received inthe maintenance setting.Treatment failure of bortezomib includes those patients who havepreviously received a course of bortezomib during which there was nodisease progression, but are not eligible for bortezomib retreatment at thetime of disease relapse.
ROMIDEPSIN CHRNPHRM
For patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)who are ineligible for transplant & who have undergone previous systemictherapy.Eastern Cooperative Performance Status (ECOG) of 0 to 2.Dosing: Romidepsin 14mg/m2 intravenously on days 1, 8 and 15 (cyclelength is 28 days)Treatment will continue until progression or unacceptable toxicity.
RITUXIMAB CHRNPHRM
For severe RA, when used in combination with methotrexate and whenfailure of anti-TNF trial. On recommendation of a Specialist.Specialistsconsult to be provided. COVERAGE FOR 6 MONTHS. Re-treatmentconsidered for patients who have achieved a response, followed by loss ofeffect after an interval of no less than 6 months since dose.
PEMBROLIZUMAB CHRNPHRM
For the treatment of patients with advanced melanoma (unresectable ormetastatic melanoma) for the following indications;-patients who are naive to ipilimumab treatment (patients with BRAFmutation positive may or may not have received BRAF targeted therapy)and-patients who have failed ipilimumab and, if BRAF mutation positive, havealso failed BRAF mutation therapyTreatment in either setting should be in patients with an ECOGperformance status 0 or 1, and who have stable brain metastases (ifpresent).
PONATINIB HCL CHRNPHRM
For the treatment of patients with chronic phase, accelerated phase orblast phase chronic myeloid leukemia (CML) or Philadelphia chromosomepositive acute lymphoblastic leukemia (Ph+ ALL) for whom other tyrosinekinase inhibitor (TKI) therapy is not appropriate, including CML or Ph+ ALLthat is T315i mutation positive or where there is resistance or intoleranceto prior TKI therapy. Funding will be for ECOG performance status 0-2.Treatment should continue until unacceptable toxicity or diseaseprogression. Other TKI therapy is not appropriate for patients who;-have confirmed T315i mutation positive disease, independent of previousTKI therapy-have CML or Ph+ ALL who have resistance/disease progression after atleast two prior lines of TKI therapy where Iclusig would be available asthird line TKI option, or who have intolerance to prior TKI therapy
BOSUTINIB CHRNPHRM
For treatment of patients with chronic, accelerated or blast phasePhiladelphia chromosome positive (Ph+) chronic myelogenous leukemia(CML) who have resistance/disease progression after at least one prior lineof tyrosine kinase inhibitor (TKI) therapy or who have intolerance to priorTKI therapy and for whom treatment with bosutinib is considered the mostclinically appropriate option.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
255
ENZALUTAMIDE CHRNPHRM
For treatment of patients with metastatic castration resistant prostatecancer, who have progressed on docetaxel-based chemotherapy with anECOG performance status 2 and no risk factors for seizures and would bean alternative to abiraterone for patients in the post-docetaxel setting butwould would not be an add-on therapy to abiraterone treatment;ANDFor the treatment of patients with asymptomatic or mildly symptomaticmetastatic castration-resistant prostate cancer (mCRPC) who haveevidence of disease progression following androgen deprivation therapy(ADT), who have not received prior chemotherapy for mCRPC and whohave an ECOG performance status of 0 or 1, and no risk factor forseizures.
IDELALISIB CHRNPHRM
Idelalisib (Zydelig) in combination with rituximab for the treatment ofpatients with relapsed chronic lymphocytic leukemia (CLL). Treatmentshould continue until unacceptable toxicity or disease progression.
OBINUTUZUMAB CHRNPHRM
In combination with chlorambucil for previously untreated chroniclymphocytic leukemia (CLL) & adequate renal function, for whomfludarabine-based treatment is considered inappropriate.ORIn combination with chlorambucil for previously untreated CLL wherefludarabine-based therapy is considered inappropriate & the patient hasinitated treatment with single-agent chlorambucil in the past 3 months.
RAMUCIRUMAB CHRNPHRM
In combination with paclitaxel for the treatment of patients with advancedor metastatic gastric cancer or gastro-esophageal junction (GEJ)adenocarcinoma with an Eastern Cooperative Oncology Group (ECOG)performance status of 0 or 1 and with disease progression following first-line chemotherapy.
ABIRATERONE ACETATE CHRNPHRM
In combination with prednisone for the treatment of metastatic prostatecancer (castration-resistant prostate cancer) in patients who:-are asymptomatic or mildly symptomatic after failure of androgendeprivation therapy AND-have received prior chemotherapy containing docetaxel after failure ofandrogen deprivation therapy
DABRAFENIB MESYLATE CHRNPHRM
Monotherapy as a first-line BRAF-mutation targeted treatment for patientswith BRAF V600 mutation-positive, unresectable or metastatic melanomawith an ECOG performance status of 0 or 1. If brain metastases arepresent, patients should be asymptomatic or have stable symptoms.Treatment should continue until disease progression or the developmentof unacceptable toxicity.Tafinlar and Mekinist combination therapy as a first-line BRAF-mutationtargeted treatment for patients with BRAF V600 mutation postitive,unresectable or metastatic melanoma & who have an ECOG performancestatus of 0 or 1. Treatment should continue until disease progression. Ifbrain metastases are present, patients shuld be asymptomatic or havestable symptoms.Tafinlar is NOT approved in patients who have progressed on a prior BRAFinhibitor therapy.
TRAMETINIB CHRNPHRM
Monotherapy as a first-line BRAF-mutation targeted treatment of patientswith BRAF V600 mutation-positive, unresectable or metastatic melanomaand with an ECOG performance of 0 or 1. If brain metastases are present,patients should be asymptomatic or have stable symptoms. Treatmentshould continue until disease progression or the development ofunacceptable toxicity.Mekinist and Tafinlar combination therapy as a first-line BRAF-mutationtargeted treatment for patients with BRAF V600 mutation positive,unresectable or metastatic melanoma and who have an ECOG performancestatus of 0 or 1. If brain metastases are present patients should beasymptomatic or have stable symptoms. Treatment should continue untildisease progression.Mekinist is NOT approved in patients who have progressed on a prior BRAFinhibitor therapy.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
256
BEVACIZUMAB CHRNPHRM
On recommendation of a specialist for treatment of age-related maculardegeneration, or diabetic macular edema, or visual impairment due tomacular edema secondary to central vein occlusion.
IBRUTINIB CHRNPHRM
On recommendation of an oncologist. For patients with chroniclymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) who havereceived at least one prior therapy and are considered inappropriate fortreatment or retreatment with a fludarabine-based regimen.
GEFITINIB CHRNPHRM
On recommendation of an oncologist.For the first line, monotherapy treatment of locally advanced (notamenable to curative therapy) or metastatic non-small cell lung cancer(NSCLC) in patients who are EGFR Positive.The patient is to be assessed for disease status at least every two monthsand treatment will be discontinued if there is evidnece of diseaseprogression.Dose reimbursed: 250mg orally once dailyIressa will NOT be granted funding in the following circumstances;-Patients with EGFR wild-type mutation (ie. negative for mutation); Patientswith EGFR unknown mutation;-2nd or 3rd line or maintenance NSCLC;Renewal will be considered for patients until there is any evidence ofdisease progression, at which point, treatment with gefitinib must bediscontinued.Approval for 6 months
CAPECITABINE CHRNPHRM
On recommendation of oncologist and all criteria established by canceragency must be followed. Coverage for 12 months.
DASATINIB CHRNPHRM
On recommendation of oncologist and all criteria established by canceragency must be followed. Coverage for 12 months.
EVEROLIMUS CHRNPHRM
On recommendation of oncologist and all criteria established by canceragency must be followed. Coverage for 12 months.
LAPATINIB CHRNPHRM
On recommendation of oncologist and all criteria established by canceragency must be followed. Coverage for 12 months.
PERTUZUMAB/TRASTUZUMAB CHRNPHRM
On recommendation of oncologist and all criteria established by canceragency must be followed. Coverage for 12 months.
IMATINIB CHRNPHRM
On recommendation of oncologist. a) For treatment of patients with newly diagnosed Philadelphiachromosome-positive (Ph+ALL)b)For treatment of patients with Philadelphia chromosome-positive (Ph+)chronic myeloid leukemia (CML)c) For treatment of gastrointestinal stromal tumours (GIST), confirmed byC-Kit positivity, when tumours are inoperable
ERLOTINIB CHRNPHRM
On recommendation of specialist. Specialists consult to be provided. Initialapproval for 6 months to be followed by written confirmation that there isno evidnece of disease progression.
SUNITINIB CHRNPHRM
On recommendation of specialist. Specialists consult to be provided. Initialapproval for 6 months to be followed by written confirmation that there isno evidnece of disease progression.
INTERFERON ALFA-2B CHRNPHRM
Positive Hepatitis C serology and ALT > 1.5 times normal for 6 monthswithout any other cause for hepatitis (i.e. Alcohol), and onrecommendation of Gastroenterologist or Infectious DiseaseSpecialist. COVERAGE WILL BE PROVIDED FOR 1 YEAR. Coverage for onecourse of treatment only.
CRIZOTINIB CHRNPHRM
Second-line therapy for patients with ALK-positive advanced non-smallcell lung cancer (NSCLC) with an ECOG performance status 2.ANDFirst-line therapy for patients with an ALK-positive NSCLC with an ECOGperformance status of 0 - 2.
12.00 AUTONOMIC DRUGS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
257
12:04.00 -PARASYMPATHOMEMETIC(CHOLINERGIC) AGENTSDONEPEZIL HYDROCHLORIDE CHRN
PHRMFor mild or moderate Alzheimer's (with MMSE score 10-26 within previous3 months). Reviewed on a case-by-case basis. Review after first 6 months,then yearly. Reapply with updated MMSE score each time. Only one drugapproved at any time; no combination therapy. Not for patients alreadyliving in a dementia care facility.
DONEPEZIL HYSROCHLORIDE CHRNPHRM
For mild or moderate Alzheimer's (with MMSE score 10-26 within previous3 months). Reviewed on a case-by-case basis. Review after first 6 months,then yearly. Reapply with updated MMSE score each time. Only one drugapproved at any time; no combination therapy. Not for patients alreadyliving in a dementia care facility.
GALANTAMINEHYDROBROMIDE
CHRNPHRM
For mild or moderate Alzheimer's (with MMSE score 10-26 within previous3 months). Reviewed on a case-by-case basis. Review after first 6 months,then yearly. Reapply with updated MMSE score each time. Only one drugapproved at any time; no combination therapy. Not for patients alreadyliving in a dementia care facility.
RIVASTIGMINE CHRNPHRM
For mild or moderate Alzheimer's (with MMSE score 10-26 within previous3 months). Reviewed on a case-by-case basis. Review after first 6 months,then yearly. Reapply with updated MMSE score each time. Only one drugapproved at any time; no combination therapy. Not for patients alreadyliving in a dementia care facility.
RIVASTIGMINE CHRNPHRM
For patients who cannot use the oral form.
12:08.08 -ANTIMUSCARINICSANTISPASMODICSGLYCOPYRRONIUM BROMIDE CHRN
PHRM1) For COPD, if symptoms persist after 2-3 months of short actingbronchodilator therapy (salbutamol or ipratropium at optimal doses). 2)Please provide post-bronchodilator spirometric evidence of at leastmoderate to severe airflow obstruction. * 3) If spirometry cannot beobtained, other evidence regarding severity of condition must be providedfor consideration. * moderate to severe airflow obstruction, ie FEV1< 65%and FEV1/ FVC ratio < 0.7, and significant symptoms (i.e. MRC 3-5 fromCanadian Thoracic Society COPD Guidelines) MRC=Medical ResearchCouncil Dyspnea Scale. Note: Coverage of combination therapy withGlycopyrronium or Tiotropium + LABA/ ICS considered for moderate tosevere COPD.
TIOTROPIUM CHRNPHRM
1) For COPD, if symptoms persist after 2-3 months of short actingbronchodilator therapy (salbutamol or ipratropium at optimal doses). 2)Please provide post-bronchodilator spirometric evidence of at leastmoderate to severe airflow obstruction. * 3) If spirometry cannot beobtained, other evidence regarding severity of condition must be providedfor consideration. * moderate to severe airflow obstruction, ie FEV1< 65%and FEV1/ FVC ratio < 0.7, and significant symptoms (i.e. MRC 3-5 fromCanadian Thoracic Society COPD Guidelines) MRC=Medical ResearchCouncil Dyspnea Scale. Note: Coverage of combination therapy withGlycopyrronium or Tiotropium + LABA/ ICS considered for moderate tosevere COPD.
UMECLIDINIUM CHRNPHRM
1) For COPD, if symptoms persist after 2-3 months of short actingbronchodilator therapy (salbutamol or ipratropium at optimal doses). 2)Please provide post-bronchodilator spirometric evidence of at leastmoderate to severe airflow obstruction. * 3) If spirometry cannot beobtained, other evidence regarding severity of condition must be providedfor consideration. * moderate to severe airflow obstruction, ie FEV1< 65%and FEV1/ FVC ratio < 0.7, and significant symptoms (i.e. MRC 3-5 fromCanadian Thoracic Society COPD Guidelines) MRC=Medical ResearchCouncil Dyspnea Scale. Note: Coverage of combination therapy withGlycopyrronium or Tiotropium + LABA/ ICS considered for moderate tosevere COPD.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
258
OPIUM & BELLADONNA SUP. CHRN For an approved chronic conidtion. Specialist's consult with full detailsrequired.
ACLIDINIUM BROMIDE CHRNPHRM
For patients diagnosed with COPD where spirometry measures are:FEV1 as a percentage of predicted value less than or equal to 65% ANDratio of actual FEV1/FVC less than 0.7 ANDinadequate response after 3 month trial of ipratropium at maximumdosage
ACLIDINIUM/FORMOTEROL CHRNPHRM
For treatment of moderate to severe COPD (Medical Research Councildyspnea scale score 3 to 5 and spirometric results of FEV1 < 60% andFEV1/FVC < 0.7) Spirometric results to be provided. ANDInadequate response to long-acting bronchodilator (long-acting beta-2-agonist (LABA) or long-acting anticholinergic (LAAC))
GLYCOPYRRONIUM/INDACATEROL
CHRNPHRM
For treatment of moderate to severe COPD (Medical Research Councildyspnea scale score 3 to 5 and spirometric results of FEV1 < 60% andFEV1/FVC < 0.7) Spirometric results to be provided. ANDInadequate response to long-acting bronchodilator (long-acting beta-2-agonist (LABA) or long-acting anticholinergic (LAAC))
OLODATEROL/TIOTROPIUM CHRNPHRM
For treatment of moderate to severe COPD (Medical Research Councildyspnea scale score 3 to 5 and spirometric results of FEV1 < 60% andFEV1/FVC < 0.7) Spirometric results to be provided. ANDInadequate response to long-acting bronchodilator (long-acting beta-2-agonist (LABA) or long-acting anticholinergic (LAAC))
12:12.00 -SYMPATHOMIMETIC(ADRENERGIC) AGENTSFORMOTEROLFUMARATE/BUDESONIDE
CHRNPHRM
1. Treatment of asthma -for patients not adequately controlled on optimalanti-inflammatory treatment - for patients who are stabilized on inhaledcorticosteroids & a long-acting beta2-agonist2. For treatment of moderate to severe COPD (MRC dyspnea scale score 3to 5 and spirometric results of FEV1< 60% and FEV1/FVC < 0.7)MRC=medical research council
SALMETEROL /FLUTICASONE CHRNPHRM
1. Treatment of asthma -for patients not adequately controlled on optimalanti-inflammatory treatment - for patients who are stabilized on inhaledcorticosteroids & a long-acting beta2-agonist2. For treatment of moderate to severe COPD (MRC dyspnea scale score 3to 5 and spirometric results of FEV1< 60% and FEV1/FVC < 0.7)MRC=medical research council
EPINEPHRINE PHRM Cases reviewed individully: For patients at very high risk of anaphylaxis.
EPINEPHRINE HCL PHRM Cases reviewed individully: For patients at very high risk of anaphylaxis.
UMECLIDINIUM/VILANTEROL CHRNPHRM
For treatment of moderate to severe COPD (Medical Research Councildyspnea scale score 3 to 5 and spirometric results of FEV1 < 60% andFEV1/FVC < 0.7) ANDInadequate response to a long-acting bronchodilator (long-acting beta-2agonist (LABA) or long-acting anticholinergic (LAAC))
FLUTICASONEFUROATE/VILANTEROL
CHRNPHRM
For treatment of moderate to severe COPD (Medical Research Councildyspnea scale score 3 to 5 and spirometric results of FEV1 < 60% andFEV1/FVC < 0.7).In Asthma;For patients not adequately controlled on optimal anti-inflammatorytherapy ORFor patients who are stabilized on inhaled corticosteroids & a long actingbeta2-agonist
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
259
INDACATEROL CHRNPHRM
For treatment of moderate to severe COPD (Medical Research Councildyspnea scale score 3 to 5 and spirometric results of FEV1 < 60% andFEV1/FVC < 0.7).In Asthma;For patients not adequately controlled on optimal anti-inflammatorytherapy ORFor patients who are stabilized on inhaled corticosteroids & a long actingbeta2-agonist
FORMOTEROL FUMARATE CHRNPHRM
Treatment of asthma -for patients not adequately controlled on optimalanti-inflammatory treatmentCOPD-for moderate to severe COPD (MRC dyspnea scale score 3 to 5 &spirometric results FEV1<60% & FEV1/FVC < 0.7) MRC=medical researchcouncil
SALMETEROL XINAFOATE CHRNPHRM
Treatment of asthma -for patients not adequately controlled on optimalanti-inflammatory treatmentCOPD-for moderate to severe COPD (MRC dyspnea scale score 3 to 5 &spirometric results FEV1<60% & FEV1/FVC < 0.7) MRC=medical researchcouncil
12:16.00 - SYMPATHOLYTIC(ADRENERGIC BLOCKING)AGENTSRIZATRIPTAN CHRN Treatment secondary to an approved chronic disease.
12:92.00 - MISCELLANEOUSAUTONOMIC DRUGSVARENICLINE PHRM For adults who have failed to quit smoking and desire pharmacologic
assistance. Limited to 12 weeks course (165 tablets) within a 12 monthperiod and should be combined with intensive counselling.
VARENICLINE PHRM Will be provided for 12 months only.
20.00 BLOOD FORMATION AND COAGULATION
20:04.04 - IRONPREPARATIONSIRON (FERRIC GLUCONATECOMPLEX
CHRNPHRM
On recommendation of a specialist for renal failure/dialysis. Specialistsconsult to be provided.
IRON DEXTRAN CHRNPHRM
On recommendation of a specialist for renal failure/dialysis. Specialistsconsult to be provided.
IRON POLYSACCHARIDECOMPLEX
CHRNPHRM
On recommendation of a specialist for renal failure/dialysis. Specialistsconsult to be provided.
IRON SUCROSE CHRNPHRM
On recommendation of a specialist for renal failure/dialysis. Specialistsconsult to be provided.
IRON (FERROUS SULFATE) PHRM Patients unable to swallow solid oral dosage forms.
20:12.04 -ANTICOAGULANTS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
260
APIXABAN CHRNPHRM
For at-risk patients with NON-VALVULAR ATRIAL FIBRILLATION, for theprevention of stroke and systemic embolism AND in whom:1. Anticoagulation is inadequate following at least a 2 month trial ofwarfarin OR2. Anticoagulation with warfarin is contraindicated or not possible due toinability to regularly monitor the patient via International Normalized Ratio(INR) testing (no reasonable access to INR testing services at a healthcenter, labratory or clinic)Exclusions: Patients with impaired renal function (creatinine clearance orestimated glomerular filtration rate < 25mL/min) OR;patients who have prosthetic heart valves OR;patients with hemodynamically significant rheumatic valvular heart disease(especially mitral stenosis) OR;patients > 75 years of age who do NOT have documented stable renalfunction NOTES:At-risk patients with atrial fibrillation are defined as those with a CHADS2score of 1. Prescribers may consider an antiplatelet regimen or oralanticoagulation for patients with a CHADS2 score of 1.Inadequate anticoagulation is defined as INR testing results that areoutside the desired INR range for at least 35% of the tests during themonitoring period (adequate anticoagulation is defined as INR test resultsthat are within the desired INR range for at least 65% of the tests duringthe monitoring period).Dosing: the usual recommended dose is 5mg twice daily; a reduced doseof apixaban 2.5mg twice daily is recommended for patients with at leasttwo of the following; 80 years of age, body weight 60kg, or serumcreatinine 133 micromole/litre.Since renal impairment can increase bleeding risk, renal function shouldbe regularly monitored. Other factors that increase bleeding risk shouldalso be assessed & monitoredVTE PROPHYLAXIS:For the prophylaxis of venous thromboembolism (VTE) following electivetotal hip replacement surgery or elective total knee replacement surgery,where the inital post-operative doses are administered in an acute care(hospital) setting.Dose: 2.5mf twice dailyApproval period: Up to a 35 days total following hip replacement and up toa 14 day total following knee replacementNOTES:The first dose is typically given 12 to 24 hours after surgery if adequatehemostasis has been achieved.The ADVANCE clinical trial program did not evaluate the efficacy or safetyof sequential use of molecular weight heparin followed by apixaban for theprophylaxis of VTE. As such, Yukon coverage is not intended for thispractice.Apixaban has not been studied in clinical trials in patients undergoing hipfracture surgery, & is not recommended in these patients.VTE TREATMENTFor the treatment of VTE (deep vein thrombosis (DVT) or pulmonaryembolism(PE))Approval period up to 6 months total.The recommended dosage for patients initiating treatment is 10mg twicedaily for 7 days, followed by 5mg twice daily for up to 6 months.Drug plan coverage of apixaban is an alternative to heparin/warfarin forup to 6 months. When used for more than 6 months, apixaban is morecostly than heparin/warfarin. Patients with an intended duration of therapyof more than 6 months should be considered for initiation onheparin/warfarin.Since renal impairment can increase bleeding risk, it is important tomonitor renal function regularly. Other factors that increase bleeding risksshould also be assessed and monitored.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
261
RIVAROXABAN CHRNPHRM
For prophylaxis of venous thromboembolism following total knee or hipreplacement surgery, as alternative to low molecular weight heparins. Upto 35 days after surgery.
DALTEPARIN SODIUM CHRN For treatment of approved chronic condition. (Please specify treatmentduration). For long-term outpatient prophylaxis in patients who areintolerant to, or have failed, Warfarin therapy.
ENOXAPARIN CHRN For treatment of approved chronic condition. (Please specify treatmentduration). For long-term outpatient prophylaxis in patients who areintolerant to, or have failed, Warfarin therapy.
FONDAPARINUX SODIUM CHRN For treatment of approved chronic condition. (Please specify treatmentduration). For long-term outpatient prophylaxis in patients who areintolerant to, or have failed, Warfarin therapy.
NADROPARIN CALCIUM CHRN For treatment of approved chronic condition. (Please specify treatmentduration). For long-term outpatient prophylaxis in patients who areintolerant to, or have failed, Warfarin therapy.
TINZAPARIN CHRN For treatment of approved chronic condition. (Please specify treatmentduration). For long-term outpatient prophylaxis in patients who areintolerant to, or have failed, Warfarin therapy.
20:12.18 - PLATELETAGGREGATION INHIBITORSTICAGRELOR CHRN
PHRMIn combination with ASA 75mg-150mg (see note a) below) daily forpatients with acute coronary syndrome (ie: ST elevation myocardialinfarction (STEMI), non-ST elevation myocardial infarction (NSTEMI) orunstable angina (UA) with ONE of the following;1. Failure on optimal clopidogrel & ASA therapy as defined by definitestent thrombosis (see note b) below), or recurrent STEMI, or NSTEMI or UAafter revascularization via percutaneous coronary intervention (PCI), ifprescribed by the interventional cardiologist OR2. STEMI, NSTEMI or UA & undergoing revascularization via PCI, ifprescribed by the interventional cardiologist ORFunding approval is for up to one year.Notes:a) Co-administration of ticagrelor with high maintenance dose ASA(greater than 150mg daily) is not recommended.b) Definite stent thrombosis, according to the Academic ResearchConsortium, is a total occlusion originating in or within 5mm of the stent,or is a visible thrombus within the stent, or is within 5mm of the stent inthe presence of an acute ischemic clinical syndrome within 48 hours.Definite stent thrombosis must be confirmed by angiography or bypathologic confirmation of acute thrombosis.c) Ticagrelor is contraindicated in patients with active pathologicalbleeding, in those with a history of intracranial hemorrhage & moderate tosevere hepatic impairment.
20:16.00 - HEMATOPOIETICAGENTSDARBEPOETIN ALFA CHRN
PHRMFor treatment of anemia in chronic renal disease prior to initiation ofdialysis on recommendation of Specialist. Specialists consult to beprovided.
FILGRASTIM CHRNPHRM
On recommendation of Hematologist or Specialist. Specialists consult to beprovided. For cancer: restricted to curative treatment protocolsrecommended by Cancer Agency.
PEGFILGRASTIM CHRNPHRM
On recommendation of Hematologist or Specialist. Specialists consult to beprovided. For cancer: restricted to curative treatment protocolsrecommended by Cancer Agency.
EPOETIN ALFA CHRNPHRM
~ For anemia in chronic renal disease on recommendation of Nephrologist.Specialists consult to be provided. ~ For anemia in HIV or transplantpatients on recommendation of Specialist. Specialists consult to beprovided. ~ For cancer: non-myeloid malignancies with curative treatentprotocols recommended by cancer Agency.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
262
20:24.00 -HEMORRHEOLOGIC AGENTSCLOPIDOGREL BISULFATE CHRN
PHRM1) For the prevention of cerebrovascular (e.g. stroke, TIA) and non-cerebrovascular ischemic events in patients who have a contraindication toASA. 2) For treatment of patients who have experienced a TIA or strokewhile on ASA. 3) For prevention of thrombosis when prescribed followingintracoronary stent placement. Coverage provided for maxiumum oneyear. 4) For reduction of recurrent risk of MI in patients with acutecoronary syndrome (ie. unstable angina or non-STEMI) concurrently withASA. Coverage provided for maximum one year.
24.00 CARDIOVASCULAR DRUGS
24:06.00 - ANTILIPEMICDRUGSEZETIMIBE CHRN
PHRMFor patients intolerant to statins or patients not adequately managed onoptimum doses of statins.
24:12.00 - VASODILATINGDRUGSSILDENAFIL CHRN
PHRMFor NYHA functional class III or IV PAH; idiopathic (primary) PAH, familial(heritable) PAH, anorexigen-induced PAH, or PAH secondary to connectivetissue disease.Diagnosis of PAH to be confirmed by right heart catheterization.Approved after an inadequate response to maximal appropriateconventional therapy such as calcium channel blockers. Please providedetails.Specialist's consult to be provided.Only a 30 day's supply to be dispensed at one time for the first twomonths.First approval for one year. Subsequent renewals approved for five years.
TADALAFIL CHRNPHRM
For NYHA functional class III or IV PAH; idiopathic (primary) PAH, familial(heritable) PAH, anorexigen-induced PAH, or PAH secondary to connectivetissue disease.Diagnosis of PAH to be confirmed by right heart catheterization.Approved after an inadequate response to maximal appropriateconventional therapy such as calcium channel blockers. Please providedetails.Specialist's consult to be provided.Only a 30 day's supply to be dispensed at one time for the first twomonths.First approval for one year. Subsequent renewals approved for five years.
DIPYRIDAMOLE/ASA CHRNPHRM
For treatment of patients who have had a stoke or TIA while on ASA.
24:12.92 - MISCELLANEOUSVASODILATATING AGENTSRIOCIGUAT PHRM For the treatment of inoperable chronic thromboembolic pulmonary
hypertension (CTEPH, World Health Organization (WHO) Group 4) orpersistent or recurrent CTEPH after surgical treatment in adult patients (18 years of age) with WHO Functional Class 2 or 3 pulmonaryhypertension.Specialist's consult to be provided.
24:32.20 -MINERALOCORTICOID(ALDOSTERONE) RECEPTORANTAGONISTSEPLERENONE CHRN
PHRMOn recommendation of a specialist; consult to be provided.For persons suffering from New York Heart Association (NYHA) class IIchronic heart failure with left ventricular systolic dysfunction (with ejectionfraction 35%), as a complement to standard therapy.
28.00 CENTRAL NERVOUS SYSTEM DRUGS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
263
28:08.04 - NONSTEROIDALANTI-INFLAMMATORYAGENTSCELECOXIB CHRN Treatment of approved chronic disease where NSAIDSs are contraindicated
or patient on concurrent Warfarin or Prednisone therapy. For treatmentfailure or intolerance to at least three listed NSAIDS¿s in Formulary.Additionally, for OA patients, a failure of adequate Acetaminophen trialmust be documented.
28:08.08 - OPIATEAGONISTSACETAMINOPHEN/CODEINE CHRN
PHRMFor patients with contraindication or intolerance to caffeine.
CODEINE CHRN Treatment in approved conditions where the use of immediate releaseCodiene preparations are no longer effective.
28:08.12 - OPIATE PARTIALAGONISTSBUPRENORPHINE/NALOXONE CHRN Secondary to an approved mental health Chronic condition. As an adjunct
for patients currently receiving mental health pharmacotherapy.
28:10.00 - OPIATEANTAGONISTSNALTREXONE HCL CHRN Secondary to an approved mental health Chronic condition. As an adjunct
for patients currently receiving mental health pharmacotherapy.
28:12.12 - HYDANTOINS
LEVOCARNITINE CHRN Recommended by a Specialist. Specialists consult to be provided.
28:12.92 - MISCELLANEOUSANTICONVULSANTSPERAMPANEL CHRN
PHRMAs adjunctive therapy in patients with refractory partial-onset seizureswho have had an inadequate response or significant intolerance to at leastthree other less costly anticonvulsants. On recommendation of aneurologist.
OXCARBAZEPINE CHRNPHRM
For patients unable to use the solid dosage form.
TOPIRAMATE CHRNPHRM
For patients unable to use the solid dosage form.
ESLICARBAZEPINE ACETATE CHRNPHRM
For patients with refractory partial-onset seizures who are under the careof a physician experienced in the treatment of epilepsy, and are currentlyreceiving two or more antiepileptic agents, and in whom all otherantiepileptic medications are ineffective or not appropriate.
LACOSAMIDE CHRNPHRM
For patients with refractory partial-onset seizures who
• are under the care of a physician experienced in the treatment ofepilepsy, and • are currently receiving two or more antiepileptic agents, and • in whom all other antiepileptic medications are ineffective or notappropriate
28:16.04 -PSYCHOTHERAPEUTICAGENTS(ANTIDEPRESSANTS)
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
264
DULOXETINE CHRNPHRM
As per the Common Drug Review, duloxetine is not a benefit for thetreatment of depression.In the Chronic Disease Program, only for neuropathic pain secondary to anapproved condition covered by the program, eg: diabetes. In Pharmacareand the Chronic Disease program, for treatment of neuropathic painin patients unresponsive to adequate courses of at least two less costlyalternatives such as tricyclic antidepressant or anticonvulsant agent.Maximum daily dose 60mg.
ESCITALOPRAM CHRNPHRM
For treatment of depression where adequate trials (at least 2 months) ofcitalopram, and at least 2 other antidepressants, have failed.
28:16.08 -PSYCHOTHERAPEUTICAGENTS (ANTIPSYCHOTICAGENTS)ASENAPINE CHRN
PHRMFor the treatment of manic or mixed episodes associated with bipolar Idisorder. As co-therapy with lithium or divalproex, after sufficient trials ofless expensive antipsychotic agents have failed due to intolerance or lackof response. OR as monotherapy, after sufficient trials of lithium ordivalproex have failed AND trials of less expensive atypical antipsychoticagents have failed.History of drug therapy must be included.
ARIPIPRAZOLE CHRNPHRM
For treatment of schizophrenia & related disorders in patients who havefailed other, less expensive antipsychotic agents because of intolerance orlack of response, and on recommendation of a psychiatrist. Specialistsconsult to be provided.
LURASIDONE HCL CHRNPHRM
For treatment of schizophrenia & related disorders in patients who havefailed other, less expensive antipsychotic agents because of intolerance orlack of response, and on recommendation of a psychiatrist. Specialistsconsult to be provided.
ARIPIPRAZOLE CHRNPHRM
On recommendation of a psychiatrist. Specialist's consult to be provided.For treatment of schizophrenia & related disorders in patients who havefailed other, less expensive antipsychotic agents because of intolerance orlack of response after an adequate trial.Injectible formulation is for patients with a history of non-adherence toantipsychotic medications resulting in negative outcomes such as repeatedhospitalizations.
PALIPERIDONE CHRNPHRM
On recommendation of a psychiatrist. Specialist's consult to be provided.For treatment of schizophrenia & related disorders in patients who havefailed other, less expensive antipsychotic agents because of intolerance orlack of response after an adequate trial.Injectible formulation is for patients with a history of non-adherence toantipsychotic medications resulting in negative outcomes such as repeatedhospitalizations.
RISPERIDONE CHRNPHRM
Treatment of schizophrenia and related disorders on recommendation ofPsychiatrist. Consult to be provided. For patients who have tried oralrisperidone AND at least one other antipsychotic agent AND continure tobe inadequately controlled at maximally tolerated doseOR for patients who are currently on a conventional depot antipsychoticAND experiencing significant side effects such as extrapyramidalsymptoms or tardive dyskinesiaOR patients with a history of non-adherence to antipsychotic medicationsresulting in important negative outcomes such as repeatedhospitalizations
28:20.00 - ANOREXIGENICAGENTS & RESPIRATORYAND CEREBRALSTIMULANTS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
265
DEXTROAMPHETAMINE SO4 CHRNPHRM
-for the treatment of psychiatric disorders on recommendation of aPsychiatrist or Pediatrician. Specialist's consult to be provided.-for the treatment of fatigue in multiple sclerosis. Approval for 3 monthsto start, then can be renewed indefinitely.
METHYLPHENIDATE HCL CHRNPHRM
Treatment of psychiatric disorder on recommendation of Psychiatrist orPediatrician after a trial of short-acting formulations. Specialists consult tobeprovided.
METHYLPHENIDATE HCL CHRNPHRM
Treatment of psychiatric disorder on recommendation of Psychiatrist orPediatrician. Specialists consult to be provided.
MODAFINIL PHRM ~ on the advice of a Neurologist or sleep disorder Specialist forPharmacare. Specialists consult to be provided.
MODAFINIL CHRN ~ on the advice of a Neurologist or sleep disorder Specialist for approvedcondition For chronic Disease. Specialists consult to be provided.-for the treatment of fatigue in multiple sclerosis. Approval for 3 monthsto start, then can be renewed indefinitely.
28:20.04 - AMPHETAMINES
LISDEXAMFETAMINEDIMESYLATE
CHRNPHRM
For the treatment of psychiatric disorders on recommendation of apsychiatrist or pediatrician. Specialist consult to be provided.
LISDEXAMFETAMINEDIMESYLAYE
CHRNPHRM
For the treatment of psychiatric disorders on recommendation of apsychiatrist or pediatrician. Specialist consult to be provided.
28:24.08 -BENZODIAZEPINESLORAZEPAM CHRN For short term only treatment of approved psychiatric condition, or as a
muscle relaxant for appropriate condition.
DIAZEPAM CHRN For use in the treatment of epilepsy.
LORAZEPAM CHRN Not covered for chronic treatment.
28:24.92 - MISCELLANEOUSANXIOLYTICS SEDATIVESAND HYPNOTICSCHLORAL HYDRATE CHRN Treatment of approved psychiatric condition.
28:36.16 - DOPAMINEPRECURSORSCARBIDOPA/LEVODOPA CHRN
PHRMInitial patient assessment and approval as appropriate for Duodopatreatment must be made at a movement disorders clinic and approval bythe STEDT Program in Alberta (or a comparable program when it becomesavailable in B.C.). Specialist's consult to be provided and must includedetails pertaining to the severity of the patient's disability while in the offstate and a complete history of all previous & current medications (eg.,name, start date & duration of therapy, dosages used & response). Forpatients with-at least 25% of the waking day in the off state AND-have severe disability while in the off state as assessed by a MovementDisorder specialist AND-have received an adequate trial of maximally tolerated doses of levodopa,with demonstrated clinical response AND-have failed adequate trials of other adjunctive medications (entacapone,dopamine agonists, MAO-B inhibitors) if not contraindicated.(contraindication must be specified)Patients are not eligible if they have-a contraindication to a PEG tube OR-severe psychosis or demenia
28:92.00 - MISCELLANEOUSCENTRAL NERVOUS SYSTEMAGENTSRILUZOLE CHRN
PHRMFor patients diagnosed with ALS on recommendation of Specialist.Specialists consult to be provided.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
266
ATOMOXETINE CHRNPHRM
For treatment of ADHD in patients who failed treatment ofmethylphenidate & an amphetamine, on recommendation of a specialist.Specialists consult to be provided.
DIMETHYL FUMARATE CHRNPHRM
Initial: As monotherapy for the treatment of RRMS when prescribed by anMS neurologist. Specialist's consult to be provided. For patients who meetALL of the following criteria:-patient has had at least two (2) clinical relapses in the previous two (2)years AND-patient is ambulatory with or without aid (EDSS of 6.5 or less) AND-patient is 18 years or olderApproval period: 1 yearRenewal: When prescribed by an MS neurologist for patients whodemonstrate continued therapeutic benefit outweighing any potentialrisks, as shown by relapse rate, EDSS, MRI scan (when possible), andoverall clinical impression. Specialist's consult to be provided.A relapse is defined as the appearance of new symptoms or worsening ofold symptoms, lasting at least 24 hours in the absence of fever, andpreceded by stability for at least one (1) month. Approval for 1 year.Only a one month supply to be dispensed at a time for the first year.
ACAMPROSATE CALCIUM CHRN Secondary to an approved mental health Chronic condition. As an adjunctfor patients currently receiving mental health pharmacotherapy.
RASAGILINE CHRNPHRM
Used as adjunct therapy for Parkinson's Disease on advice of Specialist.Specialists consult to be provided.
40.00 ELECTROLYTIC, CALORIC AND WATER BALANCE
40:12.00 - REPLACEMENTPREPARATIONSPHOSPHORUS CHRN For treatment of dialysis patients.
MAGNESIUMGLUCOHEPTONATE
CHRN Treatment of hypomagnesemia secondary to an approved chronic disease(renal/ dialysis).
MAGNESIUMGLUCOHEPTONATE
PHRM Treatment of hypomagnesemia.
MAGNESIUM GLUCONATE PHRM Treatment of hypomagnesemia.
MAGNESIUM OXIDE PHRM Treatment of hypomagnesemia.
40:28.00 - DIURETICS
FUROSEMIDE CHRNPHRM
As recommended by a Specialist. Specialists consult to be provided.
BUMETANIDE CHRNPHRM
Patients unable to tolerate Furosemide.
48.00 COUGH PREPARATIONS
48:02.00 -
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
267
NINTEDANIB CHRNPHRM
For adult patients with a diagnosis of mild to moderate idiopathicpulmonary fibrosis (IPF):-diagnosis confirmed by a respirologist & a high-resolution CT scan withinthe previous 24 months.-all other causes of restrictive lung disease (e,g, collagen vasculardisorder, or hypersensitivity pneumonitis) should be excluded.-mild to moderate IPF is defined as forced vital capacity (FVC) greater thanor equal to 50% of predicted.-patient is under the care of a physician with experience in IPF-Specialists consult to be provided.Initial approval period: seven months (including 4 weeks allowed for repeatpulmonary function tests)First Renewal Criteria at 6 months:-Patients must NOT demonstrate progression of disease defined as anabsolute decline in percent predicted FVC of 10% from initiation oftherapy until renewal (first 6 month treatment period) If a patient hasexperienced progression as defined above, then the results should bevalidated with a confirmatory pulmonary function test conducted 4 weekslater.Approval period: 6 monthsSecond and subsequent renewals (at 12 months & thereafter):Patients must not demonstrate progression of disease defined as anabsolute decline in percent predicted FVC of 10% within any 12 monthperiod. If a patient has experienced progression as defined above, then theresults should be validated with a confirmatory pulmonary function testconducted 4 weeks later.Approval period for 12 months.Note: Combination use of Ofev and Esbriet will not be funded. Patientswho have experienced intolerance or failure to Ofev or Esbriet will beconsidered for the alternate agent provided that the patient continues tomeet the above coverage criteria.
48:14.12 -
IVACAFTOR CHRN For the treatment of cystic fibrosis (CF) in patients age 6 years & older whohave a documented G551D mutation in the Cystic FibrosisTransmembraneconductance Regulator (CFTR) gene. Initial coverage may be approved forup to 150mg every 12 hours for 6 months. Patients will be limited toreceiving a one-month supply per prescription.Renewal Criteria: The sweat chloride level will then be re-checked 6months after starting treatment to determine whether the full reduction (asdetailed below) has been achieved. Thereafter sweat chloride levels will bechecked annually.Patients will be considered to have responded to treatment if either:a) the patient's sweat chloride test falls below 60mmol/litre: ORb) the patient's sweat chloride test falls by at least 30%In cases where the baseline sweat chloride test is already below60mmol/litre, the patient will be considered to have responded totreatment if eitherc) the patient's sweat chloride test falls by at least 30%; ORd) the patient demonstrates a sustained absolute improvement in FEV1 ofat least 5%. In this instance FEV1 will be compared with the baseline pre-treatment level one month and three months after starting treatment.If the expected reduction in sweat chloride does not occur, the patient's CFclinician will first explore any problems in following the recommendeddosing schedule for ivacaftor. The patient's sweat chloride will then beretested around one week later & funding discontinued if the patient doesnot meet the above criteria. Renewal coverage may be approved for up to 150mg every 12 hours for 6months. Patients will be limited to receiving a one-month supply perprescription.
48:24.00 - MUCOLYTICAGENTSACETYLCYSTEINE PHRM As a mucolytic agent, by inhalation/ nebulization.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
268
DORNASE ALFA CHRNPHRM
On recommendation of Specialist (Cystic Fibrosis). Specialists consult to beprovided.
48:92.00 - RESPIRATORYAGENTS, MISCELLANEOUSOMALIZUMAB PHRM For patients with moderate to severe chronic idiopathic urticaria (CIU) who
remain symptomatic (presence of hives/or associated itching) despiteoptimum management with available oral therapies defined as-H1 antihistamines at up to 4 times the standard daily dose-montelukastSpecialist's consult requiredInitial approval period of 24 weeks at a maximum dose of 300mg every 4weeks.Continued coverage will be authorized if the patient has achieved;-complete symptom control for less than 12 consecutive weeks; OR-partial response to treatment, defined as at least a 9.5 point reductionin baseline urticaria activity score over 7 days (UAS7)Treatment cessation should be considered for patients who experiencecomplete symptom control for at least 12 consecutive weeks at the end ofa 24 week treatment period.In patients where treatment is discontinued due to temporoary symptomcontrol, treatment re-initiation should be considered should CIUsymptoms reappear.
52.00 EYE, EAR, NOSE AND THROAT PREPARATIONS
52:08.00 - ANTI-INFLAMMATORY AGENTSPREDNISOLONE SODIUMPHOSPHATE
PHRM For patients who cannot effectively use a dropper bottle.
DEXAMETHASONE CHRN Ophthalmic conditions secondary to approved chronic disease.
FLUOROMETHOLONE CHRN Ophthalmic conditions secondary to approved chronic disease.
PREDNISOLONE ACETATE CHRN Ophthalmic conditions secondary to approved chronic disease.
52:24.00 - MYDRIATICS
HOMATROPINEHYDROBROMIDE
CHRN For Palliative only.
52:28.00 - MOUTHWASHESAND GARGLESBENZYDAMINE CHRN For treatment of mucositis, ulcerative complications of chemotherapy. For
use in immuno-compromised patients at risk of mucosal breakdown.
52:36.00 - MISCELLANEOUSE.E.N.T. DRUGSBRIMONIDINE TARTRATE CHRN
PHRMFor patients intolerant to Benzalkonium Chloride.
DORZOLAMIDE HCL/TIMOLOL CHRNPHRM
For patients intolerant to Benzalkonium Chloride.
RANIBIZUMAB CHRNPHRM
On recommendation of a specialist for treatment of age-related maculardegeneration, or visual imparment due to macular edema secondary tocentral vein occlusion..
52:92.00 - EENT DRUGS,MISCELLANEOUSAFLIBERCEPT CHRN
PHRMOn recommendation of a specialist for age-related macular degeneration,or diabetic macular edema, or visual impairment due to macular edemasecondary to central vein occlusion.
56.00 GASTROINTESTINAL DRUGS
56:22.00 - ANTI-EMETICS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
269
APREPITANT CHRNPHRM
For use with emetogenic chemotherapy as per cancer agency protocol.Approval for 1 year, then renew as required.
DOLASETRON CHRNPHRM
For use with emetogenic chemotherapy as per cancer agency protocol.Approval for 1 year, then renew as required.
GRANISETRON CHRNPHRM
For use with emetogenic chemotherapy as per cancer agency protocol.Approval for 1 year, then renew as required.
ONDANSETRON CHRNPHRM
For use with emetogenic chemotherapy as per cancer agency protocol.Approval for 1 year, then renew as required.
NABILONE CHRNPHRM
For use with emotogenic chemotherapy as per cancer agency protocol.Approval for one year then renew.
56:40.00 - MISCELLANEOUSGASTROINTESTINAL DRUGSLANSOPRAZOLE CHRN Approved on case-by-case basis: For treatment of patients at high risk for
GI bleeding when NSAID or steroid therapy cannot be avoided for approvedchronic disease. For patients with Barrett's Esophagus. Standard doseapproved - include reasons if high dose required. GERD, dyspepsia orpeptic ulcer disease are not covered by Chronic Disease Program.
OMEPRAZOLE CHRN Approved on case-by-case basis: For treatment of patients at high risk forGI bleeding when NSAID or steroid therapy cannot be avoided for approvedchronic disease. For patients with Barrett's Esophagus. Standard doseapproved - include reasons if high dose required. GERD, dyspepsia orpeptic ulcer disease are not covered by Chronic Disease Program.
PANTOPRAZOLE CHRN Approved on case-by-case basis: For treatment of patients at high risk forGI bleeding when NSAID or steroid therapy cannot be avoided for approvedchronic disease. For patients with Barrett's Esophagus. Standard doseapproved - include reasons if high dose required. GERD, dyspepsia orpeptic ulcer disease are not covered by Chronic Disease Program.
RABEPRAZOLE CHRN Approved on case-by-case basis: For treatment of patients at high risk forGI bleeding when NSAID or steroid therapy cannot be avoided for approvedchronic disease. For patients with Barrett's Esophagus. Standard doseapproved - include reasons if high dose required. GERD, dyspepsia orpeptic ulcer disease are not covered by Chronic Disease Program.
64.00 HEAVY METAL ANTAGONISTS
64:00.00 - HEAVY METALANTAGONISTSDEFERIPRONE CHRN
PHRMFor the treatment of patients with transfusional iron overload due tothalassemia syndromes when current chelation therapy is inadequate.
66.00
66:16.12 -
RALOXIFENE CHRN For treatment of osteoporosis in women unable to tolerate listedbisphosphonates.
68.00 HORMONES AND SUBSTITUTES
68:08.00 - ANDROGENS
TESTOSTERONE ENANTHATE CHRN Coverage for hormonal replacement required for an approved chroniccondition (e.g. primary hypogonadism, pituitary disorders). Cases reviewedindividually.
68:16.12 - ESTROGENAGONIST-ANTAGONISTSRALOXIFENE CHRN
For treatment of osteoporosis in patients unable to tolerate listedbisphosphonates.
68:20.04 - BIGUANIDES
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
270
LINAGLIPTIN/METFORMIN CHRNPHRM
For combination treatment of Type II diabetes for patients approved forlinagliptin coverage and already stabilized on combination treatment withmetformin.
METFORMIN/SAXAGLIPTIN CHRNPHRM
For the treatment of Type II diabetes for patients who are alreadystabilized on therapy with metformin, a sulfonylurea and saxagliptin toreplace the individual components of saxagliptin and metformin AND forwhom insulin is not an option, for reasons other than "needle phobia"..
68:20.05 - DIPEPTIDYLPEPTIDASE-4 (DPP-4)INHIBITORSLINAGLIPTIN CHRN
PHRMIn addition to metformin and a sulfonylurea for patients with inadequateglycemic control on metformin and a sulfonylurea AND for whom insulin isnot an option, for reasons other than "needle phobia".
SAXAGLIPTIN HCL CHRNPHRM
In addition to metformin and a sulfonylurea for patients with inadequateglycemic control on metformin and a sulfonylurea AND for whom insulin isnot an option, for reasons other than "needle phobia".
68:20.08 - INSULINS
INSULIN DETEMIR CHRNPHRM • Adults diagnosed with Type 1 or 2 diabetes requiring insulin & are
currently taking insulin NPH and/or pre-mix insulin at optimal dosingAND • Have experienced unexplained nocturnal hypoglycemia at least oncea month despite optimal management OR • Have documented severe or continuing allergic reaction to existinginsulin (full documentation required) • must be prescribed by an endocrinologist or visiting internalmedicine specialist. Specialists consult to be provided.
INSULIN GLARGINE CHRNPHRM • Adults diagnosed with Type 1 or 2 diabetes requiring insulin & are
currently taking insulin NPH and/or pre-mix insulin at optimal dosingAND • Have experienced unexplained nocturnal hypoglycemia at least oncea month despite optimal management OR • Have documented severe or continuing allergic reaction to existinginsulin (full documentation required) • must be prescribed by an endocrinologist or visiting internalmedicine specialist. Specialists consult to be provided.
68:20.18 - Sodium-GlucoseCotransporter 2 (SGLT2)InhibitorsDAPAGLIFLOZIN CHRN
PHRMAdded on to metformin for patients: -who have inadequate glycemic control on metformin -who have a contraindication or intolerance to a sulfonylurea-for whom insulin is not an option, for reasons other than needle phobiaAdded on to a sulfonylurea for patients;-who have inadequate glycemic control on a sulfonylurea-who have a contraindication or intolerance to metformin-for whom insulin is not an option, for reasons other than needle phobia
CANAGLIFLOZIN CHRNPHRM
In addition to metformin and a sulfonylurea for patients with inadequateglycemic control on metformin and a sulfonylurea AND for whom insulin isnot an option, for reasons other than needle phobia.
EMPAGLIFLOZIN CHRNPHRM
In addition to metformin and a sulfonylurea for patients with inadequateglycemic control on metformin and a sulfonylurea AND for whom insulin isnot an option, for reasons other than needle phobia.
68:20.92 - ANTI DIABETICDRUGS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
271
SITAGLIPTIN CHRNPHRM
As add-on therapy for the treatment of Type 2 diabetes in patients withinadequate glycemic control on:metformin AND a sulfonylureaAND for whom insulin is not an option, for reasons other than "needlephobia".
SITAGLIPTIN/METFORMIN CHRNPHRM
For combination treatment of type 2 diabetes mellitus for patientsapproved for sitagliptin coverage and already stabilized on combinationtreatment with the individual components of metformin and sitagliptin.
PIOGLITAZONE CHRNPHRM
Treatment of diabetes in patients who are not adequately controlled onmaximum tolerated doses of metformin AND a sulfonylurea.
ROSIGLITAZONE CHRNPHRM
Treatment of diabetes in patients who are not adequately controlled onmaximum tolerated doses of metformin AND a sulfonylurea.
68:24.00 - PARATHYROID
CALCITONIN CHRNPHRM
For the treatment of fracture with bone pain for a maximum duration of 3months.
68:28.00 - PITUITARY
DESMOPRESSIN CHRNPHRM
For treatment of vasopressin sensitive central diabetes insipidus.
80.00 SERUMS, TOXOIDS AND VACCINES
80:12.00 - VACCINES
BACILLUS CALMETTE-GUERIN(BCG)
CHRNPHRM
On recommendation of an oncologist.
84.00 SKIN AND MUCOUS MEMBRANE AGENTS
84:06.00 - ANTI-INFLAMMATORY AGENTSHALOBETASOL CHRN
PHRMHigh potency corticosteroid for resistant/severe psoriasis. Review dosageprecautions.
84:36.00 - MISCELLANEOUSSKIN & MUCOUS MEMBRANEAGENTSIMIQUIMOD CHRN
PHRMFor treatment of actinic keratosis, or superficial basal cell carcinoma, inpatients who have failed treatment with cryotherapy (where appropriate)AND 5-fluorouracil. Approval for 4 months.
ALITRETINOIN CHRN For treatment of severe chronic hand eczema in patients meeting both ofthe following criteria1. refractory to 2 months of high or ultra-high potency topical steroids2. prescribed by a dermatologist. Specialists consult to be provided.
ACITRETIN CHRNPHRM
For treatment of severe psoriasis on recommendation of Dermatologist.Specialists consult to be provided.
84:50.06 - PIGMENTINGAGENTSMETHOXSALEN CHRN On recommndation of a specialist. Specialists consult to be provided.
84:92.00 - MISC. SKIN ANDMUCOUS MEMBRANEAGENTS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
272
SECUKINUMAB CHRNPHRM
For plaque psoriasis on recommendation of a dermatologist. Consult to beprovided. For patients with body surface involvement (BSA) of >10% and aPASI of >10OR significant involvement of the face, hands, feet or genitals.For patients who are refractory or intolerant to a 12 week trial ofparenteral methotrexate AND a 12 week trial of cyclosporine.Approval for 1 year period.For maintenance therapy a yearly consult from the dermatologist isrequired showing that the patient has maintained at least 50% reductionboth in PASI and BSA from baseline.Coverage may be approved as follows: Initial dosing of 300mg doses atweeks 0, 1, 2 and 3, followed by monthly maintenance dosing of 300mgdoses starting at week 4.
86.00 SMOOTH MUSCLE RELAXANTS
86:12.00 - GENITOURINARYSMOOTH MUSCLERELAXANTSDARIFENACIN CHRN
PHRMFor patients who have insufficient response to adequate trials ofimmediate-release formulations of oxybutynin or tolterodine.
OXYBUTYNIN CHLORIDE CHRNPHRM
For patients who have insufficient response to adequate trials ofimmediate-release formulations of oxybutynin or tolterodine.
SOLIFENACIN CHRNPHRM
For patients who have insufficient response to adequate trials ofimmediate-release formulations of oxybutynin or tolterodine.
TOLTERODINE CHRNPHRM
For patients who have insufficient response to adequate trials ofimmediate-release formulations of oxybutynin or tolterodine.
86:12.08 -
MIRABEGRON CHRNPHRM
For the treatment of overactive bladder (OAB) for patients intolerant to, orwith an inadequate response to an adequate trial of oxybutinin.Not to be used in combination with other pharmacological treaments forOAB.
88.00 VITAMINS
88:08.00 - VITAMIN BCOMPLEXLEUCOVORIN CALC.(FOLINICACID)
CHRNPHRM
For folic acid deficiency from long term drug treatment, where treatmentwith folic acid is insufficient.
CYANOCOBALAMIN CHRN Treatment of pernicious anemia. For dialysis patients.
CYANOCOBALMIN CHRN Treatment of pernicious anemia. For dialysis patients.
VITAMIN B12 CHRN Treatment of pernicious anemia. For dialysis patients.
PYRIDOXINE HCL CHRN For dialysis patients.
88:08.08 -
VITAMIN B COMPLEX&VITAMIN C
CHRNPHRM
For dialysis patients
88:16.00 - VITAMIN D
CALCITRIOL CHRN For treatment of hypoparathyroidism.For treatment of hypocalcemia in dialysis patients.
VITAMIN D CHRN For treatment of hypoparathyroidism.For treatment of hypocalcemia in dialysis patients.
ALFACALCIDOL CHRN For chronic renal failure.
92.00 MISCELLANEOUS THERAPEUTIC AGENTS
92:00.00 - MISCELLANEOUSTHERAPEUTIC AGENTS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
273
OCRIPLASMIN CHRNPHRM Clinical Criteria
• Diagnosis of VMA should be confirmed through optical coherencetomography.• Patient does not have any of the following: large diameter macular holes(> 400 micrometre), high myopia (> 8 dioptre spherical correction or axiallength > 28 millimetre), aphakia, history of retinal detachment, lenszonule instability, recent ocular surgery or intraocular injection (includinglaser therapy), proliferative diabetic retinopathy, ischemic retinopathies,retinal vein occlusions, exudative age-related macular degeneration, orvitreous hemorrhage.Conditions• Ocriplasmin should be administered by retinal specialist, or qualifiedophthalmologist experienced in intravitreal injections.• Treatment with ocriplasmin should be limited to a single injection pereye (i.e. retreatments are not covered).
ADALIMUMAB CHRNPHRM For severely active Rheumatoid Arthritis on recommendation of RA
Specialist. Specialist's consult to be provided. For patients refractory orintolerant to parenteral methotrexate after at least a 12 week trial. ANDA 3 month trial of at leats 2 of the following; leflunomide, sulfasalazine,azathioprine ANDA 3 month trial of at least one DMARD combination such as a)methotrexate & cyclosporine b)methotrexate with hydroxychloroquine andsulfaslazine c) methotrexate with leflunomideFor Ankylosing Spondylitis patients with a BASDAI score greater than orequal to 4. For patients with predominantly axial diesease who arerefractory or intolerant to a minimum 4 week trial of 2 NSAIDs at maximaldosage.OR for predominantly peripheral disease, patients refractory to a 3 monthtrial of parenteral methotrexate and a 3 month trial of sulfasalazine.Rheumatologists consult to be provided.For Psoriatic Arthritis patients with moderate to severe disease who arerefractory or intolerant to a 12 week trial of parenteral methotrexate ANDan adequate trial (at least 4 months) of at least one other DMARD.Specialists consult to be provided.Approval for 12 months. After first year, a 24 month approval may berequested. For Plaque Psoriasis on recommendation of Dermatologist. Consult to beprovided. For patients with body surface involvement (BSA) of > 10%, ORsignificant involvement of face, hands, feet or genitals, AND have a PASI>12. For patientswho are refractory or intolerant to a 12 week trial ofparenteral methotrexate AND a 12 week trial of cyclosporine.For moderate to severely Active Crohn's Disease, on recommendation of aspecialist. Consult to be provided. For patients with a current HarveyBradshaw Index (HBI) >7, who are intolerant or refractory to 5-ASA (3gdaily for at least 6 weeks) AND are refractory, intolerant or dependent onglucocorticoids. AND who are refractory or intolerant to at least one ofazathioprine, 6-mercaptopurine or methotrexate after a 3 month trial.For Fistulizing Crohn's Disease on recommendation of a specialist. Consultto be provided. For patients with actively draining fistula(s) despite at leasta 3 week trial of ciprofloxacin or metronidazole, AND at least a 6 week trialof azathioprine or 6-mercaptopurine.Only one month's dose to be dispensed at a time for the first 4 months.Approval for 12 month period.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
274
DENOSUMAB CHRNPHRM
A) For the treatment of osteoporosis in patients who have experienced afurther significant decline in bone mineral density (BMD) after 1 yearcontinuous bisphosphonate therapy AND meet at least two of the followingcriteria:i) age > 75 yearsii) a BMD T-score -2.5iii) prior frigility fractureB) For the treatment of osteoporosis in patients with two of the above riskfactors, but for whom bisphosphonates are contraindicated due toa) immune-mediated hypersensitivity b) an untreatable abnormality of the esophagus, such as esophagealstricture or achalasiac) demonstrated severe gastrointestinal intolerance to a course of therapywith either alendronate or risedronate as manifested by weight loss orvomiting directly attributable to the oral bisphosphonates.
ZOLEDRONIC ACID CHRNPHRM
For patients requiring treatment of osteoporosis with at least two of thefollowing risk factorsi) age > 75yearsii) a prior fragility fractureiii) a bone mineral density (BMD) T-score -2.5AND for whom bisphosphonates are contraindicated due toa) immune-mediated hypersensitivityb) an untreatable abnormality of the esophagus, such as esophagealstricture or achalasiac) demonstrated, severe gastrointestinal intolerance to a course of therapywith either alendronate or risedronate as manifested by weight loss orvomiting directly attributable to the oral bisphosphonates.
FEBUXOSTAT CHRNPHRM
For patients with symptomatic gout who have documented hypersensitivityto allopurinol.
USTEKINUMAB CHRNPHRM
For plaque psoriasis on recommendation of a dermatologist. Consult to beprovided.For patients with body surface involvement (BSA) of >10%, and a PASI of>10, OR significant involvement of the face, hands, feet or genitals. For patients who are refractory or intolerant to a 12 week trial ofparenteral methotrexate AND a 12 week trial of cyclosporine.Only one month's dose to be dispensed at a time for the first 4 months.Approval for 1 year period.For maintenence therapy a yearly consult from the dermatologist isrequired showing that the patient has maintained at least a 50% reductionboth in PASI and BSA from baseline.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
275
CERTOLIZUMAB PEGOL CHRNPHRM
For severely active Rheumatoid Arthritis on recommendation of RASpecialist. Specialist's consult to be provided. For patients refractory orintolerant to parenteral methotrexate after at least a 12 week trial. ANDA 3 month trial of at least 2 of the following; leflunomide, sulfasalazine,azaathioprine ANDA 3 month trial of at least one DMARD combination such as a)methotrexate & cyclosporine b) methotrexate with hydroxychloroquine andsulfasalazine c)methotrexate with leflunomideOnly 1 month's dose to be dispensed at a time for the first 4 months
For Ankylosing Spondylitis patients with a BASDAI score greater than orequal to 4. For patients with predominantly axial disease who arerefractory or intolerant to a minimum 4 week trial of 2 NSAIDs at maximaldosage.OR for predominantly peripheral disease, patients refractory to a 3 monthtrial of parenteral methotrexate and a 3 month trial of sulfasalazine.Rheumatologists consult to be provided.For Psoriatic Arthritis patients with moderate to severe disease who arerefractory or intolerant to a 12 week trial of parenteral methotrexate ANDan adequate trial (at least 4 months) of at least one other DMARD.Approval for 12 month period. After first 12 months, 24 month approvalscan be requested.Only one month's dose to be dispensed at a time for the first 4 months..For Ulcerative Colitis on recommendation of a specialist. Consult to beprovided. For patients with a Mayo score >6 AND an endoscopic subscore 2 (within last 12 months)AND failed 2 weeks of oral prednisone 40mg (or 1 week IV equivalent)AND 3 months of azathioprine or 6-mercaptopurineOR stablizied on prednisone as above but the prednisone dose cannot betapered despite 3 months of DMARDS.Only one month's dose to be dispensed at a time. Approval for 12 monthperiod.
GOLIMUMAB CHRNPHRM
For severely active Rheumatoid Arthritis on recommendation of RASpecialist. Specialist's consult to be provided. For patients refractory orintolerant to parenteral methotrexate after at least a 12 week trial. ANDA 3 month trial of at least 2 of the following; leflunomide, sulfasalazine,azaathioprine ANDA 3 month trial of at least one DMARD combination such as a)methotrexate & cyclosporine b) methotrexate with hydroxychloroquine andsulfasalazine c)methotrexate with leflunomideOnly 1 month's dose to be dispensed at a time for the first 4 months
For Ankylosing Spondylitis patients with a BASDAI score greater than orequal to 4. For patients with predominantly axial disease who arerefractory or intolerant to a minimum 4 week trial of 2 NSAIDs at maximaldosage.OR for predominantly peripheral disease, patients refractory to a 3 monthtrial of parenteral methotrexate and a 3 month trial of sulfasalazine.Rheumatologists consult to be provided.For Psoriatic Arthritis patients with moderate to severe disease who arerefractory or intolerant to a 12 week trial of parenteral methotrexate ANDan adequate trial (at least 4 months) of at least one other DMARD.Approval for 12 month period. After first 12 months, 24 month approvalscan be requested.Only one month's dose to be dispensed at a time for the first 4 months..For Ulcerative Colitis on recommendation of a specialist. Consult to beprovided. For patients with a Mayo score >6 AND an endoscopic subscore 2 (within last 12 months)AND failed 2 weeks of oral prednisone 40mg (or 1 week IV equivalent)AND 3 months of azathioprine or 6-mercaptopurineOR stablizied on prednisone as above but the prednisone dose cannot betapered despite 3 months of DMARDS.Only one month's dose to be dispensed at a time. Approval for 12 monthperiod.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
276
ETANERCEPT CHRNPHRM
For severely active Rheumatoid Arthritis on recommendation of RASpecialist. Specialist's consult to be provided. For patients refractory orintolerant to parenteral methotrexate after at least a 12 week trial. ANDA 3 month trial of at least 2 of the following; leflunomide, sulfasalazine,azathioprine ANDA 3 month trial of at least one DMARD combination such as a)methotrexate & cyclosporine b) methotrexate with hydroxychloroquine andsulfasalazine c)methotrexate with leflunomide
For Ankylosing Spondylitis patients with a BASDAI score greater than orequal to 4. For patients with predominantly axial disease who arerefractory or intolerant to a minimum 4 week trial of 2 NSAIDs at maximaldosage.OR for predominantly peripheral disease, patients refractory to a 3 monthtrial of parenteral methotrexate and a 3 month trial of sulfasalazine.Rheumatologists consult to be provided.For Psoriatic Arthritis patients with moderate to severe disease who arerefractory or intolerant to a 12 week trial of parenteral methotrexate ANDan adequate trial (at least 4 months) of at least one other DMARD.Inital approval for 12 months, then for 24 months after first year. For Plaque Psoriasis on recommendation of Dermatologist. Consult to beprovided. For patients with body surface involvement (BSA) of > 10%, ORsignificant involvement of face, hands, feet or genitals, AND have a PASI>12. For patientswho are refractory or intolerant to a 12 week trial ofparenteral methotrexate AND a 12 week trial of cyclosporine.Only one month's dose to be dispensed at a time for the first 4 months. Approval for 12 month period.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
277
INFLIXIMAB CHRNPHRM
For severely active Rheumatoid Arthritis on recommendation of specialist.Specialist's consult to be provided. For patients refractory or intolerant toparenteral methotrexate after at least a 12 week trial ANDA 3 month trial of at least 2 of the following; leflunomide, sulfasalazine,azathioprine ANDA 3 month trial of at least one DMARD combination such as a)methotrexate & cyclosporine b) methotrexate with hydroxychloroquine andsulfasalazine c) methotrexate with leflunomide.For Ankylosing Spondylitis patients with a BASDAI score 4. For patientswith predominantly axial disease who are refractory or intolerant to aminimum 4 week trial of 2 NSAIDs at maximal dosage.OR for predominantly peripheral disease, patients refractory to a 3 monthtrial of parenteral methotrexate and a 3 month trial of sulfasalazine.Specialist's consult to be provided.For Psoriatic Arthritis patients with moderate to severe disease who arerefractroy or intolerant to a 12 week trial of parenteral methotrexate ANDan adequate trial (at least 4 months) of at least one other DMARD.Specialist's consult to be provided.Approval for 12 months. After first year, a 24 month approval may berequested.For Plaque Psoriasis on recommendation of Dermatologist. Consult to beprovided. For patients with body surface involvement (BSA) of > 10%, ORsignificant involvement of face, hands, feet or genitals, AND have a PASI >12. For patients who are refractory or intolerant to a 12 week trial ofparenteral methotrexate AND a 12 week trial of cyclosporine.For moderate to severely active Crohn's Disease on recommendation of aspecialist. Consult to be provided. For patients with a current HarveyBradshaw Index (HBI) >7, who are intolerant or refractroy to 5-ASA (3 gdaily for at least 6 weeks) AND are refractory, intolerant or dependant onglucocorticoids, AND who are refractory or intolerant to at least one ofazathioprine, 6-mercaptopurine or methotrexate after a 3 month trial.For fistulizing Crohn's Disease on recommendation of a specialist. Consultto be provided. For patients with actively draining fistula(s) despite a 3week trial of ciprofloxacin or metronidazole, AND at least a 6 week trial ofazathioprine or 6-mercaptopurine.For Ulcerative Colitis on recommendation of a specialist.Consult to beprovided. For patients with a Mayo score >6 AND an endoscopic subscore 2 (within last 12 months)AND failed 2 weeks of oral prednisone 40mg (or 1 week IV equivalent)AND 3 months of azathioprine or 6-mercaptopurineOR stablizied on prednisone as above but the prednisone dose cannot betapered despite 3 months of DMARDS.Only one month's dose to be dispensed at a time. Approval for 12 monthperiod.NB: All new infliximab patients will be covered for Inflectra brand only.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
278
INFLIXIMAB CHRNPHRM
For severely active Rheumatoid Arthritis on recommendation of specialist.Specialist's consult to be provided. For patients refractory or intolerant toparenteral methotrexate after at least a 12 week trial ANDA 3 month trial of at least 2 of the following; leflunomide, sulfasalazine,azathioprine ANDA 3 month trial of at least one DMARD combination such as a)methotrexate & cyclosporine b) methotrexate with hydroxychloroquine andsulfasalazine c) methotrexate with leflunomide.For Ankylosing Spondylitis patients with a BASDAI score 4. For patientswith predominantly axial disease who are refractory or intolerant to aminimum 4 week trial of 2 NSAIDs at maximal dosage.OR for predominantly peripheral disease, patients refractory to a 3 monthtrial of parenteral methotrexate and a 3 month trial of sulfasalazine.Specialist's consult to be provided.For Psoriatic Arthritis patients with moderate to severe disease who arerefractroy or intolerant to a 12 week trial of parenteral methotrexate ANDan adequate trial (at least 4 months) of at least one other DMARD.Specialist's consult to be provided.Approval for 12 months. After first year, a 24 month approval may berequested.For Plaque Psoriasis on recommendation of Dermatologist. Consult to beprovided. For patients with body surface involvement (BSA) of > 10%, ORsignificant involvement of face, hands, feet or genitals, AND have a PASI >12. For patients who are refractory or intolerant to a 12 week trialof parenteral methotrexate AND a 12 week trial of cyclosporine.For moderate to severely active Crohn's Disease on recommendation of aspecialist. Consult to be provided. For patients with a current HarveyBradshaw Index (HBI) >7, who are intolerant or refractroy to 5-ASA (3 gdaily for at least 6 weeks) AND are refractory, intolerant or dependant onglucocorticoids, AND who are refractory or intolerant to at least one ofazathioprine, 6-mercaptopurine or methotrexate after a 3 month trial.For fistulizing Crohn's Disease on recommendation of a specialist. Consultto be provided. For patients with actively draining fistula(s) despite a 3week trial of ciprofloxacin or metronidazole, AND at least a 6 week trial ofazathioprine or 6-mercaptopurine.For Ulcerative Colitis on recommendation of a specialist.Consult to beprovided. For patients with a Mayo score >6 AND an endoscopicsubscore 2 (within last 12 months)AND failed 2 weeks of oral prednisone 40mg (or 1 week IV equivalent)AND 3 months of azathioprine or 6-mercaptopurineOR stablizied on prednisone as above but the prednisone dose cannot betapered despite 3 months of DMARDS.Only one month's dose to be dispensed at a time. Approval for 12 monthperiod.OR
ANAKINRA CHRNPHRM
For severely active rheumatoid arthritis on recommendation of RASpecialist. Specialist's consult to be provided. For patients refractory orintolerant to parenteral methotrexate after at least a 12 week trial. ANDA 3 month trial of at least 2 of the following; leflunomide, sulfasalazine,azathioprine ANDA 3 month trial of at least one DMARD combination such as a)methotrexate & cyclosporine b) methotrexate with hydroxychloroquine andsulfasalazine c) methotrexate with lefunomideOnly 1 month's dose to be dispensed at a time for the first 4 monthsApproval for 12 month period. After the first year, a 24 month approvalmay be requested.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
279
TOCILIZUMAB CHRNPHRM
For severely active rheumatoid arthritis on recommendation of RASpecialist. Specialist's consult to be provided. For patients refractory orintolerant to parenteral methotrexate after at least a 12 week trial. ANDA 3 month trial of at least 2 of the following; leflunomide, sulfasalazine,azathioprine ANDA 3 month trial of at least one DMARD combination such as a)methotrexate & cyclosporine b) methotrexate with hydroxychloroquine andsulfasalazine c) methotrexate with lefunomideOnly 1 month's dose to be dispensed at a time for the first 4 monthsApproval for 12 month period. After the first year, a 24 month approvalmay be requested.
VALGANCICLOVIR CHRNPHRM
For the treatment and prophylaxis of CMC infection in transplant patients.Approval for 6 months.
NATALIZUMAB CHRNPHRM
For the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)patients who meet all the following criteriaa) for patients who have failed to respond to a full & adequate course oftreatment (6 months) with at least one of interferon OR glatiramer acetateOR dimethyl fumarate, or have contraindications/intolerance to at leasttwo of the previous three drugs ANDb) has had ONE of the following types of relapses in the past year- the occurence of one relapse with partial recovery AND has at least ONEgadolinium-enhancing lesion on brain MRI, OR significant increase in T2lesion load compared to previous MRI (ie: 3 or more new lesions) OR-the occurence of two or more relapses with partial recovery OR-the occurence of two or more relapses with complete recovery AND atleast ONE gadolinium-enhancing lesion on brain MRI, OR significantincrease in T2 lesion load compared to previous MRI c) on recommendation of a neurologist experienced in the management ofRRMS. Specialists consult to be provided.d) have a current EDSS less than or equal to 5.0e) MRI not required for intial request but detailed documentation of theabove isf) not used in combination with other disease-modifying therapyg) approval period 1 year
INCOBOTULINUMTOXIN A CHRNPHRM
For the treatment of blepharospasm ORCervical dystonia of a predominantely rotational form (SpasmoticTorticollis) ORPost-stroke spasticity of the upper limb
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
280
FINGOLIMOD CHRNPHRM
For treatment of Relapsing Remitting Multiple Sclerosis (RRMS) in patientswho meet all of the following criteria -approval period for one year-Failure to respond to adequate courses* (at least 6 months) of any onetherapy listed on the Yukon formulary OR documented intolerance** to 2therapies listed in the formulary. Intolerance does NOT include: needlephobia, skin reactions at injection site or patient preference for oral form-One or more clinical relapse in the previous year; the appearance of newsymptoms or worsening of old symptoms, lasting at least 24 hours in theabsence of fever, & preceded by stability for at least one month -Significant increase in T2 lesion load (3 or more new lesions) or at leastone gadolinium-enhancing lesion-requested and followed by a neurologist experienced with RRMS.Specialists consult to be provided.-recently expanded EDSS score (EDSS less than or equal to 5.5)***NB -will not be funded in combination with any other disease modifyingagent; in patients with EDSS > 5.5; in patients with heart conditions; or inpatients under age 18* failure to respond to full & adequate courses: defined as a trial of at least6 months of one therapy listed in the Yukon formulary AND experienced atleast one disabling relapse while on that therapy.** Intolerance is defined as: documented serious adverse effects orcontraindications that are incompatable with further use of that class ofdrug. ***Recently Expanded Disability Status Scale (EDSS) score less than orequal to 5.5 (patients must be able to ambulate at least 100 meterswithout assistance)Approval for 2 years.
BOTULINUM TOXIN TYPE A CHRNPHRM
For treatment of dystonias and other neuromuscular spasticity problems.Botox requires written prior approval and the recommendation of aSpecialist. Specialists consult to be provided.
LEFLUNOMIDE CHRNPHRM
For treatment of rheumatoid arthritis in patients who are not adequatelycontrolled or are intolerant to at least two other DMARDs or asrecommended by a Specialist. Specialists consult to be provided.
COMPOUNDED INJECTABLES CHRNPHRM
For use where manufactured products are not available or not costeffective. Must contain at least one ingredient included in the formulary.
COMPOUNDED ORALPREPARATIONS
CHRNPHRM
For use where manufactured products are not available or not costeffective. Must contain at least one ingredient included in the formulary.
COMPOUNDED TOPICALS CHRN For use where manufactured products are not available or not costeffective. Must contain at least one ingredient included in the formulary.
ALENDRONATE CHRN In order for patients to be eligible for coverage for osteoporosis treatment,the physician submitting the application must provide either the results ofa bone density test, or list at least four of the following risk factors thatpertain to the patient. High Risk Factors: - significant family history -genetic predisposition (Asian or Caucasian descent) - thin, small frame -early menopause, before age 45 - past menopause - prolonged use ofosteopenic medication - low trauma fracture
ALENDRONATE/CHOLECALCIFEROL
CHRN In order for patients to be eligible for coverage for osteoporosis treatment,the physician submitting the application must provide either the results ofa bone density test, or list at least four of the following risk factors thatpertain to the patient. High Risk Factors: - significant family history -genetic predisposition (Asian or Caucasian descent) - thin, small frame -early menopause, before age 45 - past menopause - prolonged use ofosteopenic medication - low trauma fracture
ETIDRONATE /CALCIUMCARBONATE
CHRN In order for patients to be eligible for coverage for osteoporosis treatment,the physician submitting the application must provide either the results ofa bone density test, or list at least four of the following risk factors thatpertain to the patient. High Risk Factors: - significant family history -genetic predisposition (Asian or Caucasian descent) - thin, small frame -early menopause, before age 45 - past menopause - prolonged use ofosteopenic medication - low trauma fracture
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
281
ETIDRONATE DISODIUM CHRN In order for patients to be eligible for coverage for osteoporosis treatment,the physician submitting the application must provide either the results ofa bone density test, or list at least four of the following risk factors thatpertain to the patient. High Risk Factors: - significant family history -genetic predisposition (Asian or Caucasian descent) - thin, small frame -early menopause, before age 45 - past menopause - prolonged use ofosteopenic medication - low trauma fracture
RISEDRONATE CHRN In order for patients to be eligible for coverage for osteoporosis treatment,the physician submitting the application must provide either the results ofa bone density test, or list at least four of the following risk factors thatpertain to the patient. High Risk Factors: - significant family history -genetic predisposition (Asian or Caucasian descent) - thin, small frame -early menopause, before age 45 - past menopause - prolonged use ofosteopenic medication - low trauma fracture
RISEDRONATE SODIUM CHRN In order for patients to be eligible for coverage for osteoporosis treatment,the physician submitting the application must provide either the results ofa bone density test, or list at least four of the following risk factors thatpertain to the patient. High Risk Factors: - significant family history -genetic predisposition (Asian or Caucasian descent) - thin, small frame -early menopause, before age 45 - past menopause - prolonged use ofosteopenic medication - low trauma fracture
GLATIRAMER ACETATE CHRNPHRM
Initial: As first or second-line monotherapy for the treatment of RRMSwhen prescribed by an MS neurologist. Specialist's consult to be provided.For patients who meet ALL of the following criteria:-patient has had at least two (2) clinical relapses in the previous two (2)years AND-patient is ambulatory with or without aid (EDSS of 6.5 or less), AND-patient is 18 years or olderApproval period: 1 yearRenewal: When prescribed by an MS neurologist for patients whodemonstrate continued therapeutic benefit outweighing any potentialrisks, as shown by relapse rate, EDSS, MRI scan (when possible), andoverall clinical impression. Specialist's consult to be provided. A relapse is defined as the appearance of new symptoms or worsening ofold symptoms, lasting at least 24 hours in the absence of fever, andpreceded by stability for at least one (1) month. Approval for 1 year.Only a one month supply to be dispensed at a time for the first year.
INTERFERON BETA-1A CHRNPHRM
Initial: As first or second-line monotherapy for the treatment of RRMSwhen prescribed by an MS neurologist. Specialist's consult to be provided.For patients who meet ALL of the following criteria:-patient has had at least two (2) clinical relapses in the previous two (2)years AND-patient is ambulatory with or without aid (EDSS of 6.5 or less), AND-patient is 18 years or olderApproval period: 1 yearRenewal: When prescribed by an MS neurologist for patients whodemonstrate continued therapeutic benefit outweighing any potentialrisks, as shown by relapse rate, EDSS, MRI scan (when possible), andoverall clinical impression. Specialist's consult to be provided. A relapse is defined as the appearance of new symptoms or worsening ofold symptoms, lasting at least 24 hours in the absence of fever, andpreceded by stability for at least one (1) month. Approval for 1 year.Only a one month supply to be dispensed at a time for the first year.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
282
INTERFERON BETA-1B CHRNPHRM
Initial: As first or second-line monotherapy for the treatment of RRMSwhen prescribed by an MS neurologist. Specialist's consult to be provided.For patients who meet ALL of the following criteria:-patient has had at least two (2) clinical relapses in the previous two (2)years AND-patient is ambulatory with or without aid (EDSS of 6.5 or less), AND-patient is 18 years or olderApproval period: 1 yearRenewal: When prescribed by an MS neurologist for patients whodemonstrate continued therapeutic benefit outweighing any potentialrisks, as shown by relapse rate, EDSS, MRI scan (when possible), andoverall clinical impression. Specialist's consult to be provided. A relapse is defined as the appearance of new symptoms or worsening ofold symptoms, lasting at least 24 hours in the absence of fever, andpreceded by stability for at least one (1) month. Approval for 1 year.Only a one month supply to be dispensed at a time for the first year.
TERIFLUNOMIDE CHRNPHRM
Initial: As first or second-line monotherapy for the treatment of RRMSwhen prescribed by an MS neurologist. Specialist's consult to be provided.For patients who meet ALL of the following criteria:-patient has had at least two (2) clinical relapses in the previous two (2)years AND-patient is ambulatory with or without aid (EDSS of 6.5 or less), AND-patient is 18 years or olderApproval period: 1 yearRenewal: When prescribed by an MS neurologist for patients whodemonstrate continued therapeutic benefit outweighing any potentialrisks, as shown by relapse rate, EDSS, MRI scan (when possible), andoverall clinical impression. Specialist's consult to be provided. A relapse is defined as the appearance of new symptoms or worsening ofold symptoms, lasting at least 24 hours in the absence of fever, andpreceded by stability for at least one (1) month. Approval for 1 year.Only a one month supply to be dispensed at a time for the first year.
PIMECROLIMUS CHRNPHRM
On recommendation of Dermatologist. Specialists consult to be provided.
TACROLIMUS TOPICAL CHRNPHRM
On recommendation of Dermatologist. Specialists consult to be provided.
DICITRATE SOLN PHRM On recommendation of a specialist for renal failure. Specialists consult tobe provided.
OCTREOTIDE ACETATE CHRN On recommendation of an oncologist.
MONTELUKAST SODIUM CHRNPHRM
Treatment of asthma in patients on concurrent steroid therapy.
ZAFIRLUKAST CHRNPHRM
Treatment of asthma in patients on concurrent steroid therapy.
SEVELAMER HYDROCHLORIDECHRNPHRM
For treatment of patients in end stage renal disease with intolerance toaluminum or calcium containing phosphate binding agents.
92:24.00 - BONERESORPTION INHIBITORSDENOSUMAB CHRN
PHRMOn a case-by-case basis. Specialist's consult to be provided.
92:32.00 - COMPLEMENTINHIBITORS
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
283
ICATIBANT ACETATE PHRM For the treatment of acute attacks of hereditary angioedema (HAE) inadults with lab confirmed c1-esterase inhibitor deficiency (type l or ll) ifthe following conditions are met:a) treatment of non-laryngeal attacks of at least moderate severity, orb) treatment of acute laryngeal attacksANDLimited to a single dose for self-administration per attackANDPrescribed by a physician with experience in the treatment of HAE
92:36.00 - DISEASE-MODIFYINGANTIRHEUMATIC AGENTSTOFACITINIB CHRN
PHRMFor severely active rheumatoid arthritis on recommendation of RAspecialist. Specialist's consult to be provided. For patients refractory orintolerant to parenteral methotrexate after at least a 12 week trial ANDA 3 month trial of at least 2 of the following; leflunomide, sulfasalazine,azathioprine ANDA 3 month trial of at least one DMARD combination such as a)methotrexate & cyclosporine b) methotrexate with hydroxychloroquine &sulfasalazine c) methotrexate & leflunomide
92:44.00 -IMMUNOSUPPRESSIVEAGENTSPIRFENIDONE CHRN
PHRMInitial Approval:Adult patients who have a diagnosis of mild to moderate idiopathicpulmonary fibrosis (IPF)-Confirmed by a respirologist and a high-resolution CT scan within theprevious 24 months.-All other causes of restrictive lung disease (e.g. collagen vascular disorderor hypersensitivity pneumonitis) should be excluded.-Mild to moderate IPF is defined as forced vital capacity (FVC) greater thanor equal to 50% of predicted.-Patient is under the care of a physician with experience in IPF. Consult tobe provided.Initial approval period: 7 months (including allowing 4 weeks for repeatpulmonary function tests)Initial Renewal Criteria:Patients must NOT demonstrate progression of disease defined as anabsolute decline in percent predicted FVC of 10% from initiation oftherapy until renewal (initial 6 month treatment period). If a patient hasexperienced progression as defined above, then the results should bevalidated with a confrimatory pulmonary function test conducted 4 weekslater.Approval period: 6 monthsSecond renewal (12 months after initiation of therapy) :Patients must NOT demonstrate progression of disease defined as anabsolute decline in percent predicted FVC of 10% within any 12 monthperiod. If a patient has experienced progression as defined above, then theresults should be validated with a confirmatory pulmonary function testconducted 4 weeks later.Approval period: 12 monthsExclusion criteria: Combination use of Esbriet and Ofev will not be funded.Notes: Patients who have experienced intolerance or failure to Esbriet orOfev will be considered for the alternate agent provided that the patientcontinues to meet the above criteria.
92:92.00 - OTHERMISCELLANEOUSTHERAPEUTIC AGENTSCINACALCETHYDROCHLORIDE
CHRNPHRM
On recommendation of a specialist. Specialist's consult to be provided.
99.00 PALLIATIVE CARE
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
284
99:00.98 - CD PALLIATIVERXPANTOPRAZOLE CHRN Approved on case-by-case basis: For treatment of patients at high risk for
GI bleeding when NSAID or steroid therapy cannot be avoided for approvedchronic disease. For patients with Barrett's Esophagus. Standard doseapproved - include reasons if high dose required. GERD, dyspepsia orpeptic ulcer disease are not covered by Chronic Disease Program.
ACETYLCYSTEINE PHRM As a mucolytic agent, by inhalation/ nebulization.
METHADONE CHRNPHRM
Case-by-case basis for palliative patients.
ONDANSETRON CHRNPHRM
For use with emetogenic chemotherapy as per cancer agency protocol.Approval for 1 year, then renew as required.
METHYLPHENIDATE HCL CHRNPHRM
Treatment of psychiatric disorder on recommendation of Psychiatrist orPediatrician. Specialists consult to be provided.
FLUCONAZOLE CHRN Treatment of a serious fungal infection in immuno-compromized patientssecondary to an approved chronic condition. Please provide description ofinfection.
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
285
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
(SEE A/P FILES) ..................................................... 20:15.00NYNY 46
5-AMINOSALICYLIC ACID ............................................... 56:40.00YYYY 164
ABACAVIR ............................................................ 08:18.08YYNY 14
ABACAVIR ............................................................ 08:18.08YYNY 14
ABACAVIR (ABACAVIR SULPHATE) ........................................ 08:18.08YYNY 14
ABACAVIR/DOLUTEGRAVIR/LAMIVUDI ...................................... 08:18.08EENY 14
ABACAVIR/LAMIVUDINE ................................................. 08:18.08YYNY 14
ABACAVIR/LAMIVUDINE/ZIDOVUDINE ...................................... 08:18.08YYNY 14
ABIRATERONE ACETATE ................................................. 10:00.00EENY 22
ACAMPROSATE CALCIUM ................................................. 28:92.00YENY 143
ACARBOSE ............................................................ 68:20.20YYNY 182
ACEBUTOLOL HCL ...................................................... 24:04.00YYNY 48
ACENOCOUMAROL ....................................................... 20:12.04YYYY 43
ACETAMINOPHEN ....................................................... 28:08.92YNNN 102
ACETAMINOPHEN ....................................................... 99:00.99YYNN 224
ACETAMINOPHEN ....................................................... 99:00.99YYNN 224
ACETAMINOPHEN ....................................................... 99:01.00YNNN 224
ACETAMINOPHEN LIQUID ................................................ 28:08.92YNNN 103
ACETAMINOPHEN LIQUID ................................................ 99:00.99YYNN 224
ACETAMINOPHEN/CAFFEINE/CODEINE ...................................... 28:08.08YYNY 94
ACETAMINOPHEN/CODEINE ............................................... 28:08.08EENY 95
ACETAMINOPHEN/CODEINE ............................................... 28:08.08EENY 95
ACETAZOLAMIDE ....................................................... 52:10.00YYNY 157
ACETYLCYSTEINE ...................................................... 48:24.00ENNY 152
ACETYLCYSTEINE ...................................................... 99:00.98YYNY 220
ACETYLSALICYLIC ACID ................................................ 28:08.04YNNN 87
ACETYLSALICYLIC ACID ................................................ 99:00.99YYNN 224
ACITRETIN ........................................................... 84:36.00EENY 201
ACLIDINIUM BROMIDE .................................................. 12:08.08EENY 34
ACLIDINIUM/FORMOTEROL ............................................... 12:08.08EENY 34
ACYCLOVIR ........................................................... 08:18.00YEYY 11
ACYCLOVIR ........................................................... 84:04.06YNYY 191
ADALIMUMAB .......................................................... 92:00.00EENY 208
ADAPALENE ........................................................... 84:28.00NNYY 200
ADEFOVIR DIPIVOXIL .................................................. 08:18.08EENY 14
AFATINIB ............................................................ 10:00.00EENY 22
AFLIBERCEPT ......................................................... 52:92.00EENY 161
ALENDRONATE ......................................................... 92:00.00YENY 209
ALENDRONATE ......................................................... 92:00.00YENY 209
ALENDRONATE/CHOLECALCIFEROL ......................................... 92:00.00YENY 209
ALFACALCIDOL ........................................................ 88:16.00YENY 207
ALFUZOSIN HYDROCHLORIDE ............................................. 92:00.00YNNY 209
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
286
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
ALGINIC ACID/MAGNESIUM CARB ......................................... 99:00.00YNNN 220
ALITRETINOIN ........................................................ 84:36.00NENY 201
ALLOPURINOL ......................................................... 92:00.00YYNY 209
ALMOTRIPTAN MALATE .................................................. 12:16.00YNYY 38
ALPRAZOLAM .......................................................... 28:24.08YNYY 139
ALUMINUM ACET/BENZETHONIUM CHL ...................................... 84:12.00NNYN 199
ALUMINUM/MAGNESIUM/SIMETHICONE ...................................... 99:15.00YNNN 229
AMANTADINE .......................................................... 08:18.00YEYY 12
AMCINONIDE .......................................................... 84:06.00YYYY 193
AMILORIDE HCL ....................................................... 40:28.10YYNY 151
AMILORIDE/HYDROCHLOROTHIAZIDE ....................................... 40:28.10YYNY 151
AMIODARONE .......................................................... 24:04.00YYNY 49
AMITRIPTYLINE ....................................................... 28:16.04YYYY 114
AMLODIPINE BESYLATE ................................................. 24:04.00YYNY 49
AMOXICILLIN (AMOXYCILLIN) ........................................... 08:12.16YEYY 8
AMOXICILLIN/CLAVULANIC ACID ......................................... 08:12.16YEYY 8
AMPICILLIN .......................................................... 08:12.16YEYY 9
ANAGRELIDE HCL ...................................................... 10:00.00YYNY 22
ANAKINRA ............................................................ 92:00.00EENY 210
ANASTROZOLE ......................................................... 10:00.00YYNY 22
APIXABAN ............................................................ 20:12.04EENY 43
APRACLONIDINE HCL ................................................... 52:36.00YYYY 159
APRACLONIDINE HCL ................................................... 52:36.00YYYY 159
APREPITANT .......................................................... 56:22.00EENY 162
ARIPIPRAZOLE ........................................................ 28:16.08EENY 125
ARTIFICIAL SALIVA ................................................... 02:10.00NNNN 1
ARTIFICIAL SALIVA ................................................... 99:00.99YYNN 224
ASA/CAFF/CODEINE/BUTALBITAL ......................................... 28:08.92YNNY 103
ASA/CAFFEINE/CODEINE ................................................ 28:08.08YNNN 95
ASENAPINE ........................................................... 28:16.08EENY 126
ATAZANAVIR .......................................................... 08:18.08YYNY 14
ATENOLOL ............................................................ 24:04.00YYNY 50
ATENOLOL/CHLORTHALIDONE ............................................. 24:08.00YYNY 72
ATOMOXETINE ......................................................... 28:92.00EENY 144
ATOMOXETINE ......................................................... 28:92.00EENY 144
ATORVASTATIN CALCIUM ................................................ 24:06.00YYNY 65
ATOVAQUONE .......................................................... 08:40.00YENY 21
ATROPINE SO4 ........................................................ 52:24.00YNYY 158
ATROPINE SULFATE .................................................... 99:07.00YNNY 227
AURANOFIN ........................................................... 60:00.00YYNY 171
AURANOFIN ........................................................... 60:00.00YYNY 171
AZATHIOPRINE ........................................................ 92:00.00YYNY 210
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
287
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
AZELAIC ACID ........................................................ 84:92.00YNYY 202
AZITHROMYCIN ........................................................ 08:12.12YEYY 5
BACILLUS CALMETTE-GUERIN (BCG) ...................................... 80:12.00EENY 189
BACLOFEN ............................................................ 12:20.00YYYY 40
BECLOMETHASONE DIPROPIONATE ......................................... 52:08.00YNYY 154
BECLOMETHASONE DIPROPIONATE ......................................... 68:04.00YYYY 171
BECLOMETHASONE DIPROPIONATE ......................................... 84:06.00YYYY 194
BELLADONNA /PENTOBARBITAL ........................................... 12:16.00YNYY 38
BELLADONNA/ERGOT/PHENOBARBITAL ...................................... 12:08.08YNNY 34
BENAZEPRIL HCL ...................................................... 24:08.00YYNY 73
BENZOYL PEROXIDE .................................................... 84:28.00YNYY 200
BENZOYL PEROXIDE CLINDAMYCIN ........................................ 84:04.04NNYY 190
BENZOYL PEROXIDE/ CLINDAMYCIN ....................................... 84:04.04YNYY 190
BENZOYL PEROXIDE/ ERYTHROMYCIN ...................................... 84:04.04NNYY 190
BENZOYL PEROXIDE/CLINDAMYCIN ........................................ 84:04.04NNYY 190
BENZTROPINE MESYLATE ................................................ 12:08.04YYNY 33
BENZYDAMINE ......................................................... 52:28.00YEYY 158
BETAHISTINE HYDROCHLORIDE ........................................... 92:00.00YNNY 210
BETAMETHASONE DIPROP/SALICYLIC ...................................... 84:06.00YYYY 194
BETAMETHASONE DIPROPIONATE .......................................... 84:06.00YYYY 194
BETAMETHASONE DISODIUM PHOS ......................................... 56:40.00YYYY 165
BETAMETHASONE VALERATE .............................................. 84:06.00YYYY 194
BETAXOLOL HCL ....................................................... 52:36.00YYNY 159
BETHANECHOL CHLORIDE ................................................ 12:04.00YYNY 31
BEVACIZUMAB ......................................................... 10:00.00EENY 22
BEZAFIBRATE ......................................................... 24:06.00YYNY 66
BICALUTAMIDE ........................................................ 10:00.00YYNY 22
BIMATOPROST ......................................................... 52:36.00YYNY 159
BISACODYL ........................................................... 99:04.00YNNN 225
BISOPROLOL FUMARATE ................................................. 24:04.00YYNY 51
BOCEPREVIR .......................................................... 08:18.92EENY 18
BOCEPREVIR/RIBAVIRIN/PEGINTERF ...................................... 08:18.92EENY 18
BOSUTINIB ........................................................... 10:00.00EENY 23
BOTULINUM TOXIN TYPE A .............................................. 92:00.00EENY 210
BRIMONIDINE TARTRATE ................................................ 52:36.00YYNY 159
BRIMONIDINE TARTRATE/TIMOLOL ........................................ 52:36.00YYNY 159
BRIMONIDINE/BRINZOLAMIDE ............................................ 52:40.04YYNY 161
BRINZOLAMIDE ........................................................ 52:10.00YYNY 157
BRINZOLAMIDE/TIMOLOL ................................................ 52:36.00YYNY 159
BROMAZEPAM .......................................................... 28:24.08YNYY 139
BROMOCRIPTINE MESYLATE .............................................. 92:00.00YYNY 210
BUDESONIDE .......................................................... 52:08.00YNYY 154
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
288
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
BUDESONIDE .......................................................... 56:40.00YYYY 165
BUDESONIDE .......................................................... 68:04.00YYNY 172
BUDESONIDE .......................................................... 68:04.00YYNY 172
BUMETANIDE .......................................................... 40:28.00EENY 149
BUPRENORPHINE/NALOXONE .............................................. 28:08.12YENY 102
BUPROPION HYDROCHLORIDE ............................................. 28:16.04YYYY 115
BUPROPION HYDROCHLORIDE ............................................. 28:16.04YYYY 115
BUPROPION HYDROCHLORIDE ............................................. 28:20.00YNYY 137
BUSERELIN ACETATE ................................................... 92:00.00YYNY 211
BUSERELIN ACETATE ................................................... 92:00.00YYNY 211
BUSPIRONE ........................................................... 28:24.92YYYY 142
CALCIFEROL .......................................................... 88:16.00YNNN 207
CALCIPOTRIOL ........................................................ 84:36.00YYNY 201
CALCIPOTRIOL/BETAMETHASONE DIP ...................................... 84:36.00YYNY 202
CALCIPOTRIOL/BETAMETHASONE DIP ...................................... 84:36.00YYNY 202
CALCITONIN .......................................................... 68:24.00EENY 187
CALCITRIOL .......................................................... 88:16.00YENY 207
CALCIUM ............................................................. 99:09.00YNNN 228
CALCIUM POLYSTYRENE SULFONATE ...................................... 40:18.00YNNY 149
CALCIUM 500MG ....................................................... 88:29.00YNYN 208
CALCIUM CARBONATE ................................................... 88:29.00YNYN 208
CALCIUM CARBONATE CHEW TABS ......................................... 88:29.00YNYN 208
CALCIUM CARBONATE/VITAMIN D ......................................... 88:29.00YNNN 208
CANAGLIFLOZIN ....................................................... 68:20.18EENY 181
CANDESARTAN CILEXETIL ............................................... 24:08.00YYNY 73
CANDESARTAN/HCTZ .................................................... 24:08.00YYNY 74
CANDESARTAN/HCTZ .................................................... 24:08.00YYNY 74
CANDESARTAN/HYDROCHLOROTHIAZID ...................................... 24:08.00YYNY 74
CANDESARTEN CILEXETIL ............................................... 24:08.00YYNY 74
CAPECITABINE ........................................................ 10:00.00EENY 23
CAPSAICIN ........................................................... 84:24.04YNNN 200
CAPTOPRIL ........................................................... 24:04.00YYNY 52
CARBAMAZEPINE ....................................................... 28:12.92YYNY 106
CARBIDOPA/ENTACAPONE/LEVODOPA ....................................... 28:92.00YYNY 144
CARBIDOPA/LEVODOPA .................................................. 28:36.16EENY 143
CARBOXYMETHYL CELLULOSE ............................................. 99:06.00YNNN 227
CARVEDILOL .......................................................... 24:04.00YYNY 52
CEFACLOR ............................................................ 08:12.06YEYY 3
CEFAZOLIN SODIUM .................................................... 08:12.06YENY 4
CEFIXIME ............................................................ 08:12.06YEYY 4
CEFPROZIL ........................................................... 08:12.06YEYY 4
CEFTAZIDIME ......................................................... 08:12.06YENY 4
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
289
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
CEFTRIAXONE ......................................................... 08:12.06YENY 5
CEFTRIAXONE ......................................................... 08:12.06YENY 5
CEFUROXIME AXETIL ................................................... 08:12.06YEYY 5
CELECOXIB ........................................................... 28:08.04YYYY 88
CEPHALEXIN MONOHYDRATE .............................................. 08:12.06YEYY 5
CERTOLIZUMAB PEGOL .................................................. 92:00.00EENY 211
CETIRIZINE .......................................................... 99:16.00YNNN 229
CHLORAL HYDRATE ..................................................... 28:24.92YEYY 143
CHLORAL HYDRATE ..................................................... 28:24.92YEYY 143
CHLORAMBUCIL ........................................................ 10:00.00YYNY 23
CHLORAMPHENICOL ..................................................... 52:04.04YNYY 152
CHLORDIAZEPOXIDE .................................................... 28:24.08YNYY 140
CHLORDIAZEPOXIDE .................................................... 28:24.08YNYY 140
CHLORHEXIDINE GLUCONATE ............................................. 52:28.00YNYY 158
CHLORHEXIDINE GLUCONATE ............................................. 99:06.00YNYY 227
CHLORPROMAZINE ...................................................... 28:16.08YYNY 126
CHLORPROPAMIDE ...................................................... 68:20.20YYNY 182
CHLORTHALIDONE ...................................................... 40:28.00YYNY 149
CHOLESTYRAMINE RESIN ................................................ 24:06.00YYNY 66
CHORAMPHENICOL/HC ................................................... 52:04.04YNYY 153
CHORAMPHENICOL/HC ................................................... 52:04.04YNYY 153
CICLESONIDE ......................................................... 68:04.00YYNY 172
CICLOPIROX OLAMINE .................................................. 84:04.08YNYY 191
CILAZAPRIL .......................................................... 24:08.00YYNY 74
CILAZAPRIL/HCTZ ..................................................... 24:08.00YYNY 75
CILAZAPRIL/HCTZ ..................................................... 24:08.00YYNY 75
CIMETIDINE .......................................................... 56:40.00YNYY 165
CINACALCET .......................................................... 92:92.00EENY 219
CINACALCET HYDROCHLORIDE ............................................ 92:92.00EENY 220
CINACALCET HYDROCHLORIDE ............................................ 92:92.00EENY 220
CIPROFLOXACIN ....................................................... 08:22.00YENY 18
CIPROFLOXACIN ....................................................... 52:04.12YNYY 154
CIPROFLOXACIN/DEXAMTHEASONE ......................................... 52:08.00YNYY 155
CIPROFLOXACIN/DEXAMTHEASONE ......................................... 99:00.98YYNY 220
CITALOPRAM .......................................................... 28:16.04YYYY 115
CITALOPRAM .......................................................... 99:00.98YYNY 220
CLARITHROMYCIN ...................................................... 08:12.12YEYY 6
CLINDAMYCIN HCL ..................................................... 08:12.28YEYY 11
CLINDAMYCIN PALMITATE HCL ........................................... 08:12.28YEYY 11
CLINDAMYCIN PHOSPHATE ............................................... 84:04.04YNYY 190
CLINDAMYCIN PHOSPHATE ............................................... 99:00.98YYNY 220
CLINDAMYCIN/BENZOYL PEROXIDE ........................................ 84:04.04NNYY 190
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
290
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
CLOBAZAM ............................................................ 28:12.08YYNY 104
CLOBETASOL PROPIONATE ............................................... 84:06.00YYYY 195
CLOBETASONE BUTYRATE ................................................ 84:06.00YYYY 195
CLODRONATE DISODIUM ................................................. 92:00.00YYNY 211
CLOMIPRAMINE HCL .................................................... 28:16.04YYYY 116
CLONAZEPAM .......................................................... 28:12.08YYNY 104
CLONAZEPAM .......................................................... 99:00.98YYNY 220
CLONIDINE HCL ....................................................... 24:08.00YNNY 75
CLOPIDOGREL BISULFATE ............................................... 20:24.00YYNY 48
CLORAZEPATE DIPOTASSIUM ............................................. 28:24.08YNNY 140
CLOTRIMAZOLE ........................................................ 84:04.08YNYN 191
CLOXACILLIN ......................................................... 08:12.16YEYY 9
CLOZAPINE ........................................................... 28:16.08YYNY 126
COAL TAR/JUNIPER TAR/PINE TAR ....................................... 84:28.00NNYN 201
COAL TAR/JUNIPER TAR/PINE TAR ....................................... 84:28.00NNYN 201
COBICISTAT/DARUNAVIR ................................................ 08:18.08EENY 14
COBICISTAT/EMTRICITABINE/ELVIT ...................................... 08:18.08EENY 14
CODEINE ............................................................. 28:08.08YENY 95
CODEINE PHOSPHATE ................................................... 28:08.08YYNY 95
CODEINE PHOSPHATE ................................................... 48:08.00YNNY 152
CODEINE/GUAIFENES/PHENIRAMINE ....................................... 48:08.00YNNY 152
COLCHICINE .......................................................... 92:00.00YYNY 211
COLESEVELAM HYDROCHLORIDE ........................................... 24:06.04YYNY 72
COLESTIPOL HCL RESIN ................................................ 24:06.00YYNY 66
COMPOUNDED INJECTABLES .............................................. 92:00.00EENY 211
COMPOUNDED ORAL PREPARATIONS ........................................ 92:00.00EEYY 211
COMPOUNDED TOPICALS ................................................. 92:00.00YEYY 211
CONJUGATED ESTROGENS ................................................ 68:16.04YNNY 178
CONJUGATED ESTROGENS ................................................ 99:00.98YYNY 220
CORTISONE ACETATE ................................................... 68:04.00YYYY 172
CRIZOTINIB .......................................................... 10:00.00EENY 23
CROTAMITON .......................................................... 84:04.12YNYN 192
CYANOCOBALAMIN ...................................................... 88:08.00YENY 205
CYANOCOBALMIN ....................................................... 88:08.00YENN 206
CYANOCOBALMIN ....................................................... 88:08.00YENN 206
CYCLOBENZAPRINE HCL ................................................. 12:20.00YYYY 41
CYCLOPENTOLATE HCL .................................................. 52:24.00YNYY 158
CYCLOPHOSPAMIDE ..................................................... 10:00.00YYNY 23
CYCLOSPORINE ........................................................ 92:00.00YYNY 211
CYPROHEPTADINE HYDROCHLORIDE ........................................ 99:11.00YNNN 228
CYPROTERONE ACETATE ................................................. 10:00.00YYNY 24
CYPROTERONE/ESTROGEN ................................................ 84:36.00NNYY 202
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
291
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
DABRAFENIB MESYLATE ................................................. 10:00.00EENY 24
DALTEPARIN SODIUM ................................................... 20:12.04YENY 43
DANAZOL ............................................................. 68:08.00YNYY 175
DANTROLENE SODIUM ................................................... 12:20.00YYNY 41
DAPAGLIFLOZIN ....................................................... 68:20.18EENY 182
DAPAGLIFLOZIN ....................................................... 68:20.18EENY 182
DAPSONE ............................................................. 08:26.00YEYY 21
DARBEPOETIN ALFA .................................................... 20:16.00EENY 46
DARIFENACIN ......................................................... 86:12.00EENY 203
DARUNAVIR ........................................................... 08:18.08EENY 14
DASATINIB ........................................................... 10:00.00EENY 24
DEFERIPRONE ......................................................... 64:00.00EENY 171
DEFEROXAMINE MESYLATE ............................................... 64:00.00YNNY 171
DEGARELIX ........................................................... 10:00.00YNNY 24
DENOSUMAB ........................................................... 92:00.00EENY 212
DENOSUMAB ........................................................... 92:00.00EENY 212
DENOSUMAB ........................................................... 92:24.00EENY 219
DESAMETHASONE ....................................................... 68:04.00YYYY 172
DESIPRAMINE HCL ..................................................... 28:16.04YYYY 117
DESIPRAMINE HCL ..................................................... 28:16.04YYYY 117
DESMOPRESSIN ........................................................ 68:28.00EEYY 187
DESONIDE ............................................................ 84:06.00YYYY 195
DESOXIMETASONE ...................................................... 84:06.00YYYY 196
DESOXIMETASONE ...................................................... 84:06.00YYYY 196
DEXAMETHASONE ....................................................... 52:08.00YEYY 155
DEXAMETHASONE ....................................................... 68:04.00YYYY 172
DEXAMETHASONE 21-PHOSPHATE .......................................... 68:04.00YYYY 173
DEXAMETHASONE PHOSPHATE ............................................. 68:04.00YYNY 173
DEXAMETHASONE SODIUM-PHOSPHATE ...................................... 68:04.00YYNY 173
DEXTROAMPHETAMINE SO4 ............................................... 28:20.00EENY 137
DEXTROSE/SODIUM CHLORIDE ............................................ 99:14.00YNNY 229
DEXTROSE/SODIUM CHLORIDE ............................................ 99:14.00YNNY 229
DIAZEPAM ............................................................ 28:24.08NNNY 140
DIAZEPAM ............................................................ 99:00.98YYNY 220
DICITRATE SOLN ...................................................... 92:00.00ENNN 212
DICLOFENAC DIETHYLAMINE ............................................. 28:08.04YNNN 88
DICLOFENAC POTASSIUM ................................................ 28:08.04YYYY 89
DICLOFENAC POTASSIUM ................................................ 28:08.04YYYY 89
DICLOFENAC SODIUM ................................................... 28:08.04YYYY 89
DICLOFENAC SODIUM ................................................... 52:36.00YNYY 159
DICLOFENAC SODIUM/MISOPROSTOL ....................................... 28:08.04YYYY 90
DICLOFENAC SODIUM/MISOPROSTOL ....................................... 28:08.04YYYY 90
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
292
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
DICLOFENAC SODIUM/MISOPROTOL ........................................ 28:08.04YYYY 90
DIDANOSINE .......................................................... 08:18.08YYNY 14
DIFLUCORTOLONE VALERATE ............................................. 84:06.00YYYY 196
DIFLUNISAL .......................................................... 28:08.04YYYY 90
DIGOXIN ............................................................. 24:04.00YYNY 53
DIHYDROERGOTAMINE MESYLATE .......................................... 12:16.00YNYY 38
DIIODOHYDROXYQUIN ................................................... 08:04.00YNYY 1
DILTIAZEM HCL ....................................................... 24:04.00YYNY 54
DIMENHYDRINATE ...................................................... 99:05.00YNNN 227
DIMETHYL FUMARATE ................................................... 28:92.00EENY 144
DIPHENHYDRAMINE HYDROCHLORIDE ....................................... 99:13.00YNNN 228
DIPHENHYDRAMINE HYDROCHLORIDE ....................................... 99:16.00YNNN 229
DIPHENOXYLATE HCL ................................................... 56:08.00YYYY 161
DIPIVEFRIN HCL ...................................................... 52:24.00YNYY 158
DIPYRIDAMOLE ........................................................ 24:12.00YYNY 85
DIPYRIDAMOLE/ASA .................................................... 24:12.00EENY 85
DISOPYRAMIDE ........................................................ 24:04.04YNNY 65
DITHRANOL ........................................................... 84:28.00YNNN 201
DIVALPROEX SODIUM ................................................... 28:12.92YYNY 107
DOCETAXEL ........................................................... 10:00.00YYNY 24
DOLASETRON .......................................................... 56:22.00EENY 163
DOLUTEGRAVIR ........................................................ 08:18.08EENY 15
DOMPERIDONE MALEATE ................................................. 56:40.00YYYY 166
DONEPEZIL HYDROCHLORIDE ............................................. 12:04.00EENY 31
DONEPEZIL HYSROCHLORIDE ............................................. 12:04.00EENY 32
DONEPEZIL HYSROCHLORIDE ............................................. 12:04.00EENY 32
DORNASE ALFA ........................................................ 48:24.00EENY 152
DORZOLAMIDE HCL ..................................................... 52:10.00YYNY 157
DORZOLAMIDE HCL/TIMOLOL ............................................. 52:36.00EENY 159
DORZOLAMIDE/TIMOLOL ................................................. 52:36.00YYNY 160
DOXAZOSIN MESYLATE .................................................. 24:08.00YYNY 75
DOXEPIN HCL ......................................................... 28:16.04YYYY 117
DOXYCYCLINE ......................................................... 08:12.24YEYY 10
DOXYLAMINE /PYRIDOXINE HCL .......................................... 56:22.00NNYY 163
DULOXETINE .......................................................... 28:16.04YYNY 117
DULOXETINE .......................................................... 99:00.98YYNY 220
DUTASTERIDE ......................................................... 92:00.00YNNY 212
EANALAPRIL MALEATE .................................................. 24:04.00YYNY 56
EANALAPRIL MALEATE .................................................. 24:04.00YYNY 56
EFAVIRENZ ........................................................... 08:18.08YYNY 15
EFAVIRENZ/TENOFOVIR/EMTRICITAB ...................................... 08:18.08EENY 15
EMPAGLIFLOZIN ....................................................... 68:20.18EENY 182
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
293
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
EMTRICITABINE/RILPIVIRINE/TENO ...................................... 08:18.08EENY 15
ENALAPRIL ........................................................... 24:04.00YYNY 56
ENALAPRIL /HCTZ ..................................................... 24:04.00YYNY 56
ENALAPRIL MALEATE ................................................... 24:04.00YYNY 56
ENALAPRIL SODIUM .................................................... 24:04.00YYNY 57
ENOXAPARIN .......................................................... 20:12.04YENY 44
ENOXAPARIN .......................................................... 20:12.04YENY 44
ENTACAPONE .......................................................... 28:92.00YYNY 145
ENTACAPONE .......................................................... 28:92.00YYNY 145
ENTECAVIR ........................................................... 08:18.08EENY 15
ENZALUTAMIDE ........................................................ 10:00.00EENY 24
EPINEPHRINE ......................................................... 12:12.00ENYY 36
EPINEPHRINE HCL ..................................................... 12:12.00ENYY 36
EPLERENONE .......................................................... 24:32.20EENY 87
EPOETIN ALFA ........................................................ 20:16.00EENY 47
EPROSARTAN .......................................................... 24:08.00YYNY 75
EPROSARTAN/HYDROCHLOROTHIAZIDE ...................................... 24:08.00YYNY 76
EPROSARTAN/HYDROCHLOROTHIAZIDE ...................................... 24:08.00YYNY 76
ERLOTINIB ........................................................... 10:00.00EENY 24
ERYTHROMYCIN ........................................................ 52:04.04YNYY 153
ERYTHROMYCIN BASE ................................................... 08:12.12YEYY 7
ERYTHROMYCIN ESTOLATE ............................................... 08:12.12YEYY 7
ERYTHROMYCIN ETHYLSUCCINATE ......................................... 08:12.12YEYY 7
ERYTHROMYCIN STEARATE ............................................... 08:12.12YEYY 7
ERYTHROMYCIN TRETINOIN .............................................. 84:16.00NNYY 199
ESCITALOPRAM ........................................................ 28:16.04YYNY 118
ESLICARBAZEPINE ACETATE ............................................. 28:12.92EENY 107
ESTRADIOL ........................................................... 68:16.04YNNY 178
ESTRADIOL & NORETHINDRONE ........................................... 68:16.04YNNY 178
ESTRADIOL HEMIHYDRATE ............................................... 68:16.04YNNY 179
ETANERCEPT .......................................................... 92:00.00EENY 212
ETHINYL ESTRADIOL & ETONOGESTR ...................................... 68:12.00NNYY 175
ETHINYL ESTRADIOL DROSPIRENONE ...................................... 68:12.00NNYY 175
ETHINYL ESTRADIOL/DESOGESTREL ....................................... 68:12.00NNYY 175
ETHINYL ESTRADIOL/DROSPIRENONE ...................................... 68:12.00NNYY 176
ETHINYL ESTRADIOL/ETHYNODIOL ........................................ 68:12.00NNYY 176
ETHINYL ESTRADIOL/L-NORGESTREL ...................................... 68:12.00NNYY 176
ETHINYL ESTRADIOL/NORGESTIMATE ...................................... 68:12.00NNYY 176
ETHINYLESTRADIOL/LEVONORGESTRE ...................................... 68:12.00NNYY 177
ETHINYLESTRADIOL/LEVONORGESTRE ...................................... 68:12.00NNYY 177
ETHINYLESTRADIOL/NORETHINDRONE ...................................... 68:12.00NNYY 177
ETHOPROPAZINE ....................................................... 12:08.04YYNY 33
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
294
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
ETHOSUXIMIDE ........................................................ 28:12.20YYNY 106
ETIDRONATE /CALCIUM CARBONATE ....................................... 92:00.00YENY 212
ETIDRONATE DISODIUM ................................................. 92:00.00YENY 212
ETODOLAC ............................................................ 28:08.04YYYY 90
ETOPOSIDE ........................................................... 10:00.00YYNY 24
EVEROLIMUS .......................................................... 10:00.00EENY 25
EVEROLIMUS .......................................................... 10:00.00EENY 25
EXEMESTANE .......................................................... 10:00.00YYNY 25
EZETIMIBE ........................................................... 24:06.00EENY 66
FAMCICLOVIR ......................................................... 08:18.00YEYY 12
FAMOTIDINE .......................................................... 56:40.00YNYY 166
FEBUXOSTAT .......................................................... 92:00.00EENY 212
FELODIPINE .......................................................... 24:08.00YYNY 76
FENOFIBRATE ......................................................... 24:06.00YYNY 66
FENOFIBRATE ......................................................... 24:06.06YYNY 72
FENTANYL ............................................................ 28:08.08YYNY 95
FENTANYL ............................................................ 99:01.00YNNY 224
FENTANYL CITRATE .................................................... 28:08.08NNNY 97
FENTANYL CITRATE .................................................... 28:08.08NNNY 97
FENTANYL CITRATE .................................................... 99:00.98YYNY 220
FERROUS FUMARATE .................................................... 20:04.04YNYN 42
FERROUS GLUCONATE ................................................... 20:04.04YNYN 42
FERROUS GLUCONATE ................................................... 99:00.99YYNN 224
FERROUS SULPHATE .................................................... 20:04.04YNYN 42
FILGRASTIM .......................................................... 20:16.00EENY 48
FILGRASTIM .......................................................... 20:16.00EENY 48
FINASTERIDE ......................................................... 92:00.00YNNY 212
FINGOLIMOD .......................................................... 92:00.00EENY 213
FINGOLIMOD .......................................................... 92:00.00EENY 213
FLAVOXATE HCL ....................................................... 86:12.00YYYY 203
FLECAINIDE .......................................................... 24:04.00YYNY 57
FLOCTAFENINE ........................................................ 28:08.92YNYY 103
FLUCONAZOLE ......................................................... 08:12.04YEYY 2
FLUCONAZOLE ......................................................... 99:00.98YYNY 221
FLUDARABINE PHOSPHATE ............................................... 10:00.00YYNY 25
FLUDROCORTISONE ACETATE ............................................. 68:04.00YYYY 173
FLUMETHASONE PIVALATE ............................................... 84:06.00YNYY 196
FLUNARIZINE HCL ..................................................... 12:16.00YNYY 39
FLUNARIZINE HCL ..................................................... 12:16.00YNYY 39
FLUNISOLIDE ......................................................... 52:08.00YNYY 155
FLUOCINOLONE ACETONIDE .............................................. 84:06.00YYYY 196
FLUOCINONIDE ........................................................ 84:06.00YYYY 196
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
295
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
FLUOROMEHTOLONE ..................................................... 52:08.00YNYY 155
FLUOROMETHOLONE ..................................................... 52:08.00YEYY 155
FLUOROMETHOLONE ACETATE ............................................. 52:08.00YNYY 155
FLUOROURACIL ........................................................ 84:36.00YNNY 202
FLUOXETINE .......................................................... 28:16.04YYYY 118
FLUPENTHIXOL DECANOATE .............................................. 28:16.08YYNY 126
FLUPENTHIXOL DIHYDROCHLORIDE ........................................ 28:16.08YYNY 127
FLUPENTHIXOL DIHYDROCHLORIDE ........................................ 28:16.08YYNY 127
FLUPHENAZINE DECANOATE .............................................. 28:16.08YYNY 127
FLUPHENAZINE HCL .................................................... 28:16.08YYNY 127
FLURAZEPAM HCL ...................................................... 28:24.08YNYY 140
FLURBIPROFEN ........................................................ 28:08.04YYYY 90
FLUTAMIDE ........................................................... 10:00.00YYNY 25
FLUTIASONE FUROATE .................................................. 52:08.08YYYY 157
FLUTICASONE FUROATE ................................................. 52:08.00YNYY 155
FLUTICASONE FUROATE ................................................. 52:08.08YYYY 157
FLUTICASONE FUROATE/VILANTEROL ...................................... 12:12.00EENY 36
FLUTICASONE PROPIONATE .............................................. 52:08.00YNYY 155
FLUTICASONE PROPIONATE .............................................. 68:04.00YYYY 173
FLUVASTATIN SODIUM .................................................. 24:06.00YYNY 67
FLUVOXAMINE MALEATE ................................................. 28:16.04YYYY 119
FOLIC ACID .......................................................... 88:08.00YNYY 206
FONDAPARINUX SODIUM ................................................. 20:12.04EENY 44
FORMOTEROL FUMARATE ................................................. 12:12.00EENY 36
FORMOTEROL FUMARATE/BUDESONIDE ...................................... 12:12.00EENY 36
FOSINOPRIL .......................................................... 24:08.00YYNY 76
FRAMYCETIN SO4 ...................................................... 84:04.04YNYY 190
FRAMYCETIN/GRAMICIDIN/DEXAMETH ...................................... 52:08.00YNYY 155
FUROSEMIDE .......................................................... 40:28.00YNNY 149
FUROSEMIDE .......................................................... 40::2.8.YNNY 151
FUROSEMIDE .......................................................... 99:00.98YYNY 221
FUSIDIC ACID ........................................................ 52:04.12YNYY 154
FUSIDIC ACID ........................................................ 84:04.04YNYY 190
FUSIDIC ACID 2%/HYDROCORTISONE ...................................... 84:04.04YYYY 190
GABAPENTIN .......................................................... 28:12.92YYNY 107
GALANTAMINE HYDROBROMIDE ............................................ 12:04.00EENY 32
GANCICLOVIR SO4 ..................................................... 08:18.00YENY 13
GANCICLOVIR SO4 ..................................................... 08:18.00YENY 13
GATIFLOXACIN ........................................................ 52:04.04YNNY 153
GEFITINIB ........................................................... 10:00.00EENY 25
GEMFIBROZIL ......................................................... 24:06.00YYNY 67
GENTAMICIN .......................................................... 84:04.04YNYY 190
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
296
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
GENTAMICIN S04 ...................................................... 08:12.02EENY 2
GENTAMICIN SO4 ...................................................... 52:04.04YNYY 153
GENTAMICIN/BETAMETHASONE SOD ........................................ 52:08.00YNYY 156
GLATIRAMER ACETATE .................................................. 92:00.00EENY 213
GLICLAZIDE .......................................................... 68:20.20YYNY 182
GLUCAGON ............................................................ 68:20.92YYNY 183
GLYBURIDE ........................................................... 68:20.20YYNY 182
GLYCERINE ........................................................... 99:04.00YNNN 225
GLYCOPYRROLATE ...................................................... 99:07.00YNNY 228
GLYCOPYRRONIUM BROMIDE .............................................. 12:08.08EENY 34
GLYCOPYRRONIUM/INDACATEROL .......................................... 12:08.08EENY 34
GOLIMUMAB ........................................................... 92:00.00EENY 213
GOSERELIN ACETATE ................................................... 92:00.00YYNY 213
GRANISETRON ......................................................... 56:22.00EENY 163
HALOBETASOL ......................................................... 84:06.00EENY 197
HALOBETASOL ......................................................... 84:06.00EENY 197
HALOPERIDOL ......................................................... 28:16.08YYNY 127
HALOPERIDOL ......................................................... 99:00.98YYNY 221
HALOPERIDOL DECANOATE ............................................... 28:16.08YYNY 128
HALOPERIDOL DECANOATE ............................................... 28:16.08YYNY 128
HEPARIN ............................................................. 20:12.04YYNY 44
HOMATROPINE HYDROBROMIDE ............................................ 52:24.00YEYY 158
HYDRALAZINE HCL ..................................................... 24:08.00YYNY 76
HYDROCHLOROTHIAZIDE ................................................. 40:28.00YYYY 150
HYDROCODONE /PHENYLEPHRINE HCL ...................................... 48:08.00YNYY 152
HYDROCORTISONE ...................................................... 56:40.00YYYY 166
HYDROCORTISONE ...................................................... 68:04.00YYYY 173
HYDROCORTISONE ...................................................... 84:06.00YNYN 197
HYDROCORTISONE ACETATE .............................................. 84:06.00YNYY 197
HYDROCORTISONE VALERATE ............................................. 84:06.00YYYY 198
HYDROCORTISONE/PRAMOXINE ............................................ 84:06.00NNYN 198
HYDROMORPHONE BITARTRATE ............................................ 28:08.08YNNY 97
HYDROMORPHONE HCL ................................................... 28:08.08YYNY 97
HYDROXYCHLOROQUINE SO4 .............................................. 08:20.00YYNY 18
HYDROXYUREA ......................................................... 10:00.00YYNY 25
HYDROXYZINE ......................................................... 28:24.92YYYY 143
HYOSCINE BUTYLBROMIDE ............................................... 12:08.08YNYY 34
HYOSCINE BUTYLBROMIDE ............................................... 99:00.98YYNY 221
IBRUTINIB ........................................................... 10:00.00EENY 25
IBUPROFEN ........................................................... 28:08.04YNNN 90
IBUPROFEN ........................................................... 99:00.99YYNN 224
IBUPROFEN ........................................................... 99:01.00YNNN 225
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
297
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
IBUPROFEN ........................................................... 99:01.00YNNN 225
ICATIBANT ACETATE ................................................... 92:32.00ENNY 219
IDELALISIB .......................................................... 10:00.00EENY 25
IMATINIB ............................................................ 10:00.00EENY 25
IMIPRAMINE .......................................................... 28:16.04YYYY 120
IMIQUIMOD ........................................................... 84:36.00EENY 202
INCOBOTULINUMTOXIN A ................................................ 92:00.00EENY 213
INDACATEROL ......................................................... 12:12.00EENY 36
INDAPAMIDE .......................................................... 40:28.00YYNY 150
INDAPAMIDE/PERINDOPRIL .............................................. 24:08.00YYNY 76
INDINAVIR SULPHATE .................................................. 08:18.08YYNY 15
INDOMETHACIN ........................................................ 28:08.04YNYY 91
INFLIXIMAB .......................................................... 92:00.00EENY 213
INSULIN LISPRO (BIPHASIC) .......................................... 68:20.08YYNY 180
INSULIN (REGULAR) LISPRO ............................................ 68:20.08YYNY 180
INSULIN ASPART ...................................................... 68:20.08YYNY 180
INSULIN DETEMIR ..................................................... 68:20.08EENY 180
INSULIN GLARGINE .................................................... 68:20.08EENY 180
INSULIN GLULISINE ................................................... 68:20.08YYNY 180
INSULIN ISOPHANE HUMAN BIOSYNT ...................................... 68:20.08YYNY 180
INSULIN ISOPHANE PORK ............................................... 68:20.08YYNY 180
INSULIN LISPRO ...................................................... 68:20.08YYNY 181
INSULIN LISPRO ...................................................... 68:20.08YYNY 181
INSULIN PORK ........................................................ 68:20.08YYNY 181
INSULIN(ASPART/ASPART PROTAMIN ...................................... 68:20.08YYNY 181
INSULIN(ISOPHANE) HUMAN BIOSYN ...................................... 68:20.08YYNY 181
INSULIN(LENTE)HUMAN BIOSYNTHET ...................................... 68:20.08YYNY 181
INSULIN(REG./ISOPHANE) HUMAN ........................................ 68:20.08YYNY 181
INSULIN(REGULAR)HUMAN BIOSYNTH ...................................... 68:20.08YYNY 181
INTERFERON ALFA-2B .................................................. 10:00.00EENY 26
INTERFERON BETA-1A .................................................. 92:00.00EENY 213
INTERFERON BETA-1B .................................................. 92:00.00EENY 213
IODOCHLORHYDROXYQUIN/FLUMETHAS ...................................... 52:08.00YNYY 156
IPILIMUMAB .......................................................... 10:00.00EENY 26
IPRATROPIUM /SALBUTAMOL ............................................. 12:08.08YYNY 34
IPRATROPIUM BROMIDE ................................................. 12:08.08YYNY 34
IPRATROPIUM/FENOTEROL ............................................... 12:12.00YYNY 37
IPRATROPIUM/FENOTEROL ............................................... 12:12.00YYNY 37
IPRATROPIUM/SALBUTAMOL .............................................. 12:08.08YYNY 35
IRBESARTAN .......................................................... 24:08.00YYNY 77
IRBESARTAN .......................................................... 24:08.00YYNY 77
IRBESARTAN/HYDROCHLOROTHIAZIDE ...................................... 24:08.00YYNY 77
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
298
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
IRON (FERRIC GLUCONATE COMPLEX ...................................... 20:04.04EENY 42
IRON (FERROUS SULFATE) .............................................. 20:04.04ENYN 42
IRON DEXTRAN ........................................................ 20:04.04EENY 43
IRON POLYSACCHARIDE COMPLEX ......................................... 20:04.04EENY 43
IRON SUCROSE ........................................................ 20:04.04EENY 43
ISOSORBIDE DINITRATE ................................................ 24:12.00YYNY 85
ISOSORBIDE-5 MONONITRATE ............................................ 24:12.00YYNY 85
ISOTRETINOIN ........................................................ 84:36.00NNYY 202
ITRACONAZOLE ........................................................ 08:12.04EEYY 3
IVACAFTOR ........................................................... 48:14.12EENY 152
KCL/SOD.BICARB/NACI/CARBOWAX ........................................ 99:04.00YNNY 225
KETAMINE HCL ........................................................ 28::0.4.YNNY 147
KETAMINE HCL ........................................................ 99:00.98YYNY 221
KETOCONAZOLE ........................................................ 08:12.04YEYY 3
KETOCONAZOLE ........................................................ 84:04.08YNYY 191
KETOCONAZOLE ........................................................ 99:00.98YYNY 221
KETOPROFEN .......................................................... 28:08.04YNYY 91
KETOROLAC ........................................................... 28:08.04YNNY 91
KETOROLAC TROMETHAMINE .............................................. 28:08.04YYYY 91
KETOROLAC TROMETHAMINE .............................................. 52:08.00YNYY 156
KIVEXA .............................................................. 08:18.08YYNY 15
L-TRYPTOPHAN ........................................................ 28:16.04YYNY 120
LABETALOL HCL ....................................................... 24:08.00YYNY 78
LACOSAMIDE .......................................................... 28:12.92EENY 109
LACTIC ACID/SALICYLIC ACID .......................................... 84:28.00NNYN 201
LACTULOSE ........................................................... 99:04.00YNNN 225
LAMIVUDINE .......................................................... 08:18.08YYNY 15
LAMIVUDINE/ZIDOVUDINE ............................................... 08:18.08YYNY 16
LAMOTRIGINE ......................................................... 28:12.92YYNY 109
LANSOPRAZOLE ........................................................ 56:40.00YEYY 166
LANSOPRAZOLE ........................................................ 99:05.00YNNY 227
LANSOPRAZOLE/CLARITHROMYC/AMOX ...................................... 56:40.00YNYY 167
LAPATINIB ........................................................... 10:00.00EENY 26
LATANOPROST ......................................................... 52:36.00YYNY 160
LATANOPROST/TIMOLOL ................................................. 52:36.00YYNY 160
LEDIPASVIR/SOFOSBUVIR ............................................... 08:18.40EENY 17
LEFLUNOMIDE ......................................................... 92:00.00EENY 214
LEFLUNOMIDE ......................................................... 92:00.00EENY 214
LENALIDOMIDE ........................................................ 10:00.00EENY 26
LETROZOLE ........................................................... 10:00.00YYNY 27
LETROZOLE ........................................................... 10:00.00YYNY 27
LEUCOVORIN CALC.(FOLINIC ACID) ...................................... 88:08.00YENY 206
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
299
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
LEUPROLIDE .......................................................... 10:00.00YYNY 27
LEVETIRACETAM ....................................................... 28:12.92YYNY 110
LEVOBUNOLOL HCL ..................................................... 52:36.00YYNY 160
LEVOCABASTINE HYDROCHLORIDE ......................................... 52:36.00YNYY 160
LEVOCARNITINE ....................................................... 28:12.12NENY 105
LEVODOPA/BENZERAZIDE ................................................ 28:92.00YYNY 145
LEVODOPA/CARBIDOPA .................................................. 28:92.00YYNY 145
LEVOFLOXACIN ........................................................ 08:22.00YENY 20
LEVOFLOXACIN ........................................................ 08:22.00YENY 20
LEVOFLOXACIN IV ..................................................... 08:22.00EENY 20
LEVONORGESTREL ...................................................... 68:12.00NNYY 177
LEVOTHYROXINE (SODIUM) .............................................. 68:36.04YYNY 188
LIDOCAINE ........................................................... 99:13.00YNNN 228
LIDOCAINE 1%-50 ML .................................................. 99:13.00YNNN 228
LIDOCAINE/PRILOCAINE ................................................ 99:13.00YNNN 228
LINAGLIPTIN ......................................................... 68:20.05EENY 179
LINAGLIPTIN/METFORMIN ............................................... 68:20.04EENY 179
LIOTHYRONINE SODIUM ................................................. 68:36.04YYNY 189
LISDEXAMFETAMINE DIMESYLATE ......................................... 28:20.04EENY 138
LISDEXAMFETAMINE DIMESYLAYE ......................................... 28:20.04EENY 139
LISINOPRIL .......................................................... 24:04.00YYNY 57
LISINOPRIL/HYDROCHLOROTHIAZIDE ...................................... 24:04.00YYNY 58
LITHIUM CARBONATE ................................................... 28:28.00YYNY 143
LODOXAMIDE TROMETHAMINE ............................................. 52:36.00YNYY 160
LOMUSTINE ........................................................... 10:00.00YYNY 27
LOPERAMIDE .......................................................... 99:15.00YNNN 229
LOPINAVIR/RITONAVIR ................................................. 08:18.08YYNY 16
LORATADINE .......................................................... 04:08.00NNYN 1
LORAZEPAM ........................................................... 28:24.08YNYY 141
LORAZEPAM ........................................................... 28:24.08YNYY 141
LORAZEPAM ........................................................... 99:00.98YYNY 221
LOSARTAN /HYDROCHLOROTHIAZIDE ....................................... 24:08.00YYNY 78
LOSARTAN POTASSIUM .................................................. 24:08.00YYNY 79
LOSARTAN/HYDROCHLOROTHIAZIDE ........................................ 24:08.00YYNY 79
LOVASTATIN .......................................................... 24:06.00YYNY 68
LOVASTATIN .......................................................... 24:06.00YYNY 68
LOXAPINE SUCCINATE .................................................. 28:16.08YYNY 128
LURASIDONE HCL ...................................................... 28:16.08EENY 128
MAG OXIDE/CITRIC ACID/PICOSULF ...................................... 99:04.00YNNN 225
MAGNESIUM CITRATE ................................................... 99:04.00YNNN 226
MAGNESIUM CITRATE ................................................... 99:04.00YNNN 226
MAGNESIUM GLUCOHEPTONATE ............................................ 40:12.00EENY 148
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
300
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
MAGNESIUM GLUCONATE ................................................. 40:12.00ENNN 148
MAGNESIUM HYDROX/MINERAL OIL ........................................ 99:04.00YNNN 226
MAGNESIUM OXIDE ..................................................... 40:12.00ENYN 148
MAPROTILINE ......................................................... 28:16.04YYYY 120
MEBENDAZOLE ......................................................... 08:08.00YNYY 1
MECLIZINE HCL ....................................................... 56:22.00YNNN 163
MEDROXYPROGESTERONE ACETATE ......................................... 68:32.00YNYY 188
MEDROXYPROGESTERONE ACETATE ......................................... 99:00.98YYNY 221
MEFENAMIC ACID ...................................................... 28:08.04YYYY 92
MEFENAMIC ACID ...................................................... 28:08.04YYYY 92
MEGESTROL ACETATE ................................................... 10:00.00YYNY 27
MELOXICAM ........................................................... 28:08.04YYYY 92
MELPHALAN ........................................................... 10:00.00YYNY 28
MEPERIDINE HCL ...................................................... 28:08.08YYNY 98
MERCAPTOPURINE ...................................................... 10:00.00YYNY 28
METFORMIN ........................................................... 68:20.90YYNY 183
METFORMIN ........................................................... 68:20.92YYNY 183
METFORMIN HYDROCHLORIDE ............................................. 68:20.92YYNY 184
METFORMIN/SAXAGLIPTIN ............................................... 68:20.04EENY 179
METHADONE ........................................................... 99:00.98EENY 221
METHADONE HYDROCHLORIDE ............................................. 28:08.08YNNY 98
METHAZOLAMIDE ....................................................... 52:10.00YYNY 157
METHENAMINE MANDELATE ............................................... 08:36.00YNNY 21
METHIMAZOLE ......................................................... 68:36.08YYNY 189
METHOCARBAMOL/ACETAMINOPHEN ......................................... 12:20.00YNNN 41
METHOCARBAMOL/CODEINE ............................................... 12:20.00YNNY 41
METHOTREXATE ........................................................ 10:00.00YYNY 28
METHOTREXATE SODIUM ................................................. 10:00.00YYNY 28
METHOTREXATE SODIUM INJ ............................................. 10:00.00YYNY 28
METHOTRIMEPRAZINE ................................................... 28:16.08YYNY 128
METHOTRIMEPRAZINE ................................................... 99:00.98YYNY 222
METHOXSALEN ......................................................... 84:50.06NENY 202
METHSUXIMIDE ........................................................ 28:12.20YYNY 106
METHYLDOPA .......................................................... 24:08.00YYNY 80
METHYLDOPA/HYDROCHLOROTHIAZIDE ...................................... 24:08.00YYNY 80
METHYLPHENIDATE HCL ................................................. 28:20.00EENY 137
METHYLPHENIDATE HCL ................................................. 99:00.98YYNY 222
METHYLPREDNISOLONE .................................................. 68:04.00YYYY 173
METHYLPREDNISOLONE ACETATE .......................................... 68:04.00YYNY 174
METHYLPREDNISOLONE SOD SUCCIN ....................................... 68:04.00YYNY 174
METOCLOPRAMIDE HCL .................................................. 56:40.00YYYY 167
METOLAZONE .......................................................... 40:28.00YYNY 151
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
301
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
METOLAZONE .......................................................... 40:28.00YYNY 151
METOPROLOL TARTRATE ................................................. 24:04.00YYNY 58
METRONIDAZOLE ....................................................... 08:40.00YEYY 21
METRONIDAZOLE ....................................................... 84:04.16YNYY 193
MEXILETINE HCL ...................................................... 24:04.00YYNY 59
MICONAZOLE NITRATE .................................................. 84:04.08YNYY 192
MICONAZOLE NITRATE .................................................. 84:04.08YNYY 192
MIDAZOLAM ........................................................... 99:00.98YNNY 222
MIDODRINE ........................................................... 12:12.00YYNY 37
MINERAL OIL ......................................................... 99:04.00YNNN 226
MINOCYCLINE HCL ..................................................... 08:12.24YEYY 10
MINOXIDIL ........................................................... 24:08.00YYNY 80
MIRABEGRON .......................................................... 86:12.08ENNY 204
MIRTAZAPINE ......................................................... 28:16.04YYNY 120
MISOPROSTOL ......................................................... 56:40.00YYYY 167
MOCLOBEMIDE ......................................................... 28:16.04YYYY 121
MODAFINIL ........................................................... 28:20.00EENY 138
MOMETASONE FUROATE .................................................. 52:08.00YNYY 156
MOMETASONE FUROATE .................................................. 84:06.00YYYY 198
MONTELUKAST SODIUM .................................................. 92:00.00EENY 214
MORPHINE ............................................................ 28:08.08YYYY 99
MORPHINE ............................................................ 28:08.08YYYY 99
MORPHINE INJ ........................................................ 28:08.08YYNY 101
MOXIFLOXACIN ........................................................ 08:22.00EENY 20
MOXIFLOXACIN HYDROCHLORIDE .......................................... 52:04.04YNYY 153
MUPIROCIN ........................................................... 84:04.04YNYY 191
MUPIROCIN ........................................................... 84:04.04YNYY 191
MYCOPHENOLATE ....................................................... 92:00.00YYNY 215
MYCOPHENOLATE ....................................................... 92:00.00YYNY 215
MYCOPHENOLATE MOFETIL ............................................... 92:00.00YYNY 215
MYCOPHENOLIC ACID ................................................... 92:00.00YYNY 215
NABILONE ............................................................ 56:22.00EENY 163
NABUMETONE .......................................................... 28:08.04YYYY 92
NADOLOL ............................................................. 24:04.00YYNY 59
NADROPARIN CALCIUM .................................................. 20:12.04YENY 44
NALTREXONE HCL ...................................................... 28:10.00YENY 103
NAPROXEN ............................................................ 28:08.04YYYY 92
NAPROXEN SODIUM ..................................................... 28:08.04YYYY 93
NARATRIPTAN HCL ..................................................... 12:16.00YNYY 39
NATALIZUMAB ......................................................... 92:00.00EENY 215
NELFINAVIR MESYLATE ................................................. 08:18.08YYNY 16
NEOMYC/GRAM/NYS/TRIAMCINOLONE ....................................... 84:06.00YNYY 199
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
302
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
NEOMYC/GRAM/NYS/TRIAMCINOLONE ....................................... 84:06.00YNYY 199
NEOSTIGMINE BROMIDE ................................................. 12:04.00YNNY 32
NEPAFENAC ........................................................... 52:36.00YNNY 160
NEVIRAPINE .......................................................... 08:18.08YYNY 16
NIACIN .............................................................. 88:08.00YNNN 206
NIFEDIPINE .......................................................... 24:04.00YYYY 60
NILUTAMIDE .......................................................... 10:00.00YYNY 28
NINTEDANIB .......................................................... 48:02.00EENY 151
NITRAZEPAM .......................................................... 28:12.08YYNY 105
NITROFURANTOIN ...................................................... 08:36.00YEYY 21
NITROFURANTOIN MONOHYDRATE .......................................... 08:36.00YEYY 21
NITROGLYCERIN ....................................................... 24:12.00YYNY 86
NITROGLYCERIN ....................................................... 24:12.00YYNY 86
NIZATIDINE .......................................................... 56:40.00YNYY 167
NORETHINDRONE ....................................................... 68:12.00NNYY 178
NORETHINDRONE ....................................................... 68:12.00NNYY 178
NORFLOXACIN ......................................................... 08:22.00YEYY 20
NORTRIPTYLINE ....................................................... 28:16.04YYYY 121
NYSTATIN ............................................................ 08:12.04YEYY 3
NYSTATIN ............................................................ 84:04.08YNYN 192
NYSTATIN ............................................................ 99:00.99YYNN 224
OBINUTUZUMAB ........................................................ 10:00.00EENY 28
OCRIPLASMIN ......................................................... 92:00.00EENY 215
OCTREOTIDE .......................................................... 92:00.00YNNY 215
OCTREOTIDE .......................................................... 99:00.98YYNY 222
OCTREOTIDE ACETATE .................................................. 92:00.00YENY 216
OFLOXACIN ........................................................... 52:04.12YNYY 154
OLANZAPINE .......................................................... 28:16.08YYNY 129
OLANZAPINE .......................................................... 28:16.08YYNY 129
OLANZAPINE .......................................................... 99:00.98YYNY 222
OLMESARTAN .......................................................... 24:08.00YYNY 80
OLMESARTAN/HYDROCHLOROTHIAZIDE ...................................... 24:08.00YYNY 80
OLODATEROL/TIOTROPIUM ............................................... 12:08.08EENY 35
OLOPATADINE ......................................................... 04:00.00YNYY 1
OLOPATDINE .......................................................... 04:00.00YNYY 1
OLSALAZINE SODIUM ................................................... 56:40.00YYYY 168
OMALIZUMAB .......................................................... 48:92.00ENNY 152
OMBITASVIR/PARITAPREVIR/RITONA ...................................... 08:18.40EENY 18
OMBITASVIR/PARITAPREVIR/RITONA ...................................... 08:18.40EENY 18
OMEPRAZOLE .......................................................... 56:40.00YEYY 168
ONDANSETRON ......................................................... 56:22.00EENY 163
ONDANSETRON ......................................................... 99:00.98YYNY 222
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
303
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
OPIUM & BELLADONNA SUP. ............................................. 12:08.08YENY 35
ORCIPRENALINE SO4 ................................................... 12:12.00YYYY 37
ORPHENADRINE CITRATE ................................................ 12:20.00YNNN 41
OXAZEPAM ............................................................ 28:24.08YNYY 141
OXCARBAZEPINE ....................................................... 28:12.92YYNY 110
OXTRIPHYLLINE ....................................................... 86:16.00YYNY 204
OXTRIPHYLLINE/GUAIFENESIN ........................................... 86:16.00YYNY 204
OXYBUTYNIN CHLORIDE ................................................. 86:12.00YNYY 203
OXYCODONE ........................................................... 28:08.08YYYY 101
OXYCODONE ........................................................... 99:00.98YYNY 222
OXYCODONE HCL/ACETAMINOPHEN ......................................... 28:08.08YYYY 101
OXYCODONE HCL/ACETOMINOPHEN ......................................... 28:08.08YYYY 101
OXYCODONE/ACETYLSALICYLIC ACID ...................................... 28:08.08YYNY 102
OXYCODONE/ACETYLSALICYLIC ACID ...................................... 28:08.08YYNY 102
PALIPERIDONE ........................................................ 28:16.08EENY 130
PAMIDRONATE DISODIUM ................................................ 92:00.00YYNY 216
PANCRELIPASE (LIPASE/AMYL/PROT ...................................... 56:16.01YYNY 162
PANCRELIPASE(LIPASE/AMYL/PROT) ...................................... 56:16.00YYNY 162
PANTOPRAZOLE ........................................................ 56:40.00YEYY 168
PANTOPRAZOLE ........................................................ 99:00.98YYNY 222
PANTOPRAZOLE MAGNESIUM .............................................. 56:40.00YEYY 169
PAROXETINE .......................................................... 28:16.04YYYY 122
PAZOPANIB HCL ....................................................... 10:00.00YYNY 28
PEGFILGRASTIM ....................................................... 20:16.00EENY 48
PEMBROLIZUMAB ....................................................... 10:00.00EENY 28
PENICILLAMINE ....................................................... 64:00.00YNNY 171
PENICILLIN V (POTASSIUM) ............................................ 08:12.16YEYY 9
PENTAZOCINE ......................................................... 28:08.12YNNY 102
PENTAZOCINE ......................................................... 99:00.98YYNY 223
PENTAZOCINE ......................................................... 99:00.98YYNY 223
PENTOSAN POLYSULFATE SO4 ............................................ 92:00.00YNYY 216
PENTOXIFYLLINE ...................................................... 20:24.00YYNY 48
PERAMPANEL .......................................................... 28:12.92EENY 111
PERICYAZINE ......................................................... 28:16.08YYNY 131
PERINDOPRIL ERBUMINE ................................................ 24:08.00YYNY 80
PERMETHRIN .......................................................... 84:04.12NNYN 193
PERMETHRIN .......................................................... 84:04.12NNYN 193
PERPHENAZINE ........................................................ 28:16.08YYNY 131
PERTUZUMAB/TRASTUZUMAB .............................................. 10:00.00ENNY 29
PERTUZUMAB/TRASTUZUMAB .............................................. 10:00.00ENNY 29
PETROLEUM DISTILLATE ................................................ 84:04.12NNYN 193
PHENELZINE SO4 ...................................................... 28:16.04YYYY 122
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
304
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
PHENOBARBITAL ....................................................... 28:12.04YYYY 104
PHENOBARBITAL SODIUM ................................................ 28:12.04NNNY 104
PHENOBARBITAL SODIUM ................................................ 99:00.98YYNY 223
PHENYTOIN ........................................................... 28:12.12YYNY 105
PHOSPHORUS .......................................................... 40:12.00YENY 148
PILOCARPINE HCL ..................................................... 12:04.00YNNY 32
PILOCARPINE HCL ..................................................... 52:20.00YYYY 158
PIMECROLIMUS ........................................................ 92:00.00EENY 216
PIMOZIDE ............................................................ 28:16.08YYNY 131
PINAVERIUM BROMIDE .................................................. 12:08.08YNYY 35
PINDOLOL ............................................................ 24:04.00YYNY 60
PINDOLOL/HYDROCHLOROTHIAZIDE ........................................ 24:08.00YYNY 81
PIOGLITAZONE ........................................................ 68:20.92EENY 184
PIPERACILLIN/TAZOBACTAM ............................................. 08:12.16YENY 10
PIRFENIDONE ......................................................... 92:44.00EENY 219
PIROXICAM ........................................................... 28:08.04YYYY 93
PIZOTYLINE HYDROGEN MALATE .......................................... 12:16.00YNYY 39
PODOPHYLLIN ......................................................... 84:36.00YNYY 202
PODOPHYLLOTOXIN ..................................................... 84:28.00YNYY 201
POLYETHYLENE GLYCOL 3350 ............................................ 99:04.00YNNN 226
POLYMIXIN B/TRIMETHOPRIM ............................................ 52:04.04YNYY 153
POLYMIXIN B/TRIMETHOPRIM ............................................ 99:00.98YYNY 223
POLYMYX/BACIT/NEOM/HYDROCORT ........................................ 84:06.00YNYY 199
POLYMYX/NEOMYC/HYDROCORTISONE ....................................... 52:08.00YNYY 156
POLYMYX/NEOMYCIN/BACITRACIN ......................................... 84:04.04YNYY 191
POLYMYX/NEOMYCIN/DEXAMETHASONE ...................................... 52:08.00YNYY 156
POLYMYXIN B/TRIMETHOPRIM ............................................ 52:04.04YNYY 153
POLYMYXIN/NEOMYCIN/GRAMICIDIN ....................................... 52:04.04YNYY 153
POMALIDOMIDE ........................................................ 10:00.00EENY 29
PONATINIB HCL ....................................................... 10:00.00EENY 29
POTASSIUM CHLORIDE .................................................. 40:12.00YNNY 148
POTASSIUM CHLORIDE .................................................. 99:00.98YYNY 223
POTASSIUM CITRATE ................................................... 40:12.00YNNN 148
PRAMIPEXOLE DIHYDROCHLORIDE ......................................... 28:92.00YYNY 145
PRAVASTATIN ......................................................... 24:06.00YYNY 68
PRAZOSIN ............................................................ 24:08.00YYNY 81
PREDNISOLONE ACETATE ................................................ 52:08.00YNYY 156
PREDNISOLONE SODIUM PHOSPHATE ....................................... 52:08.00ENNY 156
PREDNISOLONE SODIUM PHOSPHATE ....................................... 68:04.00YYYY 174
PREDNISONE .......................................................... 68:04.00YYYY 174
PREGABALIN .......................................................... 28:12.92YYNY 111
PRENATAL VITAMINS ................................................... 88:28.01NNYN 208
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
305
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
PRIMIDONE ........................................................... 28:12.04YYNY 104
PROCAINAMIDE HCL .................................................... 24:04.00YYNY 60
PROCARBAZINE ........................................................ 10:00.00YYNY 29
PROCHLORPERAZINE .................................................... 28:16.08YYYY 131
PROCYCLIDINE HCL .................................................... 12:08.04YYNY 33
PROGESTERONE ........................................................ 68:32.00YNNY 188
PROPAFENONE HCL ..................................................... 24:04.00YYNY 61
PROPOXYPHENE ........................................................ 28:08.08YYYY 102
PROPOXYPHENE ........................................................ 99:00.98YYNY 223
PROPRANOLOL ......................................................... 24:04.00YYYY 61
PROPYLTHIOURACIL .................................................... 68:36.08YYYY 189
PYDIROXINE HCL ...................................................... 88:08.00YEYN 206
PYRANTEL PAMOATE .................................................... 08:08.00NNYN 1
PYRIDOSTIGMINE BROMIDE .............................................. 12:04.00YNNY 32
PYRIDOXINE HCL ...................................................... 88:08.00YEYN 206
QUETIAPINE .......................................................... 28:16.08YYNY 132
QUINAPRIL HCL ....................................................... 24:08.00YYNY 81
QUINAPRIL/HYDROCHLOROTHIAZIDE ....................................... 24:08.00YYNY 81
RABEPRAZOLE ......................................................... 56:40.00YEYY 169
RALOXIFENE .......................................................... 66:16.12YENY 171
RALOXIFENE .......................................................... 68:16.12YENY 179
RALTEGRAVIR ......................................................... 08:18.08EENY 16
RAMIPRIL ............................................................ 24:04.00YYNY 62
RAMIPRIL/HCTZ ....................................................... 24:04.00YYNY 63
RAMUCIRUMAB ......................................................... 10:00.00EENY 29
RANIBIZUMAB ......................................................... 52:36.00EENY 160
RANITIDINE .......................................................... 56:40.00YNYY 169
RANITIDINE .......................................................... 99:00.98YYNY 223
RANITIDINE .......................................................... 99:15.00YNNY 229
RASAGILINE .......................................................... 28:92.00EENY 146
REGORAFENIB ......................................................... 10:00.00EENY 29
REPAGLINIDE ......................................................... 68:20.92YYNY 186
REPAGLINIDE ......................................................... 68:20.92YYNY 186
RIBAVIRIN ........................................................... 08:18.32EENY 17
RIBAVIRIN/PEGINTERFERON ALFA2A ...................................... 08:18.00EENY 13
RIBAVIRIN/PEGINTERFERON ALFA2B ...................................... 08:18.00EENY 13
RIFABUTIN ........................................................... 08:12.28YENY 11
RIFAMPIN ............................................................ 08:12.28YENY 11
RIFAXIMIN ........................................................... 08:12.28EENY 11
RILPIVIRINE HCL ..................................................... 08:18.08EENY 16
RILUZOLE ............................................................ 28:92.00EENY 147
RILUZOLE ............................................................ 28:92.00EENY 147
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
306
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
RIMEXOLONE .......................................................... 52:08.00YNNY 157
RIMEXOLONE .......................................................... 52:08.00YNNY 157
RIOCIGUAT ........................................................... 24:12.92ENNY 87
RISEDRONATE ......................................................... 92:00.00YENY 216
RISEDRONATE SODIUM .................................................. 92:00.00YNNY 216
RISPERIDONE ......................................................... 28:16.08YYNY 133
RITONAVIR ........................................................... 08:18.08YYNY 16
RITUXIMAB ........................................................... 10:00.00EENY 29
RIVAROXABAN ......................................................... 20:12.04EENY 44
RIVASTIGMINE ........................................................ 12:04.00EENY 32
RIZATRIPTAN ......................................................... 12:16.00YNNY 39
ROMIDEPSIN .......................................................... 10:00.00EENY 29
ROPINIROLE .......................................................... 28:92.00YYNY 147
ROSIGLITAZONE ....................................................... 68:20.92EENY 186
ROSUVASTATIN ........................................................ 24:06.00YYNY 69
RUXOLITINIB ......................................................... 10:00.00ENNY 29
SALBUTAMOL (SALBUTAMOL SO4) ......................................... 12:12.00YYYY 37
SALBUTAMOL (SALBUTAMOL SO4) ......................................... 99:00.98YYNY 223
SALMETEROL /FLUTICASONE ............................................. 12:12.00EENY 38
SALMETEROL XINAFOATE ................................................ 12:12.00EENY 38
SAQUINAVIR .......................................................... 08:18.08YYNY 17
SAXAGLIPTIN HCL ..................................................... 68:20.05EENY 180
SAXAGLIPTIN HCL ..................................................... 68:20.05EENY 180
SCOPOLAMINE N-BUTYLBROMIDE .......................................... 99:07.00YNNY 228
SECUKINUMAB ......................................................... 84:92.00EENY 203
SECUKINUMAB ......................................................... 84:92.00EENY 203
SECURA .............................................................. 99:10.00YNNN 228
SELEGILINE HCL ...................................................... 28:92.00YYNY 147
SENNA ............................................................... 99:04.00YNNN 226
SENNA/SOD DIOCT.SULFOSUCCINATE ...................................... 99:04.00YNNN 226
SENNOSIDES .......................................................... 99:04.00YNNN 226
SERTRALINE HYDROCHLORIDE ............................................ 28:16.04YYYY 123
SERTRALINE HYDROCHLORIDE ............................................ 28:16.04YYYY 123
SEVELAMER HYDROCHLORIDE ............................................. 92:00.00EENY 217
SILDENAFIL .......................................................... 24:12.00EENY 86
SILVER SULFADIAZINE ................................................. 84:04.16YNYY 193
SIMEPREVIR .......................................................... 08:18.40EENY 18
SIMVASTATIN ......................................................... 24:06.00YYNY 70
SIROLIMUS ........................................................... 92:00.00YYNY 217
SITAGLIPTIN ......................................................... 68:20.92EENY 186
SITAGLIPTIN/METFORMIN ............................................... 68:20.92EENY 186
SOD CITRATE/SULFOACET/SORBITOL ...................................... 99:04.00YNNN 226
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
307
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
SOD PHOSPHATE DI- & MONOBASIC ....................................... 99:04.00YNNN 226
SOD POLYSTYRENE SULFONATE SUSP ...................................... 40:18.00YNNY 149
SODIUM AUROTHIOMALATE ............................................... 60:00.00YYNY 171
SODIUM CHLORIDE ..................................................... 40:12.00YNNN 148
SODIUM CHLORIDE ..................................................... 99:00.98YYNY 223
SODIUM CHLORIDE ..................................................... 99:00.99YYNN 224
SODIUM CHLORIDE NEBS ................................................ 40:12.00YYNN 149
SODIUM CROMOGLYCATE ................................................. 52:36.00YNYY 160
SODIUM CROMOGLYCATE ................................................. 92:00.00YNNY 217
SODIUM DIOCTYL SULFOSUCCINATE ....................................... 99:03.00YNNN 225
SODIUM POLYSTYRENE SULFONATE ........................................ 40:18.00YNNY 149
SODIUM POLYSTYRENE SULFONATE ........................................ 99:00.98YYNY 223
SOFOSBUVIR .......................................................... 08:18.92EENY 18
SOLIFENACIN ......................................................... 86:12.00YNNY 203
SOLIFENACIN ......................................................... 86:12.04YNNY 204
SOMATROPIN .......................................................... 68:28.00NYNY 187
SOTALOL HCL ......................................................... 24:04.00YYNY 63
SPIRONOLAC/HYDROCHLOROTHIAZIDE ...................................... 40:28.00YYNY 151
SPIRONOLACTONE ...................................................... 40:28.10YYYY 151
STAVUDINE ........................................................... 08:18.08YYNY 17
SUCRALFATE .......................................................... 56:40.00YYYY 170
SUFENTANIL .......................................................... 99:01.00YNNY 225
SULFA/TRIMETH(CO-TRIMOXAZOLE) ....................................... 08:40.00YEYY 21
SULFACETAMIDE (SODIUM) .............................................. 52:04.08YNYY 154
SULFACETAMIDE/COLLOIDALSULPHUR ...................................... 84:04.16YNYY 193
SULFACETAMIDE/PREDNISOLONE .......................................... 52:08.00YNYY 157
SULFASALAZINE ....................................................... 56:40.00YYYY 170
SULFINPYRAZONE ...................................................... 40:40.00YYNY 151
SULINDAC ............................................................ 28:08.04YYYY 94
SUMATRIPTAN ......................................................... 12:16.00YNYY 39
SUNITINIB ........................................................... 10:00.00EENY 30
SUNITINIB ........................................................... 10:00.00EENY 30
TACROLIMUS .......................................................... 92:00.00YYNY 217
TACROLIMUS TOPICAL .................................................. 92:00.00EENY 218
TADALAFIL ........................................................... 24:12.00EENY 86
TAMOXIFEN CITRATE ................................................... 10:00.00YYNY 30
TAMSULOSIN HCL ...................................................... 92:00.00YNNY 218
TAZAROTENE .......................................................... 84:36.00NYNY 202
TELAPREVIR .......................................................... 08:18.92EENY 18
TELMISARTAN ......................................................... 24:08.00YYNY 82
TELMISARTAN/AMLODIPINE .............................................. 24:08.00YYNY 82
TELMISARTAN/HCTZ .................................................... 24:08.00YYNY 82
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
308
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
TEMAZEPAM ........................................................... 28:24.08YNYY 141
TEMOZOLOMIDE ........................................................ 10:00.00YYNY 30
TENOFOVIR ........................................................... 08:18.08EENY 17
TENOFOVIR/EMTRICITABINE ............................................. 08:18.08EENY 17
TERAZOSIN HCL ....................................................... 24:08.00YYNY 83
TERAZOSIN HCL ....................................................... 24:08.00YYNY 83
TERBINAFINE ......................................................... 08:12.04YEYY 3
TERBINAFINE HCL ..................................................... 84:04.08YNYY 192
TERBUTALINE SULPHATE ................................................ 12:12.00YYYY 38
TERCONAZOLE ......................................................... 84:04.08YNYY 192
TERIFLUNOMIDE ....................................................... 92:00.00EENY 218
TESTOSTERONE CYPIONATE .............................................. 68:08.00YNNY 175
TESTOSTERONE ENANTHATE .............................................. 68:08.00YENY 175
TESTOSTERONE UNDECANOATE ............................................ 68:08.00YNNY 175
TETRABENAZINE ....................................................... 92:00.00YYNY 218
TETRACYCLINE ........................................................ 08:12.24YEYY 10
THEOPHYLLINE (ANHYDROUS) ............................................ 86:16.00YYNY 205
THEOPHYLLINE (ANHYDROUS) ............................................ 86:16.00YYNY 205
THIOTHIXENE ......................................................... 28:16.08YYNY 136
THYROTROPIN ......................................................... 68:60.00YYNY 189
TIAPROFENIC ACID .................................................... 28:08.04YYYY 94
TICAGRELOR .......................................................... 20:12.18EENY 46
TICLOPIDINE HCL ..................................................... 20:24.00YYNY 48
TIMOLOL MALEATE ..................................................... 24:04.00YYNY 64
TIMOLOL MALEATE ..................................................... 52:36.00YYNY 161
TIMOLOL MALEATE ..................................................... 52:36.00YYNY 161
TIMOLOL MALEATE ..................................................... 99:00.98YYNY 223
TIMOLOL/TRAVOPROST .................................................. 52:36.00YYNY 161
TINZAPARIN .......................................................... 20:12.04YENY 44
TIOTROPIUM .......................................................... 12:08.08EENY 35
TIZANIDINE .......................................................... 92:00.00YYNY 218
TOBRAMYCIN .......................................................... 08:12.02EENY 2
TOBRAMYCIN .......................................................... 52:04.04YNYY 154
TOBRAMYCIN .......................................................... 52:04.04YNYY 154
TOBRAMYCIN SULFATE .................................................. 08:12.02EENY 2
TOBRAMYCIN/DEXAMETHASONE ............................................ 52:08.00YNYY 157
TOCILIZUMAB ......................................................... 92:00.00EENY 218
TOFACITINIB ......................................................... 92:36.00EENY 219
TOLBUTAMIDE ......................................................... 68:20.20YYNY 183
TOLTERODINE ......................................................... 86:12.00YNNY 204
TOLTERODINE ......................................................... 86:12.00YNNY 204
TOPIRAMATE .......................................................... 28:12.92YYNY 112
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
309
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
TRAMETINIB .......................................................... 10:00.00EENY 30
TRANDOLAPRIL ........................................................ 24:08.00YYNY 83
TRANEXAMIC ACID ..................................................... 92:00.00YNNY 219
TRANEXAMIC ACID ..................................................... 92:00.00YNNY 219
TRANYLCYPROMINE SO4 ................................................. 28:16.04YYYY 123
TRASTUZUMAB EMTANSINE ............................................... 10:00.00EENY 31
TRASTUZUMAB EMTANSINE ............................................... 10:00.00EENY 31
TRAVOPROST .......................................................... 52:36.00YYNY 161
TRAZODONE ........................................................... 28:16.04YYYY 123
TRETINOIN ........................................................... 84:16.00NNYY 199
TRIAMCINOLONE ....................................................... 68:04.00YYYY 174
TRIAMCINOLONE ACETONIDE ............................................. 52:08.00YNYY 157
TRIAMCINOLONE ACETONIDE ............................................. 68:04.00YYYY 175
TRIAMCINOLONE ACETONIDE ............................................. 68:04.00YYYY 175
TRIAMCINOLONE ACETONIDE ............................................. 84:06.00YYYY 199
TRIAMTERENE/HYDROCHLOROTHIAZID ...................................... 24:08.00YYNY 84
TRIAMTERENE/HYDROCHLOROTHIAZID ...................................... 24:08.00YYNY 84
TRIAZOLAM ........................................................... 28:24.08YNYY 142
TRIFLUOPERAZINE ..................................................... 28:16.08YYNY 136
TRIFLURIDINE ........................................................ 52:04.06YNYY 154
TRIHEXYPHENIDYL HCL ................................................. 12:08.04YYNY 33
TRIMEBUTINE MALEATE ................................................. 12:08.08YNYY 35
TRIMEPRAZINE TARTRATE ............................................... 04:00.00YNYY 1
TRIMETHOPRIM ........................................................ 08:36.00YEYY 21
TRIMIPRAMINE ........................................................ 28:16.04YYYY 124
TRYPTOPHAN .......................................................... 28:16.04YYNY 124
UMECLIDINIUM ........................................................ 12:08.08EENY 36
UMECLIDINIUM ........................................................ 12:08.08EENY 36
UMECLIDINIUM/VILANTEROL ............................................. 12:12.00EENY 38
URSODIOL ............................................................ 56:14.00YYNY 162
USTEKINUMAB ......................................................... 92:00.00EENY 219
VALACYCLOVIR ........................................................ 08:18.00YEYY 13
VALGANCICLOVIR ...................................................... 08:18.00EENY 13
VALGANCICLOVIR ...................................................... 92:00.00EENY 219
VALPROIC ACID ....................................................... 28:12.92YYNY 114
VALPROIC ACID ....................................................... 28:12.92YYNY 114
VALSARTAN ........................................................... 24:08.00YYNY 84
VALSARTAN/HYDROCHLOROTHIAZIDE ....................................... 24:08.00YYNY 84
VANCOMYCIN HCL ...................................................... 08:12.28YENY 11
VARENICLINE ......................................................... 12:92.00YNNY 42
VENLAFAXINE HYDROCHLORIDE ........................................... 28:16.04YYYY 125
VENLAFAXINE HYDROCHLORIDE ........................................... 28:16.04YYYY 125
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
310
Alphabetical Index of Pharmaceutical Products
PCCF: Pharmacare, Chronic Disease, Children's Drugs, Fill Fee
Values: (Y)es, (N)o, or (E)xception
PCCF Product Name Pharma Page
VENLAFAXINE HYDRPCHLORIDE ........................................... 28:16.04YYYY 125
VERAPAMIL HCL ....................................................... 24:04.00YYYY 64
VIGABATRIN .......................................................... 28:12.92YYNY 114
VISMODEGIB .......................................................... 10:00.00EENY 31
VITAMIN B COMPLEX &VITAMIN C ........................................ 88:08.08EENN 207
VITAMIN B12 ......................................................... 88:08.00YENN 206
VITAMIN D ........................................................... 88:16.00YNNY 207
VITAMIN D ........................................................... 99:00.99YYNN 224
VORICONAZOLE ........................................................ 08:12.04EENY 3
WARFARIN ............................................................ 20:12.04YYYY 45
ZAFIRLUKAST ......................................................... 92:00.00EENY 219
ZIDOVUDINE .......................................................... 08:18.08YYNY 17
ZIPRASIDONE ......................................................... 28:16.08YYNY 136
ZOLEDRONIC ACID ..................................................... 92:00.00EENY 219
ZOLMITRIPTAN ........................................................ 12:16.00YNYY 40
ZOPICLONE ........................................................... 28:24.08YNYY 142
ZOPICLONE ........................................................... 99:00.98YYNY 223
ZUCLOPENTHIXOL ACETATE .............................................. 28:16.08YYNY 136
ZUCLOPENTHIXOL DECANOATE ............................................ 28:16.08YYNY 137
ZUCLOPENTHIXOL DECANOATE ............................................ 28:16.08YYNY 137
ZUCLOPENTHIXOL DIHYDROCHLORIDE ...................................... 28:16.08YYNY 137
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26
311
Health and Social Services
Insured Health & Hearing Services (H-2) Printed: 2017-01-26